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Abstract 
Spontaneous (non-traumatic) intracerebral haemorrhage accounts for ~10% of all 
strokes in Western populations.  Investigations may identify intracerebral haemorrhage 
(ICH) as ‘secondary’ to underlying causes such as tumours or aneurysms, but ~80% of 
ICHs which have no apparent underlying cause (so-called ‘primary’ ICH) tend to be 
attributed to small vessel vasculopathies such as arteriolosclerosis or cerebral amyloid 
angiopathy (CAA), on the basis of an adult’s risk factors and clinical and radiographic 
features of the ICH. 
The commonly accepted hypothesis is that CAA contributes to lobar ICH and 
arteriolosclerosis causes non-lobar ICH.  In the following thesis, I set out to explore 
whether (a) the baseline demographic, clinical features and apolipoprotein E genotype 
of adults with lobar and non-lobar ICH differ, (b) the prognosis of adults with lobar and 
non-lobar ICH differ and (c) the neuroimaging correlates of small vessel disease in 
adults with lobar and non-lobar ICH differ since this might provide clues to the 
vasculopathies underlying lobar and non-lobar ICH. I explored (d) the strength of the 
association between CAA and ICH by systematically reviewing neuropathological case 
control studies and (e) the radiological and pathological features of lobar ICH to 
examine the nature of CAA in persons with lobar ICH and whether any computed 
tomography (CT) features of ICH are associated with CAA-related lobar ICH. 
I set up a prospective, community-based inception cohort study of adults with ICH in 
South East Scotland. Adults with spontaneous primary definite ICH had the 
opportunity to consent to participate in the Lothian Study of IntraCerebral 
Haemorrhage, Pathology, Imaging and Neurological Outcome (LINCHPIN), an 
ethically-approved, prospective community-based research study examining the causes 
of ICH using apolipoprotein E genotyping, brain MRI and research autopsy in case of 
death.  
Of 128 adults with first-ever spontaneous primary definite ICH diagnosed during 2010-
2011, age and pre-morbid hypertension did not differ by ICH location but a history of 
dementia was more common in adults with lobar ICH.  The proportion of adults with 
one or more non-lobar brain microbleed (BMB) was significantly higher in adults with 
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non-lobar ICH but I did not find any other differences in the severity or distribution of 
other neuroimaging correlates of small vessel disease between lobar and non-lobar ICH.  
The apolipoprotein ε4 allele was more common in participants with lobar ICH in 
comparison to those with non-lobar ICH but the frequency of the ε2 allele did not 
differ by ICH location.  Adults with lobar ICH were significantly more likely to survive 
one year after their ICH in comparison to those with non-lobar ICH after adjustment 
for other known predictors of outcome.  
From a systematic review of neuropathological case control studies of CAA and ICH, 
stratified by ICH location, I found a significant association between CAA and lobar 
ICH but not with ICH in other locations. I examined the radiological and pathological 
features of 33 adults with first-ever lobar ICH.  The presence of CAA or vasculopathy 
and the severity of CAA in a lobe affected by ICH was concordant with that of the 
corresponding contralateral unaffected lobe.  Capillary CAA was associated with severe 
CAA.  Subarachnoid extension of the ICH tended to be more frequent in those with 
CAA-related strictly lobar ICH. 
Having explored the incidence, risk factors and prognosis of lobar and non-lobar ICH, 
in future work I would aim to establish the strength of the association between CAA 
and ICH in different brain locations in a neuropathological case control study.  Future 
work should examine the radiopathological features of lobar ICH in a larger cohort and 
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1 Introduction 
1.1 Intracerebral haemorrhage 
1.1.1 The importance of intracerebral haemorrhage 
Stroke is the third commonest cause of death worldwide, after ischaemic heart disease 
and all cancers, combined [Strong, Mathers, & Bonita 2007;Lozano et al. 2013].  
Intracerebral haemorrhage (ICH) accounts for ∼15% stroke in the UK [Lovelock, 
Molyneux, & Rothwell 2007] and two million [Sudlow & Warlow 1997] of about 15 
million strokes globally each year.  As the incidence of ICH increases with age [van 
Asch et al. 2010], and the world’s population continues to age, there will be an 
increasing demand placed on stroke services [Di Carlo A. 2009]. 
Spontaneous non-traumatic ICH results from the rupture of blood vessels into the brain 
parenchyma.  The ICH is not thought to have been caused by a head injury [Steiner et 
al. 2011].   
ICH should be distinguished from other types of intracranial haemorrhage [Al-Shahi 
Salman, Labovitz, & Stapf 2009] including subarachnoid haemorrhage, pure 
intraventricular haemorrhage, subdural haemorrhage and extradural haemorrhage 
although an ICH may extend into one or more of these intracranial compartments 
(Figure 1 on page 52).  The relevance of this distinction is that the risk factors, causes 
and management options for each differ [Al-Shahi Salman, Labovitz, & Stapf 2009].  
1.1.2 Incidence 
A systematic review and meta-analysis of population-based studies of ICH found that 
the overall incidence of ICH was 24.6 per 100 000 person-years (95% confidence 
interval [CI] 19.7-30.7) [van Asch et al. 2010].  Five population-based studies [Broderick 
1993;Inagawa et al. 2003;Labovitz et al. 2005;Zahuranec et al. 2006;Lavados et al. 2010] 
which quantified the incidence of lobar and non-lobar ICH found an excess of non-
lobar in comparison to lobar ICH and one study found a higher incidence of lobar ICH 
[Tatu et al. 2000]. 
  Chapter 1 
34 
1.1.3 Prognosis 
Based on a recent meta-analysis, the one month case fatality following primary ICH is 
40% [van Asch et al. 2010].  The pooled one year survival estimate from nine 
population-based studies is 46% [Poon, Fonville, & Al-Shahi Salman 2013].   
Two studies [Nilsson et al. 2002;Sacco et al. 2009], one of which was population-based 
[Sacco et al. 2009], have reported lower one year survival in those with lobar ICH in 
comparison to supratentorial deep ICH although this was not reported by two other 
hospital-based studies [Faught et al. 1989;Franke et al. 1992].   
The recurrence rate of all strokes in survivors of primary ICH is 4% per person-year 
[Bailey et al. 2001a].  In two studies of 696 patients, the recurrence rate of lobar ICH 
was higher than that of non-lobar ICH [Poon, Fonville, & Al-Shahi Salman 2013].  This 
may support lobar and non-lobar ICH having different contributory causes; lobar ICH 
may be more strongly associated with cerebral amyloid angiopathy (CAA) than non-
lobar ICH (Chapter 9). 
1.1.4 Classification of ICH 
1.1.4.1 Primary vs. secondary ICH 
ICH has been traditionally classified as either ‘primary’ or ‘secondary’ [Al-Shahi Salman, 
Labovitz, & Stapf 2009].  
Primary ICH has no detectable underlying secondary cause [Ikram, Wieberdink, & 
Koudstaal 2012] and is commonly attributed to a presumed small vessel vasculopathy, 
most commonly arteriolosclerosis or CAA.  This decision is usually made on the basis 
of an adult’s risk factors and the clinical and radiological features of the ICH 
[Cordonnier et al. 2010a].   
Secondary ICH is attributable to a variety of structural causes including tumours, arterial 
aneurysms, intracranial venous thrombosis, arteriovenous malformations (AVMs), 
systemic diseases such as vasculitis and haemostatic disorders [Warlow et al. 2008;Al-
Shahi Salman, Labovitz, & Stapf 2009].   
Approximately 80% ICH are ‘primary’ [Warlow et al. 2008] although in practice, 
determining whether an ICH is ‘primary’ or ‘secondary’ will also be dependent upon the 
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extent to which a clinician investigates a patient for secondary causes and is therefore 
subject to detection bias [Cordonnier et al. 2010a]. 
1.1.4.2 SMASH-U classification 
The recent SMASH-U classification subdivides ICH into one of the following causes: 
Structural, Medication (antithrombotic medications, intravenous thrombolysis), Amyloid 
angiopathy, Systemic or other disease (except for anticoagulation, hypertension or 
CAA), Hypertension and Undetermined [Meretoja et al. 2012].  Although it has been 
validated in a retrospective notes review and shown to have good inter-observer 
agreement, each category is mutually exclusive which is unlikely to be representative of 
ICH in clinical practice where one or more causes may overlap. 
A single ICH may be the result of several factors [Warlow et al. 2008]; for example: 
predisposing risk factors such as older age, male sex, hypertension and high alcohol 
consumption [Ariesen et al. 2003], precipitants such as antithrombotic medications or 
structural causes.  One such example is an elderly patient with a past history of 
ischaemic heart disease for which he is prescribed aspirin and hypertension who is 
admitted with an ICH.  Both antithrombotic use and hypertension are risk factors 
[Ariesen et al. 2003;Gorelick & Weisman 2005] which are likely to have contributed to 
their ICH.  Even in patients with a known structural cause such as an aneurysm, other 
factors such as hypertension contribute to the risk of rupture [Rinkel 2005]. 
1.1.5 Lobar vs. non-lobar ICH 
Supratentorial ICH is typically subdivided by location as ‘lobar’ or ‘deep’, where deep 
commonly refers to ICH involving the basal ganglia and/or thalamus [Warlow et al. 
2008].  The assumption underlying this is that the risk factors and causes of lobar and 
deep ICH may differ.  Lobar ICH in the elderly is commonly attributed to CAA 
[Viswanathan & Greenberg 2011] and deep ICH  is attributed to hypertension-related 
arteriolosclerosis [Cordonnier et al. 2010a].  The location of the ICH has also been used 
to classify cause; that is lobar ICH is labelled as probable ‘CAA-related’ and non-lobar 
ICH as probable ‘hypertension-related’ [Arima et al. 2010], although this 
dichotomisation is likely to be too simplistic since any single ICH is likely to be caused 
by several factors.    
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1.1.5.1 Previous definitions of lobar ICH 
Of 41 observational studies which have compared lobar vs. other types of ICH, 20 did 
not define lobar location [Brott, Thalinger, & Hertzberg 1986;Fieschi et al. 1988;Franke 
et al. 1992;Berlit & Tornow 1994;Graffagnino et al. 1994;Giroud et al. 1995;Greenberg 
et al. 1996;Rosenow et al. 1997;Inagawa et al. 2003;Karapanayiotides et al. 
2004;Labovitz et al. 2005;Zahuranec et al. 2006;Zia et al. 2006;Seifert et al. 2006;Telman 
et al. 2010;Kuramatsu et al. 2011;Ruiz-Sandoval et al. 2011;Matsukawa et al. 2012;Chen 
et al. 2012;Hu, Wang, & Luo 2013] and 21 used various definitions of ‘lobar’ ICH, 
including ICH which was: cortical and/or subcortical [Broderick 1993;Anderson et al. 
1994;Nilsson et al. 2000;Bilbao et al. 2005;Weimar et al. 2011;Biffi et al. 2011b], or 
cerebellar [Pezzini et al. 2013], predominantly cortical and/or  involving underlying 
white matter [Woo et al. 2002;Tveiten et al. 2012;Martini et al. 2012], subcortical or in a 
hemisphere excluding the basal ganglia or thalamus [Lipton et al. 1987;Massaro et al. 
1991;Boonyakarnkul et al. 1993] or in any lobe(s) of the brain [Radberg, Olsson, & 
Radberg 1991;Yaqub et al. 1991;Ruiz-Sandoval, Cantu, & Barinagarrementeria 
1999;Tatu et al. 2000;Sacco et al. 2009;Lavados et al. 2010;Jamieson et al. 2012;Arboix & 
Grive 2012].   
1.1.5.2 Previous definitions of non-lobar ICH 
There may be more of a consensus regarding how to define non-lobar ICH.  Of 28 
studies which defined ‘non-lobar’ ICH, 20 defined ‘non-lobar’ as involving the basal 
ganglia or infratentorial regions [Brott, Thalinger, & Hertzberg 1986;Lipton et al. 
1987;Massaro et al. 1991;Radberg, Olsson, & Radberg 1991;Yaqub et al. 
1991;Boonyakarnkul et al. 1993;Greenberg et al. 1996;Rosenow et al. 1997;Ruiz-
Sandoval, Cantu, & Barinagarrementeria 1999;Tatu et al. 2000;Inagawa et al. 
2003;Zahuranec et al. 2006;Lavados et al. 2010;Weimar et al. 2011;Ruiz-Sandoval et al. 
2011;Biffi et al. 2011b;Matsukawa et al. 2012;Arboix & Grive 2012;Tveiten et al. 
2012;Pezzini et al. 2013], seven included deep periventricular white matter [Broderick 
1993;Anderson et al. 1994;Nilsson et al. 2000;Woo et al. 2002;Bilbao et al. 
2005;Jamieson et al. 2012;Martini et al. 2012] and one included ‘subcortical’ structures 
[Sacco et al. 2009]. 
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1.1.5.3 Mixed ICH 
‘Mixed’ ICH, involving both lobar and deep regions of the brain has only been 
accounted for in six studies [Fieschi et al. 1988;Boonyakarnkul et al. 1993;Anderson et 
al. 1994;Bilbao et al. 2005;Telman et al. 2010;Biffi et al. 2011b]. 
1.1.5.4 Definition of lobar and non-lobar ICH 
I have defined an ICH as lobar if it involves one or more lobes of the brain (Figure 2 on 
page 53).  The following ICHs are lobar: 
• a single ICH involving any of the following areas: frontal, frontotemporal, 
frontoparietal, parietal, parieto-temporal, parieto-occipital, temporal, temporo-
occipital or occipital or 
• an ICH which involves both lobar and supratentorial ‘deep’ regions of the brain or 
• multiple ICHs in either solely lobar locations or where at least one ICH involves a 
lobar location. 
I have defined an ICH as non-lobar if it does not extend to a lobar area (Figure 3 on 
page 54).  The following ICHs are non-lobar: 
• a single infratentorial ICH (involving the brainstem and/or cerebellum) or 
• a single supratentorial deep ICH (involving the basal ganglia, internal capsule, 
external capsule and/or thalamus) or 
• multiple ICHs in solely non-lobar locations (either supratentorial deep or 
infratentorial). 
1.1.5.5 Risk factors for lobar and non-lobar ICH  
Studies which have examined the risk factors for lobar and non-lobar ICH have 
reported conflicting results (Table 5 on page 140).  Four hospital based studies reported 
that female sex was more common in lobar ICH [Massaro et al. 1991;Weimar et al. 
2011;Matsukawa et al. 2012;Arboix & Grive 2012] and in seven studies (only one of 
which was population-based [Labovitz et al. 2005]) those with lobar ICH were older 
than non-lobar ICH [Graffagnino et al. 1994;Greenberg et al. 1996;Weimar et al. 
2011;Kuramatsu et al. 2011;Biffi et al. 2011b;Matsukawa et al. 2012].  Non-lobar ICH 
has been associated with Hispanic and Mexican-American ethnicity [Labovitz et al. 
2005;Zahuranec et al. 2006].   
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1.1.6 Diagnosis of ICH 
To date a scoring system to reliably clinically differentiate between ICH and infarction 
does not exist [Weir et al. 1994].  The only reliable method of detecting ICH in life is 
early brain imaging [Davenport & Dennis 2000].   
1.1.6.1 Computed tomography and magnetic resonance imaging 
The widespread availability of computed tomography (CT) in many countries and its 
rapid acquisition time makes it the first test an individual with a suspected stroke might 
have following their initial presentation.  The CT imaging characteristics of ICH are 
determined by the extent to which X-rays are attenuated by the haematocrit and 
haemoglobin content of the ICH [Kidwell & Wintermark 2008].  In the hyperacute and 
acute phases the ICH is hyperdense in comparison to the brain parenchyma.  The 
density of the haematoma increases in the first seven days with clot retraction and 
extrusion of serum [Chewning & Murphy 2010].  It then becomes less dense due to lysis 
of red blood cells and haemoglobin, so that within weeks it is indistinguishable from an 
infarct [Kidwell & Wintermark 2008]. 
Early studies of magnetic resonance imaging (MRI) for the diagnosis of ICH suggested 
that MRI was insensitive for the detection of acute blood, although this may have been 
related to the weak field strengths of the scanners used and a lack of haem-sensitive 
MRI sequences [Weingarten et al. 1991].  The strengths of MRI lie in its ability to 
distinguish ICH from haemorrhagic transformation of an infarct (HTI) using diffusion-
weighted imaging (DWI) [Lovelock et al. 2009] and the detection of chronic 
haemorrhages; since haem-sensitive gradient recalled echo (GRE) T2* images show 
haemosiderin-related signal drop-out in the majority of people indefinitely [Wardlaw & 
Statham 2000].  However, the use of MRI continues to be limited by both its availability 
and the difficulty using it in acutely unwell patients who have metal implants or a 
pacemaker, or are unable to lie flat for the scan duration [Kidwell & Wintermark 2008] 
(Chapter 6). 
1.1.6.2 Detection of secondary ICH 
Detection of a structural cause for an ICH may influence a patient’s management and 
prognosis.  There is no standardised imaging approach to detect structural lesions.  
Clinicians are more likely to investigate a patient with ICH if they are younger, do not 
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have a past history of hypertension or have ICH in a lobar location [Cordonnier et al. 
2010a].  However, the diagnostic utility studies on which these assumptions are based 
have been small, retrospective and suffered from both selection and work-up biases 
[Laissy et al. 1991;Zhu, Chan, & Poon 1997;Yeung et al. 2009]. 
Non-contrast CT may reveal certain clues to a structural cause such as calcification or 
enlarged vessels along the margin of an ICH, suggestive of an AVM or an empty delta 
sign within the superior sagittal sinus [Lee 2002], suggesting cerebral venous sinus 
thrombosis.  These features have been combined with age (18-45 years = two points, 
46-70 years = one point,  ≥ 71 years= zero points), gender (female=one, male=zero) 
and neither a known history of hypertension or coagulopathy (Yes=one, No=zero) to 
form the secondary ICH score.  A total score of >two has 86% sensitivity and 72% 
specificity for the detection of vascular lesions [Delgado Almandoz et al. 2010], 
although the score is yet to be independently prospectively validated. 
MRI is helpful in demonstrating tumours and cerebral cavernous malformations 
(CCMs) [Steiner et al. 2006].  Although intra-arterial digital subtraction arteriography 
(IADSA) is regarded as the reference standard for the diagnosis of aneurysms and 
arteriovenous malformations [Chewning & Murphy 2010], its limited availability and 
small (∼0.7%) but appreciable risk of stroke [Cloft, Joseph, & Dion 1999;Willinsky et al. 
2003], make it unsuitable for use in every case of ICH.   
Non-invasive angiographic techniques (CT angiography, MR angiography) have 90% 
sensitivity for the detection of aneurysms larger than three millimetres when compared 
to IADSA in patients with subarachnoid haemorrhage or patients without a known 
aneurysm but with symptoms that could be attributed to an aneurysm [White, Wardlaw, 
& Easton 2000].  CT angiography and venography have been shown to have 100% 
sensitivity (95% CI 92%-100%) and 99% specificity (95% CI 94%-100%) in comparison 
to IADSA for the diagnosis of intracranial vascular malformations [Wong et al. 2011].  
1.2 What causes spontaneous primary ICH?  
Hypertension-related arteriolosclerosis and CAA are commonly thought to be the main 
contributory factors causing spontaneous primary ICH.  In the following section I will 
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outline the early pathological studies of arteriolosclerosis and describe the clinical, 
pathological and genetic basis of CAA. 
1.2.1 Arteriolosclerosis 
In 1868 Charcot and Bouchard first noted tiny (250-400 micrometre) outpouchings 
from the walls of cerebral blood vessels at autopsy in individuals who had died from 
ICH [Charcot & Bouchard 1868].  The outpouchings were preferentially seen in the 
thalamus and basal ganglia.  They termed these ‘miliary aneurysms’ and postulated that 
these were the source of bleeding.  Nearly a century later, in an autopsy study of 54 
cases, Ross Russell replicated these findings, and by comparing cases with and without 
hypertension (defined as an initial diastolic recording on hospital admission of at least 
110mmHg), found that the aneurysms were associated with hypertension [Ross Russell 
1963]. 
The role  of these aneurysms remains contentious since it has rarely been possible to 
link an ICH to the rupture of a particular aneurysm [Caplan 1992].  In 1971, Miller-
Fisher published the findings from a case series of three patients with putaminal and 
pontine ICH in which he had identified multiple sources of bleeding [Fisher 1971].  He 
also noted degenerative changes of arteriolosclerosis, manifesting as both fibrinoid 
necrosis and segmental disorganisation with thickening of the walls of deep perforating 
arterioles.  The latter was later called ‘lipohyalinosis’, because lipid containing 
macrophages within the wall stained readily for fat.  Although other studies [Ooneda et 
al. 1973] have reported these changes and aneurysms in patients with so called 
‘hypertensive ICH’ studies have been small case series which have not defined 
hypertension.   
1.2.2 Clinical manifestations of cerebral amyloid angiopathy 
In the 1970s clinicopathological case reports and case series first noted the co-existence 
of CAA in individuals with ICH [Vinters 1987].  Since then, there have been several case 
control and cross-sectional studies which have noted an association between CAA and 
lobar ICH (Chapter 9). 
ICH attributable to CAA has been postulated to be multiple [Gilles et al. 1984;Zhan et 
al. 2004], recurrent [Zhan et al. 2004] and associated with dementia [McCarron et al. 
1999b] but studies have been small case series [Gilles et al. 1984;McCarron et al. 1999b], 
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hospital-based [Zhan et al. 2004] and lacked standardised methods for assessing CAA 
[Gilles et al. 1984;McCarron et al. 1999b;Zhan et al. 2004].  
There are at least three other manifestations of CAA: cognitive impairment, transient 
focal neurological symptoms and rapidly progressive cognitive and neurological decline. 
Two population-based studies have confirmed an association between pathologically 
proven CAA and dementia [Neuropathology Group of the Medical Research Council 
Cognitive Function and Ageing Study (MRC CFAS) 2001;Pfeifer et al. 2002], which 
remains after adjustment for age, brain weight, neurofibrillary tangles, neuritic plaques, 
Lewy bodies and hippocampal atrophy [Matthews et al. 2009].  There is only one study 
of the nature of cognitive impairment found in CAA which showed that moderate to 
severe CAA was associated with decreased perceptual speed and episodic memory 
although not other cognitive domains [Arvanitakis et al. 2011]. 
 There has been an increasing number of case series in recent years of persons with 
recurrent episodes of transient stereotyped positive or negative neurological symptoms 
[Okazaki, Reagan, & Campbell 1979;Raposo et al. 2011].   A subsequent MRI brain scan 
with T2*-weighted imaging may show lobar ICH in up to three quarters of patients, 
brain microbleeds (BMBs) in a lobar distribution or cortical subarachnoid haemorrhage, 
suggestive of CAA [Charidimou et al. 2012].  Of note however, is that as yet there have 
been no larger prospective studies of this phenomenon which have correlated clinical 
and radiographic with pathological findings. 
Rarely, CAA may present as Aβ-related angiitis (also called CAA-related inflammation) 
with rapid cognitive decline, headache, behavioural changes, seizures and focal 
neurological deficits [Scolding et al. 2005].  MRI may show extensive white matter 
hyperintensities on T2-weighted sequences or FLAIR but for a definitive diagnosis brain 
biopsy or autopsy is required showing CAA within the vessels of the affected area and 
perivascular or transmural inflammation [Chung et al. 2011]. 
1.2.3 Neuroimaging correlates of cerebral amyloid angiopathy 
The neuroimaging correlates of CAA on MRI include BMBs, superficial siderosis and 
cortical subarachnoid haemorrhage. 
BMBs are small hypointense foci on T2*-weighted haem-sensitive MRI sequences and 
BMBs in a strictly lobar distribution are thought to be a biomarker of CAA (Chapter 6).  
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Superficial siderosis is defined as superficial, cortical, linear deposits of haemosiderin on 
T2*-weighted images [Linn et al. 2008] and is distinguished from convexity 
subarachnoid haemorrhage in which the bleeding extends into the adjacent 
subarachnoid space without involvement of adjacent parenchyma, interhemispheric 
fissure, basal cisterns or ventricles [Kumar et al. 2010].   
Both superficial siderosis and subarachnoid haemorrhage have been associated with 
CAA on the basis of case reports [Karabatsou 2007;Linn et al. 2008], hospital-based 
retrospective case series [Kumar et al. 2010;Charidimou et al. 2012] and cross-sectional 
studies [Linn et al. 2010] in which the diagnosis of CAA has typically been made using 
MRI imaging without pathological confirmation of CAA [Kumar et al. 2010;Charidimou 
et al. 2012].  In one retrospective study of 60 participants which compared ICH 
attributed to pathologically-confirmed CAA vs. ICH without CAA, superficial siderosis 
was detected in 61% participants with CAA-related ICH and none of those without 
CAA [Linn et al. 2010], but the study used a highly selective cohort with no mention of 
the time interval between the ICH and imaging, despite the imaging appearances of 
haemorrhage being known to change over time [Kidwell & Wintermark 2008].  More 
recently, disseminated superficial siderosis (involving more than three sulci) has been 
associated with an increased risk of symptomatic lobar ICH in those with CAA 
[Charidimou et al. 2013d] diagnosed according to the Boston criteria [Knudsen et al. 
2001].   
Larger prospective studies using haem-sensitive MRI sequences performed at a standard 
time interval after presentation with pathological correlation are needed, especially since 
superficial siderosis is not unique to CAA and may be seen in brains without 
pathologically proven CAA [De Reuck et al. 2013]. 
1.2.4 Ante-mortem diagnosis of cerebral amyloid angiopathy 
The reference standard for the diagnosis of CAA is pathological confirmation using 
biopsy or autopsy specimens.  Since participants with ICH may not undergo surgery and 
with a declining number of autopsies in recent years [Kretzschmar 2009], efforts have 
been made to develop criteria for the ante-mortem diagnosis of CAA which utilise not 
only pathological findings but other clinical and radiographic features of the ICH.  The 
Boston criteria for the diagnosis of ‘CAA-related ICH’ categorise first-ever or recurrent 
lobar ICH as definite, probable or possible CAA-related ICH by using pathological 
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findings if available, radiographic features such as multiple ICHs or BMBs and clinical 
features such as the absence of coagulopathy [Knudsen et al. 2001]. 
1.2.5 Definition of cerebral amyloid angiopathy 
Although the definition of a disease entity is traditionally described before its clinical 
and imaging features, I define CAA at this point, since it is by using this definition that 
the subtypes (Section 1.2.7, page 44), genetic basis (Section 1.2.7, page 44) and 
pathogenesis (Section 1.2.9, page 46) of CAA are understood. 
CAA is an ‘umbrella’ term which describes a group of diverse disorders [Revesz et al. 
2009], unified by the pathological findings of deposition of amyloid fibrils in 
leptomeningeal and cortical arteries, arterioles, capillaries and rarely veins; sometimes 
associated with additional spread into the adjacent neuropil [Attems 2005].  ‘Amyloid’ is 
a morphological term referring to at least 20 different proteins [Attems 2005] which 
form insoluble fibrils that unite in a β-pleated sheet structure.   
CAA is thought to be distinct from systemic amyloidoses, in part because some 
amyloidogenic precursor proteins are too large to diffuse across the blood brain barrier 
[Banks 2009;Sattianayagam, Hawkins, & Gillmore 2009].  It is not associated with senile 
systemic amyloidosis [Tanskanen et al. 2006].  Although amyloid-beta (Aβ) is found 
both in the systemic circulation and in the cerebrospinal fluid (CSF) and brain interstitial 
fluid, most Aβ is derived from neurons (Section 1.2.9.4, page 47) and transgenic mice 
which produce increased amounts of systemic Aβ do not develop cerebral Aβ deposits, 
providing further evidence against CAA being derived from systemic Aβ 
[Kawarabayashi et al. 1996].  
The most common form of CAA is due to Aβ protein [Revesz et al. 2009] and I will 
focus on the subtypes, genetic risk factors and pathology of Aβ CAA below. 
1.2.6 Amyloid precursor protein and Aβ 
Aβ protein is derived from amyloid precursor protein (APP); the gene for which is sited 
on the long arm of human chromosome 21.  The function(s) of APP in the central 
nervous system are not well described, although evidence from in vitro studies suggests 
that APP may function as a cell surface receptor [Zheng & Koo 2011] and mediate the 
adhesion and growth of neurons and non-neuronal cells [Coughlan & Breen 2000].   
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Aβ protein is routinely produced by many cell types.  It is thought that Aβ may regulate 
synapses; that is, increases in neuronal activity lead to increased production of Aβ which 
then via a negative feedback loop reduce synaptic function [Pena et al. 2006].  
Consistent with this, Aβ has been shown to reduce glutamatergic transmission by 
reducing the expression of NMDA receptors in neurons in vitro [Snyder et al. 2005]. 
Unlike the parenchymal Aβ plaques found in Alzheimer’s dementia which are 
predominantly composed of Aβ of 42 amino acid length (Aβ42), vascular Aβ largely 
consists of a shorter more soluble Aβ fragment which is 40 amino acids long (Aβ40) and 
has a higher Aβ40:Aβ42  ratio than in an Aβ plaque [Roher et al. 1993;Attems, Lintner, & 
Jellinger 2004].  
1.2.7 Sporadic and Hereditary CAA 
Aβ-CAA may be sporadic or hereditary.  Hereditary CAA may result from mutations of 
the APP gene or mutations of genes which control the processing of APP or Aβ within 
the brain or chromosomal abnormalities such as trisomy 21 (Down’s syndrome) since 
the extra copy of the APP gene leads to increased APP, Aβ40 and Aβ42 [McCarron, 
Nicoll, & Graham 1998]. 
1.2.7.1 Sporadic CAA 
The majority of Aβ-CAA is sporadic.  It rarely occurs under the age of 50 years [Masuda 
et al. 1988] and its prevalence increases each decade and approaches 50% in those aged 
90 years and above [Masuda et al. 1988;Neuropathology Group of the Medical Research 
Council Cognitive Function and Ageing Study (MRC CFAS) 2001].  Males and females 
are equally affected.  The prevalence of CAA varies from 21% in a population-based 
cohort [Neuropathology Group of the Medical Research Council Cognitive Function 
and Ageing Study (MRC CFAS) 2001] to 80% in hospital based cohorts of patients with 
Alzheimer’s dementia [Mandybur 1975;Esiri & Wilcock 1986] and is significantly higher 
than in controls of a similar age without dementia [Neuropathology Group of the 
Medical Research Council Cognitive Function and Ageing Study (MRC CFAS) 2001].  
CAA is also more severe in those with Alzheimer’s dementia compared to controls 
without [Yamada 2002]. 
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1.2.7.2 Hereditary CAA due to Aβ deposition 
Missense mutations of the APP gene can occur either within or outside the coding 
region of the Aβ peptide.  Mutations within the coding region of the peptide lead to a 
phenotype in which CAA is prominent [Revesz et al. 2009], one example of which is 
Hereditary Cerebral Haemorrhage with Amyloidosis of Dutch type (HCHWA-D) 
characterised by recurrent lobar ICH and dementia [Bornebroek et al. 1996].  Mutations 
outside the coding region lead to clinicopathological phenotypes of early onset 
Alzheimer’s dementia [Revesz et al. 2009]. 
1.2.7.3 Genetic risk factors for sporadic CAA 
The most well known genetic risk factor for CAA is apolipoprotein E although other 
gene polymorphisms implicated in Alzheimer’s dementia are also known risk factors for 
CAA such as presenilin-1 and neprilysin. 
The apolipoprotein E gene codes for a protein of the same name, which is expressed in 
several organs including the liver and the brain.  The protein assists in the transport of 
triglycerides to the liver.  In the brain, astrocytes and microglia express apolipoprotein E 
which functions as a ligand to assist in the endocytosis of lipoproteins [Kim, Basak, & 
Holtzman 2009].  
The epsilon form of the apolipoprotein gene, is contained on the long arm of 
chromosome 19 [Verghese, Castellano, & Holtzman 2011].  Single base changes in the 
gene determine the three common alleles ε2, ε3 and ε4 [Zannis et al. 1982] and lead to 
changes in the function of the resulting protein isoforms.  The E4 isoform may 
accelerate the formation of Aβ plaques by acting as an Aβ binding protein [Wisniewski 
& Frangione 1992]. 
The ε2 and ε4 alleles are both associated with sporadic Aβ-CAA [Verghese, Castellano, 
& Holtzman 2011] with the ε4 allele having a dose-dependent effect on CAA severity 
[Premkumar et al. 1996]. 
Neprilysin is a proteolytic enzyme responsible for the catabolism of Aβ in the brain and 
inhibition of the enzyme leads to increased accumulation of Aβ42 in rat brains [Iwata et 
al. 2000].  Moreover increased CAA severity has been associated with decreased 
neprilysin activity in human brain tissue [Miners, Kehoe, & Love 2011].  Mutations of 
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presenilin-1, a protein involved in the processing of APP, can lead to early-onset familial 
Alzheimer’s dementia [Sherrington et al. 1995].  One small study showed an association 
between presenilin-1 polymorphisms and CAA severity [Yamada et al. 1997] although 
this requires further exploration. 
1.2.8 A historical perspective 
The earliest report of CAA is likely to be by Oppenheim [Oppenheim 1909] when he 
described ‘drusige Nekrosen’ (translated as gland-like necrosis) in the brain parenchyma 
adjacent to hyalinised capillary walls in six out of 14 brains of individuals with dementia 
and the pathological changes of Alzheimer’s disease.  Scholz published the first study of 
CAA in 1938 [Scholz 1938].  In 15 of 104 autopsied brains he noted an abnormality of 
the cerebral blood vessels and immediately adjacent brain parenchyma with the 
morphological and staining properties of ‘drusige Entartung’ (literally glandular 
degeneration) and postulated that this might be amyloid. 
Sixteen years later Pantelakis provided the first description of CAA limited to the blood 
vessels without adjacent parenchymal involvement and coined the term ‘congophilic 
angiopathy’ because it appeared apple green when stained with Congo Red and viewed 
under polarised light [Pantelakis 1954]. 
1.2.9 Pathology of cerebral amyloid angiopathy 
1.2.9.1 Morphology 
Severe CAA is visible as acellular thickening of blood vessel walls on haematoxylin and 
eosin stained tissue sections although this appearance is non-specific, occurring with 
other small vessel diseases such as arteriolosclerosis [Attems 2005].  Stains for Aβ 
include Thioflavin S or T (which fluoresce under ultraviolet light) and Congo Red.  In 
recent years immunohistochemical stains for Aβ have become more widely used 
because they offer greater standardisation and increase the specificity of diagnoses as 
accumulation of abnormal proteins can be detected with morphology and location 
[Dickson 2005].   
CAA deposition is progressive, initially occurring in the tunica media of the blood vessel 
wall.  In the early stages, the vessel wall structure remains intact but as the severity of 
CAA increases, there is loss of smooth muscle cells as Aβ infiltrates all layers of the 
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wall.  With severe CAA the vessel wall splits akin to an onion skin (so called ‘double 
barrelling’) and leakage of Aβ into the neuropil may occur (Figure 4 on page 55) 
[Attems 2005].  
1.2.9.2 Pathological subtypes of CAA 
Cross-sectional studies of patients with Alzheimer’s dementia and controls suggest that 
there are two subtypes of CAA: CAA type one, which is characterised by the presence 
of CAA in capillaries with or without CAA in larger vessels and CAA type two, which is 
restricted to leptomeningeal and cortical arteries, arterioles and occasionally veins [Thal 
et al. 2002a].  Although the presence of capillary CAA has been associated with more 
extensive Aβ plaques deposition in Alzheimer’s dementia [Thal et al. 2010], most studies 
have taken place in the setting of dementia and the significance of it in those with ICH 
is yet to be determined.   
1.2.9.3 Distribution of CAA 
Sporadic CAA is thought to preferentially distribute in the occipital lobes followed by 
either frontal, temporal or parietal lobes but studies have had differing results [Mann et 
al. 2001], been limited by a lack of blinding of neuropathologists to sampling location 
[Yamada et al. 1987;Premkumar et al. 1996;Pfeifer et al. 2002;Tian et al. 2003;Tian et al. 
2004;Attems, Jellinger, & Lintner 2005], variation in the assessment of CAA severity 
with no assessment of inter-observer agreement [Yamada et al. 1987;Premkumar et al. 
1996;Pfeifer et al. 2002;Tian et al. 2003;Attems, Jellinger, & Lintner 2005] and sampling 
bias [Tian et al. 2003].  The basal ganglia, thalamus, cerebellum and brainstem are less 
frequently affected [Attems 2005].   
Although Aβ plaques in Alzheimer’s dementia appear to be deposited sequentially with 
the plaques initially seen in the neocortex, followed in order by the allocortex, 
diencephalon and striatum, brainstem nuclei and cerebellum [Thal et al. 2002b], 
sequential deposition of CAA is yet to be proven.   
1.2.9.4 Pathogenesis of CAA 
Several transgenic mouse models exist that carry human gene mutations known to cause 
hereditary Aβ-CAA.  The APPDutch mouse has an APP gene containing the familial 
Alzheimer’s disease mutation E693Q leading to a phenotype with prominent CAA and 
  Chapter 1 
48 
rarely any Aβ plaques [Herzig et al. 2004].  The Tg2576 mouse overexpresses a human 
APP transgene containing the Swedish familial Alzheimer’s disease mutation [Hsiao et 
al. 1996] leading to increased expression of human APP above the levels of endogenous 
mouse APP and consequent increased production of both parenchymal and vascular Aβ 
[Shin et al. 2007].  The Tg-SWDI mouse expresses the human Swedish, Dutch and Iowa 
mutations in the APP gene [Davis et al. 2004], leading to production of Dutch/Iowa 
mutant Aβ and subsequent development of early onset and progressive capillary CAA 
[Davis et al. 2004].   
The greatest limitation of murine models is that their generalisability to humans is 
limited.  Even with prominent CAA, ICH may not occur in APPDutch mice and does 
not occur in Tg2576 and Tg-SWDI mice [Herzig, Van Nostrand, & Jucker 2006].  In 
Tg-SWDI mice, CAA occurs in a different distribution (thalamic and subiculum regions) 
to that seen in humans [Davis et al. 2004] and CAA occurs in these animals when they 
are younger than humans who may also have multiple comorbidities.   
Despite these caveats, they have provided the following valuable insights into the 
pathogenesis of sporadic Aβ-CAA. 
(i) Most vascular Aβ  is derived from neurons [Herzig, Van Nostrand, & Jucker 
2006].  Previous hypotheses regarding the pathogenesis of CAA proposed that 
Aβ in vessel walls may have derived from vascular smooth muscle cells.  
However, mice that overexpress human Aβ solely in neurons develop CAA 
[Calhoun et al. 1999] and CAA can occur in capillaries that do not have smooth 
muscle cells [Herzig, Van Nostrand, & Jucker 2006]. 
(ii) CAA is likely to result from reduced Aβ clearance through perivascular 
lymphatic drainage pathways in the brain [Weller et al. 2008].  CAA may 
result from increased production of Aβ or decreased clearance.  Although 
several gene or chromosomal defects (for example: mutations in presenilin-1 
and presenilin-2 [Revesz et al. 2009] or Down’s syndrome [Naito, Sekijima, & 
Ikeda 2008]) lead to increased production of Aβ-CAA the majority of cases of 
CAA and Alzheimer’s dementia are sporadic [Nicoll et al. 2004] and therefore 
not accounted for by these mechanisms.  The drainage pathways of interstitial 
fluid and solutes have been outlined in transgenic mice.  If a fluorescent tracer is 
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injected into the mouse brain it rapidly reaches and delineates the perivascular 
lymphatic pathways [Carare et al. 2008].  Moreover, drainage of intracerebral 
injected solutes is impaired in ageing Tg2576 mice with CAA [Hawkes et al. 
2011]. 
(iii) Increases in the ratio of Aβ40: Aβ42 lead to increased vascular Aβ (rather 
than parenchymal Aβ) deposition.  This is shown by humans with HCHWA-
D and APPDutch mice who have a very high ratio of Aβ40:Aβ42 and develop 
severe CAA [Herzig et al. 2004].  However, Aβ40 alone may not be sufficient to 
develop CAA since mice that produce increased Aβ40 without Aβ42 do not 
develop CAA, whereas those which produce both Aβ40 and Aβ42 produce both 
CAA and parenchymal Aβ [McGowan et al. 2005]. 
(iv) Apolipoprotein ε4 increases the ratio of Aβ40:Aβ42  and promotes the 
formation of CAA in Tg2576 mice.  Tg2576 mice expressing the human 
apolipoprotein E4 isoform have prominent CAA with very little parenchymal 
Aβ in contrast to the combination of CAA and plaques seen in Tg2576 mice 
with murine apolipoprotein E [Fryer et al. 2005].   
1.2.10 Why might sporadic CAA be associated with lobar ICH?    
There are several reasons why sporadic CAA may be associated with lobar ICH.  Firstly, 
sporadic CAA is most common in the lobar regions of the brain (Section 1.2.9.3, page 
47).  Secondly, hereditary amyloidoses such as HCHWA-D cause recurrent lobar ICH 
[Bornebroek et al. 1996].  Thirdly, a plausible explanation for an association between 
CAA and lobar ICH might relate to the differing structures of the walls of cortical and 
deep arteries.  The tunica media of the walls of cortical arteries is adjacent to a single 
layer of leptomeninges which in turn is next to the perivascular glia limitans.  There is 
no expandable perivascular space.  In contrast, the deep arteries have a double layer of 
leptomeninges which functions as an expandable perivascular space (Figure 5 on page 
56) [Weller, Boche, & Nicoll 2009].  
Interstitial fluid and solutes are thought to drain out of the brain along the basement 
membranes in the walls of capillaries and arteries in the opposite direction to blood flow 
[Weller et al. 2009a].  It is postulated that each arterial pulsation produces a wave in the 
  Chapter 1 
50 
opposite direction which propels solutes out of the brain.  In older people, 
arteriolosclerosis leads to stiffening of the arterial walls [Nagasawa et al. 1979] which 
may reduce the elastic recoil of vessels, both reducing cerebral blood flow and 
compromising the drainage of solutes out of the brain.  The lobar regions may be more 
prone to CAA because they lack a perivascular space and therefore are more vulnerable 
to deposition of Aβ which cannot be drained.  
1.3 Aims of the thesis 
ICH continues to be a devastating condition with a high early case fatality, whose 
incidence is likely to increase in an ageing population.  If advances are to be made in the 
primary prevention and management of ICH, it will be essential to understand more 
about the risk factors and underlying causes of the condition.  This will require large 
clinico-radio-pathological prospective studies of ICH with comprehensive case 
ascertainment and careful phenotyping of participants. 
In June 2010 I set up a prospective community-based study of ICH in the Lothian 
region of Scotland with the aim of answering the following questions. 
• How should I design a community-based study of ICH? (Chapter 2) 
• What is the incidence of ICH in the Lothian region of Scotland and do the risk 
factors differ for lobar and non-lobar ICH? (Chapter 5) 
• What are the frequencies of definite, probable and possible CAA according to the 
Boston criteria in a community-based cohort of participants with lobar ICH? 
(Chapter 5) 
• Do neuroimaging correlates of CAA such as BMBs differ between lobar and non-
lobar ICH? (Chapter 6) 
• Which variables determine prognosis following ICH? (Chapter 7) 
• Does apolipoprotein E genotype differ between lobar and non-lobar ICH? 
(Chapter 8) 
• Does the presence of an ε2 or ε4 allele influence outcome following an ICH? 
(Chapter 8) 
• What is the strength of the association between CAA and ICH? (Chapter 9) 
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• Do any imaging features of lobar ICH on CT discriminate between ICH related to 
CAA and those which are unrelated to CAA? (Chapter 10) 
• What proportion of participants consent to a research autopsy limited to the brain 
and do any demographic or clinical factors differ in those who consent vs. those 
who do not? (Chapter 11) 
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Figure 1 Schematic diagram of the brain showing types of intracranial haemorrhage 
reproduced from [Al-Shahi Salman, Labovitz, & Stapf 2009] 
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Figure 2 Lobar ICHs 
A  Axial CT demonstrates a left frontal lobar ICH 
B  Coronal CT demonstrates a right frontal lobar (periventricular) ICH 
C  Axial CT demonstrates a right hemisphere lobar ICH with compression but no 
involvement of the right lentiform nucleus (arrow) 
D  Sagittal CT demonstrates a left frontoparietal lobar ICH 
E  Axial CT demonstrates a left hemisphere ICH involving both lobar and deep regions 
F  Axial CT demonstrates a right hemisphere ICH involving both lobar and deep regions  
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Figure 3 Non-lobar ICHs 
A   Axial CT demonstrates a left thalamic ICH 
B   Axial CT demonstrates multiple cerebellar ICHs 
C1 and C2 Multiple non-lobar ICHs in the same patient: C1 Axial CT demonstrates a left 
lentiform nucleus ICH and C2 Axial CT demonstrates an acute pontine ICH  
     
   
A B 
C1 C2 
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Figure 4 Progression of CAA (reproduced from [Attems 2005]) 
Normal: normal blood vessel wall 
Mild: some Aβ deposition within the tunica media but with preservation of smooth muscle 
cells in tunica media 
Moderate: Abundant Aβ deposition through all layers of blood vessel wall with loss of 
smooth muscle cells 
Severe: Blood vessel wall replaced by Aβ deposition 
Severe with double barrelling: Disruption and fragmentation of blood vessel wall 
Severe with dyshoric changes: Fragmentation of blood vessel wall leads to leakage of Aβ 
into the adjacent neuropil 
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Figure 5 Schematic diagram comparing structure of vessel walls of a cortical artery 
(A) and basal ganglia artery (B) (adapted from [Weller, Boche, & Nicoll 2009]) 
A  Cortical artery with a single outer layer of leptomeninges and no expandable perivascular 
space 
B Basal ganglia artery with a second layer of leptomeninges. A perivascular space 
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2 Methods of a prospective community-based study of intracerebral 
haemorrhage 
2.1 Introduction 
Although there have been a considerable number of incidence studies of spontaneous 
ICH, prior studies have had various limitations.  Studies have lacked a clear reproducible 
definition of ICH [van Asch et al. 2010], and frequently not distinguished primary from 
secondary ICH and first-ever from recurrent ICH (Chapter 1).  Comprehensive case 
ascertainment is essential for an incidence study of ICH [Sudlow & Warlow 1997].  ICH 
is one cause of sudden death which may occur before a person reaches hospital. Even 
population-based incidence studies of ICH which have reasonable case ascertainment 
methods often do not screen sudden deaths or deaths that occur soon after reaching 
hospital emergency departments, leading to potential under-ascertainment of cases [van 
Asch et al. 2010].  Measures of disease incidence will also be dependent upon defining 
and enumerating a stable population at risk [Sudlow & Warlow 1997], which ideally 
should be sufficiently large to obtain a precise estimate. 
Cross-sectional studies which have compared the risk factors for lobar and non-lobar 
ICH have reported inconsistent associations between risk factors such as dementia and 
hypertension and ICH (Chapter 1).  Studies have lacked both clear reproducible 
definitions of risk factors, based on a participant’s pre-ICH health status [Jackson & 
Sudlow 2006] and clear definitions of ICH location (Chapter 1). 
Therefore I set up a prospective, community-based observational cohort study (with 
nested cross-sectional comparisons) in Spring 2010 to study the incidence of 
spontaneous primary lobar and non-lobar ICH and its risk factors. 
Data collection started on 1st June 2010.  This chapter describes the study design, case 
ascertainment, definition of ICH and its date of onset and methods of data collection at 
baseline and during follow up.  I will illustrate the complexities in diagnosing 
spontaneous primary ICH using several case histories and describe the strengths and 
limitations of my methods of case ascertainment and follow up. 
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2.2 Study design 
2.2.1 Inclusion criteria 
I recruited patients if they met all of the following criteria. 
• First-ever or recurrent spontaneous (non-traumatic) ICH confirmed by brain 
imaging or pathology (biopsy or post-mortem examination) or sudden deaths where 
a diagnosis of ICH was suspected but the diagnosis remained unconfirmed.   
• Aged 16 years or over at the time of diagnosis. 
• Resident in the area served by the National Health Service (NHS) Lothian Health 
board at the time of the ICH. 
• Date of diagnosis 1st June 2010-31st May 2016. 
2.2.2 Exclusion criteria 
I excluded patients if they met any of the following criteria. 
• ICH definitely attributable to trauma. 
• Exclusively extra-axial intracranial haemorrhage.   
• ICH attributable to HTI. 
2.3 Study setting 
I recruited participants who were resident in the region served by the NHS Lothian 
Health board. The Registrar General for Scotland’s mid-2010 estimate for the 
population served by NHS Lothian is 836,711 of whom 695 335 were adults aged 16 
and above.  The population is stable with net migration of 8786 (population change 
+1%) from mid 2009 to mid 2010 (www.gro-scotland.gov.uk).  The sex ratio (male 
population divided by the female population) is 0.94.  
The region is served by three hospitals with emergency departments or acute medical 
receiving units in NHS Lothian (Western General Hospital, Edinburgh; Royal Infirmary 
of Edinburgh, or St John’s Hospital at Howden, West Lothian).  Each hospital provides 
acute in-patient stroke services with access to specialist stroke unit care.  There are rapid 
access neurovascular clinics for patients with suspected transient ischaemic attacks and 
strokes at the Western General Hospital and St John’s Hospital. 
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2.4 Sources of case ascertainment 
I used multiple overlapping sources of case ascertainment to identify all potentially 
eligible adults meeting our inclusion criteria.  I prospectively identified the majority of 
cases using a ‘hot pursuit’ model, enabling assessment of possible cases of ICH soon 
after their presentation to hospital.  I also used various retrospective sources to 
supplement my case ascertainment methods. 
 
2.4.1 Prospective sources of case ascertainment 
2.4.1.1 Screening of all CT brain scans 
I reviewed all CT brain scans done in the three hospitals in NHS Lothian.  On a 
Monday morning or following a public holiday, this included all brain scans done over 
the weekend or holiday period.  I reviewed radiology reports for scans when they were 
available.  
2.4.1.2 Collaborative network 
I developed a collaborative clinical network comprising consultants, trainee doctors and 
specialist nurses in the following specialties: stroke (n=17), neurology (n=25), 
neurosurgery (n=21), (neuro)radiology (n=15), neurorehabilitation (n=4), acute and 
general medicine (n=24), care of the elderly (n=7), emergency care (n=15), pathology 
(n=7) and stroke audit personnel (n=3).  Collaborators were able to notify us of 
potential cases in person, use a designated mobile telephone, fax to a designated NHS 
Sources of case ascertainment 
Prospective sources 
• Screening of all CT brain scans 
• Collaborative network 
• Multidisciplinary meetings 
Retrospective sources 
• Electronic patient records system 
• Office of the Procurator Fiscal 
• Liaison with stroke audit personnel 
• Centralised coding of hospital discharge data 
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office or email to a secure nhs.net email address.  Our collaborators received a monthly 
email reminder of the ongoing study and I placed study posters in their respective 
departments to encourage notification.  I also provided teaching sessions about 
intracerebral haemorrhage for medical and nursing staff and allied health professionals 
to increase awareness.  I updated our list of collaborators as staffing at the three 
recruiting hospitals changed. 
2.4.1.3 Multidisciplinary meetings 
I attended a daily multidisciplinary neuroradiology meeting (comprising neurologists, 
neurosurgeons and neuroradiologists.)  I also attended a weekly multidisciplinary stroke 
radiology meeting.  If I was unavailable, other doctors and stroke fellows notified me of 
patients.  
2.4.2 Retrospective sources of case ascertainment 
2.4.2.1 Electronic patient records system 
Each hospital attendance to one of the hospitals in NHS Lothian is recorded using an 
electronic patient records system called TRAK. Every six months I searched the system 
to identify patients who had either been brought in dead to the emergency department 
or acute medical receiving unit or who had died in any of these departments.  I screened 
the medical records of any patients listed.  I identified two groups of patients:  
(i) those who had died suddenly or soon after the onset of symptoms who had a 
confirmed diagnosis of ICH before death using brain imaging or at post-mortem 
examination; and 
(ii) those who had a history suggestive of stroke but died before they could undergo 
brain imaging and did not undergo post-mortem examination.  
I recorded these cases to ascertain the number of potentially eligible patients with ICH 
who might have been missed by the lack of further investigation. 
2.4.2.2 Office of the Procurator Fiscal 
In Scotland, the Crown Office and Procurator Fiscal Service is responsible for the 
investigation of sudden or suspicious deaths.  The Procurator Fiscal Service keeps paper 
records of all calls concerning sudden deaths made to the office and their subsequent 
outcomes.  The log includes both unexplained in-hospital and all out-of-hospital sudden 
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deaths referred to the Procurator Fiscal.  The Fiscal office may decide that there is 
sufficient clinical information available to issue a death certificate or if this is not 
possible, that a fiscal post-mortem examination is required.  The Procurator Fiscal office 
in Edinburgh receives all calls from the Lothian region.   
With the necessary approvals from the Procurator Fiscal, in October 2011 I searched 
their record of deaths from 1st June 2010-31st May 2011 to identify any sudden deaths 
confirmed as ICH at post-mortem examination and cases where an ICH or other type 
of stroke was suspected to be the primary cause of death.  If I identified a case of ICH 
which had been diagnosed at post-mortem examination, I recorded the fiscal post-
mortem examination number which allowed the post-mortem examination report to be 
obtained from the Pathology Department based in the Western General Hospital, 
Edinburgh. 
2.4.2.3 Liaison with stroke audit personnel 
The Scottish Stroke Care Audit was established in 2002 and audits the care of all stroke 
patients at hospitals with stroke services in Scotland.  The Scottish Stroke Care Audit 
ascertains cases using a variety of different methods including: screening registers of 
admissions to the emergency department and stroke units, screening of discharge 
summaries from stroke units, liaison with multidisciplinary stroke services, review of 
radiology reports and reviewing handover lists in medical, neurology and care of the 
elderly wards [Borthwick et al. 2005].  In addition, clinicians seeing patients in 
neurovascular outpatient clinics complete an audit form which includes the final 
diagnosis.  The audit codes ICH as ‘haemorrhagic stroke’ and distinguishes it from HTI 
or ischaemic stroke.  The audit does not include patients with subarachnoid 
haemorrhage.   
I liaised with stroke audit personnel weekly to ascertain cases from all three hospitals. 
Every six months during 1st June 2010-31st May 2011 I liaised with the audit personnel 
to cross-check their known cases of ICH with cases that I had identified.  
2.4.2.4 Centralised coding of hospital discharge data 
In NHS Lothian, every episode of hospital care is coded using the tenth revision of the 
International Classification of Diseases (ICD-10) to categorise the patient’s main 
diagnosis and comorbidities (up to six subsidiary diagnoses).  This information is held 
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by the Information Services Division (ISD).  In September 2011, after acquiring the 
necessary regulatory approvals, ISD supplied a list of hospital discharges during the 
period 1st June 2010-31st May 2011 in which ICH was listed as any one of the six 
diagnoses.  I used CT brain imaging and the electronic patient records system to check 
whether any cases ascertained by this search, which I had not already identified 
prospectively, were eligible. 
2.5 Diagnosis of ICH 
To increase the reproducibility and internal validity of the study I have based my 
diagnosis of ICH on imaging or pathological criteria supported by a participant’s clinical 
history. 
2.5.1 Clinical diagnosis  
I defined spontaneous ICH as ‘a symptomatic event (new headache, altered level of 
consciousness or neurological symptoms), with or without new neurological signs, 
referable to a focal collection of blood within the brain parenchyma (seen on brain 
imaging or at post-mortem examination), with signal characteristics on brain imaging or 
organisation of the haematoma at post-mortem examination consistent with the time of 
symptom onset, which was not attributable to prior trauma or HTI or an alternative 
explanation.’ 
Those with first-ever ICH did not have any previous ICHs but may have had a previous 
ischaemic stroke.  If a case had a previous stroke of undetermined type, I reviewed their 
history, primary and secondary care records and imaging to determine whether the 
stroke may have been ischaemic or haemorrhagic.  If the type of stroke remained 
unclear, I included the case as a ‘first-ever ICH’ but recorded a history of prior stroke of 
undetermined type in the database.  
2.5.2 Imaging diagnosis  
Acute ICH is visible on CT as a hyperdense area in the brain parenchyma (although it 
may also extend into one or more extra-axial compartments), typically in the range of 
50-80 Hounsfield units [Dennis et al. 1987].  Interpretation of imaging findings in the 
context of the clinical history helps to differentiate blood from other causes of 
hyperdensity on CT, most commonly calcification (Figure 6 on page 77).  Although 
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fresh blood will appear hyperdense, as haemoglobin breaks down, the attenuation of 
blood declines so that within two weeks a haematoma may appear isodense with brain 
tissue.  Therefore a diagnosis of ICH may be missed if CT imaging is delayed. In those 
who present late, MRI using haem-sensitive GRE sequences will show previous ICH as 
a low signal ring indefinitely [Wardlaw & Farrall 2004]. 
2.5.3 Pathological diagnosis 
If a biopsy or post-mortem is done soon after an ICH, ICH is macroscopically visible at 
post-mortem examination as extravasated blood.  It may be large enough to disrupt the 
architecture of adjacent structures and cause rupture into the ventricles.  If an ICH is 
not fatal, macrophages clear the blood over months leaving a cavity, which may be 
impossible to distinguish from a prior infarct [Love 2011]. 
2.5.4 Certainty 
A diagnosis of ICH cannot always be established with certainty on imaging.  It may be 
difficult to determine whether a haemorrhage has any parenchymal component or is 
purely extra-axial or to distinguish ICH from HTI [Lovelock et al. 2009] (Figure 7 on 
page 78).  If there is a history of trauma, it is necessary to differentiate clinically whether 
the trauma preceded the haemorrhage or vice versa (Figure 8 on page 79). 
2.5.4.1 Haemorrhagic transformation of infarction vs. primary ICH 
Two types of HTI may occur: petechial haemorrhage without mass effect or 
parenchymal haemorrhage, manifesting as a blood clot with mass effect [Larrue et al. 
1997].  It is the latter which can mimic primary ICH.  It has previously been estimated 
that 7% of primary ICH may be major HTI [Mead et al. 2002].   
Certain clinical factors may lead a clinician to consider a diagnosis of HTI ahead of 
ICH, such as a step-wise clinical deterioration following an initial diagnosis of ischaemic 
stroke or a delay in the time of onset of symptoms to scan since 9% cases of HTI may 
occur in the first week following an ischaemic stroke [Paciaroni et al. 2008].  Although 
prior use of antithrombotic medication is a risk factor for both HTI and ICH, use of 
these medications in combination with suggestive radiological features should lead to 
consideration of HTI.  There are no validated radiological features of HTI but some 
features are suggestive including an occluded cerebral artery visible on CT imaging 
supplying the territory of the ICH or a patchy appearance to the haematoma rather than 
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the haematoma being uniformly white [Mead et al. 2002].  In addition the area of 
hypodensity around a haematoma may reach the cortex and be wedge-shaped, indicative 
of an arterial blockage affecting a vascular territory (Figure 7 on page 78).  
2.5.4.2 Traumatic ICH 
When a patient presents with ICH it may difficult to disentangle the sequence of events 
leading to presentation and distinguish ICH resulting from head trauma from 
spontaneous ICH which led to a fall and subsequent injury (Figure 8 on page 79). 
Certain clinical and radiological factors may aid differentiation: 
(i) Clinical history – A good history from either the patient or a witness is 
essential to identify whether there were any symptoms of stroke prior to trauma.  
(i) Examination findings – The patient may have signs of head trauma such as 
bruising or a scalp haematoma implying significant head trauma. 
(ii) Radiology findings – Despite an absence of validated signs of traumatic ICH, 
some features on non-contrast CT imaging would be indicative.  There may be 
multiple foci of blood in different brain areas, contusions and blood may be 
seen in both parenchymal and extra-axial compartments.  Imaging may show 
signs of ‘coup-contrecoup’ injury where at the site of head trauma (coup site) a 
skull fracture or extra-axial blood is seen.  Injury on the opposite side of the 
brain (contrecoup) results from the brain on the opposite side initially being 
pulled away from the dura but striking the dura once again on recoil. Although 
haemorrhage can occur at both the coup and contrecoup sites, it is thought to 
be more common at the contrecoup site [Gean 2004]. 
However, the examination and radiology findings outlined in (ii) and (iii) may occur with 
both spontaneous ICH (which results in a fall) and traumatic ICH so the clinical history 
remains essential to differentiate them.  Review of brain imaging is valuable to assess if 
the distribution of blood is consistent with both spontaneous and traumatic ICH. 
2.5.5 Neuroradiology review 
To minimise these uncertainties, at a weekly stroke radiology meeting I presented the 
history and examination findings after which all available diagnostic brain imaging was 
reviewed by a neuroradiologist with a special interest in stroke imaging.  The meeting 
comprised an expert panel of at least one neuroradiologist in addition to at least one of 
Chapter 2 
  67 
each of the following: an experienced consultant stroke physician, a neurologist and a 
stroke fellow.  At most meetings more than one member of each category was present. 
Where there was uncertainty, the panel reached a consensus decision through 
discussion, and recommended further imaging if appropriate.  If additional information 
became available subsequently, I presented the case again and revised the diagnosis if 
necessary.  Any participant found to have an incorrect diagnosis of ICH was excluded.  
2.5.6 Suspected ICH 
Since ICH is one cause of sudden death, those affected may die before reaching hospital 
or before the diagnosis can be confirmed by imaging.  By reviewing cases that died 
before or soon after reaching hospital, I aimed to identify patients who might have had 
ICH as well as those who definitely did.  A case met the criteria for a suspected ICH if 
the ICH was unconfirmed by imaging or pathological means and the person met both 
of the criteria listed below:  
(i) The clinical history was suggestive of a stroke.  Features suggestive of a 
stroke were either the development of headache, which is common at the onset 
of ICH [Tatu et al. 2000] or focal neurological symptoms.  Both of these may 
have been of new onset or represented marked worsening of prior symptoms.  I 
also reviewed records for any factors in their medical history which might make 
an ICH more likely, such as a previous ICH, haematological disorders, use of 
anticoagulant or antiplatelet medications or alcohol misuse. 
(ii) The examination findings were suggestive of a stroke – for example, a new 
focal neurological deficit on examination, signs of raised intracranial pressure 
(pupillary asymmetry, hypertension with associated bradycardia), or a 
progressive reduction in conscious level. 
2.6 Onset of ICH  
When a patient develops symptoms of ICH they typically present to hospital where a 
diagnosis of ICH may be confirmed using radiological or pathological methods.  
However, patients may die before a diagnosis can be reached or conversely, if symptoms 
are mild, their presentation and subsequent investigations may be delayed.  I sought to 
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identify patients at an early and uniform point in the course of their ICH (inception 
point, [Sackett, Haynes, & Tugwell 1991]) which I have defined below. 
2.6.1 Date of ICH 
For the date of the ICH, I used the date on which symptoms attributable to the ICH 
started.  I determined this from the clinical history obtained from the patient or the 
person who witnessed the stroke or found them.  This date was the inception point for 
participants entering the study and prospective follow up began from this point 
onwards.  I did not use the date of admission to hospital or scan date as the inception 
point, since neither of these dates applied to all participants.  If a patient presented with 
a recurrent ICH, the date of the ICH remained as the date of onset of symptoms 
attributable to the ICH which had led to their notification although I recorded the 
date(s) of their prior ICH(s). 
2.6.2 Timing & onset of ICH 
I recorded the nature of onset of the ICH according to whether the person was awake 
at the onset of symptoms, awoke from sleep with symptoms or whether the time of 
onset was uncertain but the person was known to have last been well at a certain time.  
If the person (or their relative) knew the time when symptoms relating to the ICH 
began (or were first noted), this was documented.  If an exact time was not known but 
the person was last seen well in the morning the time of onset was recorded as 0800hrs, 
in the afternoon it was recorded as 1200hrs and in the evening it was recorded as 
2200hrs.  To obtain a best estimate of the time of onset of symptoms I also compared 
information from participants and their families with records from the Scottish 
Ambulance Service and GP notes (where a patient’s GP had been contacted prior to the 
patient reaching hospital). 
2.6.3 Incidental ICH 
Exceptionally, an ICH may be found incidentally or as part of investigations for other 
conditions such as cognitive impairment or hyponatraemia (Figure 9 on page 80).  In 
such cases it was often not possible to determine a time or nature of onset.  In these 
cases, the date of the ICH was the date of hospital admission (or the date the person 
was first seen in an outpatient clinic) which precipitated imaging.  
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2.6.4 Suspected ICH 
If a patient died of a suspected ICH before the diagnosis could be confirmed, the date 
of the ICH was the date of onset of symptoms which were thought to be attributable to 
a suspected ICH or if this was unknown, the date the person was last seen well. 
2.7 Baseline data collection 
I obtained a history from each patient and where this was not possible, I obtained 
collateral information from relatives or from both primary care records and hospital 
electronic and paper records.  I collected clinical, radiological and pathological 
information (where applicable) on a proforma; (Appendix). 
2.7.1 History 
Clinical variables included demographic data (date of birth, address and GP), sources of 
case notification, past medical history, with particular reference to any past history of 
ICH, ischaemic stroke, acute coronary syndrome and vascular risk factors, history of the 
current ICH, current & recent medications (including any exposure to antithrombotic 
medications or recent intravenous thrombolysis), a family history of ICH or dementia 
and social history.  I assessed a participant’s premorbid level of functioning using the 
modified Rankin Scale [van Swieten et al. 1988] having successfully completed the 
modified Rankin Scale training programme (http://www.rankinscale.org/links.shtml).  
If the participant was dead at presentation, I recorded the date and time of death, the 
documented cause of death on their death certificate and whether a post-mortem 
examination was undertaken.  I collected post-mortem reports from the Pathology 
Department, University of Edinburgh to obtain information on a participant’s 
presenting symptoms, salient past medical history and the features of their ICH. 
2.7.2 Examination findings 
I recorded the following examination findings on admission: systolic and diastolic blood 
pressure, Glasgow Coma Scale (GCS) and severity of impairment as measured by 
whether the participant had the ability to talk, was orientated to time (morning or 
afternoon), place and person, could lift both arms from bed and was able to walk 
unaided [Counsell et al. 2002].  
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2.7.3 Investigations  
If blood samples had been taken on the day of admission, I recorded their results.  I 
collected the following radiological variables on review of the diagnostic imaging: the 
location of the ICH, the presence of extension of the ICH from the parenchyma into 
the ventricles or subarachnoid or subdural compartments.  
2.8 Data collection during follow-up 
2.8.1 Survivors of ICH 
I followed up each survivor of ICH on an annual basis using three methods:   
(i) NHS Lothian’s electronic patient records system (TRAK): This records if a 
patient is deceased and any attendances to a hospital within NHS Lothian. 
(ii) Scottish Care Information Store (SciStore): This is a database developed by 
NHS Scotland, accessible by GPs and secondary care doctors in the Lothian 
health board, which stores clinic letters, discharge summaries, test results (both 
blood and imaging) and if applicable, a participant’s date of death. 
(iii)  GP annual questionnaires: A one page annual GP questionnaire requests 
confirmation of a participant’s address and that they are still alive, their most 
recent GP electronic summary of comorbidities and current medications and 
information regarding any new diagnoses of vaso-occlusive events [stroke, 
transient ischaemic attack (TIA), acute coronary syndrome, deep vein 
thrombosis (DVT) or pulmonary embolism (PE)], haemorrhagic events 
(intracerebral haemorrhage or other intracranial haemorrhage, gastrointestinal 
haemorrhage or other extracranial haemorrhage), dementia or hypertension.  
The GP is asked to assess the patient’s level of disability according to the 
modified Rankin scale.  If I did not receive a response I sent a repeat 
questionnaire after one month before telephoning the practice if a response was 
still outstanding. 
(iv) I also gave participants the opportunity to participate in a research study on 
ICH, Lothian Study of INtracerebral Haemorrhage, Pathology, Imaging and 
Neurological Outcome (LINCHPIN).  I followed up those who gave consent to 
the research study in person six months after their ICH, typically with a phone 
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call.  However, if participants wished they could attend a specialist ICH clinic 
which was an opportunity for any ongoing issues to be managed.  In addition, I 
provided all participants with our contact details, giving them the opportunity to 
contact me if they had any questions.  
2.8.2 Deaths 
When a participant dies or if an ICH is diagnosed at either a fiscal or hospital post-
mortem examination, I obtained their entire GP records from Practitioner Services.  
Practitioner Services is a division of NHS National Services Scotland.  It manages the 
transfer of medical records between GP practices and assists practitioners in 
maintaining accurate patient registers.  After death, a GP practice sends paper copies of 
a participant’s primary care record to Practitioner Services.  I also sought copies of their 
hospital notes, a copy of their death certificate from the General Register Office for 
Scotland and if applicable, a copy of the post-mortem examination report.   
2.9 Data management 
The study team designed a relational database for the purposes of data entry, analysis, 
and effective follow-up (Figure 10 on page 81).  The password protected database was 
built using Microsoft SQL Server 2000 with identifiable information held securely on an 
NHS server and only anonymised data held on a University of Edinburgh server.  I 
entered data from the data collection sheet and kept these sheets in files within a locked 
cabinet held in a locked office within the Division of Clinical Neurosciences, Western 
General Hospital.  I restricted access to the database to the core members of the study 
team with each member being given appropriate rights for their role.  Certain range 
checks were programmed into the database to minimise errors; for example – it was not 
possible to enter a participant with an age of under 16 years on the date of their index 
ICH.  I linked the database to a spreadsheet containing all residential postcode sectors 
served by the NHS Lothian Health Board so that any potential participant who was not 
resident in one of these sectors could not be entered into the database either.  
When I had completed our first year of case ascertainment, I checked the entire data set 
for missing data and inconsistencies.  I performed various consistency checks including: 
• ensuring a date of death was inserted if the patient was deceased; 
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• the date of the ICH was on the same day as or preceded the date of death; 
• the date of the ICH was on the same day as or preceded the date of admission; 
• the imaging features of each ICH visible on diagnostic imaging were recorded if the 
number of bleeds was recorded as ‘multiple’; 
• the fields indicating whether a patient was on anticoagulant or antiplatelet 
medications at the time of their ICH were concordant with their medications list;  
• their list of comorbidities (coded using the ICD-10 classification) matched the fields 
indicating if they had a past history of ischaemic stroke, TIA, DVT, PE, atrial 
fibrillation, diabetes mellitus or cardiovascular disease;  
• the verbal component of the GCS on admission was five if the participant was able 
to talk and orientated; and 
• if an International Normalised Ratio (INR) was elevated there was an explanation; 
typically anticoagulant use or liver disease.  
I also performed various range checks including:  
• Systolic and diastolic blood pressure on admission; and 
• Full blood count, INR and renal function on admission. 
I also checked the completeness of all variables included in analyses including the 
following: 
• Demographic variables: age, gender, 
• Clinical variables: first-ever vs. recurrent ICH, hypertension, diabetes, dementia, 
smoking, alcohol use, antithrombotic use, GCS; and 
• Investigation variables: INR, ICH location, single vs. multiple ICH, ICH volume, 
presence of intraventricular extension, presence of subarachnoid extension, 
presence of subdural extension. 
2.10 Evaluation of sources of case ascertainment 
I ascertained 166 ICH cases during 1st June 2010-31st May 2011.  Figure 11 on page 82 
shows that 140 cases out of 166 identified (84%) were ascertained by more than one 
source.  Where a case was identified by one source alone, review of CT brain scans was 
the most common source of ascertainment.  Although identification of every ICH case 
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by at least two sources of notification would be ideal, >80% overlap between sources is 
good.  
Figure 12 on page 83 shows the degree of overlap between sources of case 
ascertainment.   
The majority of cases were ascertained by review of CT imaging, liaison with our 
collaborative network and ISD.  Although CT brain imaging was the most fruitful 
source of ascertainment, it was not sufficient alone to detect all cases of ICH.  Six cases 
of ICH were detected by methods other than screening of CT brain scans.  Three cases 
were fatal out-of-hospital deaths where the diagnosis was confirmed at post-mortem 
examination.  In two more cases, patients had had CT imaging performed but the ICH 
was missed when the scan was reviewed and both these cases were detected by other 
sources of ascertainment.  In a further case, the patient died soon after the development 
of symptoms and before CT brain imaging could be conducted.  The diagnosis was 
confirmed at post-mortem examination. 
2.11 Summary 
• This is a community-based, prospective incidence and longitudinal cohort study of 
spontaneous primary ICH which uses multiple sources of case ascertainment and 
follow-up. 
• The study includes adults aged 16 years or over at the time of their ICH, resident in 
the region served by the NHS Lothian Health board and diagnosed between 1st June 
2010-1st June 2016. 
• I confirmed the diagnosis of ICH by review of diagnostic imaging or post-mortem 
examination reports. 
• I ascertained cases of suspected ICH in which the history was suggestive of ICH but 
the diagnosis of ICH was unconfirmed before or after death.  
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2.12 Discussion 
2.12.1 Case ascertainment 
This study meets almost all the criteria for an ‘ideal’ stroke incidence study [Sudlow & 
Warlow 1997;Feigin & Carter 2004]. 
(i) It has a prospective population based design using multiple overlapping sources 
for both case and outcome ascertainment. 
(ii) It uses a standard generalisable definition of ICH and has an inception cohort 
assembled at an early point during the course of the illness. 
(iii) The population is well defined and stable, allowing at least 100 000 person-years 
of observation. 
(iv) I confirm the diagnosis of ICH by imaging or post-mortem examination in 
≥80% cases. 
(v) I distinguish first-ever in a lifetime ICH from recurrent ICH. 
(vi) The denominator for incidence calculations uses reliable current data. 
(vii)  I present incidence data separately for each sex and age band (Chapter 5). 
A recent systematic review of incidence studies of ICH categorised studies which had 
used multiple case finding methods, including regional hospitals, family doctors and 
death certificates as excellent [van Asch et al. 2010].  In addition to these methods our 
study uses surveillance of Procurator Fiscal records and electronic patient records to 
ascertain those who died of an ICH confirmed at pathological examination before 
reaching hospital and those who died of a suspected ICH before investigations could 
confirm a diagnosis.  In a disease such as ICH with a high early case fatality, this is 
essential to begin to identify the unmeasured burden of the disease (the iceberg concept, 
[Bhopal 2002]) since cases of ICH who die before reaching hospital are likely to 
represent more severe cases of the disease.  
2.12.1.1 Limitations of case ascertainment 
However, despite the study fulfilling many of the criteria for an ‘ideal’ stroke incidence 
study potentially eligible patients may have been missed if:  
(i) MRI was the imaging modality used to diagnose an ICH rather than CT, since I 
did not routinely screen all MRI brain scans.  Although CT remains the most 
frequently used imaging modality if an acute ICH is suspected [Muir & Santosh 
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2005], MRI may be used occasionally, particularly if the presentation is atypical 
or delayed [Muir et al. 2006].   
(ii) A resident served by NHS Lothian had an ICH whilst in a different region.  
(iii) Neither radiographic nor pathological examination was performed on a person 
who died suddenly or rapidly in the community after an illness suggestive of 
stroke.  
I mitigated the effects of (i) and (ii) by using overlapping sources of case ascertainment. 
In particular our extensive collaborative network did occasionally notify me of patients 
found to have an ICH on MRI or if a patient returned to NHS Lothian having had an 
ICH elsewhere and accessed in-patient or outpatient stroke services.  I considered 
routine screening of MRI brain scans, but since MRI is used only very occasionally in 
the diagnosis of acute stroke in the Lothian region with two out of three hospitals 
having on-site access to MRI within working hours, I suspected that the potential yield 
would be low.  
I mitigated the effects of (iii) by screening the electronic patient records system to 
identify people who were brought into hospital dead or people who died soon after 
admission to hospital with a history suspicious of a stroke but before a diagnosis could 
be confirmed.  I did not ascertain all potential cases who had died suddenly in the 
community without admission to hospital or post-mortem examination to confirm a 
diagnosis and whose cause of death on their death certificate was listed as a ‘stroke.’  
In future, the study design could be improved by use of post-mortem imaging 
techniques to confirm a diagnosis of ICH in those who die rapidly soon after the onset 
of symptoms and routine screening of all MRI brain scans and screening of all death 
certificates to ascertain cases where ‘stroke’ has been listed as one of the primary causes 
of death. 
2.12.1.2 Evaluation of completeness of case ascertainment 
Evaluation of the completeness of case ascertainment is challenging.  Both indirect 
statistical methods such as capture-recapture and direct assessment have been proposed.  
Inherent in capture-recapture methods are assumptions that sources of ascertainment 
are independent and that all individuals have the same probability of being captured 
[Tilling 2001].  In our population neither of these assumptions holds true since some 
sources of ascertainment such as the collaborative network and neuroradiology meetings 
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are inter-dependent and ICHs which either cause sudden death or less severe symptoms 
may be missed.  Although adjustment can be made for these assumptions using 
covariates, in our population this would lead to small numbers in certain categories and 
imprecise estimates. 
An example of direct assessment is accessing all primary care records in a defined 
population to quantify the number of cases that had presented to primary care with 
symptoms of stroke but had not been notified to the study [Coull et al. 2004].  The size 
of the population (~700,000 adults in Lothian) is likely to preclude screening of all 
adults’ primary care records but in the future it may be possible to use information held 
by ISD to produce a sampling frame of all adults in NHS Lothian and select a random 
age-stratified sample of adults whose records could be screened for previously 
unidentified cases of ICH. 
2.12.2 Methods of follow up 
I used several methods of follow up which are designed to ensure that I have a 
minimum of survival data at one year for each patient, and for the majority, have a 
record of other key outcomes including disability, reported by the participant’s current 
GP according to the modified Rankin scale.  Although the reliability of using a proxy 
report of the modified Rankin Scale in comparison to patient report has recently been 
shown to be limited [McArthur et al. 2012], the patient’s health status should be well 
known to their GP and the modified Rankin Scale is the most commonly used 
functional outcome measure in studies of stroke [Quinn et al. 2009] .  Face-to-face 
interview with ICH survivors would not have been possible and other methods such as 
extrapolation from records is not valid [Quinn et al. 2008].  Structured telephone 
interview with participants would be an alternative since it has been shown to have good 
validity in comparison to face-to-face interview in patients with subarachnoid 
haemorrhage [Janssen et al. 2010].   
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Figure 6 Unilateral basal ganglia calcification 
 




A 96 year old lady was admitted to hospital with a two day history of urinary frequency. 
She was noted to be disorientated to time and place which was unusual for her.  The 
medical team requested a CT brain scan to look for an intracranial cause of her 
confusion (image A).  A high density area was noted in left lentiform nucleus (arrow) 
which was thought most likely to represent a small ICH. 
Two months later the lady was readmitted with delirium and she was treated for a 
suspected lower respiratory tract infection.  However when she failed to respond to 
treatment, she had a repeat CT brain scan (image B).  The repeat CT scan shows that 
the high signal lesion is unchanged in appearance and therefore in retrospect, the lesion 
was most likely to be calcification. 
 
       Image A         Image B 
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Figure 7 Haemorrhagic Transformation of an Infarct 
 
A 54 year old gentleman was found at the 
bottom of his stairs by his neighbour.  He was 
able to recall falling and described weakness of 
his right arm and leg which occurred before 
the fall.  He was certain that the weakness had 
actually started three days previously but he 
had not sought medical help.  He had a past 
medical history of ischaemic heart disease with 
coronary artery bypass grafting, non-insulin 
dependent diabetes mellitus and atrial 
fibrillation for which he was taking warfarin.  
On examination he had weakness affecting his 
right arm and leg with no facial droop, and no higher cortical symptoms.  His INR was 
7.9. 
The axial CT image (above) shows an elliptical area of low attenuation affecting the left 
basal ganglia (short solid arrow) within which there is some high signal consistent with 
haemorrhage (long dotted arrow). 
I felt that the low attenuation lesion was most likely to be a striato-capsular infarct.  The 
area of haemorrhage within it could be explained by the prior history of warfarin use.  
The presumed HTI was lower attenuating than what would be expected for a three day 
old primary ICH. 
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Figure 8 Traumatic ICH        
           
           
           
           
           
           
           
           
           
           






A 90 year old gentleman with a past medical history of Type 2 diabetes mellitus and 
hypertension was at home with his wife when he stood up and fell.  His wife heard a 
thud when he fell but did not witness the fall.  She noted that he had not been 
complaining of any symptoms earlier in the day.  Since the fall he had been unable to 
communicate.  On examination he was agitated and disorientated.  A limited 
neurological examination did not reveal any focal deficit.  
He underwent a CT brain scan and two axial slices are shown above.  Image A shows a 
left frontal haematoma (solid arrow) with additional blood in the right subdural space 
(dotted arrow).  Image B shows a small subependymal ICH (dashed arrow).  In view of 
the multiple areas of intracranial haemorrhage in locations typical for traumatic ICH, I 
felt that the left frontal haematoma may have been traumatic in origin. 
  
    Image A Image B 
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Figure 9 Atypical presentation of spontaneous primary ICH 
 
A 93 year old lady was admitted to hospital 
with a two day history of vomiting and 
diarrhoea.  She had had a recent admission 
with constipation and had been discharged 
one week previously.  She was alert and fully 
orientated on examination although a full 
neurological examination was not performed.  
Her blood tests were unremarkable except for 
her sodium level which was 107mmol/litre.  
The initial diagnosis was of probable intestinal 
obstruction. 
An abdominal x-ray was done which showed dilated small bowel loops although a 
subsequent CT abdomen did not show evidence of obstruction or perforation.  She was 
managed conservatively and began to improve with her sodium also increasing to126 
mmol/litre over the following couple of weeks. 
However, on day 16 of her admission she fell on the ward.  Over the preceding three 
days she had been complaining of dizziness, the nature of which was not clear.  There 
was no loss of consciousness or head injury.  A subsequent electrocardiogram (ECG) 
showed trifascicular block.  The clinical team also requested a CT brain scan because of 
ongoing (although improved) hyponatraemia.  
The axial CT image (above) shows a right frontal lobar ICH (arrow) with extension into 
the subdural space (not shown) and surrounding hypodensity which was thought to be 
at least several days old.  The ICH may have been a contributory factor to her both her 
dizziness and hyponatraemia.  Her hyponatraemia improved and she was discharged to 
a rehabilitation ward.
 
     
Figure 10 Entity-relationship diagram for the database 
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Figure 12 Overlap between sources of case ascertainment (n=166) 
$
TRAK is the electronic patient records system 
* indicates one case in each group also notified by the Office of the Procurator Fiscal  
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3 Methods of a cross-sectional study of MRI brain imaging features in 
lobar vs. non-lobar intracerebral haemorrhage 
3.1 Introduction 
Ideally, studies of markers of small vessel disease should be population-based using 
participants recruited at a uniform inception point, standard definitions of variables, 
pre-specified MRI sequence parameters and validated rating scales which differentiate 
markers of small vessel disease from their mimics and enable calculation of inter-
observer agreement [Cordonnier, Wardlaw, & Al-Shahi Salman 2007;Wardlaw et al. 
2011].  In the context of ICH, the aim of the study would be to describe the distribution 
and severity of small vessel disease in patients with ICH with the aim of determining 
whether the nature of small vessel disease differs according to ICH location.  This might 
provide clues to the underlying contributing causes of lobar and non-lobar ICH. 
Neuroimaging correlates of small vessel disease are heterogeneous, including BMBs, 
white matter hyperintensities of presumed vascular origin (WMH) and enlarged 
perivascular spaces (EPVS) [Pantoni 2010;Doubal et al. 2010].   
BMBs seen as small hypointense foci on haem-sensitive MRI sequences [Cordonnier, 
Wardlaw, & Al-Shahi Salman 2007], are thought to be an indicator of CAA if in a 
strictly lobar distribution [Greenberg et al. 2009].  WMH appear as regions of patchy 
hyperintense signal on T2-weighted and fluid- attenuated inversion recovery (FLAIR) 
sequences on brain MRI in the deep and periventricular white matter, basal ganglia and 
brainstem [Wardlaw, Ferguson, & Graham 2004].  ICH has been associated with higher 
WMH volumes in comparison to other stroke subtypes [Rost et al. 2010].  EPVS are 
CSF filled cavities that surround small penetrating arterioles and can be visualised on 
brain MRI. They are commonly seen in patients with ICH [Charidimou et al. 2013c].   
In the following chapter, I will describe the development of an MRI rating proforma 
which was used to rate BMBs, WMH and EPVS on training scans and LINCHPIN 
study scans and quantify inter-observer and intra-observer agreement for markers of 
small vessel disease and their mimics.  
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3.2 Methods 
3.2.1 Development of an MRI rating proforma  
Since a validated automated method for measuring features of small vessel disease does 
not exist [Wardlaw et al. 2011], I developed a proforma to assess both scans used for 
training in the rating of small vessel disease and those done as part of the LINCHPIN 
study.  The aim was to rate both BMBs and other neuroimaging correlates of small 
vessel disease.  The imaging definition for each variable and its method of rating is 
described in the following section. 
3.2.1.1 Acute ischaemic change 
I defined acute ischaemic change as a lesion(s) suggestive of a recent cerebral infarct, 
which was hyperintense on diffusion-weighted imaging, hypointense on the 
corresponding apparent diffusion coefficient sequence map and normal to hyperintense 
on T2-weighted and FLAIR sequences.  The lesion was typically wedge-shaped or 
elliptical (if lacunar) and occupied a vascular territory.  The side of the ischaemia 
referred to the side of the cerebrum affected.  If the lesion was in the midline, then this 
was indicated.  
3.2.1.2 Acute parenchymal haemorrhage 
Acute parenchymal haemorrhage relates to a lesion(s) suggestive of a ‘recent’ 
haemorrhage.  Since signal changes vary on T1-weighted and T2-weighted MRI 
sequences as haemoglobin evolves from oxy-haemoglobin (hyperacute stage, hours after 
the event) to deoxy-haemoglobin (acute stage, one-two days) through to met-
haemoglobin (subacute stage, two days to several weeks) [Weissleder et al. 2011], 
‘recent’ haemorrhage referred to a lesion possessing signal changes which indicated that 
it was either hyperacute, acute or subacute and therefore was likely to have occurred 
within four weeks of the scan.  If more than one acute haemorrhage was visible, I rated 
the hemisphere and anatomical location of each haemorrhage listing the largest 
haemorrhage first.  I differentiated primary intracerebral haemorrhage from HTI by 
referring to other MRI sequences; for example by looking for the presence of a wider 
area of infarction surrounding the haemorrhage using DWI and apparent diffusion 
coefficient maps [Lovelock et al. 2009]. 
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3.2.1.3 Further characterisation of the haemorrhage 
I characterised the location of the ICH as lobar or non-lobar.  I used a standard 
definition of intracerebral haemorrhage location, as described in Chapter 1.  
3.2.1.4 Chronic infarcts and haemorrhages 
I rated the hemisphere and anatomical location of any chronic infarcts or haemorrhages.  
Since chronic infarcts may be confused with white matter lesions, I aimed to 
differentiate these entities using a scale validated in previous cohorts of stroke patients 
[Wardlaw et al. 1998;Wardlaw et al. 2007]. 
Chronic infarcts were defined as cortical, lacunar or infratentorial lesions which were 
hyperintense on T2-weighted and FLAIR sequences and hypointense on T1-weighted 
sequences.  I defined lacunar infarcts as lesions >three millimetres and ≤ 20 millimetres 
in maximum diameter [Potter et al. 2010] in the basal ganglia, subcortical white matter 
or brainstem and looked for evidence of cavitation and surrounding gliosis suggestive of 
chronicity.   
Chronic haemorrhages were defined as lesions which were hypointense on T1-weighted 
and gradient-echo sequences and hyperintense accompanied by a dark rim on T2-
weighted sequences [Weissleder et al. 2011]. 
3.2.1.5 Basal ganglia mineral deposits 
Pathological studies reveal that insoluble minerals which accumulate within the basal 
ganglia comprise different elements including iron due to haemosiderin deposition 
(most commonly), calcium, zinc and magnesium [Casanova & Araque 2003].  These 
deposits are visible as typically symmetrical hypointense regions on gradient-echo MRI 
sequence (Figure 13 on page 99) and may mimic BMBs [Samarasekera, Potter, & Al-
Shahi Salman 2011].  Calcium deposits can be differentiated from iron deposits since the 
former appears hypointense on T1-weighted sequences in comparison to iron which is 
undetectable.  There is no existing validated scale to rate mineral deposits.  I used a 
simple visual scale which graded deposits zero to three, which although unvalidated, has 
been used in previous studies [Penke et al. 2012]. 
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3.2.1.6 White matter hyperintensities of presumed vascular origin 
I defined WMH as parenchymal lesions which were hyperintense on T2-weighted and 
FLAIR sequences (although not as hyperintense as CSF on T2 weighted sequences) 
[Fazekas et al. 1987].  WMH were categorised as being periventricular (where they were 
contiguous with the lateral ventricles) or deep (where they were located in the white 
matter tracts) [Payne et al. 2002].  Deep hyperintensities became continuous with 
periventricular hyperintensities in those with a preponderance of white matter lesions.  I 
rated WMH using the Fazekas scale [Fazekas et al. 1987](Figure 14 on page 100).  
Although there are several different scales available for rating of WMH the Fazekas 
scale has been widely used in previous studies of stroke, increasing the generalisability of 
our findings.  It also comprises ratings for both deep and periventricular WMH which 
may be relevant when examining the profiles of small vessel disease which underlie 
lobar and non-lobar ICH.  Moreover, it is easy to apply and differentiates between 
grades of severity of WMH even at extremes unlike some of the other rating scales used 
[Wardlaw, Ferguson, & Graham 2004].  
3.2.1.7 Atrophy 
I defined atrophy as loss of grey and white matter leading to either increased 
prominence of the ventricles (deep atrophy), or enlargement of CSF spaces and 
increased prominence of cortical sulci (cortical atrophy) or both. I used a validated 
template developed from T2-weighted images of 79 subjects aged 65-70 years and 75-80 
years who were involved in studies of normal ageing [Farrell et al. 2009].  I used a scale 
of zero to three, where zero=none, one=mild (5th-25th centile on atrophy template), 
two=moderate (50th-75th centile) and three=severe (95th centile.) 
3.2.1.8 Enlarged perivascular spaces 
I defined EPVS, as CSF filled cavities which surround small blood vessels as they 
traverse from the subarachnoid space into the brain parenchyma [Braffman et al. 1988], 
which appear hyperintense on T2-weighted sequences and hypointense on T1 and 
FLAIR sequences.  I used a validated scale (http://www.bric.ed.ac.uk/documents/epvs-
rating-scale-user-guide.pdf) to rate the number of EPVS in the centrum semiovale, basal 
ganglia and hippocampal regions in each hemisphere separately and then overall (Figure 
15 on page 101). 
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3.2.1.9 Brain microbleeds 
I defined BMBs as punctuate homogeneous foci of less than 10mm in diameter seen in 
the brain parenchyma which appear hypointense (due to their haemosiderin content) 
and display ‘blooming’ properties on gradient-echo sequences [Greenberg et al. 2009].  
Raters were aware of potential mimics of BMBs including flow voids in blood vessels, 
partial volume artefact from bone, intracranial shunt tips and cavernous malformations 
[Samarasekera, Potter, & Al-Shahi Salman 2011](Figure 16 on page 102).  
Two validated scales for rating the number and distribution of BMBs have emerged in 
recent years:  the Brain Observer Microbleed Rating Scale (BOMBS) [Cordonnier et al. 
2009] and the Microbleed Anatomical Rating Scale (MARS) [Gregoire et al. 2009].    
BOMBS records certain and uncertain BMBs which are either less than five millimetres 
or five-10mm in size in the following areas: cortex/grey-white matter junction, 
subcortical white matter, basal ganglia grey matter, internal and external capsule, 
thalamus, brainstem and cerebellum.  MARS similarly rates certain and uncertain BMBs 
in different anatomical locations but for lobar BMBs, assessors can ascribe their location 
to a lobe of the brain.  It also distinguishes BMBs in the insula and corpus callosum as 
distinct from other areas and asks raters to provide totals of certain and uncertain BMBs 
in lobar, deep and infratentorial regions.  Differentiation of certain BMBs from those 
which are uncertain improves inter-rater reliability [Cordonnier et al. 2009].  
I modified BOMBS; removing the microbleed size categories (since there was 93% 
inter-observer agreement on size in the sample used to validate BOMBS) [Cordonnier et 
al. 2009], incorporating total numbers of BMBs for lobar and non-lobar regions, and 
listing each lobe of the brain in the anatomical regions.  The latter may be relevant when 
comparing the distribution of BMBs with other neuroimaging correlates of small vessel 
disease such as WMH.  Some authors have also suggested that BMBs in CAA may be 
more likely to distribute in the parietal and occipital lobes of the brain [Greenberg, 
Finkelstein, & Schaefer 1996].  
3.2.2 Selection of MRI training scans  
Prior to rating the LINCHPIN MRI scans, I practised rating markers of small vessel 
disease using a selection of training scans. 
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A neuroradiologist selected 15 MRI scans from a collection previously used in the 
development of the Brain Observer MicroBleed Scale (BOMBS) [Cordonnier et al. 
2009].  The scans selected had been the subject of inter-observer disagreement during 
the development of BOMBS.  The scans were from a subset of patients in the 
Edinburgh Stroke Study; an ethically-approved prospectively-collected hospital based 
stroke register of consecutive patients with stroke and TIA seen between April 2002 and 
May 2005 [Jackson et al. 2009].  
Following either an ischaemic or haemorrhagic stroke, participants underwent 1.5 Tesla 
MRI (GE Signal LX EchoSpeed scanner, Milwaukee, WI, USA.)  The scan protocol 
included  T1 sagittal sequences and the following axial sequences in all cases: T2-
weighted (TR 6300, TE 107, matrix 256 ×256, FoV 24×18 slice thickness 5mm,slice gap 
1.5mm, NEX 2 [where TR=relaxation time, TE=echo time, FoV=field of view, NEX = 
number of excitations]), DWI (TR 9999, TE 98.8, matrix 128×128, FoV 24×24, slice 
thickness 5mm, slice gap 1mm, NEX 1), FLAIR (TR 9002, TE 147, matrix 256 ×256, 
FoV 24×24, slice thickness 5mm, slice gap 1.5mm, NEX 1) and GRE (T2*, TR 620, TE 
15, flip angle 20, FoV 24×18, matrix, 256×192, slice thickness 5mm, slice gap 1mm, 
NEX 2.)  
3.2.3 Rating of training scans 
In July 2012, the training scans were anonymised and viewed independently by both 
raters blind to all clinical details, the original scan report, previous ratings of BMBs 
during the development of BOMBS and each other’s ratings.  For the intra-observer 
study I rated all scans again six months later.  Only the first set of ratings was used to 
quantify inter-observer agreement.  
3.2.4 LINCHPIN MRI scans 
Participants recruited into the LINCHPIN study (an ethically-approved interventional 
study of patients with spontaneous primary ICH), underwent brain MRI.  
3.2.4.1 MRI inclusion criteria  
Participants were eligible for brain MRI in the LINCHPIN study if they met all of the 
following inclusion criteria: 
• They had a first-ever or recurrent spontaneous primary ICH during 1st June 2010-
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31st May 2012. 
• They were resident in the Lothian region at the time of their ICH. 
• They (or their nearest relative) gave written informed consent to MRI.  
3.2.4.2 MRI exclusion criteria 
Participants were excluded if they met any of the following exclusion criteria. 
• They had a secondary ICH. 
• They were unable to tolerate brain MRI because they were too unwell, 
claustrophobic or unable to lie flat for the scan duration. 
• They had a contraindication to MRI; for example – a permanent pacemaker or metal 
implants elsewhere in their body. 
• They were too wide and were therefore unable to fit into the scanner. 
3.2.4.3 MRI procedure 
To minimise the travelling distance for participants, participants were able to undergo 
brain MRI at one of two hospitals (Western General Hospital or Royal Infirmary at 
Edinburgh) serving the Lothian health board.  MRI was done using one of two 1.5T 
MRI scanners (GE Signal LX EchoSpeed scanner, Milwaukee, WI, USA and Philips 
Gyroscan Intera scanner, Philips Ltd, Best, The Netherlands.)  The scan protocol 
consisted of T1 sagittal sequences and the following axial sequences: T2- weighted, 
FLAIR and gradient echo for all participants.  The sequence parameters are provided in 
Table 1 on page 98.  The total scan time was approximately 25 minutes. 
3.2.4.4 LINCHPIN MRI ratings 
I rated all brain scans independently, blinded to the participants’ names and clinical 
characteristics using the proforma described above (Appendix).  A consultant 
neuroradiologist with a special interest in stroke, who was also blinded to the 
participants’ names and clinical characteristics, rated BMBs and other imaging 
parameters to assess inter-observer agreement.   
3.2.5 Statistical analysis 
I assessed inter-observer agreement for both the training scans (n=15) and LINCHPIN 
MRI scans (n=50).   
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I rated binary categorical variables (presence or absence of acute ischaemic change and 
acute parenchymal haemorrhage) for which I quantified inter-observer agreement using 
an unweighted κ [Cohen 1960].  In contrast to participants whose scans were used as 
training scans who may have had either an ischaemic or a haemorrhagic stroke,  
LINCHPIN participants were all scanned following an ICH and therefore these 
variables were rated for training scans only. 
I used a weighted κ for ranked ordinal variables (basal ganglia mineral deposits, 
periventricular and deep WMH, deep and cortical atrophy, EPVS.)   
For chronic infarcts and BMBs, I dichotomised the data (presence of zero vs. one or 
more chronic infarcts and presence of zero vs. one or more BMB respectively) and used 
an unweighted  κ to calculate observer agreement for certain BMBs and uncertain and 
certain BMBs combined in lobar, deep and infratentorial areas.  To obtain an overall 
measure of the agreement regarding the numbers of lesions noted as certain or 
uncertain BMBs, I calculated the total number of certain and uncertain BMBs noted by 
each rater for all locations (lobar, infratentorial and deep) and used an intraclass 
correlation coefficient (two-way random ANOVA) model [Shrout & Fliess 1979]. 
All analyses were performed in STATA version 11.1, except 95% CI for weighted κ 
which were calculated in StatsDirect (version 2.7.8). 
3.3 Results 
3.3.1 MRI training scans 
Inter-observer agreement for the presence of acute and chronic lesions ranged from fair 
to substantial (Figure 17 on page 103).  The commonest reason for disagreement was 
misclassification of chronic ischaemic and haemorrhagic lesions as acute and vice versa. 
Some chronic ischaemic lesions still appeared hyperintense on diffusion-weighted 
imaging and I  labelled these as acute without reference to the corresponding apparent 
diffusion coefficient map, which showed that no signal drop out was present.   
There was fair-to moderate agreement on ordinal variables including WMH, EPVS and 
basal ganglia mineralisation, although 95% CI were broad reflecting the relatively small 
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number of training scans.  In almost all cases of disagreement, observers differed by 
only one grade on the respective rating scales used.   
Intra-observer agreement ranged from less than chance to substantial (Figure 17 on 
page 103).  Although intra-observer agreement was less than inter-observer agreement 
for certain variables, when my second set of ratings was compared with those of the 
neuroradiologist, inter-observer agreement was invariably greater than the intra-observer 
study (acute ischaemic change κ 0.17; 95% CI -0.30 to 0.55 acute haemorrhage κ 0.58; 
95% CI 0.05 to 0.88; chronic infarcts and haemorrhages κ 0.59; 95% CI 0.06 to 0.85); 
indicating that inter-observer agreement may have improved at the expense of intra-
observer agreement. 
Inter-observer agreement for the presence of zero vs. ≥ one BMB ranged from 
moderate to almost perfect (Figure 18 on page 104).  Common causes for disagreement 
were lesions being too pale to be sure that they were a BMB and interpretation of BMB 
mimics such as basal ganglia mineralisation, vascular flow voids and partial volume 
artefacts from the orbit or petrous temporal bone (Figure 16 on page 102).  Intra-
observer agreement was similar to inter-observer agreement for BMBs in all locations.  
The intraclass correlation coefficient across all locations for the overall number of 
certain BMBs was 0.59 (95% CI 0.14-0.84) and for the total number of BMBs (certain 
and uncertain) was 0.87 (95% CI 0.64-0.95). 
3.3.2 LINCHPIN MRI scans 
The neuroradiologist rated all scans for BMBs, atrophy, WMH and chronic infarcts and 
a subset of 38 scans to assess inter-observer agreement for EPVS and basal ganglia 
mineralisation.  
Inter-observer agreement for ordinal variables (basal ganglia mineralisation, WMH, 
EPVS, atrophy) ranged from slight to moderate (Figure 19 on page 105).  Inter-observer 
agreement for the presence of zero vs. ≥ one BMB ranged from moderate to substantial 
(Figure 20 on page 106). The intraclass correlation coefficients across all locations for 
the overall number of certain BMBs was 0.88 (95% CI 0.79-0.93) and for the total 
number of BMBs (certain and uncertain) was 0.88 (95% CI 0.80-0.93). 
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3.4 Summary 
• Inter-observer agreement when rating WMH, EPVS and atrophy on both the 
training scans and LINCHPIN MRI scans predominantly ranged from fair to 
moderate. 
• Inter-observer agreement when rating the presence of zero vs. ≥ one BMB on 
LINCHPIN MRI scans was similar to the inter-observer agreement achieved for 
training scans and ranged from moderate to substantial. 
3.5 Discussion 
3.5.1 Selection of imaging variables 
The variables which comprise the MRI rating proforma were selected to assess the 
presence and/or severity of neuroimaging correlates of small vessel disease in 
participants with ICH.  Variables were either markers of small vessel disease (WMH, 
EPVS, atrophy, BMBs) or potential mimics of small vessel disease; for example – 
chronic infarcts which needed to be differentiated from other periventricular and deep 
WMH or basal ganglia mineralisation which is acknowledged to be a microbleed mimic 
[Samarasekera, Potter, & Al-Shahi Salman 2011].  Although all the variables are subject 
to inter-observer variation, I have sought to minimise inter-observer variation by using a 
standard definition for all variables, validated scales and a systematic rating proforma 
ensuring that all variables are considered.  
3.5.2 Strengths of the study 
This study fulfils the Guidelines for Reporting Reliability and Agreement studies 
[Kottner et al. 2011] in that I have: 
(i) Explained how the sample of raters and scans was chosen; 
(ii) Specified the method of rating scans, including the MRI rating proforma used 
and the time interval between ratings in the intra-observer study; 
(iii) Specified that scans were rated independently and blinded to clinical information 
and the scan report (therefore minimising bias); 
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(iv) Stated the number of raters and scans used and the number of replicate 
observations conducted; 
(v) Described the sample characteristics of participants who underwent MRI in the 
LINCHPIN study (Chapter 6); 
(vi) Reported estimates of both inter-observer and intra-observer agreement. 
3.5.3 Inter-observer study 
On most parameters, inter-observer agreement did not improve when rating 
LINCHPIN MRI scans in comparison to training scans.  This study was small and 
exploratory in nature and factors which are likely to explain these results include the 
small numbers of both training and LINCHPIN MRI scans and restrictions in the use 
of the κ statistic. 
3.5.4 Selection of training scans 
Although I used a small subset of scans for training purposes, the scans selected were 
those which were subject to inter-observer variation when rating BMBs during the 
development of BOMBS [Cordonnier et al. 2009].  Therefore these scans were likely to 
be the most complex in terms of distinguishing BMBs from other haemorrhagic lesions 
and mimics.  The scans all contained identical sequences. All sequence parameters were 
consistent and known, increasing the generalisability of these findings.    
To obtain a more precise estimate of inter-observer agreement I would require a larger 
number of scans which would reduce the width of the 95% CI around the κ estimates.  
I did not assess whether the use of the proforma improved inter-observer agreement by 
enabling a structured assessment of both correlates of small vessel disease and their 
mimics and it would be interesting to do so in a future study. 
3.5.5 Use of the κ coefficient 
The κ coefficient is the most commonly used statistic to assess agreement between two 
observers.  Unlike measuring the overall percentage of agreement, κ takes into account 
the agreement between observers which could have occurred ‘purely by chance.’  κ  is a 
measure of agreement beyond that expected by pure chance, so called ‘true’ agreement 
[Cohen 1960]. 
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3.5.5.1 Assumptions of κ 
The study design fulfilled the assumptions inherent when using κ – the subjects were 
independent (so each subject only contributed one paired rating) and the observers were 
independent.  For both nominal and ordinal variables the categories used were mutually 
exclusive and exhaustive. 
The magnitude of κ is influenced by various factors including the prevalence of an 
attribute [Brennan & Silman 1992] and bias [Feinstein & Cicchetti 1990].   
3.5.5.2 Prevalence of an attribute 
Prevalence may influence κ when the number of paired ratings in which both raters 
have rated a variable as being ‘present’ (positive ratings) differs substantially from the 
number of paired ratings in which both raters have assessed a variable as being ‘absent’  
(negative ratings).  This is shown overleaf for the variables ‘acute haemorrhage’ and 
‘acute ischaemic change’. 
 
 
    
 
        Acute haemorrhage                 Acute ischaemic change 
For both variables the raters agreed on 12 out of 15 training scans.  For the variable 
‘acute intracerebral haemorrhage’ the prevalence of negative ratings is 11 and the 
prevalence of positive ratings is one leading to the chance agreement also being high, 
and κ is consequently low (0.29).  However, for ‘acute ischaemic change’ the number of 
positive and negative ratings is more equally distributed, and κ is higher (0.61).  This 
effect is likely to explain the relatively modest κ’s for some variables in which both the 
observed agreement and expected agreement were high, such as the presence of EPVS 
and atrophy.  
3.5.5.3 Observer bias 
Observer bias may also affect κ, for example the tendency of one rater to systematically 
rate a variable as being present or absent or under or overestimate the severity of an 
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ordinal variable.  In the example above, for the variable ‘acute ischaemic change’ all 
disagreements result from rater two assessing ischaemic change as being present.  The 
effect of bias is larger when κ is small [Byrt, Bishop, & Carlin 1993].  I was not able to 
avoid observer bias in the study design, but this should be taken into account when 
interpreting the study findings.  
3.5.6 Interpretation of weighted and unweighted κ 
The following classification of κ is the most widely used [Landis & Koch 1977] : <0 = 
agreement less than chance, 0-0.2 slight agreement, 0.2-0.4 fair, 0.4-0.6 moderate 0.6-0.8 
substantial 0.8-0.1 almost perfect.  However, the choice of these categories is recognised 
as being somewhat arbitrary [Brennan & Silman 1992]. For ordinal variables, the size of 
κ is influenced by the number of categories and the method of weighting used.  As the 
number of categories per variable increases, there is a higher likelihood of disagreement, 
resulting in a lower κ, although a linearly weighted κ is less vulnerable to this effect in 
comparison to quadratic weighting [Brenner & Kliebsch 1996].  I used κ with linear 
weighting for all ordinal variables.  All ordinal variables were rated using four point 
scales thus making it easier to compare κ across variables.  However, it is arguable as to 
whether unequal weighting might be used to reflect certain key scale divisions for 
example (no vs. mild WMH). 
   
   
Table 1 MRI scan parameters used for LINCHPIN scans  
*T1WI-T1 weighted imaging, T2WI-T2 weighted imaging 
Sequence TE 
GE        Philips 
TR 
GE        Philips 
Slice thickness 
GE        Philips 
Slice gap 
GE        Philips 
Matrix 
    GE           Philips 
Field of view 
 GE        Philips 
Flip angle 
 GE        Philips 
T1WI*(sagittal) MIN 15 380 623.0 5 5 1.5 1 384×256 256×205 24 23   
T2WI* (axial) 86.2 100 5000 4841.6 5 5 1 1 384×384 384×242 24 23   
FLAIR (axial) 140 100 9000 6000 5 5 1 1 384×224 256×161 24 23   
T2* GRE 
(axial) 
40 40 300 300 5 5 1.5 1.5 256×160 268×166 24 24 20 20 
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Figure 13 Basal ganglia mineralisation 
A No basal ganglia mineralisation visible; rated as 0 
B Subtle linearity bilaterally in Globus pallidi (arrows); rated as 1 
C Signal drop out bilaterally in lentiform nuclei (solid arrows); rated as 1 with haemosiderin                 
visible from an old right occipital infarct (dashed arrow) 
D Moderate basal ganglia mineralisation (arrows); rated as 2 
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Figure 14 White matter hyperintensities of presumed vascular origin 
A Periventricular WMH-1 (Fazekas scale) and right occipital infarct (solid arrow) 
B Deep WMH-1 (Fazekas scale) 
C Periventricular WMH-2 (Fazekas scale) & right centrum semiovale infarct (circle) 
D Deep WMH-2 (Fazekas scale) 
E Periventricular WMH-3 (Fazekas scale) 
F Deep WMH-3 (Fazekas scale) & two left hemisphere cavitated lacunar infarcts (arrows) 
       
       





  Chapter 3   
  101 
Figure 15 Enlarged perivascular spaces 
A Basal ganglia EPVS; a-rated 1, b-rated 2, c-rated 3 
     
B Centrum semiovale EPVS; a-rated 1, b-rated 2 (with 2 old right frontal cortical    
infarcts,arrowed), c-rated 3 
   
a b c
a c) b) 
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Figure 16 Brain microbleeds 
A Left occipital lobe BMB at grey-white matter junction (solid arrow) and two paler BMBs in 
right internal capsule (dashed arrow) 
B Multiple bilateral BMBs in the basal ganglia (solid arrows) and a hypointense focus R 
frontal lobe secondary to partial volume artefact mimicking a BMB (dashed arrow) 
C R parafalcine BMB (solid arrow) and a blood vessel in a cortical sulcus mimicking a BMB 
(dashed arrow) 
  




    
  
Figure 17 Inter-observer (filled boxes) and intra-observer (open boxes) agreement for 15 MRI training scans, measured by weighted 
(asterisked) & un-weighted κ, shown as point estimates with 95% confidence intervals 
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Figure 18 Inter-observer (filled boxes) and intra-observer (open boxes) agreement for 15 MRI training scans, measured by unweighted κ, 
shown as point estimates with 95% confidence intervals 
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Figure 19 Inter-observer agreement for 50 LINCHPIN MRI scans, measured by weighted (asterisked) & un-weighted κ, shown as point 
estimates with 95% confidence intervals 
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Figure 20 Inter-observer agreement for 50 LINCHPIN MRI scans, measured by unweighted κ, shown as point estimates with 95% confidence 
intervals 
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4 Methods of a cross-sectional study of apolipoprotein E genotypes 
in lobar vs. non-lobar intracerebral haemorrhage 
4.1 Introduction 
In recent years there have been numerous studies examining the associations between 
different polymorphisms of the apolipoprotein E gene and stroke phenotypes.  
The apolipoprotein E gene codes for a protein of the same name, which is expressed in 
several organs including the liver and the brain.  The protein assists in the transport of 
triglycerides to the liver.  In the brain, astrocytes and microglia express apolipoprotein E 
which functions as a ligand to assist in the endocytosis of lipoproteins [Kim, Basak, & 
Holtzman 2009].   
The apolipoprotein E gene, is contained on the long arm of chromosome 19 [Verghese, 
Castellano, & Holtzman 2011].  The three common alleles, ε2, ε3 and ε4 are determined 
by two single-base changes (single nucleotide polymorphisms, SNPs) in the coding 
region of the gene at codon positions 112 and 158 [Zannis et al. 1982].  Both SNPs are 
given RefSNP (rs) numbers: rs429358 at position 112 and rs7412 at position 158.  
Cytosine bases at both loci equal apo ε4, thymine bases at both loci equal ε2 and a 
thymine base at position 112 with a cytosine base at position 158 equals ε3.  The ε3ε3 
genotype which is the common variant of apolipoprotein E, has a cysteine amino acid at 
position 112 and an arginine at position 158.  The ε2 allele has a cysteine at position 158 
and the ε4 allele has an arginine at position 112 (Table 2 on page 116).   
Although the three common protein isoforms differ by only one or two amino acids, 
these conformational changes produce important alterations in the function of the 
protein and there is some evidence that the E4 isoform may accelerate the formation of 
amyloid plaques by acting as an Aβ binding protein [Wisniewski & Frangione 1992].  
The ε4 allele has been associated with an increased risk of ICH in comparison to 
unaffected controls [Biffi et al. 2010b]. 
Ideally, a genetic association study of apolipoprotein E and ICH should have: a 
population-based design with both comparison groups drawn from the same 
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population, careful phenotyping of participants according to a standard classification 
and explicit definitions of risk factors [Dichgans & Markus 2005].  Further 
recommendations include: reporting genotype frequencies (in preference to or, as well 
as, allele frequencies, since it is the genotype that confers risk of a certain phenotype and 
allele frequencies can be calculated from genotype frequencies), reporting markers of 
quality control of genotyping such as the proportion of samples for which a genotype 
can be obtained (genotype call rate) and reporting whether polymorphisms deviate from 
Hardy-Weinberg equilibrium, in which case potential reasons should be explored [Little 
et al. 2002;Salanti et al. 2005;Little et al. 2009]. 
Therefore in a small preliminary study I sought to determine the apolipoprotein E 
genotypes of participants with lobar and non-lobar ICH.  The participants in this study 
were recruited from 1st June 2010-31st May 2012. 
In the following chapter, I will describe: 
• the method of deoxyribonucleic acid (DNA) extraction and genotyping; 
• the quality control measures used to maintain the internal validity of the study; and 
• the results of the quality control assessment of genotyping. 
4.2 Methods 
4.2.1 Subjects 
I recruited participants into the LINCHPIN study.  The full inclusion and exclusion 
criteria for the study are given in Chapter 2.  All participants had a primary ICH during 
1st June 2010-31st May 2012 and lived in the Lothian region at the time of their ICH. 
Participants or their nearest relative gave written informed consent to a clinical 
assessment, access to their medical records and two blood samples – one for genotyping 
of apolipoprotein E and the other to be held in storage for use in future ethically-
approved stroke studies.   
4.2.2 Data and blood collection  
I collected data on baseline demographic, clinical and imaging characteristics as outlined 
in Chapter 2. As described in Chapter 2, I used multiple overlapping sources of follow-
up to determine if a participant had died and if applicable, their date of death.  I used 
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information from questionnaires sent annually to participants GPs to obtain their level 
of disability one year after their ICH using the modified Rankin scale.   
I performed venesection and transferred two ethylene-diamine-tetra-acetic acid (EDTA) 
tubes containing up to nine millilitres blood to the Wellcome Trust Clinical Research 
Facility, (WTCRF; Western General Hospital, Edinburgh) for storage and future 
genotyping.  All samples were anonymised, labelled with a unique three digit ID number 
and the participant’s date of birth.  
4.2.3 Phenotype definition 
I classified participants as having either lobar or non-lobar ICH using the definition 
outlined in Chapter 1.  Non-lobar ICH included participants with both supratentorial 
ICH involving the basal ganglia, internal capsule and/or thalamus and infratentorial 
ICH.  The neuroradiologist(s) who classified ICH location were blinded to the 
participant’s genotype. 
4.2.4 DNA extraction 
After venesection, WTCRF extracted DNA from whole blood on the day that they 
received the sample.  To extract the DNA, one blood sample was centrifuged before 
resuspending the DNA and transferring it to a flip tube which was then stored at -80°C.   
4.2.5 Genotyping 
4.2.5.1 DNA concentration 
We first quantified the concentration of DNA using Quant-iT™ PicoGreen double 
stranded DNA reagent; a highly sensitive nucleic acid stain that binds to double 
stranded DNA producing a strong fluorescent signal.  After obtaining the concentration 
of DNA in each sample, WTCRF standardised each sample to a DNA concentration of 
10ng/µl and froze the sample at -40°C.   
4.2.5.2 Polymerase chain reaction (PCR)  
A single sample of DNA is the starting point for the PCR.  PCR enables amplification 
of a single copy of the target DNA sequence by using primers and free nucleotides to 
produce multiple DNA copies (Figure 21 on page 117).  Two TaqMan assays (Assay-
On-Demand, Applied Biosystems) were used to determine the SNPs.  The assays 
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contained sequence specific primers to amplify the region of interest and fluorescent 
dye-labelled probes which anneal to the sequences and enable discrimination of alleles.  
The probe for allele X was labelled with VIC dye and the probe for allele Y was 
labelled with FAM dye.  The numbers of the assays for SNPs rs429358 and rs7412 
were c3084793 and c904973 respectively. 
The laboratory aliquoted 2µl DNA from each sample by robot (Beckman) into a 384 
well plate allowing the DNA to dry completely.  The DNA was mixed with the two 
Taqman genotyping assays (Assay-On-Demand, Applied Biosystems).  The well plate 
contained DNA from 92 blood samples and four no template controls (NTCs).  The 
controls were used for quality control purposes (Section 4.2.5.3, below).  Samples were 
plated in the order in which they arrived in the laboratory.     
PCR reactions were conducted according to the manufacturer’s protocol, with Taqman 
genotyping master mix (Applied Biosystems, PN 4731355) and DNAase RNAase free 
water using the following cycling conditions - 50°C for two minutes, followed by 95°C 
for ten minutes, followed by 40 cycles of denaturation at 92°C for fifteen seconds and 
annealing and polymerisation at 60°C for one minute.   
The laboratory ran the reaction on a ABI Prism TaqMan 7900HT Sequence Detection 
System (Applied Biosystems) and genotypes were indicated by Sequence Detection 
Software version 2.4 (Applied Biosystems).  All genotyping calls were double checked 
by two laboratory researchers and genotyping personnel were blinded to the 
participant’s phenotype.  WTCRF performed genotyping of all samples simultaneously. 
4.2.5.3 Quality control 
The laboratory conducted various quality control measures. 
• WTCRF internally validated their genotyping analysis by using no template controls 
(NTC’s) which contained all elements of the reaction except the DNA template.  
Since the NTC’s do not contain the template they should not produce any 
fluorescent signal when displayed in an allelic discrimination plot (Figure 22 on page 
118 and Figure 23 on page 119).  This allows detection of contamination occurring 
either when loading DNA templates onto the well plate or through contaminated 
reagents.   
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• WTCRF checked whether the observed and expected genotype frequencies at 
rs429358 and rs7412 were in Hardy-Weinberg equilibrium [Salanti et al. 2005].   
• WTCRF calculated the genotype call rate for each SNP by dividing the number of 
SNPs receiving a genotype by the number of SNPs on the well plate. 
•  WTCRF measured the purity of DNA in each sample.  One of the commonest 
measures of DNA purity is assessment of ultraviolet (UV) light absorption 
[Manchester 1995].  DNA light absorption peaks at 260nm and proteins (and some 
other contaminants) peak at 280nm.  Therefore the ratio of absorbance of UV light 
at 260nm and 280nm (A260/280) can be used to assess DNA purity using a 
NanodropTM ND-8000 spectrophotometer (NanoDrop, USA).  A ratio of 1.7-2.0 is 
generally accepted as ‘good quality’ DNA [Manchester 1995].   
4.2.6  Genotyping definition 
I combined the SNPs obtained from each sample to determine the alleles and genotypes 
for each participant (ε2ε2, ε2ε3, ε3ε3, ε3ε4, ε4ε4, ε2ε4).  I compared the proportions of 
participants with an undetermined genotype in the lobar and non-lobar ICH groups.  
4.2.7 Statistical analysis 
I used parametric statistics for between group comparisons when the data had a normal 
distribution and log –transformed variables or used non-parametric statistics when it did 
not.  If an estimated cell count was less than five, I used the Fisher’s exact test.  I 
conducted all statistical analyses using Stata version 11.1 (StataCorp LP, Texas, USA).  
All p values are 2-sided.  
4.3 Results 
4.3.1 Study participants 
92 participants had blood taken for apolipoprotein E genotyping.  Two participants 
were excluded from the study following genotyping because they were found to be 
living outside of the Lothian region at the time of their ICH (n=1) or their ICH was 
subsequently found to be HTI (n=1).  Of the remaining 90 participants, 48 had lobar 
ICH. 84 participants had a first-ever ICH.  Three participants had recurrent lobar ICH 
and three had recurrent non-lobar ICH.  
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4.3.2 Quality control assessment of genotyping 
4.3.2.1 DNA quality 
The mean A260/A280 ratio was 1.80; standard deviation (SD) 0.07; indicating that 
DNA samples were of adequate quality.  
4.3.2.2 Allelic discrimination plots 
Figure 22 on page 118 and Figure 23 on page 119 show the allelic discrimination plots 
for the two assays for SNPs rs429358 and rs7412 respectively.   
Each axis represents the reporter fluorescent signal intensity (Rn) for one of two probes 
(each relating to an allele).  Homozygotes (shown in blue and red) show increased 
fluorescence on either the horizontal or vertical axis; depending on which probe they 
were detected by whereas heterozygotes (shown in green) appear in the middle of the 
plot since they contain copies of both alleles and therefore produce fluorescence with 
both dyes. 
The four NTC’s (black crosses, circled) do not produce any fluorescence indicating that 
there is no evidence of cross contamination between samples.  Undetermined alleles 
(dashed circles) do not cluster within either the homozygote or heterozygote groups and 
produce an indeterminate fluorescent signal. 
4.3.2.3 Genotype call rate 
For each SNP, 88 out of 90 DNA samples were called with two alleles undetermined; a 
call rate of 98%.  No control samples were called.  All the undetermined alleles occurred 
in first-ever ICHs (n=84), giving a genotype call rate for each SNP for first-ever ICHs 
of 98%.  The proportion of participants with an undetermined genotype did not differ 
between those with lobar and non-lobar ICH (lobar: 2/48 (4%) vs. non-lobar 2/42 
(5%), χ2=0.02, p=0.891.) 
4.3.2.4   Genotype call frequencies 
Table 3 on page 116  shows the genotype frequencies for SNPs rs429358 and rs7412 
and the corresponding epsilon genotypes of the 90 participants.  Table 4 on page 116 
shows the genotype frequencies for SNPs rs429358 and rs7412 and the corresponding 
epsilon genotypes of the 84 participants with first-ever ICH.  Both SNPs conformed to 
Hardy-Weinberg equilibrium expected proportions (rs429358 p=0.88; rs7412 p=0.32).  
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4.4 Summary 
• The genotyping process for apolipoprotein E fulfilled pre-specified quality control 
measures. 
• The genotype frequencies for SNPs rs429358 and rs7412 conformed to Hardy-
Weinberg equilibrium. 
• There was no difference in the proportion of participants with an undetermined 
genotype between the lobar and non-lobar ICH groups. 
4.5 Discussion 
The findings presented in this chapter should be viewed as a baseline assessment of 
quality control measures of genotyping of the apolipoprotein E gene. 
4.5.1 Quality control assessment of genotyping 
The study fulfilled established measures of quality control for genotyping in a genetic 
association study [Little et al. 2002] which have been included in the STrengthening the 
REporting of Genetic Association studies (STREGA) statement [Little et al. 2009] 
including: 
(i) successful internal validation of the genotyping process using NTC’s; 
(ii) blinding of laboratory personnel to participants’ phenotypes and the study 
hypothesis; 
(iii) classification of ICH location done blind to participants’ genotypes; 
(iv) a high genotype call rate; 
(v) conformation of genotype frequencies to Hardy-Weinberg equilibrium; 
(vi) automated data entry of genotypes called with third party adjudication; and 
(vii) presentation of both genotype and allele frequencies.    
4.5.1.1 Hardy-Weinberg equilibrium 
The Hardy-Weinberg law states that the genotype frequencies and allele frequencies of a 
population remain constant from one generation to the next [Lunetta 2008].  It predicts 
how gene frequencies will be inherited assuming that the following assumptions are met: 
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(i) the population is large, (ii) there is no natural selection, (iii) mutations do not occur, 
(iv) there is no migration in or out of the population and (v) all members of the 
population breed randomly and produce on average, the same number of offspring.  
Deviation from Hardy-Weinberg equilibrium may result from one or more of the 
assumptions above not being met; for example if there is non random mating or a small 
non-representative study sample leads to selection bias [Salanti et al. 2005] or if there is 
genotyping error, especially with non-differential misclassification of genotypes between 
comparison groups.   
Both loci in our study conformed to Hardy-Weinberg equilibrium, indicating that the 
Hardy-Weinberg assumptions were not rejected and providing some evidence against 
the existence of selection bias or genotyping errors. 
4.5.1.2 Genotype calls 
This small genotyping study benefits from all blood samples having been processed by 
the same laboratory with genotypes assigned simultaneously, therefore avoiding the 
misclassification bias which may occur when specimens are processed by different 
laboratories [Plagnol et al. 2007].  Bias may also be introduced by treating undetermined 
genotypes as ‘missing’ when the proportion of undetermined genotypes varies between 
comparison groups, since this may lead to a false association between a genotype and 
phenotype (Type one error) [Sampson & Zhao 2009].  The proportion of undetermined 
genotypes may be higher when multiple laboratories are used for genotyping because of 
variation in the processing of samples [Clayton et al. 2005].  In this study, the 
proportion of participants with an undetermined genotype was small (4%) and did not 
differ between comparison groups.  However, it is a small study in which all samples 
were processed by a single laboratory.  To obtain meaningful results in genetic-
association studies, larger scale studies are necessary, using pooled data from multiple 
cohorts.  These problems might then be overcome by all samples being genotyped by a 
single centre or using statistical techniques such as the gene counting method in which 
missing information is imputed based upon estimates of haplotype frequencies [Hawley 
& Kidd 1995]. 
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Table 2 Variation in gene nucleotides (SNPs) at codon positions 112 and 158 with 
corresponding amino acids 
T= thymine, G=guanine, C=cytosine 
 
 
Table 3 Genotype number (with frequencies, %) for SNPs rs429358 and rs7412 in 90 




TT TC CC  Undetermined 
CC 47 (53) [ε3/ε3] 19 (21) [ε3/ε4] 3 (3) [ε4/ε4] 2 (2) 
CT 11 (12) [ε2/ε3] 6 (7) [ε2/ε4] - - 
TT 0  (0) [ε2/ε2] - - - 
Undetermined 1 (1) 1 (1) - - 
 
Table 4 Genotype number (with frequencies, %) for SNPs rs429358 and rs7412 in 84 
participants with first-ever ICH [with the corresponding alleles]
Apolipoprotein E isoform Gene nucleotide position (corresponding amino acid) 
3937 (112) 4075 (158) 
SNP ID rs429358 rs7412 
ApoE2 TGC (Cysteine) TGC (Cysteine) 
ApoE3 TGC (Cysteine) CGC (Arginine) 




TT TC CC  Undetermined 
CC 44 ( 52) [ε3/ε3] 17 (20) [ε3/ε4] 3 (4) [ε4/ε4] 2 (3) 
CT 11 (13) [ε2/ε3] 5 (6) [ε2/ε4] - - 
TT 0  (0) [ε2/ε2] - - - 
Undetermined 1 (1) 1 (1) - - 
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Figure 21 Schematic diagram of the Polymerase Chain Reaction (PCR) 
A The target DNA sequence 
B DNA is denatured at 92°C separating the strands by breaking the hydrogen bonds. 
C The temperature is reduced to 60°C enabling primers (shown in red) in the genotyping 
assays to anneal to the complementary base pair sequences in the target DNA. 
D The DNA TaqPolymerase enzyme begins polymerisation, adding nucleotides to the end 
of each primer (shown in green), eventually forming two copies of the target sequence of 
DNA.  The assay contains many copies of the primer and nucleotides to perform 
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Figure 22 Allelic discrimination plot for assay c3084793 (rs429358) for 92 participants 
from the LINCHPIN study 
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Figure 23 Allelic discrimination plot for assay c904973 (rs7412) for 92 participants 
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5 Results of a community-based, cross-sectional study of 
intracerebral haemorrhage-incidence and baseline characteristics 
5.1 Introduction 
From my review of studies of ICH including those which have compared lobar and 
non-lobar ICH (Chapter 1), it was apparent that there is a paucity of larger population-
based studies of spontaneous primary ICH, which have used multiple overlapping 
sources of case ascertainment, explicitly defined ICH location (lobar vs. non-lobar vs. 
mixed ICH), distinguished primary from secondary ICH and first-ever from recurrent 
ICH and defined pre-ICH risk factors.   
Moreover the findings from previous studies of lobar vs. non-lobar ICH have been 
inconsistent (Table 5 on page 140).  40 studies involving 4923 individuals with lobar and 
7473 with non-lobar ICH have compared the risk factors for these ICH subtypes.  
Associations between certain risk factors and subtypes of ICH (such as hypertension 
and non-lobar ICH [Jackson & Sudlow 2006], older age and lobar ICH [Greenberg et al. 
1996;Labovitz et al. 2005;Biffi et al. 2011b], and female gender and lobar ICH [Weimar 
et al. 2011;Matsukawa et al. 2012]) have been more commonly reported in hospital 
based studies rather than population-based ones but these findings are likely to be 
biased by the cohorts selected and the definitions of risk factors used.  There are no 
consistent associations between prior smoking, diabetes, ischaemic stroke, ischaemic 
heart disease, cognitive impairment or dementia and subtypes of ICH.  A recent case 
control study [Martini et al. 2012] which compared cases of ICH vs. controls without 
ICH suggested that hypertension and hypercholesterolaemia were associated with non-
lobar ICH in comparison to controls (matched for age, race and gender) but the cases 
represented only 23% of all ascertained ICHs and they were significantly younger, less 
likely to die in the first 30 days after their ICH and more likely to have a past history of 
hypercholesterolaemia compared to those who did not become cases.   
Despite the development of the Boston criteria [Knudsen et al. 2001] and more recent 
modified Boston criteria [Linn et al. 2010] for the diagnosis of ‘CAA-related ICH’ in 
patients with lobar ICH and their increasing application over the last decade, especially 
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in research settings for classifying those participants without pathological confirmation 
of CAA with a probable CAA-related ICH, the criteria are yet to be applied to a 
population based cohort of participants with ICH.   
Therefore I sought to describe the incidence of both first-ever and recurrent 
spontaneous primary and secondary definite ICH in a population based study in South 
East Scotland and compare the prevalence of certain predefined risk factors in those 
with lobar vs. non-lobar ICH.  In addition, I integrated the MRI brain findings and 
post-mortem examination results (where applicable) of study participants to describe the 
frequencies of possible, probable and definite CAA-related ICH according to the 
modified Boston criteria in a population-based cohort of participants with first-ever 
lobar ICH.  These analyses are based upon participants recruited in the first complete 
year of the study (1st June 2010-31st May 2011). 
5.2 Methods 
5.2.1 Incidence 
I used the first complete year of the study (1st June 2010-31st May 2011) to calculate the 
incidence of spontaneous ICH in adults meeting our inclusion and exclusion criteria 
(Section 2.2, page 60).  The crude incidence is the proportion of the adults (aged ≥16 
years) on 1st June 2010 who had an ICH during the first year of the study.  I used mid-
2010 United Kingdom (UK) population estimates from the Office for National 
Statistics 
(http://www.ons.gov.uk/ons/taxonomy/index.html?nscl=Population+Estimates) to 
calculate age standardised incidence estimates using direct standardisation.  I 
distinguished primary from secondary ICH and first-ever from recurrent primary ICH, 
since the causes of each may differ.   
5.2.2 Comparison of lobar vs. non-lobar ICH  
I have compared baseline demographic and clinical characteristics in adults with first-
ever lobar and non-lobar ICH.  
Chapter 5 
  124 
5.2.3 Definition of lobar and non-lobar ICH 
5.2.3.1 Lobar ICH 
I categorised an ICH as lobar if it involved one or more lobes of the brain.  The 
following ICH(s) were classified as lobar: 
• a single ICH involving any of the following areas: frontal, frontotemporal, 
frontoparietal, parietal, parieto-temporal, parieto-occipital, temporal, temporo-
occipital or occipital; 
• an ICH which involved both lobar and supratentorial ‘deep’ (Section 5.2.3.2 below) 
regions of the brain; or 
• multiple ICHs in either solely lobar locations or where at least one ICH involved a 
lobar location. 
5.2.3.2 Non-lobar ICH 
I categorised an ICH as non-lobar if it did not extend to a lobar area and was: 
• a single infratentorial ICH (located in the brainstem or cerebellum); 
• a single supratentorial deep ICH (located in the basal ganglia, internal capsule or 
thalamus); or 
• multiple ICHs in solely non-lobar locations (either supratentorial deep or 
infratentorial). 
5.2.3.3 Definitions of clinical variables 
I defined the clinical characteristics of participants as follows. 
(i) Hypertension: If this diagnosis had been made prior to their ICH and recorded 
in GP or hospital notes, or if the participant had been prescribed medications 
for the treatment of hypertension. 
(ii) Diabetes: If this diagnosis had been made prior to their index ICH and recorded 
in their GP or hospital notes. 
(iii) Dementia: If these diagnoses had been made prior to their ICH and recorded in 
their GP or hospital records.  Where a relative or close friend was available I 
also used the short form of the Informant Questionnaire on Cognitive Decline 
in the Elderly (IQCODE) with a cut-off ≥ 64 for dementia [Jorm 1994].     
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(iv) Smoking: I classified participants as never having smoked, being an ex or a 
current smoker at the time of their ICH.  The definition was based on the 
history obtained from the participant or their relative and if neither was 
available, their medical records.  
(v) Alcohol: I obtained a history of average alcohol consumption in units per week 
in the month prior to the ICH from the participant or their relative where 
available, or their GP or hospital records. 
(vi) Antithrombotic use: A participant was classified separately as taking antiplatelet 
or anticoagulant medications if they had been taking either medication until their 
ICH.  
5.2.3.4 Definitions of other radiological variables 
I defined other radiological characteristics of ICHs as follows. 
(i) Multiple ICH: If there was more than one acute ICH present on the diagnostic 
brain imaging obtained at presentation.  ‘Acute’ ICH was determined 
radiologically by the presence of a hyperdense area in the brain parenchyma 
(Section 2.5.2, page 64).  
(ii) Intraventricular extension: If any blood was present within the ventricles of the 
brain on review of the imaging by a neuroradiologist with a special interest in 
stroke. 
(iii) Subarachnoid extension: If any blood was present within the subarachnoid 
compartment of the brain on review of the imaging by a neuroradiologist with a 
special interest in stroke. 
(iv) Subdural extension: If any acute blood was present within the subdural 
compartment of the brain on review of the imaging by a neuroradiologist 
without any clinical or radiological evidence of trauma (Section 2.5.4.2, page 66). 
(v) ICH volume: Arthur Fonville (Medical Student, University of Amsterdam) 
measured ICH volume on the first CT brain scan following the participant’s 
presentation with ICH (the diagnostic scan) using Quantomo computerised 
planimetry software (Cybertrial Inc, Calgary, Canada) [Kosior et al. 2011], which 
has been shown to have greater reliability for quantifying ICH volume in 
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comparison to the ABC/2 method [Kothari et al. 1996].  In the ABC/2 method, 
A is the longest diameter on the axial CT slice which shows the largest volume 
of ICH, B is the diameter perpendicular to A and C is the depth of the 
haemorrhage as measured by the number of axial CT slices on which the ICH is 
visible [Kothari et al. 1996].  Quantomo allows tailoring of individual 
haematoma shapes whereas ABC/2 approximates haematomas to ellipsoids 
which may lead to an overestimation of ICH volume.  
5.2.4 Statistical analyses 
I calculated 95% CI around incidence estimates using the Wilson score interval 
[Newcombe 1998].  I used parametric statistics for between group comparisons when 
the data had a normal distribution and log-transformed variables or used non-
parametric statistics when it did not.  If an estimated cell count was less than five, I used 
the Fisher’s exact test.  I conducted all statistical analyses using Stata version 11.1 
(StataCorp LP, Texas, USA).  All p values are two-sided.  
5.2.5 Modified Boston criteria for cerebral amyloid angiopathy 
I applied the modified Boston diagnostic criteria for CAA [Knudsen et al. 2001;Linn et 
al. 2010] to our cohort to determine the frequency of possible, probable and definite 
CAA-related ICH in a population-based cohort of those with first-ever lobar ICH. 
5.2.5.1 Pathological specimens 
Since the modified Boston criteria require confirmation of CAA on at least one 
pathology specimen for a diagnosis of ‘definite CAA’ or ‘probable CAA with supporting 
pathology’ I reviewed the pathology findings for participants with lobar ICH who had 
undergone post-mortem examination (Chapter 10).   
To fulfil the criteria for ‘definite CAA’, vasculopathy and ‘severe’ CAA must be present 
in at least one pathology specimen.  To fulfil the criteria for ‘probable CAA with 
supporting pathology’ CAA of any severity must be present in at least one pathology 
specimen without vasculopathy and without an alternative cause of ICH [Knudsen et al. 
2001].   
Dr Colin Smith (Consultant Neuropathologist, University of Edinburgh) rated CAA 
according to the Bristol rating scale [Love et al. 2014] which rates the severity of both 
Chapter 5 
  127 
parenchymal and meningeal CAA, presence or absence of CAA in the capillaries and 
extent of vasculopathy in each of the lobes of the brain (Table 6 on page 144).  
Vasculopathy is defined as the presence of fibrinoid necrosis, thrombosis, haemorrhage 
or circumferential splitting of the vessel wall.  I used parenchymal and meningeal CAA 
ratings of two (‘some circumferential amyloid’) and three (‘widespread circumferential 
amyloid’) as markers of ‘severe’ CAA. 
5.2.5.2 Brain imaging 
The presence of multiple ICHs restricted to lobar, cortical or subcortical regions 
(including the cerebellum) differentiates probable CAA-related ICH (without 
pathological confirmation) from possible CAA-related ICH, in which only a single ICH 
is present [Knudsen et al. 2001]. 
The definition of ‘multiple’ ICHs is: 
• more than one acute lobar or cerebellar ICH on axial CT or MRI; 
• more than one lobar or cerebellar ICH on T2*-weighted sequences (in which case 
the haemorrhage(s) may be acute or chronic);  
• one ICH in addition to at least one BMB on T2*-weighted MRI sequences, both of 
which are restricted to lobar or cerebellar regions of the brain; or 
• recurrent lobar or cerebellar ICH; that is: one acute ICH in addition to evidence of 
at least one previous ICH on either CT or T2*-weighted MRI sequences, both 
restricted to lobar or cerebellar regions of the brain. 
Since I applied the modified Boston criteria to those with first-ever lobar ICH, I did not 
categorise any participants with recurrent ICH as having probable CAA-related ICH.  A 
neuroradiologist with a special interest in stroke rated all MRI scans according to a 
modified version of the Brain Observer MicroBleed rating scale (BOMBS [Cordonnier 
et al. 2009]; Chapter 3 and Appendix).  The scale rates BMBs according to their 
certainty, and for the purposes of this analysis, only ‘certain’ BMBs were used.  
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5.3 Results 
5.3.1 ICH cases 
Figure 24 on page 147 illustrates the identification of adults with spontaneous ICH from 
1st June 2010 to 31st May 2011.  Of 216 possible cases 27 were excluded, leaving 166 
definite cases of primary and secondary ICH and 23 suspected (but unconfirmed) cases 
of ICH.  Of 166 definite cases, the diagnosis of ICH was confirmed by CT brain 
imaging in 162 (98%) cases with the remainder diagnosed at post-mortem examination.  
CT brain imaging was done within two days of ICH onset in 144 (87%) cases.  There 
were 141 cases of spontaneous primary ICH of which 128 (91%) were first-ever. 
5.3.2 Secondary ICH 
The causes of 25 secondary ICHs are shown in Figure 24 on page 147.  Adults with 
secondary ICH were significantly younger than those with primary ICH (median age 
(years) 57, interquartile range [IQR] 49-63 vs. 79; IQR 66-83; p<0.001).  19 (76%) were 
lobar. 
5.3.3 Suspected ICH 
23 adults died from suspected but unconfirmed spontaneous ICH.  These adults tended 
to be older than adults with a confirmed diagnosis of spontaneous primary ICH (median 
age (years) 86, IQR 79-91 vs.79; IQR 66-83; p<0.001).  13 died in the Emergency 
department and were identified through surveillance of the electronic patient records 
system and the remainder died in the community before a diagnosis of ICH could be 
reached and were identified through calls made by GPs to the Office of the Procurator 
Fiscal.  When a participant’s final illness had been witnessed, the modes of presentation 
were rapid onset loss of consciousness (n=11), hemiparesis (n=3), sudden severe 
headache (n=2) and seizure followed by cardiac arrest (n=1).  Four adults were found 
dead at home and a stroke was suspected because of their past medical histories of 
stroke.  In two cases, ‘stroke’ had been listed as the main cause of death on their death 
certificates without any further details being available.  
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5.3.4 Crude incidence of definite ICH (confirmed by imaging or post-mortem 
examination) 
The crude incidence of first-ever and recurrent spontaneous (primary and secondary) 
definite ICH in adults in the Lothian health board region of Scotland during 1st June 
2010-31st May 2011 was 0.24 per 1000 per year (95% CI 0.21 to 0.27).  The incidence of 
first-ever spontaneous primary definite ICH was 0.18 per 1000 per year (95% CI 0.16 to 
0.22).  If all suspected ICH cases (Section 5.3.3, page 128) were confirmed as 
spontaneous primary ICH the incidence would be 0.22 per 1000 per year (95% CI 0.19 
to 0.25). 
5.3.5 Age standardised incidence of first-ever spontaneous primary definite ICH 
The age-standardised incidence of first-ever spontaneous primary definite ICH, directly 
adjusted to the mid-2010 population estimates for the UK was 0.21 per 1000 per year 
(95% CI 0.20 to 0.21), which is very similar to the crude incidence of spontaneous 
primary definite ICH (Section 5.3.4, above). 
5.3.6 Age and sex-specific incidence of first-ever spontaneous primary definite 
ICH 
As expected, the incidence of first-ever spontaneous primary definite ICH increased 
with age (Figure 25 on page 148).  Although males had a higher incidence of ICH in the 
45-54 years age band there was no overall difference in the incidence of ICH in males 
vs. females (Table 7 on page 145). 
5.3.7 Age specific incidence of lobar and non-lobar first-ever spontaneous primary 
definite ICH 
The incidence of both first-ever lobar and non-lobar ICH increased across all age 
groups (Table 7 on page 145).  The incidence of lobar ICH was higher than non-lobar 
ICH in the 75-84 years age band but 95% CI were broad and the overall incidences of 
lobar and non-lobar ICH were similar.  
5.3.8 Locations of haemorrhages in adults with first-ever spontaneous primary ICH 
Primary first-ever ICH locations were single lobar (n=61), single non-lobar (n=59), 
single lobar extending to non-lobar regions (n=4), multiple lobar and non-lobar (n=2), 
multiple lobar (n=1) and multiple non-lobar (n=1).  68 participants (53%) had a lobar 
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ICH (an ICH which involved at least one lobe of the brain) and 60 participants had 
non-lobar ICH. 
5.3.9 Baseline characteristics of adults with first-ever lobar and non-lobar ICH 
The characteristics of adults found to have an ICH involving any lobar region (n=68) 
are compared with those with ICH in non-lobar regions (n=60) in Table 8 on page 146.  
An IQCODE was available for 47 participants (37%).  There was no difference in age 
(has IQCODE: mean 75 years, IQR 66-81 vs. no IQCODE: mean 79, IQR 68-85; 
p=0.14), gender (males 19/47 (40%) vs. 36/81 (44%); χ2 =0.20, p=0.66) or ICH 
location (any lobar 27/47 (57%) vs. 41/81 (51%); χ2 =0.56, p=0.46) between 
participants who had an IQCODE and those who did not.  A history of dementia was 
more common in adults with lobar ICH.  Pre-morbid hypertension did not vary 
according to ICH location. 
65 out of 128 participants (51%) were using antithrombotic medication prior to their 
ICH and this proportion did not vary according to ICH location.  The incidence of 
primary first-ever ICH associated with anti-thrombotic medication use was 0.09 per 
1000 per year (95% CI 0.07 to 0.12).  
Admission GCS scores were significantly higher and ICH volumes were larger in the 
lobar ICH group.  Extension of the ICH into the subdural and subarachnoid 
compartments was more common in the lobar ICH group.  In a post-hoc analysis, 
extension of ICHs into the subdural and subarachnoid compartments of the brain was 
associated with larger ICH volumes (subarachnoid extension; present - median ICH 
volume (ml3) 44; IQR 24-77; absent -12; IQR 4 -37; p<0.001 and subdural extension; 
present - median ICH volume (ml3) 42; IQR 15-78; absent - 20; IQR 5-49; p=0.046).  
5.3.10 Application of the modified Boston criteria to adults with first-ever 
spontaneous primary lobar ICH 
Of 68 participants with first-ever lobar ICH, five were aged less than 55 years at the 
time of their ICH and four had ICH involving both lobar and supratentorial deep 
regions and therefore could not be considered as having CAA (Figure 26 on page 149).  
14 participants out of the remaining 59 had MRI with T2*-weighted sequences available 
for interpretation of brain BMBs and a further 13 had post-mortem examination 
specimens. 
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Six participants with lobar ICH fulfilled the criteria for definite CAA-related ICH; five 
had probable CAA-related ICH (without supporting pathology) and one had probable 
CAA-related ICH with supporting pathology.  47 out of 59 eligible participants (80%) 
fulfilled the criteria for possible CAA-related ICH.  No participants had superficial 
siderosis on MRI.  
5.4 Summary 
• During 1st June 2010-31st May 2011 the crude incidence of spontaneous definite 
ICH was 0.24 per 1000 per year (95% CI 0.21 to 0.27) and the incidence of first-
ever spontaneous primary definite ICH was 0.18 per 1000 per year (95% CI 0.16 to 
0.22) and did not vary by ICH location. 
• Lobar ICHs were more likely to have a past history of dementia in comparison to 
non-lobar ICH, but there were no other differences in pre-ICH characteristics 
between lobar and non-lobar ICH. 
• Lobar ICHs were associated with a lower GCS score on admission.  
• Lobar ICHs were larger and associated with extension of the ICH into the 
subarachnoid and subdural compartments of the brain. 
• 12 out of 59 participants with first-ever lobar ICH eligible to be considered under 
the modified Boston criteria, fulfilled the criteria for definite or probable CAA-
related ICH. 
5.5 Discussion 
5.5.1 Strengths of the study 
Strengths of the study include its prospective, population-based design with multiple 
overlapping sources of case ascertainment, comprehensive data collection and the 
availability of post-mortem examination findings using an extensive sampling protocol 
for CAA.  Although I did not formally assess the inter-rater reliability of classifying ICH 
location, all ICHs were classified as lobar or non-lobar by an experienced 
neuroradiologist with a special interest in stroke, in a multi-disciplinary meeting in which 
usually more than one neuroradiologist was present, and a consensus decision was 
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reached.  There has been good inter-observer agreement in the assessment of  
supratentorial ICH location even for larger haematomas [Wermer et al. 2002]. 
5.5.2 Limitations of the study 
It was difficult to apply the modified Boston criteria to this population-based cohort of 
participants with ICH because I was only able to obtain brain MRI, despite being 
funded to do so, on 24% of patients with first-ever lobar ICH (Section 5.5.3.9, page 
138). 
5.5.3 Study findings 
5.5.3.1 Incidence of spontaneous primary definite ICH 
The incidence of spontaneous primary definite ICH in our study is comparable to the 
findings of a recent systematic review and meta-analysis in which the incidence of ICH 
had not changed for several decades [van Asch et al. 2010].  The age-standardised 
incidence of ICH when adjusted to the population of the UK was very similar to the 
unadjusted incidence of ICH, indicating that the Lothian health board population is 
likely to be demographically representative. 
In keeping with other studies [van Asch et al. 2010], the incidence of ICH increased 
with age with the highest incidences in those aged 65 years or older.  This is of particular 
significance given the ageing population of the UK in which the proportion of those 
aged 65 years or older is set to increase from 17% to 24% between 2010 and 2051 
[Office for National Statistics 2012]. 
5.5.3.2 Incidence of suspected (unconfirmed) ICH 
12% of potential ICH cases were suspected but unconfirmed.  These patients tended to 
be older, and were either found dead or deteriorated rapidly soon after symptoms were 
first noted so that nearly half died before reaching hospital.  A diagnosis of stroke is 
recognised as being harder to confirm in the elderly [Giroud et al. 1991].  Prior 
comorbidities may dictate that a patient is too unwell for hospital transfer and further 
investigation.  Presentations may be atypical leading to a delay in suspecting a diagnosis 
of stroke.  Although this raises the possibility that I under-ascertained ICH in older age 
groups, the incidence of ICH in those aged 85 and above is almost identical to that 
found in other studies [van Asch et al. 2010].  Future studies might seek to determine 
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the incidence of ICH in those who die suddenly in the community by use of post-
mortem imaging techniques [Roberts et al. 2012].  
5.5.3.3 Secondary ICH 
It is unsurprising that those adults with secondary ICH were younger than adults with 
primary ICH since clinicians are more likely to investigate younger adults with ICH for 
underlying causes whereas an ICH in an older person may be attributed to CAA or pre-
existing hypertension [Cordonnier et al. 2010a].  The findings are therefore subject to 
detection bias since the label of ‘primary’ ICH is dependent on no other secondary 
cause having been ascertained.  Ideally, the impact of detection bias might be evaluated 
by screening all ICH participants routinely using angiographic imaging +/- MRI.  
However, since many participants are too unwell this would be impossible.  A 
systematic review of studies investigating spontaneous ICH for a secondary cause, 
revealed that the prevalence of underlying AVMs and aneurysms in participants who 
had undergone IADSA was 20% and 13% respectively [Cordonnier et al. 2010a].  Even 
though the incidence of AVMs and aneurysms in my cohort is lower (3% [95% CI 1-
7%] and 6% [95% CI 3-11%]) respectively, the participants formed an unselected 
cohort, the majority of whom were older than patients included in studies identified by 
the systematic review [Cordonnier et al. 2010a].  Moreover, in the 58 participants (45%) 
with first-ever spontaneous primary ICH who underwent further investigation (MRI 
(n=30), post-mortem examination (n=25), CT angiography (n=2), IADSA (n=1)) I did 
not find a secondary cause, and therefore it is less likely that I have under-ascertained a 
considerable number of secondary ICHs. 
5.5.3.4 Lobar and non-lobar ICH 
If the main causative factor for non-lobar ICH is hypertension and CAA is implicated in 
lobar ICH, one might expect a decrease in the incidence of non-lobar ICH given the 
decreases in mean systolic blood pressures in recent years in Western European 
populations [Danaei et al. 2011].   
I did not demonstrate this and possible reasons are: 
(i) I had small numbers of ICHs producing broad estimates of incidence and a lack 
of power to detect such a difference. 
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(ii)  Since both hypertension and CAA are more prevalent with increasing age, they 
are likely to co-exist with each other and therefore dichotomisation of CAA as 
the main cause of lobar ICH and hypertension for non-lobar ICH may be too 
simplistic.   
5.5.3.5 Pre-ICH clinical characteristics  
The frequency of antithrombotic medication use was comparable to that of another 
contemporary population-based cohort [Bejot et al. 2013].  A past medical history of 
dementia was more common in participants with lobar ICH but I did not demonstrate 
any other significant differences in pre-ICH characteristics between non-lobar and lobar 
ICHs.   
There are several possible explanations for this.  The size of the cohort is relatively small 
and may lack sufficient power.  Continued recruitment of participants over the next few 
years will determine whether the lack of difference in most baseline characteristics in the 
first year remains in a larger cohort.  Although I was unblinded to the location of the 
participant’s ICH when assessing characteristics, any information bias introduced by this 
would have been more likely to lead to a Type one error rather than mask a significant 
difference between the groups. 
It is plausible that some exposures such as smoking or alcohol consumption were 
incorrectly reported if participants or their relatives provided an answer which they 
thought would appear favourable.  However, I sought to minimise this by corroborating 
information with primary care records in which the documentation of exposure 
predated the occurrence of ICH.  Participants were also unaware of the study 
background and therefore any misclassification of exposure is likely to have been non-
differential (equal likelihood of subjects in both lobar and non-lobar ICH having their 
baseline characteristics misclassified) and therefore biased results towards the null.  The 
extent of misclassification bias could in the future be assessed by comparing the 
responses obtained for variables such as smoking or alcohol consumption when the 
participant is interviewed vs. a relative vs. review of their GP records. 
5.5.3.6 Dementia 
I demonstrated an association between dementia and lobar ICH which is consistent 
with the findings of three previous hospital-based studies [Cordonnier et al. 2010b;Biffi 
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et al. 2011b;Jamieson et al. 2012] although two other hospital-based studies failed to 
find any association [Lipton et al. 1987;Greenberg et al. 1996]. 
The prevalence of prior dementia of 13% (95% CI 9-20%) in our population-based 
cohort is very similar to the only previous study which recruited consecutive patients 
with ICH [Cordonnier et al. 2010b]. 
I classified prior cognitive impairment and dementia on the basis of medical records and 
used an IQCODE where available.  An IQCODE was available for 37% (n=47) of the 
cohort.  Its use was limited by the substantial number of participants who died either 
prior to hospital admission (n=3) or soon after admission when it was not appropriate 
to approach a close relative for completion of a questionnaire (n=37).  The IQCODE 
formed part of the clinical assessment in the LINCHPIN research study and therefore 
its use was limited to those who gave written informed consent.  Some participants 
either did not consent to participate in the study (n=37), lacked a suitable friend or 
relative of longstanding (n=2) or did not want a relative to complete a questionnaire 
regarding their memory (n=2). 
It is notable that when the IQCODE was compared to medical records alone for the 
detection of pre-existing cognitive impairment or dementia (using the IQCODE as the 
gold-standard), medical records had 30% sensitivity (95% CI 15-52%) and 100% 
specificity (95% CI 88-100%).  Screening of medical records alone did not detect two 
cases of dementia and 12 cases of cognitive impairment.  Therefore it is plausible that I 
failed to detect some cases of dementia which would have been detected by more 
widespread use of the IQCODE and therefore the frequency of dementia might be even 
higher than demonstrated.  However, since there was no difference in demographic 
characteristics or ICH location between participants for whom an IQCODE was 
obtained and others any misclassification of exposure is likely to have been non-
differential. 
Since both lobar ICH and senile dementia of Alzheimer’s type are associated with CAA 
[Esiri & Wilcock 1986;Chalmers, Wilcock, & Love 2003] it is plausible that dementia is 
associated with lobar ICH.  However, the majority of those with lobar ICH do not have 
dementia and therefore other factors such as a past history of hypertension are likely to 
contribute to lobar ICH.  It would be useful in a larger sample to compare the 
characteristics of demented and undemented participants with lobar ICH to assess 
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whether the clinical picture of lobar ICH differs, for example in risk factors, radiological 
features or prognosis.  One hospital-based study has shown an association between 
dementia and mortality from lobar ICH at 90 days (although not at earlier time points) 
[Jamieson et al. 2012].  However, the authors assessed dementia retrospectively, entered 
numerous variables into their multivariate analysis and did not account for other 
indicators of poor prognosis such as intraventricular extension of the ICH.  
Future studies should seek to link clinical diagnoses of pre-existing dementia in patients 
with ICH with their neuropathological correlates, which may guide further research into 
the roles of small vessel disease such as CAA in causing ICH.    
5.5.3.7 Hypertension 
I did not demonstrate any association between hypertension and either lobar or non-
lobar ICH. 
There are several possible explanations.  Firstly, a recent systematic review of 
hypertension in lobar and deep supratentorial ICH showed that although overall, 
hypertension was more common in deep ICH the association was weaker in population-
based studies  which used a pre-stroke definition of hypertension and did not include 
recurrent ICH [Jackson & Sudlow 2006].  Moreover, given that my sample was relatively 
small, I may have been underpowered to detect any association if one does exist.  Since 
prescription of antihypertensive medications reduces the risk of recurrence of both 
ICHs attributed to CAA and hypertension [Arima et al. 2010], hypertension is likely to 
be a risk factor for both lobar and non-lobar ICH, so a much larger sample is likely to 
be needed to demonstrate an association between hypertension and non-lobar  (in 
comparison to lobar) ICH. 
Secondly, there is the possibility that incorrect categorisation of supratentorial ICHs as 
lobar or non-lobar may have caused misclassification bias.  I think this is less likely since 
one or more neuroradiologists with a special interest in stroke reviewed every diagnostic 
scan.  However, radiologists were unblinded to the clinical history to enable 
consideration of alternative diagnoses such as HTI and secondary causes of ICH which 
may have inevitably led to bias.   
Thirdly, the proportion of people classified as hypertensive may also differ depending 
upon whether the definition is based upon medical records, recent blood pressure 
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measurements or both and whether those with treated hypertension in which the most 
recent blood pressure measurement is ≤ 140/90 mmHg are excluded [Lovelock, 
Molyneux, & Rothwell 2007].  I classified a participant has having pre-ICH hypertension 
if they had a diagnosis of hypertension listed in their medical records or they were taking 
antihypertensive medications prior to their ICH.  One study which compared different 
definitions of hypertension for using in a model to predict future diabetes found that 
using a combination of medical records and antihypertensive medications to define 
hypertension had the highest sensitivity for detection of diabetes [Gulliford, Charlton, & 
Latinovic 2006], although the impact of using different definitions of hypertension in a 
population-based cohort with ICH is unknown. 
 Lastly, I included infratentorial ICH in my definition of non-lobar ICH.  A further 
possibility is that the association between hypertension and infratentorial ICH is weaker 
than it is for supratentorial deep ICH and by classifying both types as non-lobar, any 
association is obscured.  
5.5.3.8 Imaging variables 
I demonstrated that lobar ICHs were larger and more commonly associated with 
subarachnoid and subdural haemorrhage in comparison to non-lobar ICH.  ICHs which 
extended into these compartments were also larger than those that did not.  This is 
anatomically plausible given the proximity of superficial lobar ICHs to the subarachnoid 
and subdural compartments of the brain and consistent with previous studies [Patel et 
al. 2009;Kuramatsu et al. 2011].   
I did not record whether any subdural haemorrhage occurred in the contralateral 
hemisphere to the ICH although one previous study did not observe any contralateral 
subdural haemorrhages in association with ICH [Patel et al. 2009].  Subdural 
haemorrhage is commonly associated with trauma but I think it is unlikely that I 
misclassified traumatic ICHs as spontaneous because of comprehensive review of both 
the participant’s clinical history and their brain imaging (Chapter 2). 
Both subarachnoid and subdural haemorrhage (without ICH) have been found in 
association with CAA in neuropathological case series studies [Vinters 1987] and one 
study which correlated radiological with pathological findings in seven people with ICH 
found that ICHs related to CAA extended into the subarachnoid space [Millar, 
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Wardlaw, & Lammie 1999].  Radiopathological correlation of lobar ICHs (Chapter 10) 
should clarify whether these radiological features discriminate between lobar ICHs 
related to CAA and those where no CAA is found. 
5.5.3.9 Application of the modified Boston criteria to my cohort 
The study shows the difficulty in distinguishing probable or definite CAA-related ICH 
cases from possible CAA-related ICH cases using the modified Boston criteria in an 
unselected cohort of participants with lobar ICH, even though 42% of them (n=25) had 
either MRI or post-mortem examination specimens.  47 (80%) participants out of 59 
who were eligible to be categorised under the modified Boston criteria had possible 
CAA-related ICH.  Although many of our participants did not have MRI, 16 
participants (27% of those eligible for consideration under the modified Boston criteria) 
underwent MRI as part of the LINCHPIN research study, none of whom would have 
had MRI routinely, since CT remains the most frequently used imaging modality for the 
diagnosis of stroke in the UK [Muir & Santosh 2005].   
The Boston criteria were validated in a selected sample of 39 participants at a tertiary 
referral centre and their sensitivity for detection of CAA was 45% (95% CI 28-62%), 
(specificity 100%; 95% CI 77-100%) [Knudsen et al. 2001].  The number of 
neuropathological samples viewed per brain and their locations is unclear, which may 
influence the likelihood of finding other pathologies in the brain such as small vessel 
disease and determining the relative contribution of each to the ICH.   
The presence of superficial siderosis on T2*-weighted MRI sequences is thought to 
improve the sensitivity of the criteria for detecting CAA [Linn et al. 2010] but this did 
not increase the proportion of participants in our cohort with probable CAA-related 
ICH since only two participants had superficial siderosis; one of whom was less than 55 
years of age (and therefore not eligible for consideration under the modified Boston 
criteria) and another, who had BMBs in a lobar distribution and therefore already had 
probable CAA-related ICH. 
5.5.4 Future directions  
The findings of this study indicate the need to increase our understanding of the causes 
of ICH by using uniform definitions of both risk factors and outcomes (especially ICH 
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location) and improving the sensitivity of the modified Boston criteria for diagnosing 
CAA. 
Since the association between hypertension and ICH is likely to vary depending on the 
definition of hypertension used, it would be useful in future studies to compare how the 
association between hypertension and ICH location varies with exposure definition and 
whether its effect is modified when adjusted for other risk factors such as age. 
It is essential to ensure consistency in assigning ICH locations.  There are only two 
studies to my knowledge which have examined the inter-rater reliability of ICH 
categorisation as lobar or deep in a total of 93 selected CT brain scans [Wermer et al. 
2002;Parameswaran et al. 2003].  Both studies used radiologists with extensive 
experience in neuroradiology and reported excellent inter-rater reliability as measured by 
the kappa coefficient (κ 0.78-0.96).  In the future, it would be useful to study the inter-
rater and intra-rater reliability of categorisation of ICH location on consecutive scans 
(both blinded and unblinded to clinical details) using clinicians with a variety of 
radiology experience (such as general radiologists, neurologists and stroke physicians) 
and explore whether certain factors are associated with lower inter-rater agreement; for 
example, larger ICHs or involvement of regions such as the insula. 
The majority of those with first-ever lobar ICH in my community-based cohort had 
only possible CAA-related ICH according to the modified Boston criteria which is of 
limited clinical value in determining ICH cause.  Consideration of other features such as 
a pre-ICH history of dementia or the distribution of WMH on MRI, since an occipital-
predominant WMH distribution has been associated with lobar ICH [Zhu et al. 2012], 
might improve the sensitivity of the criteria.  Radio-pathological correlation studies of 
lobar ICH may lead to ascertaining CT imaging features which distinguish lobar ICH 
related to CAA from other lobar ICH.  Addition of these would increase the external 
validity of the criteria which are currently limited by their need for MRI which is often 




















































































































































































































































































































































































































































Population-based studies                  
Boonyakarnkul (1993) 57 (27/30) ○   ○              
Broderick (1993) 163 (97/66)    ○              
Anderson (1994) 60 (32/28)    ○              
Giroud (1995) 117 (64/53)    ○  ○     ○ ○  ○ ○   
Nilsson (2000) 341 (165/176) ○ ○  ○  ○ ○ ○  ○  ○ ○     
Tatu (2000) 326 (128/198)    ○         ○  ○    
Inagawa (2003) 350 (297/53)    ●  ○        ○ ○  ○ 
Karapanyiotides (2004) 330 (163/167)    ●  ○            
Labovitz (2005) 150 (101/49) ○ ● ●
2
 ●  ○        ○ ○   
Zahuranec (2006) 260 (173/87)   ●~
2 



















































































































































































































































































































































































































































Zia (2006) 141 (90/51)    ○  ○     ○   ○ ○  ○ 
Sacco (2009) 415 (205/210) ○ ○  ●              
Lavados (2010) 58 (43/15) ○ ○  ○  ○     ○ ○ ○ ○ ○   
Other studies                   
Brott (1986) 140 (67/73)    ○              
Lipton (1987) 112 (70/42) ○ ○ ●
1
 ● ○   ○    ●    ○  
Fieschi (1988) 101(60/41)    ○              
Massaro (1991) 172 (107/65) ● ○    ○ ○ ○      ○    
Radberg (1991) 200 (120/80)    ○              
Yaqub (1991) 13 (10/3) ○ ○    ○ ○           
Franke (1992) 157 (97/60)  ○  ○        ○      
Berlit (1994) 321 (67/254)    ○              



















































































































































































































































































































































































































































Greenberg (1996) 63 (18/45)  ●  ○            ○  
Rosenow (1997) 871 (430/441)    ●              
Ruiz-Sandoval (1999) 179 (69/110)    ●              
Woo (2002) 188 (121/67)    ●  ● ○ ○    ○ ○ ○ ○   
Bilbao (2005) 356 (190/166)    ●              
Seifert (2006) 189 (128/61)    ○  ○            
Telman (2010) 464 (282/182) ○~ ○~  ○~  ○~     ○~    ○~   
Biffi (2011) 384 (196/188) ○ ● ○ ● ○ ○ ●  ○   ○ ○   ● ● 
Ruiz-Sandoval (2011) 540 (342/198) ○ ○  ●              
Kuramatsu (2011) 174 (96/78) ○ ●  ○  ○   ○ ○ ○  ○ ○ ○  ○ 
Weimar (2011) 780 (509/271) ● ●  ● ○ ● ○ ○  ○ ○   ○ ○   
Arboix (2012) 189 (92/97) ● ○  ● ○ ○ ○  ○ ○ ○ ○  ○ ○  ● 



















































































































































































































































































































































































































































Jamieson (2012) 136 (83/53) ○ ○  ○  ○  ○    ○ ○   ●  
Matsukawa (2012) 361 (283/78) ● ●  ●   ○  ○  ○ ○ ○ ● ○  ○ 
Martini (2012)* 597 (380/217)  ○  ●     ○   ○  ○ ○   
Tveiten (2012) 110 (61/49) ○ ○  ● ○ ○ ○ ○       ●   
Pezzini (2013) 777 (490/287)                 ● 
○=no association  ●=significant association 
1
lobar ICH more common in whites, 
2
Hispanic and Mexican American ethnicity more common in non-lobar 
ICH, 
$
- variable definitions of alcohol use,  ~ –  multivariable analysis, *case control comparison 
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Table 6 Bristol rating scale for the assessment of CAA 
Score Parenchymal CAA Meningeal CAA Capillary CAA Vasculopathic 
score 
0 Absent Absent Absent Absent 
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Table 7: Crude incidence of first-ever spontaneous primary ICH in the Lothian health 




 May 2011 with 95% confidence intervals, 




Incidence (per 100,000 adults/year); 
(95% CI) 
Incidence (per 100, 000 adults/year); 
(95% CI) 
 Males Females Lobar ICH Non-lobar ICH 
16-44 0.6 (0.1-3.2) 1.1 (0.3-4.0) 0.6 (0.2-2.0) 2.8 (0.05-1.6) 
45-54 14.3 (7.2-28.1) 5.0 (1.7-14.7) 3.4 (1.3-8.9) 6.0 (2.9-12.4) 
55-64 13.2 (6.1-28.9) 14.5 (7.0-29.9) 8.5 (4.3-16.9) 5.3 (2.3-12.5) 
65-74 39.9 (22.8-69.7) 34.3 (19.6-59.9) 15.4(8.4-28.3) 21.5 (12.8-36.1) 
75-84 97.6 (61.0-156.3) 118.7 (83.2-169.4) 72.6 (51.2-103.1) 37.5 (23.1-60.9) 
85+ 216.8 (121.1-387.8) 170.3 (109.1-265.8) 80.1 (46.8-137.0) 104.7 (65.4-167.7) 
Overall 19.3 (15.1-24.6) 21.2 (17.0-26.5) 9.8 (7.7-12.4) 8.6 (6.7-11.1) 
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Table 8 Baseline characteristics of 128 adults with any lobar vs. non-lobar first-ever 
spontaneous primary ICH 
 Any lobar (n=68) Non-lobar ICH (n=60) p value 
Sex (male), (%) 26 (38) 29 (48) 0.25 
Age (years); median (IQR) 79 (15) 76 (19) 0.84 
History of hypertension* 







History of diabetes* 







History of dementia 







History of smoking* 
Never (n, %) 
Ex-smoker (n, %) 















 2 (0-14) 4 (0-14) 0.70 
Premorbid medication 
Antiplatelet use* (n, %) 


















































*Data missing in one case 
$
average number of units per week (median; IQR); data missing in 9 cases 
** data missing in five cases (three of whom died in the community) 
^data missing in four cases for whom the diagnosis was confirmed at autopsy
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 May 2011 
 
 
Total number of 
notifications  
n=216 
Excluded cases n=27 
Haemorrhagic transformation=13 


















































































Possible CAA (n=47) 
No MRI available (n=32) 
No CAA on post-mortem examination (n=5) 
No BMB^ on T2* MRI (n=7) 
BMBs in lobar & deep regions (n=1) 
BMBs in lobar regions only with INR>3.0 (n=1) 
Some degree of CAA on ≥1 post-mortem 
examination specimen with INR>3.0 (n=1) 
Probable CAA (n=6) 
≥1 BMB on T2* MRI in lobar or 
cerebellar region (n=3) 
Multiple lobar or cerebellar ICHs 
(n=2) 
Some degree of CAA on ≥1 post-
mortem examination specimen (n=1) 
 
Definite CAA (n=6) 
Severe CAA with 
vasculopathic changes on at 
least 1 post-mortem 
examination specimen (n=6) 
Lobar ICH (n=68) 
Excluded (n=9) 
Lobar and deep ICH (n=4) 
Age <55 (n=5) 
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6 A cross-sectional study of magnetic resonance imaging features in 
adults with lobar vs. non-lobar intracerebral haemorrhage 
6.1 Introduction 
The neuroimaging correlates of small vessel disease include BMBs, WMH and enlarged 
perivascular spaces (EPVS) [Pantoni 2010;Doubal et al. 2010].   
BMBs in a lobar distribution have been associated with lobar ICH whereas 
supratentorial deep BMBs (in the basal ganglia or thalamus) have been associated with 
ICH in deep regions of the brain [Lee et al. 2004].  Non-lobar BMBs (both in 
supratentorial deep and infratentorial regions) have been associated with hypertension in 
population-based studies [Vernooij et al. 2008].  Lobar BMBs are associated with 
apolipoprotein ε4 allele, which is in turn associated with CAA [Greenberg et al. 
1995;Vernooij et al. 2008].  This may support lobar and non-lobar ICH having different 
underlying causes. 
There has been little research into the relationship between distribution of WMH and 
ICH location.  WMH are independently associated with BMBs [Yamada et al. 2012].  
Although ICH has been associated with higher WMH volumes in comparison to other 
stroke subtypes [Rost et al. 2010], previous studies comparing WMH in lobar vs. deep 
ICH have had conflicting results, with both more severe occipital predominant WMH in 
lobar ICH in comparison to deep ICH [Zhu et al. 2012] and no difference in WMH 
volume [Smith et al. 2010] reported. 
Evidence from tracer studies suggests that perivascular spaces facilitate the drainage of 
solutes and interstitial fluid from the brain parenchyma [Weller et al. 2009a].  Lobar 
(cortical) arterioles do not have a perivascular space whereas deep arterioles in the basal 
ganglia have an expandable perivascular space [Weller, Boche, & Nicoll 2009].  The 
more effective drainage of solutes such as Aβ from deep regions (in comparison to 
lobar) may offer some explanation for why CAA is preferentially seen in the lobar 
regions of the brain.  Both basal ganglia EPVS and non-lobar BMBs are independently 
associated with lacunar stroke [Vernooij et al. 2008] .  Since lacunar strokes and deep 
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intracerebral haemorrhage occur in similar locations and share similar risk factors 
[Lammie 2002], the distribution of EPVS might also differ in lobar vs. non-lobar ICH. 
In a population-based study of ICH, I therefore sought to: 
• ascertain the proportion of participants with at least one BMB in lobar and non-
lobar ICH; 
• compare the distribution of BMBs in lobar and non-lobar ICH and  




Participants recruited into the LINCHPIN study (an ethically-approved interventional 
study of patients with spontaneous primary ICH), underwent MRI.  This chapter 
describes the findings of participants who underwent MRI in the first two years of the 
study (1st June 2010 – 31st May 2012).  The MRI inclusion and exclusion criteria and 
MRI procedure are described in Chapter 3. 
6.2.2 Data collection 
Data were collected on an MRI rating proforma using standard definitions (Chapter 3 
and Appendix).  I rated all brain scans blind to the participants’ names and clinical 
characteristics.  A consultant neuroradiologist with a special interest in stroke rated 
BMBs on all scans.  The BMB analysis uses BMBs categorised as ‘certain’ according to 
BOMBS [Cordonnier et al. 2009] by a neuroradiologist. I have used my ratings for the 
analyses of WMH, EPVS and atrophy. 
6.2.3 Statistical analysis 
I compared features of small vessel disease in participants with lobar and non-lobar 
ICH.  I used parametric statistics for between group comparisons when the data had a 
normal distribution and log-transformed variables or used non-parametric statistics 
when it did not.  If an estimated cell count was less than five, I used the Fisher’s exact 
test.  I conducted all statistical analyses using Stata version 11.1 (StataCorp LP, Texas, 
USA).  All p values are two-sided. 
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6.3 Results 
6.3.1 LINCHPIN MRI scans 
6.3.1.1 Participant flowchart 
Figure 27 on page 164 illustrates the recruitment of participants for the LINCHPIN 
MRI study from 1st June 2010-31st May 2012.  80 participants consented to an MRI 
brain scan of which 20 were too unwell to tolerate a scan, six were unable to tolerate 
MRI because of agitation or claustrophobia, in three incorrect sequences were obtained 
and a further one was excluded because her MRI scan identified a secondary cause for 
the ICH (a cavernous malformation).  50 participants (17% of those who were eligible 
for an MRI scan) entered the analysis of which 25 had lobar ICH.  46 participants were 
scanned using a 1.5T GE Signal LX EchoSpeed scanner (GE, Milwaukee, WI, USA) 
and the remainder were scanned using a 1.5T Philips Gyroscan Intera scanner (Philips 
Ltd, Best, The Netherlands.)  The mean interval between the ICH date and scan date 
was 85 days (SD 52 days) and this did not differ between those with lobar and non-
lobar ICH (77 days, SD=11 vs. 93 days, SD=10; p=0.30.) 
6.3.1.2 Characteristics of participants who underwent MRI vs. those who did not 
Table 9 on page 160 shows the characteristics of participants who had an MRI scan in 
year 1 vs. those who did not for those in the first year of the study only (1st June 2010-
31st May 2011).  Those who had an MRI scan were younger and had higher admission 
GCS scores, smaller ICHs and less frequent extension of the ICH into the ventricles. 
6.3.1.3 Baseline characteristics of LINCHPIN MRI participants 
The characteristics of participants who underwent MRI are given in Table 10 on page 
161.  There was no difference between participants with lobar ICH and non-lobar ICH 
in any demographic or clinical characteristics.  
6.3.1.4 Microbleeds in lobar and non-lobar ICH 
24 people (48%, 95% CI 35-62%) had ≥ one BMB and this did not differ between lobar 
(10/25; 40%, 95% CI 23-59%) and non-lobar ICH (14/25; 56%, 95% CI 37-73%; 
p=0.26).  There was no difference in the total number of certain BMBs and the number 
of certain lobar BMBs between those with lobar and non-lobar ICH.  Participants with 
non-lobar ICH seemed to have a greater number of non-lobar BMBs compared to 
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those with lobar ICH (p=0.052) (Table 11 on page 162).  This was unchanged in a 
sensitivity analysis in which all non-lobar BMBs (both certain and uncertain) were 
included.  The proportion of participants with ≥ one non-lobar BMB was greater in 
those with non-lobar ICH. 13 participants (26%; 95% CI 16-40%) had BMBs in both 
lobar and non-lobar distributions and the proportions of participants with both lobar 
and non-lobar BMBs did not differ between those with lobar and non-lobar ICH.  
6.3.1.5 White matter hyperintensities, atrophy and EPVS in lobar and non-lobar 
ICH 
There was no difference in the distribution or severity of deep and periventricular 
WMH, deep and cortical atrophy and basal ganglia and centrum semiovale EPVS 
between the lobar and non-lobar ICH groups (Table 11 on page 162 & Table 12 on 
page 163).   Hippocampal EPVS seemed more frequent in the lobar group but this was 
not statistically significant (p=0.050). 
6.4 Summary 
• The proportion of participants with one or more non-lobar BMB was significantly 
higher in participants with non-lobar ICH.   
• There was no difference in the severity or distribution of lobar BMBs, WMH, EPVS 
and atrophy between lobar and non-lobar ICH. 
6.5 Discussion 
6.5.1 Strengths and limitations of the study 
The study meets the recently established STandards for ReportIng Vascular changes on 
neuroImaging (STRIVE) [Wardlaw et al. 2013] in that I have reported: 
(i) the proportions of participants with vascular risk factors and their method of 
measurement (Chapters 2 & 5); 
(ii) the interval between the ICH date and date of scan; 
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(iii) the procedure for image acquisition including the MRI sequences used, the use 
of two MRI scanners and their characteristics and the  acquisition parameters on 
both scanners (Chapter 3); 
(iv) that scans were viewed blinded to participants’ clinical details and 
(v) the rating scales used for rating deep and periventricular WMH, basal ganglia, 
centrum semiovale and hippocampal EPVS, atrophy and BMBs. 
Nevertheless, this is a small study which should be viewed as a preliminary assessment 
of small vessel disease in participants with ICH for future larger studies.  Only 17% of 
those eligible to have an MRI scan were scanned, and those who had an MRI scan were 
younger and had less severe ICHs than those who did not.  Therefore these participants 
are unlikely to be representative of all those with ICH.   
6.5.2 Neuroimaging correlates of small vessel disease in lobar and non-lobar ICH 
6.5.2.1 Brain microbleeds 
The proportion of participants with ≥ one BMB in our study is similar to previous 
studies [Cordonnier, Wardlaw, & Al-Shahi Salman 2007].  I demonstrated that non-
lobar BMBs were commoner in participants with non-lobar ICH but did not show any 
difference in total or lobar BMBs between lobar and non-lobar ICH.  
The finding that non-lobar BMBs were commoner in those with non-lobar ICHs is 
consistent with previous studies showing that supratentorial deep BMBs are more 
common in those with deep ICH [Lee et al. 2004;Smith et al. 2010].  Although this 
supports the theory of non-lobar BMBs and non-lobar ICHs having a similar underlying 
pathology, 26% participants had both lobar and non-lobar BMBs and this is comparable 
to a previous study which examined the distribution of BMBs (although not cerebellar 
BMBs) in participants with ICH [Smith et al. 2010].  Lobar BMBs and ICHs are 
commonly thought to be due to CAA and non-lobar BMBs and ICHs to be due to 
hypertension [Greenberg et al. 2009].  However, in view of the substantial proportion of 
participants with a mixed distribution of BMBs this dichotomisation may be too 
simplistic.   
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6.5.2.2 Lack of association between lobar BMBs and lobar ICH 
Several factors require consideration when explaining why I did not demonstrate that 
lobar BMBs were commoner in lobar ICH.   
Firstly, our cohort was small and therefore may have lacked power to detect a 
difference.   
Secondly, I used two MRI scanners, and although the scans contained the same 
sequences it was not possible for the parameters to be identical.  
Thirdly, the detection of BMBs is dependent on imaging characteristics such as the 
magnetic field strength, pulse sequence and spatial resolution [Greenberg et al. 2009].  A 
higher field strength [Stehling et al. 2008] or the use of susceptibility-weighted imaging 
(which enhances T2* effects to increase signal drop out and detection of BMBs) 
[Greenberg et al. 2009] may have increased the detection of lobar BMBs.  However, 
without radio-pathological correlation of presumed BMBs to confirm their histology, it 
may be that these techniques lead to greater sensitivity at the cost of specificity for BMB 
detection.  A recent study which correlated BMBs and ‘mini-bleeds’ (areas of 
haemosiderin of 200-500µm) on 7.0T post-mortem MRI with their histological 
appearances showed that although the sensitivity of MRI for haemosiderin detection 
ranged from 85-96%, the specificity was 38-50% [De Reuck J et al. 2011].  Perforating 
vessels or perivascular iron deposits were frequently mistaken for BMBs.  I restricted 
the analysis of BMBs to those classified as ‘certain’ according to BOMBS to increase the 
specificity of BMB detection and internal validity of the findings but it is notable that 
the findings remained consistent in a sensitivity analysis in which both certain and 
uncertain BMBs were included. 
Lastly, it is possible that lobar BMBs were missed although all scans were rated by a 
neuroradiologist with a special interest in stroke and extensive previous experience in 
rating BMBs. 
The incidence rate of new BMBs following symptomatic ICH is as yet unknown.  In a 
study of 26 participants with probable or possible CAA according to the Boston criteria, 
12 (46%) developed new BMBs during follow up (median interval between baseline and 
follow up scan 1.1 years) [Chen et al. 2006].  Although I attempted to arrange scans 
within three months of the participant’s ICH, the interval between the ICH and the scan 
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was frequently substantially longer, due to the participant being too unwell soon after 
their ICH to either tolerate the scan or give informed consent.  In some patients the 
scan was intentionally delayed allowing greater resorption of blood to look for a 
secondary cause of the ICH.  Importantly, the interval between the ICH and scan date 
did not differ significantly between the lobar and non-lobar ICH groups so it is unlikely 
that this affected the findings. 
6.5.2.3 White matter hyperintensities 
I did not demonstrate any difference in the distribution of periventricular and deep 
WMH in participants with lobar and non-lobar ICH. 
The study was most likely underpowered to detect a difference if one truly exists.  A 
future study in a larger cohort would have greater power to detect a difference in WMH 
distribution in ICH subtypes after adjusting for other covariates including age, gender 
and risk factors for stroke such as hypertension and diabetes.  Previous studies have 
examined both WMH distribution [Zhu et al. 2012] and WMH volume [Smith et al. 
2010;Rost et al. 2010].  The automated techniques previously used for measuring WMH 
volume in this context [Smith et al. 2010] such as Freesurfer 
(http://surfer.nmr.mgh.harvard.edu),  have not been validated against either histological 
derived or manually measured values and therefore the accuracy and reliability of these 
techniques are as yet unknown [Gronenschild et al. 2012].  
6.5.2.4 Enlarged perivascular spaces and atrophy 
I did not demonstrate any difference in either the prominence of basal ganglia or 
centrum semiovale EPVS or distribution of atrophy in participants with lobar and non-
lobar ICH.  
Although hippocampal EPVS were more common in the lobar ICH group, the 
relevance of this finding in a small sample is unclear.  ‘Severe’ (>40) centrum semiovale 
EPVS have been associated with probable or possible CAA-related ICH according to 
the Boston criteria [Charidimou et al. 2013c].  In a recent study, centrum semiovale 
EPVS were more common in pathologically-proven CAA compared to ICH unrelated 
to CAA [Charidimou et al. 2013b], although the study was small and used a combination 
of sampling methods to assess for CAA, potentially leading to misclassification of CAA-
related ICH.  Although I rated EPVS (rather than a neuroradiologist) inter-observer 
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agreement for centrum semiovale EPVS was fair (κ=0.30; Chapter 3).  17/50 (34%) 
participants had moderate or severe WMH which may have made the severity and 
distribution of co-existing EPVS difficult to determine [Wardlaw et al. 2013].  I may 
have lacked sufficient power to detect a difference in EPVS distribution between lobar 
and non-lobar ICH if one does exist.     
Lobar ICH has been associated with dementia which in turn, was associated with 
atrophy in one hospital based study [Cordonnier et al. 2010b].  Since dementia is more 
common in lobar ICH (Chapter 5), the prevalence or severity of atrophy might also be 
expected to be greater in those with lobar ICH.   
It would be of interest to repeat the study in a larger cohort to determine if the 
distribution of EPVS and atrophy differs and correlate radiological with pathological 
findings.   
6.5.3 Future directions 
Although this is a small, preliminary study of small vessel disease markers in ICH, it 
indicates that questions regarding the significance of these markers remain unanswered.  
In particular, the sensitivity and specificity of strictly lobar BMBs for pathologically 
proven CAA should be determined in a larger cohort of participants with ICH. 
Given the difficulty distinguishing BMBs from their mimics on imaging, pathological 
correlation of presumed BMBs observed either on ante mortem and/or post-mortem 
MRI will be invaluable to confirm them either as true BMBs containing haemosiderin or 
mimics such as pseudoaneurysms or perforating vessels [Shoamanesh, Kwok, & 
Benavente 2011] and determine the underlying histology.  There have only been six 
radio-pathological correlation studies of BMBs involving a total of 44 patients [Tanaka 
et al. 1999;Fazekas et al. 1999;Kikuta et al. 2007;Tatsumi, Shinohara, & Yamamoto 
2008;Schrag et al. 2010;De Reuck J et al. 2011] of which four correlated pathological 
findings with post-mortem rather than ante mortem MRI [Fazekas et al. 1999;Tatsumi, 
Shinohara, & Yamamoto 2008;Schrag et al. 2010;De Reuck J et al. 2011].  Three further 
studies examined the pathology of BMBs [Dichgans et al. 2002;Fisher et al. 2010] and 
so-called ‘microscopic haemorrhages’ [Tanskanen et al. 2012] without radiological 
correlation.  Post-mortem MRI for BMBs would overcome the technical difficulties of 
using MRI in patients with ICH who are clinically unwell, facilitating larger and more 
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generalisable samples of participants.  However, a lack of studies correlating ante 
mortem with post-mortem BMB appearances means that the effect of a protracted 
terminal phase of death on BMB formation is as yet unknown and informed consent for 
whole brain donation (rather than tissue samples only) would also be mandatory. 
Given the increasing use of radio-labelled ligands such as 11C-Pittsburgh Compound B 
(PiB) for the in-vivo detection of cerebral β- amyloid using PET imaging both in 
patients with ICH and Alzheimer’s dementia [Ly et al. 2010], a future study could also 
compare strictly lobar BMBs seen on MRI vs. PiB vs. pathologically proven CAA (as 
the gold standard) to assess the diagnostic accuracy of these different methods for CAA 
detection. 
A future priority is also to develop a larger population-based study to increase the power 
to detect differences in WMH, EPVS and atrophy distribution between lobar and non-
lobar ICH if they truly exist.  It would be important to continue using standardised 
definitions of these variables to increase external validity and to compare findings 
between different cohorts and quantify inter-observer agreement between raters with 
varying levels of expertise. 
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Table 9 Baseline characteristics of participants who had an MRI scan vs. those who 




 May 2011) 
 MRI (n=28) No MRI (n=113) p value 
Sex (male), % 13 (46) 51 (45) 0.90 
Age (years); median (IQR) 72 (59-79) 79 (68-85) 0.003 
















History of smoking* 
Never (n, %) 
Ex-smoker (n, %) 













































*data missing in one case 
**data missing in nine cases 
***data missing in five cases 
****data missing in four cases 
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Table 10 Baseline characteristics of 50 participants with lobar and non-lobar ICH who 
underwent MRI 
 Any lobar ICH (n=25) Non-lobar ICH (n=25) p value 
Sex (male), % 12 (48) 14 (56) 0.57 
Age (years); median (IQR) 72 (15) 70 (14) 0.14 
Previous stroke 
ICH Yes (n, %) 
Ischaemic stroke  













History of hypertension 







History of diabetes 







History of smoking 
Never (n, %) 
Ex-smoker (n, %) 
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Table 11 Comparison of microbleeds, white matter hyperintensities and atrophy in 
participants with lobar and non-lobar ICH 





















≥1 BMB -any location (n,%) 
≥1 Lobar BMB 
≥1 Non-lobar BMB 



























































































  163 
Table 12 Comparison of Enlarged Perivascular Spaces in participants with lobar and 
non-lobar ICH 
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Not approached (n=114) 
Died before LINCHPIN discussed (n=71) 
Late ascertainment (n=27) 
Clinical team did not think it was 
appropriate to discuss LINCHPIN (n=11) 




LINCHPIN study declined (n=66) 
Consented to LINCHPIN study but 
declined MRI (n=39) 




Too unwell for MRI scan (n=20) 
MRI not tolerated (n=6) 
Incorrect sequences obtained (n=3) 
Excluded after secondary cause for 
ICH identified on MRI (n=1) 
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Chapter 7 Results of a community-based study of intracerebral 
haemorrhage-death, prognosis and survival outcomes 
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7 Results of a community-based study of intracerebral haemorrhage-
death, prognosis and survival outcomes 
7.1 Introduction 
Studies of case fatality and disease outcomes require comprehensive case ascertainment 
and pre-specified standard definitions (of both the disease being studied and any 
outcomes) to increase external validity (Chapter 2).  The study should be prospective 
with outcomes being assessed equally between groups to avoid information bias 
[Grimes & Schulz 2002a], and there should be at least 80% follow-up to minimise loss 
to follow-up bias [Wells et al. 2002].  
In the context of ICH, the aim of such a study would be to describe case fatality and 
level of disability at standard time points after the inception point and determinants of 
prognosis, leading to the refinement of existing prognostic models and potentially the 
selection of subgroups of participants who may benefit from interventions and might be 
entered into a randomised controlled trial.  In the longer term, the study would describe 
the incidence of both haemorrhagic and vaso-occlusive outcomes following an ICH, 
since survivors of ICH have risk factors for both haemorrhagic and vaso-occlusive 
outcomes [Ariesen et al. 2003], with comparison of outcomes stratified by ICH location. 
Studies of prognosis after ICH [Portenoy et al. 1987;Franke et al. 1992;Lisk et al. 
1994;Tuhrim et al. 1995;Fogelholm, Avikainen, & Murros 1997;Hemphill et al. 
2001;Ariesen et al. 2005;Weimar, Benemann, & Diener 2006;Flaherty et al. 2006;Ruiz-
Sandoval et al. 2007;Rost et al. 2008;El-Senousey et al. 2010;Stein et al. 2010;Mittal & 
Lele 2011;Chen et al. 2011;Nag et al. 2012;Li et al. 2012], have identified various 
determinants of outcome.  These have included demographic and clinical variables such 
as age at diagnosis of ICH [Lisk et al. 1994;Hemphill et al. 2001;Weimar, Benemann, & 
Diener 2006;Flaherty et al. 2006;Ruiz-Sandoval et al. 2007;Rost et al. 2008;El-Senousey 
et al. 2010], diabetes [Flaherty et al. 2006;Chen et al. 2011], pre-ICH cognitive 
impairment [Rost et al. 2008], anticoagulation use [Flaherty et al. 2006], pulse pressure 
[Tuhrim et al. 1995], GCS score on admission [Portenoy et al. 1987;Franke et al. 
1992;Lisk et al. 1994;Tuhrim et al. 1995;Hemphill et al. 2001;Ruiz-Sandoval et al. 
Chapter 7 
  167 
2007;Rost et al. 2008;El-Senousey et al. 2010;Chen et al. 2011], brainstem reflexes 
[Mittal & Lele 2011], NIHSS score [Weimar, Benemann, & Diener 2006] and blood 
glucose [Fogelholm, Avikainen, & Murros 1997;Li et al. 2012].  ICH features which help 
to determine outcome include its volume [Portenoy et al. 1987;Franke et al. 1992;Lisk et 
al. 1994;Tuhrim et al. 1995;Hemphill et al. 2001;Ruiz-Sandoval et al. 2007;Rost et al. 
2008;Chen et al. 2011], presence of intraventricular [Portenoy et al. 1987;Hemphill et al. 
2001;Ruiz-Sandoval et al. 2007;Stein et al. 2010;Chen et al. 2011] or subarachnoid 
[Fogelholm, Avikainen, & Murros 1997] extension, ICH location [Tuhrim et al. 
1995;Hemphill et al. 2001;Ruiz-Sandoval et al. 2007;Rost et al. 2008], midline shift [Nag 
et al. 2012] and hydrocephalus [Ariesen et al. 2005;Stein et al. 2010].  However, all of the 
studies listed above except one [Fogelholm, Avikainen, & Murros 1997] have used 
hospital based cohorts and many have been retrospective [Portenoy et al. 1987;Hemphill 
et al. 2001;Stein et al. 2010;Chen et al. 2011;Li et al. 2012].  The ICH score [Hemphill et 
al. 2001] is a prognostic score for determining 30 day case fatality following ICH and 
comprises age, GCS score on admission, ICH location (supratentorial vs. infratentorial), 
intraventricular extension and ICH volume.  It is the only score for modelling prognosis 
after ICH which has been externally validated, albeit using a hospital-based cohort 
[Hemphill, Farrant, & Neill 2009]. 
Although infratentorial ICH is known to have a higher risk of death [Hemphill et al. 
2001;Flaherty et al. 2006], the majority of ICHs are supratentorial.  Determining 
whether supratentorial ICH location influences outcome may help to guide treatment 
options.  Lobar ICH may have a better prognosis in comparison to ICH in other 
locations [Juvela 1995;Garibi et al. 2002;Rost et al. 2008;Zia et al. 2009] but the results 
of studies conflict [Castillo et al. 1994;Nilsson et al. 2002;Inagawa et al. 2003;Rodriguez-
Luna et al. 2011;Nag et al. 2012;D'Amore et al. 2013;Palm et al. 2013]. 
 I therefore sought to describe 30 day and one year case fatality in a prospectively 
recruited population based cohort of participants following first-ever ICH, validate the 
ICH score and determine whether ICH location affected case fatality after adjusting for 
other known prognostic factors.  I will also describe the incidence of haemorrhagic and 
vaso-occlusive events during one year follow up, stratified by ICH location. 
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7.2 Methods 
7.2.1 Case fatality at one month and one year 
I used multiple overlapping sources of follow up to determine whether a participant had 
died and if applicable, their date of death.  I used the following sources: 
(i) the hospital electronic patient records system which records whether a patient 
has died and clinical letters pertaining to their most recent admission; 
(ii) the participant’s GP, who completed an annual questionnaire which requests 
confirmation that the participant is still alive; 
(iii) death certificates obtained from the General Register Office for Scotland and 
(iv) the Office of the Procurator Fiscal which records information relating to any 
sudden deaths later found to be as a result of ICH at post-mortem examination. 
7.2.1.1 The influence of ICH location on case fatality 
Based on existing knowledge regarding prognostic factors following ICH, I selected a 
priori five variables (variables comprising the ICH score [Hemphill et al. 2001] and prior 
anticoagulant use [Stead et al. 2010]) in addition to whether the haemorrhage involved a 
lobar region of the brain or not (Section 1.1.5.4, page 37) to examine their influence on 
case fatality. 
I applied the ICH score to our cohort to assess how well it discriminated between those 
who died and those who survived in the first 30 days following ICH.   
7.2.1.2 One year modified Rankin scale, recurrent ICH and vaso-occlusive events 
I used information from questionnaires (Appendix), sent annually to participants’ GPs 
to obtain the level of disability one year after their ICH using the modified Rankin scale 
and assess whether they had suffered from the following conditions over the subsequent 
year:   
(i) Myocardial infarction (MI)-defined as clinical symptoms accompanied where 
available by electrocardiographic and biochemical cardiac marker changes or 
confirmed at post-mortem examination [Mendis et al. 2010]. 
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(ii) Venous thromboembolism-defined as the occurrence of symptomatic DVT or 
PE confirmed by imaging [National Institute for Health and Clinical Excellence 
(NICE) 2010].   
(iii) TIA-defined as rapidly developing clinical signs of focal disturbance of cerebral 
function lasting less than 24 hours with no alternative explanation [Thorvaldsen 
et al. 1997]. 
(iv) Ischaemic stroke- defined as rapidly developing clinical signs of focal (or global) 
disturbance of cerebral function lasting for at least 24 hours, with no alternative 
explanation [Thorvaldsen et al. 1997]. 
(v)  Recurrent ICH – confirmed by imaging, which I reviewed with a 
neuroradiologist or at post-mortem examination.  
If a GP was unable to complete the modified Rankin scale [van Swieten et al. 1988], I 
contacted participants and completed the modified Rankin scale using a semi-structured 
telephone interview [Wilson et al. 2002].  I corroborated information received from 
questionnaires with information from participants and from the hospital electronic 
records system (which records all in-patient and out-patient appointments to hospitals 
serving the Lothian health board) to validate all outcome events.  
7.2.2 Statistical analysis 
7.2.2.1 Logistic regression model for predictors of case fatality 
I entered ICH location (any lobar ICH vs. non-lobar ICH) and covariates into two 
logistic regression models in which the dependent variables were death within 30 days 
and one year following the index ICH.  I checked for variables which substantially 
changed the effect estimate by using the chest command in Stata which selects 
variables in a stepwise fashion depending on the size of adjusted and unadjusted effect 
estimates [Wang 2007].  The variable which is included first produces the largest change 
in effect estimate and the selection of variables continues till all are included in the 
model.  I assessed the performance of the logistic regression model and checked that its 
assumptions were met as follows: 
(i) In logistic regression, the log odds of the outcome (dependent variable) is modelled 
as the linear combination of the predictor (independent) variables.  This assumes 
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that there is no specification error; that is I have not included any variables that 
should not be in the model and have also included all relevant variables and should 
not be able to find any other statistically significant predictors except by chance.  I 
used the Stata command linktest to check that this assumption was met.      
(ii) I tested the calibration of the model using a likelihood ratio test which examined the 
predictive value of the model with these predictors in comparison to a null model 
with no predictors.  I also used Hosmer and Lemeshow’s goodness of fit test which 
divides subjects into deciles based on predicted probabilities of case fatality and 
calculates a χ2 based upon observed and expected frequencies of deaths in each 
decile.  A p value of >0.05 indicates that there is no significant difference between 
the observed and model-predicted values, implying that the model fits the data 
adequately. 
7.2.2.2 Validation of the ICH score 
I entered the variables comprising the ICH score into a regression model in which the 
dependent variable was 30 day case fatality and used the roctab command in Stata to 
plot a receiver operator curve and measure the area under the curve (AUROC).  An 
AUROC of 0.5 indicates that the discrimination of the ICH score is no better than 
chance and an AUROC of 1.0 indicates that the ICH score discriminates perfectly.   
7.2.2.3 Survival analysis 
I calculated the total person-years of follow up using the sum of follow-up times 
irrespective of whether an event took place or whether the person was censored.  I 
quantified the completeness of follow-up data by calculating the sum of follow-up times 
(days) divided by the sum of potential follow-up times which could have been obtained 
before death or the end of the one year follow-up period [Clark, Altman, & De Stavola 
2002].  I used Kaplan-Meier survival curves and life tables with log rank tests to analyse 
follow up data for outcome events during one year follow-up and used Cox regression if 
proportional hazards assumptions were satisfied [Bradburn et al. 2003].  Survival 
analyses of the time to an event started on the date of the ICH and ended either on the 
date of the first event or on the date of censoring if no event occurred.  I censored 
follow-up on the date of death or one year after their ICH depending on which 
occurred first.   
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7.2.2.4 Other analyses 
I used parametric statistics for between group comparisons when the data had a normal 
distribution and log-transformed variables or used non-parametric statistics when it did 
not.  If an estimated cell count was less than five, I used the Fisher’s exact test.  I 
conducted all statistical analyses using Stata version 11.1 (StataCorp LP, Texas, USA).  
All p values are two-sided.  
7.3 Results 
7.3.1 Prognosis after first-ever spontaneous primary ICH 
7.3.1.1 Completeness of follow up 
 I obtained complete data regarding survival at one month and one year and dates of 
death, where applicable. I obtained the level of disability at one year as measured by the 
modified Rankin scale for 124 out of 128 participants (97%).  I obtained 63 person-
years of follow up for all vaso-occlusive and ICH outcomes (97% completeness).  
7.3.1.2 Case fatality in the first 30 days and at one year 
In the first 30 days following a first-ever spontaneous primary ICH, 55 adults (43%, 
95% CI 35-52%) died.  The proportions did not differ between lobar and non-lobar 
ICH (lobar 32/68 (47%); non-lobar 23/60 (38%); χ2 =0.99, p=0.32). Figure 28 on page 
188 shows a Kaplan-Meier of survival time in the first 30 days following first-ever 
spontaneous primary ICH in participants with lobar and non-lobar ICH.  There was no 
difference in survival between those with lobar and non-lobar ICH (χ2 =0.69, p=0.40).   
By one year, 72 adults (56%, 95% CI 48-65%) had died and the proportions did not 
differ between lobar and non-lobar ICH (lobar 39/68 (57%); non-lobar 33/60 (55%); χ2 
=0.07, p=0.79).  The primary causes of death as listed in Section 1A on their death 
certificates are shown in Table 13 on page 183.  The majority of participants died as a 
result of their ICH although three different ICD-10 codes were used to classify ICH: 
‘intracerebral haemorrhage,’ ‘intracranial haemorrhage’ and ‘stroke, not classified as 
haemorrhage or infarction.’ 
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7.3.1.3 Impact of ICH location on one month case fatality  
Table 14 on page 184 shows the logistic regression model of predictors of death in the 
first month following a first-ever spontaneous primary ICH.  122 participants entered 
the model. 
Older age, lower GCS scores on admission, larger ICH volumes on the diagnostic CT 
brain scan and ICH in a non-lobar location were significant predictors of one month 
case fatality in the crude model.  The odds of death decreased by 81% (95% CI 31-95%) 
if a haemorrhage involved a lobar location.  In a sensitivity analysis restricted to adults 
with supratentorial ICH (n= 110; Table 15 on page 184), the impact of lobar ICH was 
no longer significant (OR 0.26, 95% CI 0.07-1.03; p=0.06).  There was no statistically 
relationship between 30 day case fatality and intraventricular haemorrhage or prior use 
of anticoagulants.  The model was well calibrated (Likelihood ratio test p<0.001; 
Hosmer and Lemeshow’s goodness of fit test χ2 =3.79, p=0.88) implying that there was 
no statistically significant difference between the observed values in the dataset and the 
values predicted by the model and there was no evidence of a specification error. 
7.3.1.4 Influence of ICH location on one year case fatality 
Table 16 on page 185 shows the logistic regression model of predictors of death in the 
first year following a first-ever spontaneous primary ICH. 
Older age, lower GCS scores on admission, larger ICH volumes on brain imaging and 
non-lobar ICH appeared again as significant predictors of one year case fatality in the 
crude model.  Lobar ICH was associated with a lower odds of death at one year and this 
was unchanged when the model was restricted to adults with solely supratentorial ICH; 
(OR 0.28, 95% CI 0.09-0.88; p=0.03, Table 17 on page 185). 
When the model was checked for the effect of covariates on the relationship between 
lobar ICH and death, the addition of ICH volume to the model significantly reduced the 
odds of death in the first year after a lobar ICH; suggesting that the association seen 
between non-lobar ICH and death was likely to be because of ICH volume.  None of 
the other variables substantially changed the effect estimate.  When ICH volume was 
divided into three categories (0-29, 30-59 and 60-90ml) and used to stratify ICH 
location, a lower proportion of lobar ICHs were dead at one year in every volume 
category; and in the 30-59ml category this difference was statistically significant (lobar 
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6/12 (50%) vs. non-lobar 10/11 (91%); χ2 =4.54, p=0.04; Table 18 on page 185).  The 
model was well calibrated (Likelihood ratio test p<0.001; Hosmer and Lemeshow’s 
goodness of fit test χ2 =4.43, p=0.82) with no evidence of a specification error. 
7.3.1.5 Validation of the ICH score 
Table 19 on page 186 shows that the percentage of deaths in the first 30 days following 
a first-ever spontaneous primary ICH increased from 5% with an ICH score of 0 to 
100% with a score of 5.  Table 20 on page 186 shows the logistic regression model of 30 
day case fatality using the ICH score.  Decreasing GCS score on admission, ICH 
volume (≥30ml) and infratentorial ICH were associated with death.  The AUROC was 
0.85 (95% CI 0.78-0.91) indicating that the ICH score discriminated well between 
survivors and deaths from first-ever spontaneous ICH within the first 30 days (Figure 
29 on page 189).   
7.3.1.6 Level of disability at one year following first-ever spontaneous primary ICH 
Figure 30 on page 190  shows the modified Rankin scores at one year from 124 
participants with first-ever spontaneous primary ICH.   The distribution of modified 
Rankin scores is similar in participants with lobar and non-lobar ICH.  At one year, 107 
(86%) adults were dead or dependent (modified Rankin scale score ≥ 3).  This did not 
vary by ICH location (lobar 58/66 (88%) vs. non-lobar 49/58 (84%); χ2 =0.30, p=0.58).   
7.3.1.7 Vaso-occlusive events and recurrent ICH following first-ever spontaneous 
primary ICH 
Figure 31 on page 191 shows a Kaplan-Meier curve of the time to a composite outcome 
of vaso-occlusive events or recurrent ICH in participants with lobar and non-lobar ICH. 
There was no difference in the time to events observed in the lobar and non-lobar ICH 
groups (χ2 =0.73, p=0.39). 
7.3.1.8 Recurrent ICH following first-ever spontaneous primary ICH 
Figure 32 on page 192  shows a Kaplan-Meier curve of the time to recurrent ICH in 128 
participants with first-ever spontaneous primary ICH.  There were four ICHs, all of 
which were lobar and occurred exclusively in survivors of lobar ICH (annual risk of 
recurrent ICH after lobar ICH 11.8%, 95% CI 4.6% to 28.5% vs. annual risk after non-
lobar ICH 0%).  All cases were spontaneous primary definite ICHs confirmed by 
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imaging.  There was a statistically significant excess of recurrent ICH in participants 
with lobar ICH (χ2 =4.10, p=0.04). 
7.3.1.9 Ischaemic stroke, TIA and myocardial infarction following first-ever 
spontaneous primary ICH 
Figure 33 on page 193 shows a Kaplan-Meier curve of the time to first ischaemic stroke, 
TIA or MI in 128 participants with first-ever spontaneous primary ICH.  There were 
seven events (Table 21 on page 187) (annual risk 10.8%, 95% CI 5.2%-21.7%) and the 
annual risk did not differ between adults with lobar (annual risk 9.9%, 95% CI 3.3%-
27.8%) and non-lobar ICH (annual risk 11.7%, 4.4%-29.0%) (χ2 =0.10, p=0.76). 
7.3.1.10 Venous thromboembolism following first-ever spontaneous primary ICH 
Figure 34 on page 194 shows a Kaplan-Meier curve of the time to venous 
thromboembolism in 128 participants with first-ever spontaneous primary ICH.  Four 
events (one PE and three DVTs) occurred (annual risk 6.1%, 95% CI 2.3% -15.5%) and 
the annual risk did not differ between adults with lobar (annual risk 6.7%, 95% 1.7%-
24.4%) and non-lobar ICH (annual risk 5.7%, 95% CI 1.5%-21.1%) (χ2 =0.00, p=1.00). 
7.3.1.11 Recurrent ICH vs. vaso-occlusive events 
There were 10 vaso-occlusive events and the risk of vaso-occlusive events did not differ 
between adults with lobar (16.2%, 95% CI 7.0% to 34.8%) and non-lobar ICH (14.4%, 
95% CI 6.1% to 31.9%; p=1.00).  The annual risk of any vaso-occlusive event, 
regardless of ICH location was 15.1% (95% CI 8.3% to 26.6%).  For all adults, 
regardless of ICH location, vaso-occlusive events seemed to be at least as frequent as 
recurrent ICH in the first year (Figure 35 on page 195; hazard ratio 2.66, 95% CI 0.83-
8.48, p=0.08). 
7.4 Summary 
• Case fatality at one month was 43% and at one year was 56%. 
• Lobar ICH was independently associated with a lower odds of death in the first year 
after first-ever spontaneous primary ICH after adjusting for other covariates. 
• The ICH score discriminated well between those who survived and died in the first 
30 days following a first-ever spontaneous primary ICH. 
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• There was a higher risk of recurrent ICH in the lobar ICH group. 
• There was no difference in the risk of vaso-occlusive events observed in the lobar 
and non-lobar ICH groups. 
• Regardless of ICH location, there was a non-significant excess of vaso-occlusive 
events in comparison to recurrent ICH in the first year. 
7.5 Discussion 
7.5.1 Strengths of the study 
This study has a prospective population-based design and uses multiple overlapping 
sources of follow-up.  It is the first study to externally validate the ICH score to 
determine one year survival in a population-based cohort. 
7.5.2 Limitations of the study 
The study has a short follow up period and small number of outcome events making it 
difficult to establish the recurrence risks of outcome events precisely.  I did not adjust 
for premorbid conditions which might affect outcome [Bar & Hemphill, III 2011]  
although since most demographic and clinical characteristics in both lobar and non-
lobar ICH groups were similar (Chapter 5), it is unlikely that this affected the findings. 
Similarly, I did not adjust for the presence of subarachnoid extension [Maas et al. 2013a] 
as this is associated with a larger ICH volume which is likely to be the primary 
determinant of poor outcome [Chen et al. 2013].  I only categorised the presence or 
absence of intraventricular haemorrhage rather than determining the extent of it 
(Section 7.5.6, page 181) [Hwang et al. 2012].  I assessed intraventricular haemorrhage 
on the first (diagnostic) CT and therefore may have missed patients who had delayed 
intraventricular haemorrhage [Maas et al. 2013b]. 
7.5.3 Case fatality after first-ever spontaneous primary ICH 
7.5.3.1 Ascertainment of deaths 
The 30 day and one year case fatality rates in our study following spontaneous primary 
ICH were 43% (95% CI 35-52%) and 56% (95% CI 48-65%) respectively. 
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The WHO MONICA project (World Health Organisation Monitoring Trends and 
Determinants in Cardiovascular Disease) which examined trends in cardiovascular and 
stroke epidemiology prospectively in different populations specified indicators of study 
quality in a stroke incidence study [Asplund et al. 1995].  Although the generalisability of 
these criteria to our study is somewhat limited since MONICA studies included both 
ischaemic stroke and subarachnoid haemorrhage in their cohorts, the case fatality 
outcomes in our study fulfil certain indicators:  
(i) The one month case fatality rate in our cohort is similar to other studies of ICH 
[van Asch et al. 2010].  Therefore, assuming that our population is similar to 
others in which previous ICH incidence studies have been conducted and that 
no changes in either population structure or ICH prognosis have happened over 
time, it is unlikely that I have significantly under-ascertained either fatal or non-
fatal ICHs. 
(ii) The proportion of fatal cases occurring outside of hospital in relation to all 
stroke deaths is used to estimate the completeness of data on fatal out-of-
hospital events and although the proportion may vary between populations it is 
likely to be at least 10%.  The proportion in my cohort is 7% (95% CI 3-16%). 
(iii) The proportion of fatal cases examined by a physician before death or subjected 
to post-mortem examination is used as an indication of the accuracy of the 
clinical diagnosis of stroke.  Of all definite and suspected ICH cases, 93% met 
this criterion. 
7.5.3.2 Predictors of one month and one year case fatality 
Although there was no difference in crude survival over one year, after adjusting for 
other covariates, lobar ICH was strongly associated with survival in the first year.  Lobar 
ICH location appeared to be associated with a lower odds of death in the first 30 days 
but this was not statistically significant in a sensitivity analysis restricted to supratentorial 
ICH.  Lobar ICH has been associated with a better outcome in a population-based 
study [Zia et al. 2009], but not in two others [Nilsson et al. 2002;Inagawa et al. 2003] 
which may reflect confounding by other factors which influence prognosis after ICH 
such as intraventricular haemorrhage [Hemphill et al. 2001]. 
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Although lobar ICHs were larger than non-lobar ICHs they may be associated with a 
better outcome in comparison to ICH in other locations since they are less likely to 
cause hydrocephalus [Diringer, Edwards, & Zazulia 1998] and are also associated with 
dementia which in turn is associated with cortical atrophy [Cordonnier et al. 2010b], 
which may protect against mass effect caused by lobar ICH.  The finding that 
moderately sized lobar ICHs in our cohort were significantly more likely to survive in 
the first year than similar sized non-lobar ICHs is compatible with anecdotal clinical 
observations of small infratentorial ICHs causing significant impairment because of 
their tendency to rupture into the ventricular system or cause brainstem compression.   
I did not demonstrate the same association in the first 30 days following ICH (Table 14 
on page 184 and Table 15 on page 184), which might be explained by the smaller sample 
size once infratentorial ICHs were removed with a consequent reduction in power. 
Anticoagulation use and intraventricular haemorrhage were not associated with one 
month or one year case fatality.  Only 14% of the cohort used anticoagulant medications 
at the time of their ICH and the study may have lacked sufficient power to demonstrate 
an association between anticoagulant use and case fatality.  The ICH score simply 
categorises intraventricular haemorrhage as presence or absence rather than determining 
the extent of intraventricular haemorrhage and this may have obscured an association if 
one did exist in our cohort (Section 7.5.6, page 181). 
7.5.3.3 Statistical considerations 
I examined several methods to determine the influence of ICH location on prognosis.  
I calculated a Mantel-Haenzel odds ratio for the likelihood of death stratified by ICH 
location and adjusted for pre-specified covariates.   However, continuous variables had 
to be stratified within relatively wide bands and the number of variables that could be 
adjusted for was limited because of the generation of too many strata, raising the 
possibility of residual confounding between the outcome and exposure variable within 
strata [McNamee 2005] . A Cox proportional hazards regression model of the time to 
death in lobar vs. non-lobar ICH assumes that the hazard ratio (the relative risk of death 
in both groups) is the same at all times during follow up [Bewick, Cheek, & Ball 2004].  
Although I generated a multivariable Cox regression model, when I tested the 
proportional hazards assumption using Schoenfeld residuals, the model did not meet 
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this assumption.  This was consistent with a Kaplan-Meier curve of survival following 
first-ever primary ICH which showed crossing of survival lines for lobar and non-lobar 
ICH indicating that the assumption was unmet (Figure 28 on page 188). 
I was limited in the number of variables that I could include in a multivariable analysis 
by the rule of 10 outcome events per predictor variable.  I used nine events per variable 
since in logistic regression five to nine outcome events per variable is valid, especially if 
variables are selected a priori and the associations found are plausible in the context of 
current knowledge [Vittinghoff & McCulloch 2007].  
7.5.4 ICH score 
I demonstrated that the ICH score [Hemphill et al. 2001] discriminated well when using 
it to predict 30 day case fatality.  Age and intraventricular haemorrhage were not 
significant predictors of mortality in the regression model and this may be due to the 
loss of statistical power from age being used as a categorical variable (rather than 
continuous variable as in the previous models) and the study being underpowered given 
the small sample size. 
The performance of the ICH score might also be improved by assessing intraventricular 
haemorrhage according to a validated score rather than merely the presence or absence 
of it (Section 7.5.6, page 181).   
7.5.5 Recurrent ICH and vaso-occlusive events after first-ever spontaneous 
primary ICH 
7.5.5.1 Ascertainment of events 
There are various complexities in ascertaining events.  Some participants may not seek 
medical attention; they may fail to recognise the significance of symptoms [Kainth et al. 
2004;Sprigg et al. 2009] particularly if they have cognitive impairment or the symptoms 
resolve quickly and are therefore perceived as benign.  Older age and female sex have 
also been associated with delays to presentation [Moser et al. 2006].  Since the majority 
of our cohort had significant persisting neurological deficits following their ICH, it may 
also have been difficult to ascertain a recurrent stroke given their baseline level of 
impairment.  However, since the participants’ level of dependency following ICH in our 
cohort led to many being looked after in nursing homes or by trained carers, I would 
anticipate that carers were alert to the possibility of subsequent medical problems. 
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Moreover, since ICH, MI and PE are causes of sudden death some may have been 
misclassified if a participant died suddenly without investigation.  Even if a diagnosis of 
ICH is confirmed by imaging or post-mortem examination, it may still be misclassified 
as a ‘stroke, not specified as haemorrhage or infarction’ or as ‘intracranial haemorrhage’ 
(Table 13, page 183).  However, I obtained all GP records and, if available, hospital 
records of participants who died to corroborate information recorded on their death 
certificate and determine the likelihood of such a diagnosis.  By reviewing records of all 
calls made to the Office of the Procurator Fiscal, I was also able to review the 
circumstances of sudden deaths in our cohort where the Procurator Fiscal was 
contacted. 
The study could be improved by using a second clinician to independently classify 
outcomes blinded to the location of a participant’s ICH and their clinical history.  
Interviewing all participants and/or their carer individually would also reduce the chance 
of outcomes being undetected, although this was beyond the scope of our study and 
might have led to ascertainment bias and reduced the external validity of the findings by 
influencing participants’ health-seeking behaviour.  
7.5.5.2 ICH recurrence 
I demonstrated a significantly higher risk of recurrent ICH in the lobar ICH group with 
a tendency for the recurrent ICHs to be lobar and this is consistent with other studies 
[Bailey et al. 2001a]. 
The recurrence rate in our cohort is higher than that observed in a previous population 
based study [Flynn et al. 2010] and comparable to other studies [Passero et al. 
1995;Bailey et al. 2001a;Yen et al. 2007] which makes it less likely that I have missed 
recurrent ICHs and supports the notion that different vasculopathies underlie lobar and 
non-lobar ICH. 
The study benefited from its population-based design with both hospital and 
community-based methods of ascertaining follow-up events and validation of events by 
review of medical records and diagnostic imaging by a neuroradiologist.  Other studies 
have placed more reliance upon hospital records and discharge data [Flynn et al. 
2010;Chong et al. 2012]  and/or surveillance of established stroke registries to ascertain 
outcomes [Hanger et al. 2007;Zia et al. 2009;Flynn et al. 2010].  I have maintained the 
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external validity of the study by only including symptomatic ICHs in contrast to other 
studies which also classified new BMBs seen on MRI as recurrent ICH [Viswanathan et 
al. 2006]. 
The study is limited by the short follow-up period and small cohort, which makes it 
difficult to establish the recurrence risk of ICHs precisely.  A longer follow-up period in 
a larger cohort would allow me to establish whether the absence of recurrence in the 
non-lobar ICH group has merely occurred by chance (which seems likely). 
The increased risk of recurrence of lobar ICHs supports the existing theory that lobar 
and non-lobar ICH may have different causes.  Since hypertension has a greater role in 
causing non-lobar ICH [Jackson & Sudlow 2006], then prescribing of antihypertensive 
medications for secondary prevention of an ICH may be expected to have a greater 
effect on reducing non-lobar rather than lobar ICH.  However, this has not as yet been 
demonstrated, with prescribing of antihypertensives in one study found to reduce the 
incidence of both ICHs attributed to CAA and hypertension [Arima et al. 2010], 
although since ICHs were classified according to their presumed cause instead of by 
location, misclassification of the outcome may have occurred.  In the future I could 
investigate whether the prescribing of antihypertensive medications for secondary 
prevention differentially influences the risk of lobar vs. non-lobar ICH although a large 
sample would be needed and the study would be vulnerable to the biases affecting non-
randomised observational studies. 
7.5.5.3 Vaso-occlusive events 
I did not demonstrate any difference in the risk of vaso-occlusive events between 
participants with lobar and non-lobar ICH.  I found survivors of spontaneous ICH to 
be at similar risk of both recurrent ICH and vaso-occlusive events, which creates 
dilemmas regarding the prescription of antithrombotic medications following ICH.   
The recurrence rates of ischaemic stroke are comparable to those of other population-
based studies [Hanger et al. 2007;Zia et al. 2009] and the proportion of participants who 
had a MI or venous thromboembolism is similar to a previous retrospective single 
centre hospital based study [Goldstein et al. 2009].  Strengths of this study include the 
prospective ascertainment of outcomes and population-based design.  However, I 
would need to follow a larger number of participants up for a longer period of time to 
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increase the number of outcome events detected and determine if a true difference 
exists between the risk of vaso-occlusive events and recurrent ICH following a first-ever 
ICH and whether the risk of vaso-occlusive events differs by ICH location.  If the risk 
of vaso-occlusive events is similar to the risk of recurrent ICH following first-ever ICH 
this may have implications for restarting antithrombotic medications following an ICH 
especially since patients with ICH may also have risk factors for vaso-occlusive events 
such as hypertension.  Further investigation of the effects of antithrombotic 
medications according to the underlying vasculopathy are required in observational 
studies [Biffi et al. 2010a].  This clinical dilemma is also being explored in a randomised 
controlled trial of restarting vs. avoiding antithrombotic medications in survivors of 
spontaneous ICH who were taking these medications prior to their ICH 
(www.RESTARTtrial.org, ISRCTN71907627). 
7.5.6 Future directions 
This study indicates that unanswered questions remain regarding prognosis and the risk 
of haemorrhagic and vaso-occlusive outcomes after ICH. 
The study needs replication in a larger cohort to determine whether the association 
between lobar ICH and one year case fatality is consistent.  In a larger population, I 
would also investigate residual confounding by other known adverse prognostic 
variables such as ‘Do Not Resuscitate’ (DNR) orders [Zahuranec et al. 2007] and 
hydrocephalus [Diringer, Edwards, & Zazulia 1998].  Larger studies would also be able 
to investigate biomarkers of the underlying vasculopathy  such as BMBs and superficial 
siderosis [Smith et al. 2004;Park et al. 2013;Charidimou et al. 2013a], which require 
further investigation in adequately powered studies to determine whether they are 
predictors and surrogate markers of recurrent ICH. 
Since lobar ICH has a higher risk of recurrence [Bailey et al. 2001a], secondary 
prevention (such as reducing alcohol intake [Ariesen et al. 2003] and blood pressure 
[Arima et al. 2010]) may be particularly relevant to this group of patients.   
It is interesting that I did not show any association between intraventricular 
haemorrhage and case fatality.  As mentioned in Section 7.5.3.2, page 176 measuring the 
extent of intraventricular haemorrhage might have improved the predictive value of the 
regression model even further.  The extent of intraventricular haemorrhage may be 
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measured by three validated scales: the Graeb [Graeb et al. 1982], IVH [Hallevi et al. 
2009] and Le Roux [LeRoux et al. 1992] scales.  Each relies upon assessors to judge the 
extent of filling of each of the ventricles with blood on CT brain imaging as a 
percentage of the space within the ventricle and in the case of the IVH score the 
presence of hydrocephalus is an additional parameter in determining a final score.  They 
have been shown in hospital based studies to have predictive value in determining case 
fatality following spontaneous ICH [Hwang et al. 2012] and increase the specificity of 
the ICH score [Hallevi et al. 2009].  A future study might validate these scores in our 
population based cohort and assess whether integration of this variable and ICH 
location (lobar vs. non-lobar) improves the calibration of the ICH score. 
The ICH score has also been used to predict disability at one year after ICH in a 
hospital based cohort where disability was assessed either by semi-structured interview 
or using medical records (in 9% of the cohort) [Hemphill, Farrant, & Neill 2009].  It 
would be useful to externally validate the use of the ICH score for this purpose in a 
population-based cohort.    
Vaso-occlusive events are of special significance in patients with ICH since their 
occurrence leads to the clinical dilemma of treatment with antithrombotic medications 
vs. the risk of further ICH.  In our cohort there were small but appreciable numbers of 
these outcomes.  Since antithrombotic medications are a relative contraindication 
following ICH [Keir et al. 2002] but those with ICH often have risk factors for vaso-
occlusive events, it is important to determine the risk of recurrent ICH and vaso-
occlusive events after an ICH.  Although there is some evidence that the incidence of 
vaso-occlusive events is at least as high as that of recurrent ICH after spontaneous 
primary ICH [Flynn et al. 2010], two hospital based studies have shown a higher 
incidence of ICH [Viswanathan et al. 2006;Chong et al. 2012].  I would aim to recruit 
more participants and continue prospective follow-up of participants for several years to 
increase the number of outcome events observed and determine the incidence rates of 
both recurrent ICH and vaso-occlusive events. 
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Table 13 Causes of death listed in Section 1A of the death certificate in 72 participants 
who died in the first year following first-ever spontaneous primary ICH 
Primary cause of death Frequency (%) 
Intracerebral haemorrhage  46 (64) 
Intracranial haemorrhage (non-traumatic), unspecified 7 (10) 
Stroke, not specified as haemorrhage or infarction 2 (3) 
Bronchopneumonia 13 (19) 
Acute myocardial infarction 1 (1) 
Infarcted bowel 1 (1) 
Malignant neoplasm of biliary tract 1 (1) 
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Table 14 Logistic regression model of predictors of death in the first 30 days after 
first-ever spontaneous primary ICH 
Variable OR, 95% CI p 
Age (years) 1.04 (1.00-1.09) 0.047 
Glasgow coma scale 0.70 (0.58-0.84) <0.001 
ICH volume (ml) 1.06 (1.03-1.09) <0.001 
Lobar ICH 0.19 (0.05-0.69) 0.012 
Presence of intraventricular extension 1.36 (0.41-4.51) 0.613 
Anticoagulant use 2.29 (0.43-12.20) 0.331 
 
Table 15 Logistic regression model of predictors of death in the first 30 days after 
first-ever spontaneous primary supratentorial ICH  
Variable OR, 95% CI p 
Age (years) 1.05 (1.00-1.10) 0.045 
Glasgow coma scale 0.73 (0.60-0.89) 0.002 
ICH volume (ml) 1.06 (1.03-1.10) <0.001 
Lobar ICH 0.26 (0.07-1.03) 0.06 
Presence of intraventricular extension 1.33 (0.37-4.80) 0.663 
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Table 16 Logistic regression model of predictors of death in the first year after first-
ever spontaneous primary ICH 
Variable OR, 95% CI p value 
Age (years) 1.07 (1.03-1.12) 0.001 
Glasgow coma scale 0.80 (0.67-0.95) 0.013 
ICH volume (ml) 1.05 (1.02-1.08) 0.001 
Lobar ICH  0.21 (0.07-0.64) 0.006 
Presence of intraventricular extension 0.64 (0.23-1.80) 0.430 
Anticoagulant use 2.22 (0.46-10.65) 0.319 
 
Table 17 Logistic regression model of predictors of death in the first year after first-
ever spontaneous primary supratentorial ICH 
Variable OR, 95% CI p  
Age (years) 1.07 (1.02-1.11) 0.002 
Glasgow coma scale 0.83 (0.69-1.01) 0.06 
ICH volume (ml) 1.05 (1.02-1.08) 0.001 
Lobar ICH  0.28 (0.09-0.88) 0.03 
Presence of intraventricular extension 0.66 (0.23-1.91) 0.448 
Anticoagulant use 1.44 (0.24-8.63) 0.688 
 
Table 18 Number of deaths in the first year after first-ever primary ICH, stratified by 
ICH volume 
ICH volume (ml) Lobar ICH  Non-lobar ICH  
 n Deaths in first year, n (%) n Deaths in first year, n (%) 
0-29 31 10 (32) 46 20 (43) 
30-59* 12 6 (50) 11 10 (91) 
60-90 22 20 (91) 2 2 (100) 
*p=0.04
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Table 19 Deaths in the first 30 days after first-ever spontaneous primary ICH 
according to ICH score 
ICH score n (%) Deaths in first 30 days n,(%; 95% CI) 
0 21 (17) 1 (5; 1-22) 
1 33 (27) 5 (15; 7-31) 
2 26 (21) 13 (50; 32-68) 
3 22 (18) 12 (55; 35-73) 
4 12 (10) 11 (92; 65-99) 
5 8 (7) 8 (100; 68-100) 
 
Table 20 Logistic regression model of 30 day case fatality using the ICH score after 
first-ever spontaneous primary supratentorial ICH 
Variable OR, 95% CI p 
Age (≥80 years) 1.91 (0.71-5.17) 0.20 












ICH volume (≥ 30ml) 5.75 (1.88-17.56) 0.002 
Infratentorial ICH 7.13 (1.57-32.49) 0.011 
Presence of intraventricular extension 1.19 (0.41-3.44) 0.753 
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Table 21 Frequency of myocardial infarction, TIA and ischaemic strokes observed in 
128 participants following first-ever spontaneous primary ICH 
 Lobar ICH (n=68) Non-lobar ICH (n=60) 
Myocardial infarction  0 2 
TIA 2 1 
Ischaemic stroke 1 1 
Chapter 7 
  188 
Figure 28 Kaplan-Meier curve of survival time following first-ever spontaneous 
primary ICH 
 
 Number at risk (number of deaths during subsequent 10 day period) 
Lobar 68 (26) 42 (4) 38 (2) 36 
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Figure 29 Receiver operator curve for ICH score applied to 122 participants with first-
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Figure 31 Kaplan-Meier curve of time to any vaso-occlusive event or recurrent ICH 
following first-ever spontaneous primary ICH, stratified by ICH location 
 
 Number at risk (number of events during each 100 day interval) 
Lobar 68 (4) 31 (1) 27 (3) 23 (0) 
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Figure 32 Kaplan-Meier curve of time to recurrent ICH following first-ever 
spontaneous primary ICH 
 
 Number at risk (number of events during each 100 day interval) 
Lobar 68 (3) 32 (0) 29 (1) 27 (0) 
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Figure 33 Kaplan-Meier curve of time to first-ever TIA, ischaemic stroke or myocardial 
infarction following first-ever spontaneous primary ICH 
 
 Number at risk (number of events during each 100 day interval) 
Lobar 68 (1) 32 (0) 28 (2) 24 (0) 
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Figure 34 Kaplan-Meier curve of time to DVT or PE following first-ever spontaneous 
primary ICH 
 
 Number at risk (number of events during each 100 day interval) 
Lobar 68 (0) 33 (1) 28 (1) 26 (0) 
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Figure 35 Kaplan-Meier curve of time to recurrent ICH or vaso-occlusive event 
following first-ever spontaneous primary ICH 
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8 A cross-sectional study of apolipoprotein E genotypes in lobar vs. 
non-lobar intracerebral haemorrhage 
8.1 Introduction 
The three common alleles of the apolipoprotein E gene, ε2, ε3 and ε4 lead to single 
amino acid changes in the apolipoprotein E protein [Verghese, Castellano, & Holtzman 
2011].  The ε4 allele increases the risk of pathologically-proven CAA in a dose-
dependent manner [Rannikmae et al. 2013b].  The ε4 allele has also been associated with 
an increased risk of lobar and supratentorial deep ICH in comparison to unaffected 
controls [Biffi et al. 2010b] and it may also contribute to an increased risk of death after 
ICH [Martinez-Gonzalez & Sudlow 2006] although the results of studies conflict [Biffi 
et al. 2011a].  The ε2 allele has been associated with an increased risk of haematoma 
expansion [Brouwers et al. 2012] and death [Biffi et al. 2011a] after lobar ICH. 
In the following chapter I will: 
• describe the baseline characteristics of participants who underwent genotyping in 
the first two years of the study (1st June 2010 – 31st May 2012); 
• describe the proportion of participants with ε2 and ε4 alleles stratified by ICH 
location who underwent genotyping in the first two years of the study (1st June 2010 
– 31st May 2012) and 
• compare the outcomes (death in the first 30 days following an ICH and death or 
dependency in the first year after an ICH) for those who possessed at least one ε2 
or ε4 allele vs. those who did not, for those recruited in the first year of the study 
(1st June 2010-31st May 2011). 
8.2 Methods 
8.2.1 Participants 
Participants recruited into the LINCHPIN study (an ethically-approved interventional 
study of patients with spontaneous primary ICH), underwent apolipoprotein E 
genotyping.  The inclusion and exclusion criteria, genotyping procedure and phenotype 
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definition are described in Chapter 4.  The definitions of baseline characteristics are 
described in Chapter 2. 
I applied the modified Boston criteria for CAA [Knudsen et al. 2001;Linn et al. 2010] by 
integrating MRI brain and post-mortem examination findings where available, to the 
cohort to describe the frequency of possible, probable and definite CAA-related ICH as 
described in Chapter 5.  I compared the proportion of participants with either an ε2 or 
ε4 allele in the definite or probable CAA-related ICH group vs. the possible CAA-
related ICH group.   
For participants in the first year cohort, I assessed outcomes (death in the first 30 days 
following an ICH and death or dependency in the first year after an ICH) as described 
in Chapter 7.  I examined the proportion of participants with either an ε2 or ε4 allele 
who died in the first 30 days following an ICH vs. those who did not.  Similarly, I 
compared the proportion of participants with either an ε2 or ε4 allele who died in the 
first year after an ICH or were dependent (modified Rankin scale 3-5) [Rankin 1957] 
one year after an ICH. 
8.2.2 Statistical analysis 
I used parametric statistics for between group comparisons when the data had a normal 
distribution and log-transformed variables or used non-parametric statistics when it did 
not.  If an estimated cell count was less than five, I used the Fisher’s exact test.  I 
conducted all statistical analyses using Stata version 11.1 (StataCorp LP, Texas, USA). 
All p values are two-sided.  
8.3 Results 
8.3.1 Study participants 
Of the 90 participants, 48 had lobar ICH.  84 participants had a first-ever ICH.  Three 
participants had recurrent lobar ICH and three had recurrent non-lobar ICH.  The 
baseline characteristics of 84 participants with first-ever lobar and non-lobar ICH are 
shown in Table 22 on page 206.  There were no significant differences between 
participants with lobar and non-lobar ICH in any baseline demographic or clinical 
characteristics.  One participant with recurrent non-lobar ICH was of Chinese ethnic 
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origin and the remainder were Caucasian.  Dementia was more common in those with 
lobar ICH, although this difference was not statistically significant.  The genotype 
frequencies are given in Table 3 and Table 4 on page 116. 
8.3.2 Proportion of participants with at least one ε2 allele in first-ever lobar vs. non-
lobar ICH 
There were 81 participants with first-ever ICH for whom the presence of an ε2 allele 
could be determined (Table 4 on page 116).  11 out of 42 participants (26%; 95% CI 15-
41%) with first-ever lobar ICH had one ε2 allele in comparison to five out of 39 
participants (13%; 95% CI 6-27%) with non-lobar ICH (χ2= 2.28, p=0.13).  No 
participants possessed an ε2ε2 genotype. 
8.3.3 Proportion of participants with at least one ε4 allele in first-ever lobar vs.non-
lobar ICH 
There were 81 participants with first-ever ICH for whom the presence of an ε4 allele 
could be determined (Table 4 on page 116).  18 out of 44 participants (41%; 95% CI 28-
56%) with first-ever lobar ICH had at least one ε4 allele in comparison to seven out of 
37 participants (19%; 95% CI 10-34%) with non-lobar ICH (χ2= 4.56, p=0.03).  Three 
participants with first-ever lobar ICH had an ε4ε4 genotype compared to none in the 
non-lobar ICH group but this difference was not statistically significant (p=0.25). 
8.3.4 Application of the modified Boston criteria to adults with first-ever 
spontaneous primary lobar ICH 
Two out of 45 participants (4%) with first-ever lobar ICH had an ICH involving both 
the lobar and deep regions of the brain and were therefore not eligible for classification 
under the modified Boston criteria.  A further three participants (7%) were aged under 
55 years old and the genotype of one participant (2%) was undetermined.  Of the 
remaining 39 participants, 33 (85%) had undergone either MRI (n=22) or post-mortem 
examination (n=11).  Five had definite CAA-related ICH according to the modified 
Boston criteria and eight had probable CAA-related ICH.   
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8.3.5 Proportion of participants with at least one ε2 allele in probable or definite 
CAA vs. possible CAA 
Two out of 13 participants (15%; 95% CI 4-42%) with probable or definite CAA-related 
ICH had an ε2 allele in comparison to eight out of 26 participants (31%; 17-50%) with 
possible CAA-related ICH.  There was no association between the presence of an ε2 
allele and probable or definite CAA-related ICH ((χ2=1.08, p=0.30). 
8.3.6 Proportion of participants with at least one ε4 allele in probable or definite 
CAA vs. possible CAA 
Possession of at least one ε4 allele was more frequent in the probable and definite CAA 
group (7/13 (54%); 95% CI 29-77%) vs. the possible CAA group (8/26 (31%); 95% CI 
17-50%), although this difference was not significant (χ2=1.95, p=0.16.) 
8.3.7 Possession of at least one ε2 allele and death or dependency 
49 participants were recruited in the first year of the study (1st June 2010-31st May 2011), 
all of whom had outcome data.  The presence of at least one ε2 allele could be 
determined in 48 participants.  
8.3.7.1 ε2 allele and death in the first 30 days following a first-ever ICH 
The possession of at least one ε2 allele was not associated with death in the first 30 days 
following a first-ever ICH (has at least one ε2 allele 1/8 (13%); 95% CI 2-47% vs. does 
not have an ε2 allele 8/40 (20%); 95% CI 11-35%; χ20.25, p=0.62).  In an analysis 
stratified by ICH location the results were unchanged.   
8.3.7.2 ε2 allele and death or dependency in the first year following a first-ever ICH 
The possession of at least one ε2 allele was not associated with death or dependency 
(modified Rankin scale 3-5) at one year (has at least one ε2 allele 5/8 (63%); 95% CI 31-
86% vs. does not have an ε2 allele 29/40 (73%); 95% CI 57-84%; χ20.32, p=0.57).  In 
an analysis stratified by ICH location the results were unchanged.  
8.3.8 Possession of at least one ε4 allele and death or dependency 
The presence of at least one ε4 allele could be determined in 47 participants.  
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8.3.8.1 ε4 allele and death in the first 30 days following a first-ever ICH 
The possession of at least one ε4 allele was not associated with death in the first 30 days 
following a first-ever ICH (has at least one ε4 allele 5/18 (28%); 95% CI 13-51% vs. 
does not have an ε4 allele 4/29 (14%); 95% CI 6-31%; χ21.40, p=0.24).  In an analysis 
stratified by ICH location the results were unchanged.  
8.3.8.2  ε4 allele and death or dependency in the first year following a first-ever 
ICH 
Possession of at least one ε4 allele was more frequent in those who were either dead or 
dependent (modified Rankin scale 3-5) at one year; (has at least one ε4 allele 15/18 
(84%); 95% CI 61-94% vs. does not have an ε4 allele 18/29 (62%); 95% CI 44-77%) 
but this difference was not statistically significant (χ22.40, p=0.12).  In an analysis 
stratified by ICH location the results were unchanged.  
8.4 Summary 
• The ε4 allele was significantly more common in participants with lobar ICH in 
comparison to those with non-lobar ICH. 
• There was no difference in the frequency of the ε2 allele between those with lobar 
and non-lobar ICH. 
• The ε4 allele was more frequent in those participants with probable or definite 
CAA-related ICH in comparison to those with possible CAA-related ICH according 
to the modified Boston criteria for CAA but the difference was not significant. 
• The presence of at least one ε2 allele or ε4 allele was not associated with death in 
the first 30 days following a first-ever ICH or death or dependency at one year. 
8.5 Discussion 
8.5.1 Strengths of the study 
The study meets criteria for genetic association studies including [Dichgans & Markus 
2005;Little et al. 2009]:  
(i) establishment of the hypothesis to be tested a priori;  
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(ii) consistent definitions of baseline characteristics of participants (Chapter 2); 
(iii) a population-based design; 
(iv) careful phenotyping of lobar and non-lobar ICH by a neuroradiologist with a 
special interest in stroke who was blind to the participant’s genotype and 
(v) reporting of baseline characteristics and outcome events for all participants. 
Both comparison groups were drawn from the same population and did not differ in 
either their ethnic composition or other baseline characteristics.   Since allele frequencies 
may differ by ethnicity; for example, the frequency of apolipoprotein ε4 alleles is lower 
in Asians [Tzourio et al. 2008], ethnic differences between comparison groups may lead 
to differences in allele frequencies and disease risks, giving rise to confounding 
(otherwise known as population stratification [Little et al. 2009]).  It is unlikely that 
population stratification has affected the findings of this study.  
8.5.2 Limitations of the study 
This is a small genetic association study of the apolipoprotein E gene and ICH 
phenotypes.  It should be viewed as a precursor to future larger studies using samples 
from the LINCHPIN study.   
8.5.3 Study findings 
8.5.3.1 ε2 and ε4 alleles and ICH location 
The ε4 allele was significantly more common in participants with lobar ICH in 
comparison to those with non-lobar ICH.   
This is consistent with the findings of other studies including a meta-analysis of 2189 
ICH cases and 4041 controls which showed an association between the ε4 and ε2 alleles 
and lobar ICH in comparison to controls without a past history of ICH or dementia 
[Biffi et al. 2010b].  This meta-analysis also demonstrated an association between the ε4 
allele and both deep and brainstem ICH.  If these are true associations, then the 
association observed in my study between the ε4 allele and lobar ICH might have been 
stronger had I used non-ICH controls as the comparison group, rather than participants 
with non-lobar ICH.  Although dementia appeared to be more frequent in those with 
lobar ICH in the cohort it is unlikely that dementia (through its association with CAA) is 
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acting as a confounder of the association between the ε4 allele and lobar ICH, since 
CAA is associated with the ε4 allele independent of its association with dementia 
[Rannikmae et al. 2013b].  However, the association between CAA and lobar ICH needs 
further exploration in demented and non-demented individuals. 
I did not demonstrate a statistically significant difference in the proportion of 
participants possessing an ε2 allele in the lobar ICH (vs. non-lobar ICH) group or a 
difference in the proportions of participants with an ε2 or ε4 allele when those with 
probable and definite CAA-related ICH according to the modified Boston criteria 
[Knudsen et al. 2001;Linn et al. 2010] were compared to those with possible CAA-
related ICH.  Given the small number of participants, it is likely that the study was 
underpowered to detect a difference if one did exist.  A recent meta-analysis [Biffi et al. 
2010b] which found that ε2 and ε4 alleles were associated with probable and definite 
CAA according to the modified Boston criteria [Knudsen et al. 2001;Linn et al. 2010] 
used age-matched controls without a history of ICH as a comparison group.  Since I 
used those with possible CAA-related ICH as a comparison group, any association may 
have been underestimated given the higher underlying prevalence of ε2 and ε4 alleles in 
those with lobar ICH in comparison to controls without ICH [Sudlow et al. 2006;Biffi 
et al. 2010b].   
Since the Boston criteria for possible, probable and definite CAA rely upon integrating a 
radiological description of lobar ICH with MRI findings of BMBs or superficial 
siderosis and/or pathological findings, participants may have been misclassified if: 
(i) they had a single lobar ICH and did not undergo either MRI or post-mortem 
examination in which case they could only be classified as having ‘possible’ 
CAA; 
(ii) BMBs were incorrectly assessed on MRI or 
(iii) CAA was missed at post-mortem examination.   
The majority (85%) of participants had undergone either MRI or post-mortem 
examination. A neuroradiologist reviewed all imaging (Chapter 3) and an experienced 
neuropathologist used an extensive post-mortem examination sampling protocol 
(Appendix) and rated CAA blind to the participant’s genotype.  These factors mitigate 
against misclassification of participants, although given the paucity of radio-pathological 
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correlation studies of BMBs, pathological confirmation of CAA remains the gold 
standard. 
8.5.3.2 ε2 and ε4 alleles and death or dependency 
I did not demonstrate an association between the presence of at least one ε2 or ε4 allele 
and death or dependency in the whole cohort or when subdivided by ICH location.  
The study may have been underpowered to detect an association if one does exist.  A 
recent study found that carriers of the ε2 allele (but not the ε4 allele) who had lobar 
ICH had larger ICH volumes, poorer functional outcomes (assessed by telephone using 
the modified Rankin scale at 90 days) and increased mortality [Biffi et al. 2011a].  There 
was no such association for deep ICH [Biffi et al. 2011a].  In one other study the ε4 
allele seemed to be associated with an increased likelihood of death or dependency 
following ICH although the association was not statistically significant (OR 1.38; 95% 
CI 0.99-1.92) [Martinez-Gonzalez & Sudlow 2006].  The mechanism by which either or 
both of these alleles might influence outcome is unclear and needs further exploration 
in large population-based studies using assessment of outcomes blinded to genotype at a 
standard interval following ICH. 
8.5.4 Future research 
Although the association between the ε4 allele and lobar ICH demonstrated in this 
small study is meaningful (in view of the adequate study quality and similar findings in 
other larger independent populations), the biological mechanism underlying the 
association between ε2 and ε4 alleles and lobar ICH remains unclear.  A common 
hypothesis is that the ε4 allele increases the deposition of Aβ in the vessel wall and ε2 
promotes the vasculopathic changes that lead to rupture [McCarron et al. 1999b]. 
However, an individual patient data meta-analysis of participants with pathologically 
proven CAA (without ICH) in comparison to controls did not show any association 
between the ε2 allele and vasculopathy [Rannikmae et al. 2013a].  Further studies of 
ICH which correlate genotyping information with pathological findings may clarify the 
mechanism behind the association of these alleles and lobar ICH. 
The severity of CAA is associated with the number of ε4 alleles in patients with 
Alzheimer’s dementia but a dose response relationship is yet to be established in those 
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with ICH.  When analysing data in genetic association studies several different genetic 
models exist [Lewis 2002].  In studies of apolipoprotein E the dominant model is most 
commonly used which presupposes that carrying the ε4 allele confers an increased risk 
of disease and therefore the ε2/ε4, ε3/ε4 and ε4/ε4 genotypes are pooled giving a two 
by two table in which both comparison groups are classed as ε4+ or ε4 -.  An additive 
model presupposes an increased risk of r for ε2/ε4 and ε3/ε4 genotypes and 2r for an 
ε4/ε4 genotype.  There is some evidence to support a dose response relationship since 
an additive genetic model in one study provided a more accurate prediction of disease 
status (lobar ICH vs. control) in comparison to the commonly used dominant model 
[Biffi et al. 2010b].      
The role of apolipoprotein E in non-lobar ICH is as yet unknown.  Despite one study 
showing an association between the ε4 allele and brainstem and deep ICH [Biffi et al. 
2010b], and a further study showing an association between both ε2 and ε4 alleles and 
supratentorial deep ICH [Tzourio et al. 2008], other studies have failed to show an 
association between these alleles and non-lobar ICH [Sudlow et al. 2006;Peck et al. 
2008].  Future studies should explore this, especially given the inclusion of cerebellar 
BMBs in the Boston criteria for ‘probable’ CAA [Knudsen et al. 2001].  Given the low 
incidence of infratentorial ICH a multicentre collaborative approach is likely to be 
required with meticulous phenotyping of cases. 
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Table 22 Baseline characteristics for 84 participants with first-ever ICH 
 Any lobar (n=45) Non-lobar ICH (n=39) p value 
Sex (male); (%) 18 (40) 21 (54) 0.20 
Age (years); median (IQR) 77 (69-81) 73 (59-77) 0.12 
History of hypertension 







History of diabetes 







History of dementia 







History of smoking 
Never (n, %) 
Ex-smoker (n, %) 














Antiplatelet use (n, %) 
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9 The association between cerebral amyloid angiopathy and 
intracerebral haemorrhage: a systematic review and meta-analysis 
9.1 Introduction 
During the last decade spontaneous (non-traumatic) ICH accounted for ~10% of 
strokes in high income countries and ~20% of strokes in low/middle income countries, 
where the one month case fatalities were 25–35% and 30-48% respectively [Feigin et al. 
2009].  Although time trends have varied between regions, the case fatality one month 
after ICH has remained ~40% across the globe during the last few decades [van Asch et 
al. 2010].  
Understanding that systemic arterial hypertension is the strongest modifiable risk factor 
for ICH led to trials of secondary prevention with antihypertensive drugs [Ariesen et al. 
2003;Chapman et al. 2004] which appear to improve outcome for survivors of ICH 
(regardless of its location)[Arima et al. 2010].  Further improvements in outcome could 
arise from better understanding the causes of ICH.  Because survivors of lobar ICH 
appear to be at a higher risk of recurrent ICH than survivors of deep ICH [Bailey et al. 
2001b], the causes of lobar ICH are of particular interest. 
The deposition of β-amyloid peptide in the media of cortical and leptomeningeal 
arteries, arterioles, and capillaries – now known as cerebral amyloid angiopathy (CAA) – 
was first identified in the early twentieth century [Oppenheim 1909;Scholz 1938].  CAA 
is quite prevalent in cognitively unimpaired elderly people and even more prevalent in 
those with dementia [Neuropathology Group of the Medical Research Council 
Cognitive Function and Ageing Study (MRC CFAS) 2001].   
Since the late 1970s influential case series have suggested that CAA may cause lobar 
ICH [Jellinger 1977;Okazaki, Reagan, & Campbell 1979].  However, in everyday clinical 
practice, [Cordonnier et al. 2010a] CAA is often inferred to be the cause of lobar or 
cerebellar ICH, especially if the patient is elderly, the ICHs are recurrent or multifocal, 
or haem-sensitive GRE MRI sequences demonstrate at least one lobar brain BMB 
[Knudsen et al. 2001]. 
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However, the strength of the overall association between CAA and ICH remains to be 
precisely quantified (in lobar and cerebellar locations in particular, but also in deep 
locations [Ritter et al. 2005]), so I performed a systematic review and meta-analysis of 
published neuropathological studies.  I aimed to take account of three potential 
confounding factors that should be described, and preferably controlled or adjusted for 
in comparisons of cases and controls: firstly, patients’ ages, given the increasing CAA 
prevalence with age [Neuropathology Group of the Medical Research Council Cognitive 
Function and Ageing Study (MRC CFAS) 2001]; secondly, cognitive impairment (and its 
severity), given the greater prevalence of CAA in those with cognitive impairment than 
those without dementia; [Masuda et al. 1988;Neuropathology Group of the Medical 
Research Council Cognitive Function and Ageing Study (MRC CFAS) 2001] and thirdly, 
patients’ racial origins, given racial differences in the prevalence of apolipoprotein E 
polymorphisms which have been associated with ICH due to CAA [Corbo & Scacchi 
1999;Biffi et al. 2010b] and racial differences in the proportion of ICH in a lobar 
location [Lavados et al. 2010]. 
9.2 Methods 
9.2.1 Search strategy and selection criteria 
In April 2011 I searched Ovid Medline (1950-) and Embase (1980-) using 
comprehensive electronic search strategies (Table 23 on page 218 and Table 24 on page 
219).  I searched the bibliographies of relevant publications and Google scholar for 
other papers citing each included paper.  I also searched the tables of contents of several 
journals (The Journal of Neurology, Neurosurgery and Psychiatry; The Lancet 
Neurology; Annals of Neurology; Brain; Lancet; Neurology; and Stroke) since 2005 and 
our personal files. 
9.2.2 Eligibility criteria 
Studies were eligible for inclusion if they had diagnosed CAA on pathological 
examination of a brain biopsy or at post-mortem examination and quantified the 
prevalence of CAA in patients with spontaneous (non-traumatic) ICH as well as a group 
of patients without ICH. 
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9.2.3 Data collection 
I screened all titles and abstracts for eligibility, removed duplicates and read the full text 
of articles that were potentially eligible for inclusion.  Eligible studies were read in full 
by myself and Professor Salman who extracted data independently on: study design, the 
types of cases and controls, methods of assessment and grading of CAA, the prevalence 
of CAA in cases and controls, and whether any confounders were accounted for.  We 
resolved disagreements by discussion.  
If pertinent study attributes or data were unavailable or unclear in an eligible 
publication, I sought clarification from the authors by post and email.  I also sought 
individual patient data from included publications – either in person, or by email and 
post – in order to stratify or adjust the analyses for the potential confounding variables 
of age and co-morbid cognitive impairment, as well as to explore the strength of the 
association between ICH and CAA according to neuropathological severity of CAA; 
unfortunately, only one study provided these data [Ritter et al. 2005], precluding an 
individual patient data meta-analysis. 
9.2.4 Methodological assessment 
I was guided in my assessment of the methodological quality of the included studies by 
the Newcastle-Ottawa scale [Wells et al. 2002], which uses eight items to judge the 
quality of case-control studies on their selection of study groups, the comparability of 
their cases and controls, and their ascertainment of cases’ and controls’ exposure (i.e. to 
CAA).  If a study fulfils the criteria for an item a score of one point is allocated, with the 
exception of comparability which can score up to two points, resulting in a maximum 
score of nine points. 
9.2.5 Statistical analysis 
If I identified multiple publications relating to the same cohort, I included the largest 
study.  For each study, I determined the numbers of cases and controls and the 
prevalence of CAA in each group.  I sought to stratify analyses by ICH location (deep, 
lobar, cerebellar, or all locations grouped together), age, neuropathological ratings of 
CAA severity, and racial origin of the participants.  I meta-analysed the data in 
StatsDirect statistical software version 2.7.8, using a random effects model with 
DerSimonian-Laird weights, quantified the strength of any association using the odds 
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ratio (OR) and its associated 95% CI, and assessed inconsistency with the I-squared (I2) 
statistic.  In a separate sensitivity analysis, I tested whether the restriction of our analysis 
to studies explicitly stating that all ICH were non-traumatic changed the direction or 
strength of the association between CAA and ICH in all locations.  In sub-group 
analyses, I examined the strength of the relationship between CAA and cases with lobar 
ICH in studies where the average ages of cases and controls were comparable versus 
those where average ages of cases and controls were dissimilar or unknown, and in 
studies in which participants were Asian versus those in which they were not. 
9.3 Results 
The search strategies identified 1,824 articles, of which 19 appeared to be eligible 
(Figure 36 on page 223).  I excluded nine studies because they provided insufficient data 
to quantify the numbers of cases and controls with and without CAA in seven studies 
[Tomonaga 1981;Yamada et al. 1987;Yamanouchi, Shimada, & Kuramoto 1990;Itoh et 
al. 1993;Ellis et al. 1996;Itoh & Yamada 1997;Jellinger 2006], cases were selected only if 
they were affected by CAA [Vonsattel et al. 1991], and the remaining study reported 
data already included in this systematic review [Jellinger, Lauda, & Attems 2007].  I 
included ten neuropathological studies involving 481 cases and 3,219 controls from 
China [Ng, Leung, & Wong 1991;Xu, Yang, & Wang 2003], Japan [Masuda et al. 
1988;Ishihara et al. 1991], Chile [Cartier et al. 1999], India [Badhe, Mehta, & Desai 
2005], Australia [Mastaglia et al. 2003] and Europe [Ritter et al. 2005;Attems, Lauda, & 
Jellinger 2008;Guidoux 2008]. 
9.3.1 Critical appraisal 
I compared included studies to the ideal design for a study of the association between 
CAA and lobar ICH (Table 25 on page 220), and rated them using the Newcastle-
Ottawa scale (Table 26 on page 221)[Wells et al. 2002]. 
9.3.2 Selection of study groups 
Studies’ ascertainment of cases ranged from highly representative samples of deaths in a 
community to consecutive, randomly sampled, or selected hospital autopsies (Table 26 
on page 221).  Eight studies clearly defined their cases as having spontaneous ICH 
[Ishihara et al. 1991;Ng, Leung, & Wong 1991;Cartier et al. 1999;Xu, Yang, & Wang 
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2003;Ritter et al. 2005;Badhe, Mehta, & Desai 2005;Attems, Lauda, & Jellinger 
2008;Guidoux 2008] and the corresponding author confirmed that ICH cases were 
spontaneous in another study [Mastaglia et al. 2003].  Five studies stated that the ICH 
had been clinically symptomatic [Ng, Leung, & Wong 1991;Cartier et al. 1999;Ritter et 
al. 2005;Badhe, Mehta, & Desai 2005;Guidoux 2008].  Two studies included both first-
ever and recurrent ICH [Attems, Lauda, & Jellinger 2008;Guidoux 2008], but the 
remainder did not specify the inception point for ICH cases.  Only five studies 
described the ages of included cases [Ishihara et al. 1991;Cartier et al. 1999;Ritter et al. 
2005;Attems, Lauda, & Jellinger 2008;Guidoux 2008].  Three studies did not 
systematically specify ICH locations [Ng, Leung, & Wong 1991;Xu, Yang, & Wang 
2003;Badhe, Mehta, & Desai 2005] but the remainder did albeit with different categories 
(Table 26 on page 221).  Furthermore, studies varied in their definitions of ‘lobar’ ICH, 
including: ICH that had originated in the cerebellum [Guidoux 2008], cortex or 
subarachnoid space [Ishihara et al. 1991]; subcortical, cortical or in the insular cortex 
closely related to the basal ganglia [Ritter et al. 2005]; and in another, lobar ICH was 
distinguished from multiple cortico-subcortical ICH [Attems, Lauda, & Jellinger 2008]. 
9.3.3 Comparability of cases and controls 
All but one study [Badhe, Mehta, & Desai 2005] described ascertainment of controls 
from the same population as the cases (consecutive hospital post-mortem examination 
controls [Ng, Leung, & Wong 1991;Mastaglia et al. 2003;Xu, Yang, & Wang 
2003;Attems, Lauda, & Jellinger 2008], selected hospital post-mortem examination 
controls, [Ishihara et al. 1991;Cartier et al. 1999;Ritter et al. 2005;Guidoux 2008] and 
community controls [Masuda et al. 1988]), such that the controls could have been cases 
had they been affected by ICH (Table 26 on page 221).  In three studies, 46-82% of the 
control groups had ischaemic stroke [Ishihara et al. 1991;Ritter et al. 2005;Badhe, Mehta, 
& Desai 2005].  Considering potential confounding factors, two studies included 
controls with dementia diagnosed on clinical and neuropathological grounds [Xu, Yang, 
& Wang 2003;Attems, Lauda, & Jellinger 2008], only five studies described the average 
ages of their cases [Ishihara et al. 1991;Cartier et al. 1999;Ritter et al. 2005;Attems, 
Lauda, & Jellinger 2008;Guidoux 2008] and only four studies described the average ages 
of their controls [Ishihara et al. 1991;Cartier et al. 1999;Ritter et al. 2005;Guidoux 2008], 
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but just three studies accounted for confounding by matching the ages of cases and 
controls within five years [Cartier et al. 1999;Ritter et al. 2005;Guidoux 2008]. 
9.3.4 Ascertainment of cases’ and controls’ exposures 
All studies but one [Guidoux 2008] assessed cases and controls for CAA in the same 
way (Table 27 on page 222), but only one study [Cartier et al. 1999] reported that the 
assessment was blinded (although the nature of blinding was unclear).  The extent of 
sampling varied between studies (Table 27 on page 222).  Eight studies used Congo Red 
staining to detect CAA [Masuda et al. 1988;Ishihara et al. 1991;Ng, Leung, & Wong 
1991;Cartier et al. 1999;Xu, Yang, & Wang 2003;Ritter et al. 2005;Badhe, Mehta, & 
Desai 2005;Guidoux 2008], one of which also used immunohistochemistry in every case 
[Xu, Yang, & Wang 2003].  The rating of CAA severity involved a variety of rating 
scales – many of which were bespoke being devised by the authors themselves (Table 27 
on page 222) – and CAA severity in cases and controls was seldom quantified in every 
patient.  Following communication with the corresponding author of one study [Ritter 
et al. 2005], I established that only four studies described whether CAA was specifically 
present in the vessels adjacent to the ICH (so that lobar ICH could be attributed to 
lobar CAA) [Masuda et al. 1988;Ishihara et al. 1991;Ng, Leung, & Wong 1991;Xu, Yang, 
& Wang 2003]. 
9.3.5 Association between CAA and ICH 
Our meta-analyses (Figure 37 on page 224) did not reveal an association between CAA 
and ICH in any location in all ten studies (OR 1.21, 95% CI 0.87 to 1.68, I-squared 
29%; ), nor in a sensitivity analysis omitting one study that might have included 
traumatic ICH (OR 1.19, 95% CI 0.84 to 1.67) [Masuda et al. 1988].  There was not a 
significant association between CAA and deep ICH (OR 0.81, 95% CI 0.30 to 2.19; five 
studies, I-squared 58%) [Masuda et al. 1988;Cartier et al. 1999;Mastaglia et al. 
2003;Ritter et al. 2005;Attems, Lauda, & Jellinger 2008] or cerebellar ICH, although 
there were only eight cases of cerebellar ICH (OR 2.05, 95% CI 0.55 to 7.63; four 
studies, I-squared 0%) [Masuda et al. 1988;Mastaglia et al. 2003;Xu, Yang, & Wang 
2003;Attems, Lauda, & Jellinger 2008].  However, CAA was more prevalent in lobar 
ICH cases (54/105, 51%) in comparison to controls (1,119/2,629, 43%) (OR 2.21 95% 
CI 1.09 to 4.45; six studies, I-squared 40%) [Masuda et al. 1988;Ishihara et al. 
1991;Cartier et al. 1999;Mastaglia et al. 2003;Ritter et al. 2005;Attems, Lauda, & Jellinger 
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2008].  In sub-group analyses of the association between CAA and lobar ICH, the 
association remained in the three studies where cases’ and controls’ average ages were 
comparable (OR 3.24, 95% CI 1.02 to 10.26),14;31;32 but not in those where ages were 
dissimilar or unknown (OR 1.58, 95% CI 0.91 to 2.77) [Masuda et al. 1988;Mastaglia et 
al. 2003;Attems, Lauda, & Jellinger 2008].  I could not demonstrate that the association 
between CAA and lobar ICH was different in studies of Asian patients (OR 3.02, 95% 
CI 0.44 to 20.77) [Masuda et al. 1988;Ishihara et al. 1991] or patients of other ethnic 
origins (OR 1.89, 95% CI 0.86 to 4.15) [Cartier et al. 1999;Mastaglia et al. 2003;Ritter et 
al. 2005;Attems, Lauda, & Jellinger 2008]. 
9.4 Summary 
• In a systematic review and meta-analysis of ten neuropathological cross-sectional or 
case-control studies involving 481 cases and 3,219 controls, I found a significant 
association between CAA and lobar ICH, but not with ICH in other locations. 
• There was wide variation in the methodological quality of included studies. 
• Strategies for both brain sampling and CAA detection varied between studies. 
9.5 Discussion 
9.5.1 Strengths of the study 
This systematic review and meta-analysis benefited from thorough ascertainment of 
pertinent studies, comprehensive critical appraisal to determine their inclusion, 
clarification by correspondence with study authors, and a large number of cases and 
controls in our analyses. 
9.5.2 Limitations of the study 
The systematic review was somewhat limited by the variable quality of included studies.  
Unfortunately, only three of the included studies assessed the association of CAA and 
ICH having taken other competing risk factors for ICH into account [Ishihara et al. 
1991;Ritter et al. 2005;Guidoux 2008] and just two studies described the influence on 
the association of other potential effect modifiers (Alzheimer-type pathology [Attems, 
Lauda, & Jellinger 2008] and antithrombotic drugs [Ritter et al. 2005]). 
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9.5.3 Study findings 
It is reassuring that our finding of an overall association between lobar ICH and CAA 
was confirmed by the three studies in which minimal confounding by patient age was 
evident [Ishihara et al. 1991;Mastaglia et al. 2003;Ritter et al. 2005].   
This association between CAA and lobar ICH might have been even stronger had the 
included studies accounted for potential confounding factors (for example, age, severity 
of cognitive impairment, ethnic origin, and possibly prior ischaemic stroke [Cadavid et 
al. 2000]), included a consistent definition of ‘lobar’ ICH [Biffi et al. 2010b] and 
focussed on the prevalence of severe CAA (and other vasculopathic features, such as 
microaneurysms) in the blood vessels that were anatomically related to the ICH.  The 
association might also have been stronger had the cases been selected according to the 
Boston diagnostic criteria, which ‘definitely’ attribute the cause of lobar ICH to CAA if 
there is pathological evidence of severe CAA with vasculopathy at post-mortem [Millar, 
Wardlaw, & Lammie 1999;Knudsen et al. 2001;Linn et al. 2010].   
The Boston criteria for ‘probable CAA’ have an excellent specificity and therefore do 
not misclassify people who have lobar ICH without underlying severe CAA (100%, 95% 
CI 77% to 100%), [Knudsen et al. 2001] but the sensitivity of these criteria for ‘probable 
CAA’ was 44% (95% CI 28% to 62%) and their negative predictive value was 39% 
(95% CI 22 to 58), because more than half the people with lobar ICH and severe CAA 
were not identified by the ‘probable’ criteria [Knudsen et al. 2001].   
Both systematic use of GRE MRI to identify brain BMBs and the inclusion of 
superficial siderosis in the Boston criteria have improved their diagnostic accuracy [Linn 
et al. 2010], but false positives and false negatives still exist and the role of other degrees 
of CAA severity in causing lobar ICH remains to be clarified, given that the studies in 
this meta-analysis were unable to do so. 
Further confirmation of the direction of this association between CAA and lobar ICH, 
and exploration of the strength of the association, could only arise from further research 
with an ideal study design (Table 25 on page 220), given that an individual patient data 
meta-analysis was impossible. 
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9.5.4 Future directions 
The prevalence of CAA in patients with lobar ICH and the strength of the overall 
association between CAA and lobar ICH (Figure 37 on page 224), as well as the 
diagnostic accuracy of the Boston criteria for ICH due to CAA, [Knudsen et al. 
2001;Linn et al. 2010] is consistent with CAA being one of several potential causes of 
lobar ICH in the elderly.  Although I have demonstrated an association between CAA 
and lobar ICH, this does not necessarily imply causation.  
Of Sir Austin Bradford Hill’s nine criteria [Hill 1965] that would support an association 
being causal, CAA is a plausible cause of lobar ICH [Weller, Boche, & Nicoll 2009], but 
further work is required to more reliably establish the association’s strength, 
demonstrate its consistency and evaluate its biological gradient [Hill 1965].  If the 
methodological problems noted above are addressed and cases of lobar ICH are 
carefully phenotyped (according to their history of transient neurological events and 
cognitive impairment, and the presence of strictly lobar brain BMBs on GRE MRI and 
superficial siderosis [Linn et al. 2010]), then the strength of the association between 
CAA and lobar ICH would be likely to be much stronger. However, understanding 
whether milder degrees of CAA are associated with lobar ICH is also important to 
investigate the biological gradient and explore whether there are interactions with CAA 
of milder severity that might precipitate ICH. 
Future research should include well-designed case-control and cohort studies to explore 
the CAA-ICH association (and its effect modifiers) [Schulz & Grimes 2002], individual 
patient data meta-analyses of comparable studies, further comparisons of the sensitivity 
and specificity of different methods of CAA detection (such as Congo Red staining 
versus immunohistochemistry [Haglund & Englund 2002]), and the development and 
validation of a unified rating scale for CAA distribution and severity [Greenberg et al. 
2004]. 
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Table 23 Ovid Medline search strategy 
 Search term(s) 
1 Stroke/ 
2 Cerebrovascular Disorders/ 
3  exp basal ganglia cerebrovascular disease/ or exp brain ischemia/ or carotid 
artery diseases/ or carotid artery thrombosis/ or carotid stenosis/ or exp 
intracranial arterial diseases/ or exp "intracranial embolism and thrombosis"/ or 
exp intracranial hemorrhages/ or exp brain infarction/ or hypoxia-ischemia, 
brain/ 
4 ((brain$ or cerebr$ or cerebell$ or cortical or vertebrobasil$ or hemispher$ or 
intracran$ or intracerebr$ or infratentorial or supratentorial or mca$ or middle 
cerebr$ or anterior circulation or posterior circulation or basal ganglia or 
parenchyma$ or brain?stem or posterior fossa or ganglion$ or thalam$ or 
cortical) adj5 (isch?emi$ or infarct$ or thrombo$ or emboli$ or occlus$ or 
hypox$ or obstruction or vasculopathy)).tw. 
5 ((lacunar or cortical) adj5 infarct$).tw. 
6 ((brain$ or cerebr$ or cerebell$ or intracerebr$ or intracran$ or parenchyma$ or 
intraventricular or infratentorial or supratentorial or basal gang$ or ganglion$ or 
putaminal or putamen or posterior fossa or brain?stem or intra?axial or lobar or 
deep or thalam$ or cortical or superficial or vertebrobasil$ or front$ or tempor$ 
or pariet$ or occipit$) adj5 (haemorrhage$ or hemorrhage$ or haematoma$ or 
hematoma$ or bleed$)).tw. 
7  ((h?emorrhag$ or isch?emi$) adj6 (stroke$ or cerebrovasc$ or cerebr?vasc$ or 
cerebral vasc$ or brain vasc$ or cva$ or apoplex$ or attack$ or event$ or 
insult$)).tw. 
8 1 or 2 or 3 or 4 or 5 or 6 or 7 
9 exp Pathology, Clinical/ 
10 exp Amyloid beta-Protein/ or exp Amyloid/ or exp Amyloid beta-Protein 
Precursor/ 
11 exp Cerebral Amyloid Angiopathy/ 
12 exp Congo Red/ 
13 (cerebral amyloid angiopathy or congophil$ or congo?red or amyloid$ or A?beta 
or beta?amyloid).tw. 
14 10 or 11 or 12 or 13 
15 (patholog$ or post?mortem$ or autops$ or necrops$ or biops$ or tissue$ or 
histo?patholog$ or neuro?patholog$ or clinic?patholog$).tw. 
16  9 or 15 
17 8 and 14 and 16 
18 limit 17 to humans 
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Table 24 Ovid Embase search strategy 
 Search term(s) 
1 cerebrovascular disease/ 
2 basal ganglion hemorrhage/ or cerebral artery disease/ or cerebrovascular 
accident/ or stroke/ or vertebrobasilar insufficiency/ or exp carotid artery 
disease/ or exp brain hematoma/ or exp brain hemorrhage/ or brain infarction/ or 
brain infarction size/ or brain stem infarction/or cerebellum infarction/ or exp 
brain ischemia/ or exp occlusive cerebrovascular disease/ or cerebellum injury/ 
or exp carotid artery/ 
3 ((h?emorrhag$ or isch?emi$) adj6 (stroke$ or cerebrovasc$ or cerebr?vasc$ or 
cerebral vasc$ or brain vasc$ or cva$ or apoplex$ or attack$ or event$ or 
insult$)).tw. 
4 ((brain$ or cerebr$ or cerebell$ or cortical or vertebrobasil$ or hemispher$ or 
intracran$ or intracerebr$ or infratentorial or supratentorial or mca$ or middle 
cerebr$ or anterior circulation or posterior circulation or basal ganglia or 
parenchyma$ or brain?stem or posterior fossa or ganglion$ or thalam$ or 
cortical) adj5 (isch?emi$ or infarct$ or thrombo$ or emboli$ or occlus$ or 
hypox$ or obstruction or vasculopathy)).tw. 
5 ((lacunar or cortical) adj5 infarct$).tw. 
6 ((brain or cerebr$ or cerebell$ or intracerebr$ or intracran$ or parenchyma$ or 
intraventricular or infratentorial or supratentorial or basal gang$ or ganglion$ or 
putaminal or putamen or posterior fossa or brain?stem or intra?axial or lobar or 
deep or thalam$ or cortical or superficial or vertebrobasil$ or front$ or tempor$ 
or pariet$ or occipit$) adj5 (haemorrhage$ or hemorrhage$ or haematoma$ or 
hematoma$ or bleed$)).tw. 
7 1 or 2 or 3 or 4 or 5 or 6 
8 "amyloid beta protein [1-42]"/ or exp amyloid/ or "amyloid beta protein [1-40]"/ or 
exp amyloid precursor protein/ or exp amyloid beta protein/ 
9 exp vascular amyloidosis/ 
10 exp congo red/ 
11 (cerebral amyloid angiopathy or congophil$ or congo?red or amyloid$ or A?beta 
or beta?amyloid).tw. 
12 8 or 9 or 10 or 11 
13 exp pathology/ 
14 (patholog$ or post?mortem$ or autops$ or necrops$ or biops$ or tissue$ or 
histo?patholog$ or neuro?patholog$ or clinic?patholog$).tw. 
15 13 or 14 
16 7 and 12 and 15 
17 limit 16 to human 
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Table 25 Ideal design of a pathological study of the association between CAA & 
spontaneous ICH[Wells et al. 2002;Schulz & Grimes 2002] 
Selection of cases and controls 
• Representative sample of cases, with ascertainment clearly defined 
• Independent validation of case diagnosis 
o clinical features described 
o incident cases of ICH, recruited at a specified inception point, described in 
relation to the time of neuropathological examination 
o spontaneous and traumatic ICH distinguished 
o first-ever and recurrent ICH distinguished 
o radiological confirmation of ICH diagnosis and its anatomical distribution, 
using a standardised classification of lobar vs. deep ICH (whose inter-
observer reliability has been assessed) 
• Appropriate controls 
o Derived from the same population as cases 
o Ascertained in the same way as the cases 
o Without a history of ICH (if cases were first-ever diagnoses) 
• Quantification of eligible cases and controls not included or omitted from analyses 
Assessment of CAA 
• Pathologically confirmed either at tissue biopsy or at post-mortem examination 
• Detected and rated blind to relevant clinical information 
• Methods of tissue preparation, staining and analysis identical for all cases and 
controls 
• Rated according to a standard or externally validated rating scale, and severity 
specified 
• Anatomical location specified in relation to ICH 
Reporting and analysis 
• Presentation of summary data, stratified by ICH location, age of person, past history 
of cognitive impairment 
• Cases and controls matched for major confounders (i.e. age and past history of 
cognitive impairment), or confounders adjusted for in the analysis 
 
   
 
Table 26 Characteristics of the selection and comparability of cases and controls in the included studies 



















































































































































































 >80% community deaths, age >40 yrs, Japan  ? ? × D, L, IT ?  O ?  × 6 
Ishihara 1991  Selected hospital autopsies, Japan  S ? × D+IT, D+L, L 72  IS, O 75  × 4 
Ng 1991   Consecutive hospital autopsies, age 
>40yrs, Hong Kong 
 S ✓ × ? ?  ? ?  × 5 
Cartier 
1999  
 Selected hospital autopsies, Chile  S ✓ × L, IT, BG 65  O 64  Age 5 
Mastaglia 
2003 
 Consecutive hospital autopsies, mean 
age 75 years, Australia 
 S ? × C, EC, L,  ?  IS, ? ?  × 4 
Xu 2003   Hospital autopsies, mean age 78yrs, China  S ? × ? ?  ?, D ?  × 4 
Badhe 2005   Randomly selected autopsies, aged >70yrs, 
India 
 S ✓ × ? ?  IS, O ?  × 4 
Ritter 2005   Selected consecutive hypertensive hospital 
autopsies, Hungary 
 S ✓ ✓ D+IT, L 69  IS, O 73  Age 8 
Attems 
2008  
 Consecutive hospital autopsies, Austria  S ? × D, H, L, IT 62-96  ?, D ?  × 5 
Guidoux 
2008  
 Selected consecutive hospital autopsies, 
France  
 S ✓ × D+B, L+C 76  ? 77  Age 6 ✓ - criterion met, × - criterion not met, ? – unknown, ICH = ICH 
ICH location: BG – basal ganglia, C – cerebellum, D – deep (basal ganglia/thalamus), EC – external capsule, H – hemispheric, IT – infratentorial (cerebellum or brain 
stem), L – lobar, D+B – deep includes brainstem, D+L – involving both deep and lobar locations, D+IT – deep includes infratentorial, L+C – lobar includes cerebellum 
Control type: D – dementia (diagnosed according to either clinical or pathological criteria), IS – ischaemic stroke, O – other
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Masuda 1988  6 BG, HC, I
$
, L BG, HC, L ✓ × Bespoke 
Ishihara 1991  ? B, C, GM, I, L B, C, GM, L ✓ S Bespoke 
Ng 1991  ? I,? HC, L* ✓ × Vinters 
[Vinters & 
Gilbert 1983] 
Cartier 1999  ? B, BG, C, L^ B,BG,C, L^ ✓ × Presence/ 
absence 
Mastaglia 2003  2-6 I, L** I, L** × ✓ Bespoke 
Xu 2003  ? I
$
,? ? ✓ ✓ Bespoke 
Badhe 2005  10-
12 
BG, C, HC, L BG, C, HC, L ✓ × Vinters 
[Vinters & 
Gilbert 1983] 
Ritter 2005  
 
4-5 BG, C, I, L***  BG, C, L*** ✓ × Vonsattel 
[Vonsattel et 
al. 1991] 
Attems 2008  ? B, BG, C, 
L**** 
B, BG, C, L**** × ✓ Olichney 
[Olichney et al. 
1995] & 
bespoke 
Guidoux 2008  3-5
§
 ? B, BG, C, HC, 
L***** 
✓§ ✓¶ Presence/ 
absence ✓ - criterion met, × - criterion not met, ? – unknown, S- some 
B – brainstem, BG – basal ganglia, C – cerebellum, GM – central grey matter, HC – 
hippocampus, I – site of ICH, L – lobar (every lobe unless * - Parieto-occipital only, ** - 
frontal, temporal and parietal only, *** - Fronto-parietal and occipital only, **** - Frontal, 
temporal and occipital only, ***** - temporal and occipital only, ^ - not specified) 
$
- Presence of CAA specified in vessels at the site of the ICH in CAA-positive cases, but 
unclear whether this was done for all cases 
§
 - cases, but not controls, 
¶
 - controls, but not cases 
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Figure 36 Selection of studies included in the systematic review 
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Figure 37 OR meta-analysis: CAA prevalence in cases with ICH (stratified by location) 
vs. controls Squares are point estimates of the studies, error bars are 95% CIs and 
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10 A cross-sectional study of imaging and pathology findings in 
patients with lobar intracerebral haemorrhage 
10.1 Introduction 
My application of the modified Boston criteria for CAA [Knudsen et al. 2001;Linn et al. 
2010] to a community-based cohort of participants with ICH (Chapter 5), showed that 
all participants with a single, first-ever lobar ICH who were unsuitable for an MRI brain 
looking for BMBs or superficial siderosis [Linn et al. 2010] were classified as having 
‘possible’ CAA; which may not be useful for clinicians who wish to determine the 
likelihood of a patient having CAA ante-mortem.  Since 47% of all participants with 
lobar ICH were unsuitable for MRI in our cohort (Chapter 6), the use of the criteria was 
limited.   
Although amyloid positron emission tomography (PET) imaging using Pittsburgh 
Compound B might also help to detect CAA ante-mortem, a recent small study which 
compared 11 persons with probable CAA according to the Boston criteria vs. nine 
healthy age-matched controls without a pathological gold standard, showed that despite 
reasonable sensitivity (91%, 95% CI 62-98%), its specificity for CAA was limited (55%, 
95% CI 27-81%) reflecting positivity among healthy elderly controls with probable 
asymptomatic early Alzheimer’s dementia pathology [Baron et al. 2014].  
Given that CT is as good as MRI in the diagnosis of acute ICH [Brazzelli et al. 2009], 
determining whether any radiological features of the ICH on CT discriminate between 
CAA-related lobar ICH and other lobar ICH, might  improve the sensitivity of the 
Boston criteria, enabling an ICH to be attributed to CAA without requiring pathological 
confirmation, which would be valuable in low-middle income countries in which ICH 
incidence is increasing [Feigin et al. 2014]. 
10.1.1 Ideal study design 
The ideal study design would be a radio-pathological diagnostic test accuracy study 
[Bossuyt et al. 2003;Whiting et al. 2003] of the sensitivity and specificity of CT imaging 
features of ICH for the detection of pathologically-proven CAA-related lobar ICH.  In 
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such a study, CT imaging variables potentially associated with lobar ICH could be 
selected using different strategies, including: 
a) Selection a priori based upon existing literature or clinical reasoning.     
b) Selecting variables which are reliably and accurately measured, discriminate between 
participants, are independent of each other to avoid collinearity and have minimal 
missing data since missing values may relate to participant or disease characteristics 
and could lead to bias [Lewis 2007;Bouwmeester et al. 2012].  
c) Selecting variables which are statistically significant in univariate analyses although 
this may be problematic if the sample is small and there are many candidate 
variables [Bouwmeester et al. 2012].  A general rule is that there should be ‘ten 
events per variable’ [Peduzzi et al. 1996]  but if the number of variables tested is 
large relative to the sample size, overfitting may occur; that is the model uses more 
variables than is necessary and produces optimistic prediction results that are not 
replicated in the wider population [Babyak 2004]. 
d) Selection using a multivariable analysis commonly using a stepwise selection 
algorithm, either forwards or backwards [Altman & Royston 2000].  Forwards 
selection starts with no variables in the model and enters variables in order of their 
strength of association with the outcome, checking their p value when added to the 
model and continuing till the fit of the model is optimised whilst backwards 
selection reverses this procedure.  This method is fully automated and therefore 
convenient [Altman & Royston 2000] and still requires in general, a minimum of 
ten events per variable. 
The study group for a comparative diagnostic test accuracy study can be assembled 
using a cross-sectional sample, or either retrospectively or prospectively in a cohort 
study.  Ideally, the study sample would be assembled prospectively, without selection 
bias, at a uniform inception point in the disease to give a sample representative of the 
population of patients from which they were selected with consistent definitions of 
radiological features, pathological (outcome) variables and confounders and a 
description of how any missing data were accounted for [Grimes & Schulz 2002b;von 
Elm E. et al. 2007].  The outcome would be ‘CAA-related ICH’ but although this is a 
commonly used term, it can be difficult to infer that CAA has caused an ICH (Section 
10.1.3, page 229).   
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10.1.2 Systematic review 
I systematically reviewed Ovid Medline from 1950 and Embase from 1980 to identify 
diagnostic test accuracy studies of imaging features of lobar ICH to distinguish those 
due to pathologically confirmed CAA and those not, studies that described the 
association of imaging features with lobar ICH due to pathologically confirmed CAA 
versus lobar ICH due to other causes, and lastly case series describing imaging features 
of patients with lobar ICH due to pathologically confirmed CAA.  I also searched the 
bibliographies of relevant studies and Google scholar for citations of each included 
study.  
I did not identify any diagnostic test accuracy studies or comparative association studies, 
and only found case series.  Excluding case series with less than five participants [Patel 
et al. 1984;Finelli, Kessimian, & Bernstein 1984;Sobel et al. 1985;Andoh et al. 1989], 
case series that did not report both radiological and pathological findings for lobar ICH 
[Ishii, Nishihara, & Horie 1984;Knudsen et al. 2001;Tang et al. 2013] and case series that 
used MRI [Linn et al. 2010], there have been 13 case series describing 255 patients with 
pathologically proven CAA-related supratentorial lobar ICH (Table 28 on page 264) 
[Wagle, Smith, & Weiner 1984;Brown, Coates, & Gilbert 1985;Cosgrove et al. 
1985;Yong et al. 1992;Wakai, Kumakura, & Nagai 1992;Minakawa et al. 1995;Millar, 
Wardlaw, & Lammie 1999;Izumihara et al. 1999;Lang et al. 2001;Oide et al. 2003;Chen 
et al. 2004;Patel et al. 2009;Hirohata et al. 2010].   
10.1.2.1 Critical appraisal of studies 
All studies have been hospital-based and retrospective, bar one which selected 
consecutive patients from a prospectively recruited cohort [Patel et al. 2009].  Only 
three studies stated the time interval between the ICH symptom onset and scan [Wagle, 
Smith, & Weiner 1984;Yong et al. 1992;Minakawa et al. 1995], which may affect the 
radiological appearances of an ICH (Chapter 2).  The authors of one study stated that 
imaging interpretation was performed ‘without knowledge of clinical information, 
including radiology reports’ [Patel et al. 2009] but no other studies described whether 
imaging was interpreted blind to clinical or pathological information. 
Studies have lacked clear descriptions of  radiological variables thought to be related to 
CAA such as an ‘irregular’ or ‘lobulated’ ICH [Yong et al. 1992;Izumihara et al. 
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1999;Lang et al. 2001], ICH in a ‘superficial location’ [Wagle, Smith, & Weiner 1984] or 
‘periventricular white matter lucency’ [Millar, Wardlaw, & Lammie 1999]. 
The outcome (pathologically proven ‘CAA-related’ ICH) was explicitly defined in only 
one study [Patel et al. 2009] which categorised an ICH as CAA-related according to the 
Boston criteria (which require severe CAA to be present with vasculopathy in at least 
one vessel in biopsy or post-mortem specimen(s)for a diagnosis of ‘definite’ CAA-
related ICH [Vonsattel et al. 1991;Knudsen et al. 2001]). 
10.1.2.2 Findings of studies 
Studies have described various imaging features of pathologically-proven CAA-related 
lobar ICH (Table 29 on page 265) including most commonly: multiple ICHs, extension 
of the ICH into the subarachnoid space and an ‘irregular’ or ‘lobulated’ ICH.   
10.1.3 What is ‘CAA-related’ ICH? 
10.1.3.1 CAA rating scales 
From my systematic review of neuropathological case control studies of CAA and ICH 
(Chapter 9), I knew that although multiple different scales for rating CAA exist, which 
encompass various pathological features of CAA (Figures 38-40, pages 277-279), none 
have been independently externally validated for use in patients with ICH.  A recent 
proposal [Alafuzoff et al. 2009] to standardise the rating of β-amyloid deposits achieved 
good inter-rater agreement in the assessment of CAA but neuropathologists rated only 
the presence or absence of CAA in specimens and its type rather than the severity of 
CAA.   
The various CAA rating scales are described below: 
Vinters et al. [Vinters & Gilbert 1983] have previously rated CAA symmetrically from 
each lobe and both hippocampi as 1+ if only one or two vessels had evidence of CAA, 
2+ if three to five vessels had CAA and 3+ if six or more vessels had CAA with a score 
of 3+ interpreted as having severe CAA.  Only parenchymal vessels were considered 
(not leptomeningeal) and the rating of CAA severity for each region was based solely on 
the number of vessels involved rather than the extent of CAA deposition within the 
walls of blood vessel(s).  A brain was considered to have ‘severe’ CAA if at least one of 
the ten regions sampled was given a rating of 3+. 
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Vonsattel et al.’s scale [Vonsattel et al. 1991], which was also used in the formation of 
the Boston criteria [Knudsen et al. 2001], uses ratings of CAA in either a single 
leptomeningeal or cortical vessel to infer the severity of CAA for the entire brain.  
Severity of CAA is classified as mild (when it is restricted to a rim around normal or 
atrophic smooth muscle fibres), moderate (when the tunica media is replaced by 
amyloid and is thicker than normal) or severe (when there is fragmentation of the vessel 
wall and at least one focus of perivascular leakage of blood or haemosiderin.)  If there is 
evidence of one vessel with ‘severe’ CAA, the entire brain is rated as having CAA. 
Olichney et al.’s scale [Olichney et al. 1996]  incorporates the changes seen in both 
leptomeningeal and cortical vessels in a single specimen to give an overall grade of CAA 
severity for a brain where: 0-no evidence of CAA in the leptomeningeal or superficial 
cortical vessels; 1-traces of CAA seen in either the leptomeningeal or cortical vessels; 2-
some vessels in the leptomeninges or cortex had amyloid deposits; 3-widespread 
amyloid in many leptomeningeal and superficial cortical vessels; 4-as for 3 but with the 
addition of dysphoric changes in which amyloid extends from the blood vessel into the 
adjacent parenchyma. 
Ellis et al. devised a scale to rate CAA semi-quantitatively in the parenchymal and 
meningeal vessels of five brain regions: the frontal, parietal and temporal lobes, 
hippocampus and entorhinal cortex [Ellis et al. 1996].  Their scale, used as part of the 
Consortium to Establish a Registry for Alzheimer’s Disease (CERAD) criteria, rates 
CAA in each region as 0-no CAA, 1-sparse or mild CAA, 2-moderate CAA or 3-
frequent or severe CAA.  The CAA scores for each region are either summed to give an 
‘overall’ CAA score or averaged over the five cerebral regions examined per subject to 
give a mean CAA score.  Both types of outcome measure have been used in their cohort 
[Ellis et al. 1996]. 
Thal et al. [Thal et al. 2002a] sampled the occipital lobe, temporal lobe and entorhinal 
cortex and rated CAA overall as either mild – where CAA is restricted to the blood 
vessels of one given region (for example, the occipital lobe) and is restricted to small 
deposits next to the smooth muscle cells or severe – where CAA is seen in numerous 
vessels in many regions and there is replacement of portions of the tunica media of the 
blood vessel wall by Aβ.  CAA was also classified as type one or type two (in which type 
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one CAA indicated that CAA was present in capillaries vs. type two  in which CAA was 
not present). 
Attems et al.’s scale [Attems, Jellinger, & Lintner 2005] rates leptomeningeal and cortical 
vessels separately for each lobe of the brain where 0-no Aβ positive vessels, 1-mild 
(scattered positivity in a few vessels), 2-moderate (scattered positivity in many vessels or 
strong positivity in a few vessels), 3-severe (strong positivity in many vessels), 4- severe 
with vasculopathic changes in cortical vessels.  The overall score for CAA severity is the 
mean score for all regions.  
Allen et al. [Allen et al. 2013] recently used a modified version of the scale devised by 
Attems et al. [Attems, Jellinger, & Lintner 2005]; by removing the grade 4 rating (and 
rating all such cases as grade 3) and recording the presence and severity (0-none, 1-mild, 
2-moderate, 3-severe) of capillary CAA deposition. 
The Bristol rating scale [Love et al. 2014] requires a neuropathologist to provide 
separate ratings of CAA severity for each brain region leading to an overall rating of 
CAA for the entire brain which is a composite measure of the severity of 
leptomeningeal, parenchymal, capillary CAA and vasculopathic changes in each lobe of 
the brain (Table 6 on page 144).  It is the only scale which allows evaluation of each 
aspect of CAA per lobe and other commonly used scales could also be derived from it. 
10.1.3.2 Attributing an ICH to CAA is complex 
ICH is classed as probable ‘CAA-related’ ICH (with supporting pathology) according to 
the modified Boston criteria if there is pathologically-proven CAA of any severity in a 
single specimen taken from the evacuated haematoma or a cortical biopsy in a person 
with ICH [Knudsen et al. 2001].  This assumes that CAA will be distributed uniformly 
in different regions of the brain and that its presence, in the absence of secondary 
causes, indicates that it is the likely cause of the ICH.   
However, CAA is known to co-exist with other small vessel diseases such as 
arteriolosclerosis neither of which are necessary or sufficient causes for an ICH.  CAA 
may also be patchy and segmental and may vary in presence and severity between lobes 
of the brain [Allen et al. 2013].  It is also a common incidental finding in the elderly 
[Masuda et al. 1988] and those with dementia [Neuropathology Group of the Medical 
Research Council Cognitive Function and Ageing Study (MRC CFAS) 2001].  Therefore 
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the presence of CAA does not signify that it is the sole cause of the ICH and 
conversely, CAA may be absent in a specimen because of sampling variation. 
This problem was highlighted by one study which examined the sensitivity and 
specificity of cortical biopsy for the diagnosis of CAA [Greenberg & Vonsattel 1997].  
In seven brains all of which had been previously assigned a global CAA severity rating 
of either mild, moderate or severe  (two of which had ‘CAA-related’ ICH) new biopsy 
sized specimens were prepared, stained with Congo Red and rated blind to the brain 
from which each specimen was taken.  If the previous global CAA severity rating is 
taken as the reference standard, the new specimens had 33% sensitivity (95% CI 19-
52%) for detecting mild CAA and 69% sensitivity (95% CI 54-81%) for detecting 
moderate-severe CAA. 52% specimens sampled from brains with mild CAA were rated 
as not having CAA and in the two brains with ICH attributed to CAA, CAA severity 
ranged from mild in 2% of specimens to severe with evidence of fibrinoid necrosis in 
46% of specimens. 
10.1.3.3 CAA with vasculopathy may be related to ICH 
Possible indicators of CAA severity are: the extent of leptomeningeal vessel involvment, 
the extent of parenchymal vessel involvement, the presence of capillary CAA and the 
presence of vasculopathic changes.  Vasculopathic changes may manifest as one or 
more of the following: fibrinoid necrosis, microaneurysm formation, ‘double barrelling’ 
(fragmentation) of the vessel wall and perivascular blood leakage (Figure 4 on page 
55)[Attems 2005].  
Because of the paucity of well conducted neuropathological case control studies of CAA 
and ICH (Chapter 9) and the lack of standardised externally validated rating scales for 
rating CAA, it remains unclear which markers of CAA severity are most closely related 
to ICH.  When examining brains with CAA, fibrinoid necrosis is more common in 
those with ICH compared to those without, although its specificity for ICH is 69% 
(95% CI 42-87%), since it is also found in brains with moderate-severe CAA but 
without ICH [Greenberg & Vonsattel 1997]. 
Because of the lack of diagnostic test accuracy studies, and in view of the limitations of 
the existing literature, I performed a radio-pathological study nested within a 
prospective inception cohort study of first-ever lobar ICH, using clearly pre-defined 
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clinical, imaging and pathological characteristics and blinded rating in order to ascertain 
the association and diagnostic accuracy of CT-based imaging characteristics of lobar 
ICH with pathologically proven CAA that was likely to have contributed to causing the 
lobar ICH.  
10.2 Methods 
10.2.1 Participants 
Participants were recruited into the LINCHPIN study (an ethically-approved study of 
patients with spontaneous primary ICH) and underwent a research post-mortem 
examination limited to the brain. 
10.2.1.1 Inclusion criteria 
Participants were eligible for a post-mortem examination limited to the brain in the 
LINCHPIN study if they met all of the following inclusion criteria: 
• They had a first-ever or recurrent spontaneous primary lobar ICH during 1st June 
2010-31st May 2012. 
• They were resident in the Lothian region at the time of their ICH. 
• The diagnosis of ICH was confirmed using CT imaging. 
• They (or their nearest relative) gave written informed consent to a post-mortem 
examination limited to the brain only after death. 
10.2.1.2 Exclusion criteria 
Participants were excluded if they met any of the following exclusion criteria: 
• They were known to have had a secondary ICH before death or were found to have 
a secondary cause of ICH at post-mortem examination. 
• They died before diagnostic CT brain imaging could be performed. 
• They had had a previous spontaneous primary ICH (since I aimed to obtain 
participants with first-ever ICH and therefore, a uniform inception point) as CAA is 
likely to be gradually deposited over time.  
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10.2.2 Data collection 
I collected data on baseline demographic and clinical characteristics as outlined in 
Chapter 2. I collected the following information: demographic variables – age and sex; 
clinical variables – whether the ICH was first-ever or recurrent, history of hypertension, 
dementia, ischaemic stroke and prior use of antithrombotic medications.  I collected 
information regarding the date of the ICH, the date of the diagnostic CT scan and date 
of the post-mortem examination. 
10.2.3 Imaging 
10.2.3.1 Development of a CT rating proforma 
From imaging variables identified in previous radio-pathological studies of 
pathologically proven CAA-related lobar ICH (Table 29 on page 265), I selected both 
imaging features of ICH and features of surrounding brain parenchyma which might 
plausibly be associated with CAA.  The final list of included variables and a consensus 
definition of each variable was decided upon after discussion with two consultant 
neuroradiologists (Professor J Wardlaw, University of Edinburgh and Professor P 
White, University of Newcastle-upon-Tyne) and a consultant neurologist (Professor R 
Salman, University of Edinburgh) with special interests in stroke (Appendix).  Each 
variable is described below, guided by the STRIVE guidelines if applicable [Wardlaw et 
al. 2013]. 
10.2.3.2 Included variables and their definitions 
(i) Multiple ICH: An ICH was multiple if several unconnected acute ICHs of a 
similar age (based on attenuation), separated by unaffected brain parenchyma, 
were present on the diagnostic brain imaging obtained at presentation.  ‘Acute’ 
ICH was determined radiologically by the presence of a hyperdense area in the 
brain parenchyma.  
(ii) Intraventricular extension: An ICH extended into the ventricles if any blood was 
present within the ventricles of the brain  
(iii) Subarachnoid extension: An ICH extended into the subarachnoid space if any 
blood was present within the subarachnoid compartment of the brain.  If 
subarachnoid blood was present, the rater indicated if this was adjacent to the 
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ICH (and therefore likely resulted from direct rupture of the ICH into the 
subarachnoid space) since if it was not adjacent to the ICH it might have been 
due to blood simply re-circulating, for example through the ventricles into the 
subarachnoid spaces of the contralateral hemisphere. 
(iv) Subdural extension: An ICH extended into the subdural space if any acute blood 
was present within the subdural compartment of the brain without any clinical 
or radiological evidence of trauma. 
(v) Presence of a blood or fluid level: The rater looked for the presence of a fluid 
level within each haematoma, excluding any intraventricular fluid level. 
(vi) ‘Irregular’ or ‘lobulated’ ICH: Since the terms ‘irregular’ and ‘lobulated’ have 
been used interchangeably in previous studies, I combined these terms into a 
single imaging characteristic.  An ICH was irregular if it had an ‘uneven’ margin 
or had one or more lobules arising from it, and was therefore lobulated (Figure 
41 on page 280).   
(vii) ‘Finger-like’ protrusions: If the ICH was irregular, the rater then assessed 
whether it had one or more finger-like protrusions which extended to the cortex 
since protrusions to the cortex or ICH in a ‘superficial’ location have been 
described in relation to CAA [Wagle, Smith, & Weiner 1984;Brown, Coates, & 
Gilbert 1985;Yong et al. 1992]. 
(viii) Variable density of ICH: An ICH was of ‘variable’ density if the blood within 
any single ICH was of high but not uniform attenuation (Figure 42 on page 281).  
The ICH appeared ‘patchy’ or ‘dilute’ in contrast to an ICH in which the blood 
appeared to be of uniform whiteness on CT imaging.  
(ix) Old vascular lesions: Old strokes were classified as either old infarcts (cortical, 
striatocapsular, borderzone, lacune, brainstem or cerebellar) or as probable 
haemorrhages (which were either cortical or subcortical) [Wardlaw et al. 2007]. 
(x) WMH: WMH (periventricular lucencies) were rated using the van Swieten scale 
[van Swieten et al. 1990] in which 0-no lucency, 1- lucency restricted to region 
adjoining ventricles and 2-lucency covering entire region from lateral ventricle to 
cortex. 
(xi) Atrophy: Both central (deep) and cortical atrophy were rated using a template 
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validated in previous observational studies of stroke [Farrell et al. 2009]. 
10.2.3.3 Excluded variables 
I did not include the following variables which were identified in previous radio-
pathological studies of pathologically proven CAA-related lobar ICH (Table 29 on page 
265): 
(i) ‘Surrounding oedema’ since the presence of oedema will vary depending on the 
interval between ICH onset and imaging as the haematoma matures and clot 
retraction ensues giving rising to serum extrusion and vasogenic oedema [Parizel 
et al. 2001;Venkatasubramanian et al. 2011].   
(ii) ‘High density of blood sedimenting posteriorly’ as this may depend on the head 
position of the patient and whether there is a fluid level within a haematoma in 
which case the denser posterior sediment may correspond to settled blood cells 
[Parizel et al. 2001]. 
10.2.3.4 ICH volume 
I measured ICH volume on the first CT brain scan following the participant’s 
presentation with ICH (the diagnostic scan) using Quantomo computerised planimetry 
software (Cybertrial Inc, Calgary, Canada) [Kosior et al. 2011].  Since subarachnoid 
extension is associated with a larger ICH volume [Chen et al. 2013], ICH volume may 
confound any association between subarachnoid extension and CAA-related lobar ICH. 
10.2.3.5 Rating of CT scans 
A neuroradiologist with a special interest in stroke used only the diagnostic unenhanced 
CT scan (five mm slice thickness) to rate the imaging features, blinded to the clinical 
details and post-mortem examination findings, without any other imaging studies 
performed subsequently.  A neuroradiologist classified an ICH as ‘strictly’ lobar if it was 
confined to lobar regions of the brain without any involvement of the basal ganglia, 
internal or external capsule or thalamus. 
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10.2.4 Pathology 
10.2.4.1 Ethical approval 
In Spring 2010, I sought ethical approval for the LINCHPIN study from the Scotland A 
Research Ethics Committee which assesses studies involving adults lacking mental 
capacity.  I received ethical approval (Reference Number: 10/MRE00/23) in April 2010.  
I also received approval from the NHS Lothian Research and Development office 
(Reference Number: 2010/W/NEU/04).  
10.2.4.2 Statutory requirements relating to consent for post-mortem examination 
In accordance with the Adults with Incapacity (Scotland) Act 2000 [Department of 
Health (Scotland) 2006], I deemed an individual as lacking mental capacity if they were 
unable to do any of the following as a result of mental disorder or of inability to 
communicate because of the physical disability or neurological impairment: 
• act; 
• make decisions; 
• communicate decisions; 
• understand decisions or 
• retain the memory of decisions. 
I assessed the patient and liaised with the clinical team looking after the patient to 
facilitate this decision.   
If the patient was deemed to lack the mental capacity to be able to decide whether to 
participate in the LINCHPIN study, and their clinical condition made it unlikely that 
they would regain mental capacity, I sought written informed authorisation from the 
patient’s nearest relative or their legal representative, in accordance with the statutory 
requirements of the Human Tissue (Scotland) Act 2006 [Department of Health 
(Scotland) 2006] which requires authorisation (consent) to be sought before the use of a 
deceased person’s organs, tissues or cells for medical research.  
‘Authorisation’ equates to the term ‘consent’ which is used in the Human Tissue Act 
(2004) [Department of Health 2004] and indicates that people have the right to express, 
during their lifetime, their wishes about what should happen to their bodies after death 
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in the expectation that those wishes will be respected [Department of Health (Scotland) 
2006].  
I determined which relative was the ‘nearest’ using the hierarchy of authorisation 
specified by the Human Tissue (Scotland) Act 2006, in which relatives are ranked in 
order of priority.  A spouse or civil partner is considered to be the nearest relative, 
followed in descending order of priority by a partner for over six months, child, parent, 
sibling, grandparent, grandchild, uncle or aunt, cousin, niece or nephew and a friend of 
long standing is considered the lowest ranking individual.  Where the patient’s nearest 
relative had given consent and a participant subsequently regained mental capacity, I 
sought written informed consent from the participant. 
10.2.4.3 Consent process 
Seeking consent for brain donation for research purposes is a complex process 
involving consideration of numerous factors such as when post-mortem examination 
should be discussed, how consent should be sought and how information should be 
provided.   
I liaised with the clinical team looking after the patient to decide if or when it would be 
appropriate to approach the patient or their family.  There were various factors to 
consider when making this decision, including: 
• The clinical condition of the patient.  If a patient was unlikely to survive their 
ICH, post-mortem examination would need to be discussed sooner than if the 
patient was stable.  If a patient was recovering but had impairments in speech or 
language resulting from their ICH, discussion of post-mortem examination might 
be delayed till their deficits allowed them to improve in order to express their own 
wishes. 
• Findings of other medical investigations.  If a patient was known to have a 
secondary ICH prior to death they would not be eligible for the LINCHPIN study. 
• Care discussions between the clinical team looking after the patient and the patient 
or their family; including the management of secondary complications of ICH such 
as hydrocephalus or pneumonia and placing Do Not Attempt Resuscitation orders.  
I ensured that I only discussed post-mortem examination after the medical 
management of the participant had been decided upon and this decision had been 
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communicated to the participant or their relatives.  I approached discussion of post-
mortem examination in a sensitive manner and avoided causing confusion amongst 
relatives that could result from post-mortem examination being discussed at the 
same time as potentially therapeutic interventions for the ICH. 
• The availability of relatives.  Whilst I tried to discuss consent for post-mortem 
examination in person, occasionally, for example, if the nearest relative lived a long 
distance away, I discussed consent by phone. 
• The involvement of other departments such as the Office of the Procurator 
Fiscal or the NHS Blood and Transplant team.  In Scotland, the Office of the 
Procurator Fiscal will investigate any sudden, unexplained, unexpected or accidental 
death and the Procurator Fiscal may decide that a fiscal (coroner’s) post-mortem 
examination is indicated.  In the event that an ICH was found at a fiscal post-
mortem examination, I sought consent from the patient’s family for additional brain 
tissue samples to be taken at the time of the post-mortem examination and retained 
for research purposes.   
After discussion with the clinical team, I typically sought consent in person, tailoring 
information to the participant’s wishes and frequently discussing brain donation issues 
on several occasions with different family members to ensure that all concerns were 
addressed.   
Where a patient lacked mental capacity I discussed brain donation in a separate quiet 
room.  I provided every participant or their nearest relative with a study information 
leaflet outlining the post-mortem examination process (Appendix).  The information 
leaflet had been reviewed by members of the Division of Clinical Neurosciences, 
Edinburgh and two patient representatives, both of whom had suffered ICH. 
Whenever possible I sought to give the nearest relative at least 24 hours to decide 
whether they wished to consent to brain donation and if this was not possible, I 
provided relatives with a telephone number that they could contact out-of-hours with 
their decision. 
The post-mortem examination discussion covered a range of issues including those 
generic to research studies and information and concerns specific to brain donation.   
I discussed the following generic issues [Samarasekera et al. 2013]: 
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• the voluntary nature of participation in the LINCHPIN study; 
• the right to withdraw consent at any time; 
• the need for written informed consent prior to taking brain tissue samples without 
which brain tissue would not be taken and  
• the maintenance of the donor and the family’s confidentiality at all times. 
I discussed the following issues surrounding brain donation: 
• the purpose of the LINCHPIN study and the need for brain tissue; 
• what the brain tissue retained would be used for, both now and in the future; 
• the need for demographic and clinical information pertaining to the donor;  
• the retention of brain tissue samples (not the whole brain) in a post-mortem 
examination limited to the brain; 
• the process of retrieving brain tissue, explaining that post-mortem examination 
would be conducted by a neuropathologist with a special interest in stroke; 
• the timing and location of the post-mortem examination, including the need for 
transfer of the patient’s body from their place of death to a specified mortuary if 
applicable; 
• practical arrangements that the LINCHPIN study puts in place to ensure that a 
donor’s ante-mortem wishes are fulfilled; 
• provision of contact details for the participant or their relatives and 
• provision of post-mortem examination results for relatives who wanted further 
information. 
I addressed donors’ and relatives’ concerns as appropriate; for example: 
• disagreement with previously expressed wishes of the donor; 
• disfigurement to the donor’s body resulting from tissue retrieval; 
• delay to the donor’s funeral as a consequence of brain donation; 
• financial costs incurred as a result of brain donation or 
• whether any other organs would be removed. 
 
If the participant consented to post-mortem examination, they completed the 
LINCHPIN post-mortem examination consent form (Appendix) and copies of the 
form were given to the participant and filed in their hospital medical records.  If a 
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nearest relative gave assent, they completed the LINCHPIN post-mortem examination 
consent form for adults with incapacity (Appendix).  At the time of death, I met the 
donor’s family to complete the NHS Lothian ‘Authorisation for the Hospital Post-
mortem examination on an Adult who left no formal authorisation’ which seeks the 
authorisation of the nearest relative for a limited post-mortem examination of the head 
in which brain tissue samples are retained and used for teaching, audit and research 
purposes (Appendix).   
Copies of both the research and NHS Lothian forms were required by the 
neuropathologist before a post-mortem examination could be performed.  Meeting the 
donor’s family after death also provided an opportunity to address any outstanding 
questions which might have arisen and ensure that the timing of the post-mortem 
examination would be co-ordinated with the family’s funeral arrangements. 
10.2.4.4 Requirements after obtaining consent 
If I obtained post-mortem examination consent, I ensured that everyone involved in the 
participant’s care (including nursing staff, medical staff, the participant’s GP, their 
residential or nursing home if applicable) was aware of this so that their ante-mortem 
wishes could be fulfilled at the time of death.  I also gave the participant or their nearest 
relative a study ‘donor card’ containing a contact number in case of death.  In addition, I 
requested that the participant’s GP inserted a computerised alert into their primary care 
records which would appear if the record was opened to indicate that the participant 
had given consent to brain donation. 
If a relative had wished to be informed about the results of the post-mortem 
examination, I contacted them, usually by letter, when results were available (typically 
three to four months after the post-mortem examination).  I informed relatives of 
macroscopic and histological findings.  Genetic tests were not done.  Relatives were 
invited to contact me at any time if they had further questions or comments. 
10.2.4.5 Sampling protocol at post-mortem examination  
After making an incision through the skull the brain was removed.  A neuropathologist 
with a special interest in stroke sliced the brain into one centimetre thick coronal 
sections and took one cm3 samples according to a comprehensive sampling protocol 
(Appendix).  Each lobe, the basal ganglia, thalamus and cerebellum were sampled 
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symmetrically from each hemisphere and a single sample was taken from the midbrain, 
pons, medulla and cerebellar vermis; producing 32 blocks in total. 
10.2.4.6 Sample processing 
Each tissue sample was placed in a plastic cassette.  The cassettes were placed in 10% 
formalin solution at room temperature and fixed for at least 24 hours.  No frozen 
sections were taken.  To produce paraffin blocks, each sample was dehydrated by being 
placed in a series of alcohol-based solutions of varying concentrations before being 
embedded in paraffin wax.  Once paraffin blocks were formed they were sliced into 
sections of ten micrometer thickness and placed on Superfrost slides. 
10.2.4.7 CAA assessment 
CAA was assessed by immunohistochemistry.  We used a monoclonal mouse antibody 
to human β-amyloid, (Clone 6F/3D, Dako, Copenhagen) at a concentration of 1:100.  
The procedure used 95% formic acid for pretreatment of paraffin-embedded, formalin-
fixed sections to improve amyloid immunoreactivity and immunolabelling, followed by 
staining using Novolink Polymer Detection Kit RE7280/K (Leica Biosystems, 
Wetzlar, Germany.) 
10.2.4.8 CAA rating 
The neuropathologist rated CAA using the Bristol rating scale [Love et al. 2014] (Table 
6 on page 144) which rates parenchymal and meningeal CAA from 0 to 3 where: 0 – 
CAA absent, 1 –scant deposition, 2-some circumferential amyloid, 3-widespread 
circumferential amyloid; capillary CAA as either 0 (absent) or 1 (present) and 
vasculopathy where 0-absent, 1-vasculopathy affecting occasional vessels and 2-
vasculopathy affecting many vessels.  The neuropathologist was unblinded to ICH 
location (lobar) but blinded to other imaging features of the ICH and the study 
hypothesis. 
10.2.5 Analysis: CAA-related ICH 
From my review of CAA rating scales (Section 10.1.3.1, page 229), it was apparent that 
inferring an ICH as ‘CAA-related’ is complex.  Previous rating scales have tended to 
label an ICH as ‘CAA-related’ if CAA is present in one or more tissue samples taken 
from anywhere in the brain although the distribution and severity of CAA may vary 
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between lobes of the brain [Greenberg & Vonsattel 1997;Allen et al. 2013] and CAA 
coexists with other small vessel diseases.  
The Bristol rating scale [Love et al. 2014] was validated in persons with and without 
Alzheimer’s dementia and examined the frequency and severity of CAA in different 
lobes and its association with apolipoprotein E genotype.  As yet, the scale has not been 
validated for use in ICH and there is no particular ‘cut-off’ above which an ICH would 
classified as ‘CAA-related.’ 
When forming a definition of ‘CAA-related ICH’ I considered the following factors: 
• The proximity of CAA to the ICH as ICH is a localised pathology and to infer an 
ICH as ‘CAA-related’, the CAA should be found within the vicinity of the ICH 
[Samarasekera, Smith, & Al-Shahi Salman 2012]. 
• The severity of CAA; for which I considered parenchymal or leptomeningeal CAA 
of grades 2 (some Aβ deposition) or 3 (widespread Aβ deposition) to be severe. 
• Presence of vasculopathy as vasculopathy would be expected to be present in CAA-
related ICH. 
10.2.5.1 Primary outcome 
I defined CAA-related lobar ICH as the presence of severe CAA (parenchymal or 
meningeal CAA of at least grade 2 or above) with vasculopathy (of at least grade 1), 
both occurring in at least one of the lobes affected by the ICH. 
10.2.5.2 Secondary outcomes 
I defined CAA-related lobar ICH in four other ways: 
(i) Severe CAA (parenchymal or meningeal CAA of at least grade 2 or above) with 
vasculopathy (of at least grade 1), both occurring in the same hemisphere as the 
ICH (although not in the same lobe(s) as the ICH). 
(ii) Severe CAA (parenchymal or meningeal CAA of at least grade 2 or above) without 
vasculopathy (grade 0), occurring in the same lobe(s) or in the same hemisphere as 
the ICH. 
(iii) Any degree of CAA in the same hemisphere as the ICH. 
(iv) Any degree of CAA occurring anywhere in the brain. 
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10.2.6 Analysis: Distribution of CAA in lobar ICH 
Since each autopsied brain was symmetrically sampled from each lobe (Appendix), in 
pre-specified analyses I aimed to: 
• Determine the frequency of CAA deposition in each lobe in both the hemispheres 
affected and unaffected by ICH since CAA may preferentially deposit in the 
occipital lobes [Johnson et al. 2007]; 
• Compare the severity of parenchymal and leptomeningeal CAA in lobe(s) affected 
by ICH vs. the contralateral lobe(s) to ascertain if CAA is symmetrically distributed; 
• Compare the frequency of vasculopathy in lobe(s) affected by ICH vs. the 
contralateral lobe(s) since vasculopathy might be more commonly seen in the lobe(s) 
affected by ICH; 
• Compare the severity of parenchymal CAA with leptomeningeal CAA in each lobe 
to assess if they are associated; 
• Determine whether vasculopathy is associated with severe CAA (defined as 
parenchymal or meningeal CAA of at least grade 2 or above) in the same lobe of the 
brain and 
• Determine if capillary CAA is associated with severe CAA or vasculopathy in the 
same lobe of the brain. 
10.2.6.1 CAA severity sum score 
To obtain a measure of the overall CAA severity, I calculated a CAA severity score by 
summing the components of the Bristol scale in all brain regions sampled.  Previously 
the components of the scale have been used separately to assess their association with 
apolipoprotein E genotype but not combined to assess overall CAA severity.  The 
maximum CAA score per lobe is nine, giving a maximum sum score of 72.  I assessed 
whether CAA severity was associated with age or a past history of dementia since I 
hypothesised that CAA would be more severe with any of these variables.  
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10.2.7 Univariate analyses 
10.2.7.1 Demographic and clinical characteristics of CAA-related and CAA-
unrelated lobar ICH 
I compared baseline demographic and clinical variables in participants with the primary 
outcome of CAA-related lobar ICH vs. those who with lobar ICH unrelated to CAA.  I 
compared the time interval between the date of onset of symptoms and the date of the 
diagnostic CT scan and the interval between the date of the scan and post-mortem 
examination in the two groups since these intervals may affect the radiological or 
pathological appearances of the ICH.   
10.2.7.2 Imaging characteristics of CAA-related and CAA-unrelated lobar ICH 
I pre-specified the imaging characteristics that I would compare between those with and 
without the primary outcome of CAA-related lobar ICH.  In two pre-specified 
sensitivity analyses, I firstly compared the imaging characteristics between those with 
CAA-related and CAA-unrelated lobar ICH in the entire cohort where those with a 
CAA-related lobar ICH met either the primary outcome measure or secondary outcome 
measures.  Secondly, I restricted the analysis to those with strictly lobar ICH and 
compared the imaging characteristics in those with CAA-related ICH vs. CAA-unrelated 
lobar ICH in this group. 
Since this study is limited by a small sample size (Section 10.3, page 246), I initially 
selected variables a priori after discussion with a neuroradiologist who was blinded to the 
imaging and pathology data. 
I excluded the following variables: 
• Atrophy, WMH (periventricular white matter lucency), old vascular lesions (old 
cerebral infarction)-since these variables were not features of the ICH but other 
features of the brain parenchyma and the aim of the study was to determine whether 
any ICH features differentiated between CAA-related ICH and other ICH. 
• I assessed ICH volume as a potential confounder of an association between 
subarachnoid extension and CAA-related lobar ICH, since subarachnoid extension 
is associated with a larger ICH volume [Chen et al. 2013] but did not include ICH 
volume as a candidate variable for discriminating between lobar ICH related and 
unrelated to CAA. 
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The variables selected should not have the same value for all participants and therefore I 
reviewed the imaging data blinded to the pathology results and excluded variables which 
were either very frequent or infrequent and were therefore unlikely to discriminate 
between participants (Section 10.3.2.2, page 249).   
10.2.8 Statistical analysis 
I used parametric statistics for between group comparisons when the data had a normal 
distribution and log–transformed variables or used non-parametric statistics when it did 
not.  If an estimated cell count was less than five, I used the Fisher’s exact test.  I used 
Spearman’s correlation coefficient to assess the relationship between parenchymal and 
leptomeningeal CAA in different lobes of the brain and assess whether the distribution 
of CAA was symmetrical in both hemispheres.   
I intended to choose imaging variables which differed between CAA-related lobar and 
CAA-unrelated lobar ICH in the univariate analyses to enter a logistic regression model 
of imaging features predictive of CAA-related lobar ICH, with the number of variables 
determined by the frequency of CAA-related lobar ICH in the sample.  I conducted all 
statistical analyses using Stata version 11.1 (StataCorp LP, Texas, USA).  All p values are 
2-sided.  
10.3 Results 
The following section describes descriptive analyses of CAA in participants with first-
ever lobar ICH and univariate analyses of CAA-related lobar ICH vs. CAA-unrelated 
lobar ICH.  Chapter 11 describes the participants who gave consent for post-mortem 
examination in comparison to the remainder of the cohort.  
10.3.1 Descriptive analyses 
10.3.1.1 Baseline characteristics of participants 
Of 36 potentially eligible participants with lobar ICH, 33 (92%) had first-ever ICH and 
formed the analysis group.  15 (45%) were males and the median age was 81 years (IQR 
77-86 years).  22 (67%) had a past history of hypertension, 10 (30%) had a prior history 
of dementia and seven (21%) had a prior history of ischaemic stroke.  19 (58%) were 
taking antiplatelet medications and three (9%) were taking anticoagulant medications at 
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the time of their ICH.  Table 30 on page 266 describes the locations of ICHs in all 33 
participants.      
10.3.1.2 Primary and secondary outcome measures 
Nine (27%) had no evidence of parenchymal or leptomeningeal CAA.  Table 31 on page 
267 shows the scores for each component of the Bristol scale in the lobes affected by 
ICH for the remaining 24 participants. 
12 participants met the primary outcome measure for CAA-related ICH.  
The remaining 12 participants fulfilled the criteria for a secondary outcome measure. 
Three fulfilled (i): severe CAA (parenchymal or meningeal CAA of at least grade 2 or 
above) with vasculopathy (of at least grade 1), both occurring in the same hemisphere as 
the ICH (although not in the same lobe(s) as the ICH).  Eight fulfilled (ii): severe CAA 
(parenchymal or meningeal CAA of at least grade 2 or above) without vasculopathy 
(grade 0), occurring in the same lobe(s) or in the same hemisphere as the ICH.   
One fulfilled (iii): Any degree of CAA in the same hemisphere as the ICH. 
Participants who fulfilled the primary outcome measure for CAA-related lobar ICH had 
significantly higher total CAA scores (n=12, median 54, IQR 49-58) than those who met 
a secondary outcome measure for CAA-related lobar ICH (n=12, median 33, IQR 21-
35; p<0.001).   
10.3.1.3 Distribution of CAA in every lobe 
The frequency of CAA of any severity was 22/33 (67%) in the frontal and temporal 
lobes and 24/33 (73%) in the parietal and occipital lobes and did not differ according to 
whether the lobe was in the hemisphere affected or unaffected by ICH (Figure 43 on 
page 282). 
10.3.1.4 Distribution of parenchymal and leptomeningeal CAA and vasculopathy 
between lobes affected and unaffected by ICH in participants with first-ever 
lobar ICH 
The presence or absence of CAA of any degree in a lobe(s) affected by ICH was 
concordant with the presence or absence of CAA in the corresponding contralateral 
lobe(s) (Table 32 on page 269). 
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To assess CAA severity, I used a combined sum score for parenchymal and 
leptomeningeal CAA.  The severity of CAA in the lobe(s) affected by the ICH was 
positively correlated with the contralateral corresponding lobe (frontal lobes (n=22) 
ρ=0.96; p<0.001; temporal lobes (n=6) ρ=1.00; p<0.001; parietal lobes (n=16) ρ=0.97; 
p<0.001.)  Only two participants had an ICH affecting the occipital lobes and I could 
not test for an association. 
The presence or absence of vasculopathy of any degree in a lobe(s) affected by ICH was 
concordant with the presence or absence of vasculopathy in the corresponding 
contralateral lobe(s) in frontal and parietal regions (Table 33 on page 269).  Only six 
participants had an ICH affecting their temporal lobes and only two participants had an 
ICH affecting their occipital lobes, precluding firm conclusions.  
10.3.1.5 Relationship between parenchymal and leptomeningeal CAA and 
vasculopathy 
The severity of parenchymal CAA was closely correlated with that of leptomeningeal 
CAA in all lobes of the brain, whether in the hemisphere affected or unaffected by the 
ICH (Table 34 on page 270). 
In both the affected and unaffected hemispheres the presence of severe CAA (defined 
as parenchymal or leptomeningeal CAA of at least grade 2 or above) was associated with 
vasculopathy in all lobes bar the occipital lobes, where there was a similar tendency 
which failed to reach statistical significance (Table 35 on page 271).   
Severe CAA was seen without vasculopathy in 81/264 (31%) of lobes but vasculopathy 
only occurred in four lobes (2%) in which severe CAA was absent.   
10.3.1.6 Association between CAA, vasculopathy and capillary CAA 
Capillary CAA was most frequently seen in the occipital lobes (19/66 (29%)) followed 
by the parietal (13/66(20%)), temporal (10/66 (15%)) and frontal lobes (8/66(12%)) 
[χ2=6.81, p=0.08].  Severe CAA was seen without capillary CAA in 115/264 (44%) of 
lobes but capillary CAA only occurred in one lobe (0.4%) in which severe CAA was 
absent. 
  Chapter 10 
249 
Using a sum score for parenchymal and leptomeningeal CAA in each lobe, whether in 
the hemisphere affected or unaffected by ICH the presence of capillary CAA was 
associated with significantly more severe CAA in the same lobe (Table 36 on page 272). 
 Of 264 lobes, in 31 (12%) both vasculopathy and capillary CAA were present, in 158 
(60%) both were absent, vasculopathy occurred in the absence of capillary CAA in 56 
(21%) lobes and the converse happened in 19 (7%) lobes (Table 37 on page 273). 
Examination of each lobe of the affected and unaffected hemispheres revealed that 
capillary CAA was associated with vasculopathy in the occipital lobes of both 
hemispheres (Table 37 on page 273) but not in other lobes. 
10.3.1.7 CAA total score and relationship with age and dementia 
I used a total score for CAA comprising all elements of the rating scale.  In 33 
participants with first-ever lobar ICH, there was no relationship between the CAA total 
score and age (p=0.69) or a prior history of dementia (dementia: median CAA score 34, 
IQR 29-50 vs. no dementia: median CAA score 33, IQR 0-53; p=0.52).  
10.3.2 Comparison of CAA-related lobar and CAA-unrelated lobar ICH 
10.3.2.1 CAA-related lobar and CAA-unrelated lobar ICH 
Although there tended to be more males, and fewer participants with a prior history of 
hypertension at the time of their ICH in the CAA-related ICH group, there were no 
statistically significant differences between the demographic and clinical characteristics 
of those with CAA-related lobar and CAA-unrelated lobar ICH defined as per the 
primary outcome measure (Table 38 on page 274).  The interval between the date of the 
ICH and brain imaging and between the date of imaging and post-mortem examination 
was similar in both groups (Table 39 on page 275). 
10.3.2.2 Imaging features in the cohort 
I excluded the following variables since they varied little between participants:  
• single vs. multiple ICH (31 participants had single ICHs),  
• subdural haemorrhage (only three participants had subdural haemorrhage in 
association with their ICH),  
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• presence of a blood or fluid level within the largest ICH (only five participants had a 
fluid level) and  
• an ICH with an irregular border (29 out of 33 participants had an irregular 
haematoma.)   
The final candidate variables selected for comparison between participants with CAA-
related lobar and CAA-unrelated lobar ICH were: intraventricular extension of the main 
(largest) haematoma, subarachnoid extension, variable density within the ICH and an 
irregular or lobulated ICH with one or more finger-like protrusions to the cortex (Table 
39 on page 275).  I included the latter variable in place of an ICH with an irregular 
border, since 19 participants had an ICH with one or more finger-like protrusions to the 
cortex (all of whom also were also had an irregular ICH). 
10.3.2.3 CAA–related lobar ICH vs. CAA-unrelated lobar ICH defined as per primary 
outcome measure 
12 participants met the primary outcome measure for CAA-related ICH.  There were no 
statistically significant differences in imaging variables between those with CAA-related 
lobar and CAA-unrelated lobar ICH (Table 39 on page 275). 
10.3.2.4 CAA-related lobar ICH defined as per primary and secondary outcome 
measures vs. CAA-unrelated lobar ICH 
24 participants met either the primary outcome measure for CAA-related lobar ICH or 
one of the secondary outcome measures.   
In a sensitivity analysis comparing the imaging features of those with CAA-related lobar 
ICH as per this definition (n=24) vs. the remainder (n=9), the results were unchanged 
with no differences between CAA-related lobar ICH vs. CAA-unrelated lobar ICH in 
intraventricular haemorrhage (n=15 (63%) vs. n=4 (44%); χ2=0.87, p=0.35),  
subarachnoid haemorrhage (n=19 (79%) vs. n=6 (67%); p=0.65), variable density within 
ICH (n=15 (63%) vs. n=5 (56%); p=1.00), or irregular or lobulated ICH with ≥one 
finger like protrusion to cortex (n=14 (58%) vs. n=4 (44%); p=0.69). 
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10.3.2.5 CAA-related and CAA-unrelated strictly lobar ICH 
17 participants had a strictly lobar ICH (that is, an ICH confined to lobar regions of the 
brain) of which eight (47%) met the primary outcome measure for CAA-related lobar 
ICH.   
In a sensitivity analysis comparing the imaging features of CAA-related strictly lobar 
ICH vs. the remainder in this subgroup, the presence of subarachnoid haemorrhage 
seemed to be more frequent in those with CAA–related strictly lobar ICH (n=8, 100%) 
vs. CAA-unrelated strictly lobar ICH (n=5, 56%) p=0.08) but the results were otherwise 
unchanged (Table 40 on page 276).  The sensitivity of subarachnoid haemorrhage for 
the presence of CAA was 100% (95% CI 63-100%) and the specificity was 44% (95% 
CI 14-79%). 
Since none of the imaging variables differed between the two groups, I did not perform 
a logistic regression model. 
10.4 Summary 
• Of 33 participants with first-ever lobar ICH, 9 participants (27%) did not have any 
CAA in their cerebral hemispheres. 
• The presence of CAA or vasculopathy and the severity of CAA in a lobe affected by 
ICH was concordant with that of the corresponding contralateral unaffected lobe. 
• The severity of parenchymal CAA was positively correlated with leptomeningeal 
CAA in all lobes of the brain, whether affected or unaffected by ICH. 
• Severe CAA was associated with vasculopathy. 
• Capillary CAA was associated with more severe CAA in the same lobe, whether 
affected or unaffected by ICH. 
• Capillary CAA was associated with vasculopathy in the occipital lobes of both 
hemispheres but not in the other lobes of the brain. 
• The total CAA score was not associated with participant age or a prior history of 
dementia. 
• No imaging variables were statistically significantly associated with CAA-related 
lobar ICH. 
  Chapter 10 
252 
• Subarachnoid extension tended to be more frequent in those with CAA-related 
strictly lobar ICH vs. CAA-unrelated strictly lobar ICH, with a sensitivity of 100% and 
specificity of 44% for pathologically –proven CAA-related strictly lobar ICH. 
10.5 Discussion 
This study is a preliminary radio-pathological study of CAA-related lobar ICH and its 
findings should be viewed as a precursor to larger studies. 
10.5.1 Strengths of the study 
Strengths of the study include its prospective population-based design with the 
reference standard (pathologically-proven CAA-related lobar ICH) defined using a 
comprehensive sampling protocol (Appendix) by a consultant neuropathologist, who, 
although he could not be blinded to ICH location, was blinded to other imaging 
features of the ICH and assessed CAA in all specimens using immunohistochemistry.  
Imaging features were classified independently by a consultant neuroradiologist blinded 
to the reference standard and I selected imaging features for comparison between CAA-
related and CAA-unrelated lobar ICH without knowledge of pathology results on the 
basis of previous studies and those variables whose values were not very common or 
very rare amongst participants. 
10.5.2 Limitations of the study 
The study is limited by its small sample size and it may therefore lack power to 
demonstrate differences between certain imaging features of CAA-related lobar ICH in 
comparison to CAA-unrelated lobar ICH if they truly exist.  All pathology ratings were 
done by a single experienced neuropathologist without an inter-rater comparison.  
Although I pre-specified analyses, I nevertheless performed multiple comparisons, 
increasing the likelihood of a statistically significant result occurring by chance.  Since 
this was a post-mortem examination-based study, study participants had severe strokes 
as shown by their large ICH volumes (Chapter 11).  They may therefore be less 
representative of all patients with lobar ICH.  Participant selection was partly based 
upon their ability to have the index test (CT imaging.) Since 98% of the cohort 
described in the first year of the study (Chapter 5) underwent a diagnostic CT brain 
scan, it is unlikely that this has been a significant source of selection bias.  This is the 
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first study to use the Bristol rating scale in adults with ICH and the validity and 
reliability of the rating scale has not been assessed in this group, nor is it clear how its 
constituent ratings should be used (Section 10.5.5.1, page 259). 
10.5.3 Study findings from descriptive pathological analyses 
10.5.3.1 CAA was absent in 27% of the cohort 
It is interesting that 9 (27%) of those with first-ever lobar ICH did not have any 
evidence of CAA in their hemispheres, four of whom had strictly lobar ICH.   
Although misclassification of ICH location is possible, I think it is unlikely that this has 
occurred since all ICHs were classified by a neuroradiologist with a special interest in 
stroke.  It is unlikely that CAA was missed in the supratentorial regions given the 
comprehensive sampling undertaken and the use of immunohistochemistry.  There have 
been very few studies comparing the sensitivity of different techniques for detection of 
CAA but in one study of ten samples rated by both Congo Red staining and 
immunohistochemistry, immunohistochemistry was superior in that it detected CAA in 
two specimens in which Congo Red staining had been scarce, giving Congo Red a 
sensitivity of 71% (95% CI 36-92%) for the detection of CAA [Haglund & Englund 
2002].  Ratings of the infratentorial regions were not available at the time of analysis but 
it is unlikely that this would have altered these findings since CAA is thought to deposit 
in the supratentorial regions first, possibly in the occipital lobes [Johnson et al. 2007] 
and even if CAA had been present in the infratentorial regions, the ICHs would not 
have been classified as ‘CAA-related’ according to the pre-specified definition of ‘CAA-
related ICH.’ 
This finding is of note, since it indicates that all lobar ICH cannot be thought of as 
‘possible CAA-related’ ICH and further work is needed to determine the frequency of 
underlying causes of spontaneous primary lobar ICH. 
10.5.3.2 CAA and vasculopathy are symmetrically distributed 
My systematic review of case-control and cross-sectional pathological studies of CAA 
and ICH revealed that no previous studies had systematically assessed for CAA in all 
lobes of both cerebral hemispheres [Samarasekera, Smith, & Al-Shahi Salman 2012].   
When studying a localised pathology such as ICH, it is of interest to determine whether 
  Chapter 10 
254 
the distribution of CAA is symmetrical, since if not, this may provide clues as to why 
haemorrhage as occurred in one particular region.  I did not find any differences in the 
frequency or severity of CAA deposition or frequency of vasculopathy in lobes affected 
by ICH vs. the contralateral lobe or frequency of vasculopathy supporting existing 
theories that CAA may result from diffusely compromised drainage of Aβ along 
perivascular pathways as arteries and arterioles stiffen with age, leading to vascular Aβ 
accumulation within the brain [Weller, Boche, & Nicoll 2009]. 
It is unclear why those with lobar ICH bleed in one hemisphere but not the other.  
Potential explanations include an interaction with other small vessel diseases such as 
arteriolosclerosis which might be more severe on the affected side, or an ICH may 
develop at the site of prior BMB [Gurol et al. 2012]. 
10.5.3.3 Vasculopathy is associated with severe CAA 
The severity of parenchymal CAA was correlated with leptomeningeal CAA and severe 
CAA was associated with vasculopathy. 
In patients with Alzheimer’s dementia, CAA may deposit in the leptomeningeal vessels 
first before progressing to parenchymal vessels [Thal et al. 2003].  It is unknown 
whether a similar pattern occurs in those without dementia.  I did not see patients with 
leptomeningeal CAA who lacked parenchymal CAA possibly because those with 
evidence of CAA had CAA at a more advanced stage when both leptomeningeal and 
parenchymal vessels might be affected.   
The finding that severe CAA was associated with vasculopathy in the same lobe is in 
keeping with what is known about the development of CAA, since vasculopathy 
(fibrinoid necrosis, microaneurysm formation, vessel wall fragmentation and 
perivascular leakage) is seen in the ‘end-stages’ of CAA [Attems 2005]. However lobar 
ICH occurred without vasculopathy any of the same lobe(s) as the ICH in 11/24 (46%) 
participants who had any CAA present, suggesting that vasculopathy is not a necessary 
condition for ICH to occur. One possible explanation is misclassification of 
vasculopathy as absent, particularly in larger ICHs which disrupt tissue architecture, but 
if vasculopathy was missed in the affected hemisphere, given the symmetrical 
distribution of vasculopathy (Section 10.5.3.2, page 253) I would expect vasculopathy to 
be present in the contralateral hemisphere and none of these had vasculopathy in the 
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unaffected hemisphere.  Alternatively, other small vessel diseases such as 
arteriolosclerosis or genetic factors such as presence of the apolipoprotein ε2 or ε4 
alleles may contribute to the risk of ICH with severe CAA. 
10.5.3.4 Capillary CAA is associated with severe CAA 
Lobes with capillary CAA had significantly more severe CAA than lobes without 
capillary CAA, suggesting that capillary CAA is associated with severe CAA.  
The significance of capillary CAA in adults with ICH is as yet unknown.  Previous 
hospital –based post-mortem examination studies have suggested that capillary CAA 
may be a type of CAA distinct from parenchymal or leptomeningeal CAA, since Aβ1-42 
is found in capillary CAA within the vessel wall in contrast to Aβ1-40 in larger vessels 
[Thal et al. 2002a;Richard et al. 2010].  Moreover, no difference in either CAA severity 
[Thal et al. 2002a;Attems, Lintner, & Jellinger 2004;Oshima et al. 2006] or age [Thal et 
al. 2002a] has been noted between those with and without capillary CAA, although 
those with capillary CAA might be expected to be older if capillary CAA was a 
progression from non-capillary (parenchymal or leptomeningeal) CAA.   
However, these findings might be due to a) the participants selected since the studies 
listed above have included only 121 participants, included participants only with 
capillary CAA [Richard et al. 2010] and either not described participants’ clinical 
phenotypes [Oshima et al. 2006] or used adults with and without dementia rather than 
adults with ICH [Thal et al. 2002a;Attems, Lintner, & Jellinger 2004;Richard et al. 2010], 
or b) sampling error since CAA was sampled solely from the frontal lobe [Attems, 
Lintner, & Jellinger 2004], occipital lobe [Oshima et al. 2006] or the temporal and 
occipital lobes [Thal et al. 2002a;Richard et al. 2010].   
Both in my cohort and in some previous studies [Thal et al. 2002a;Oshima et al. 
2006;Richard et al. 2010;Allen et al. 2013], capillary CAA has only occurred in the 
presence of parenchymal or leptomeningeal CAA.  Moreover, the apolipoprotein ε4 
allele is associated both with severe CAA [Rannikmae et al. 2013b] and capillary CAA 
[Richard et al. 2010;Allen et al. 2013], and for these reasons capillary CAA may be a 
manifestation of severe CAA. 
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10.5.3.5 Capillary CAA is associated with vasculopathy in the occipital lobes 
When all lobes were combined, capillary CAA was associated with vasculopathy, but on 
examination of each lobe, this association remained in the occipital lobes but not in 
other regions of the brain.  However, only rarely did capillary CAA occur without 
vasculopathy (Section 10.3.1.6, page 248) and it may be that given the small sample, the 
study lacked sufficient power to demonstrate an association between CAA and 
vasculopathy in each lobe.  Given that capillary CAA seems to be associated with severe 
CAA (Section 10.5.3.4, page 255), it is plausible that capillary CAA might be associated 
with vasculopathy. 
10.5.3.6 No association between total CAA score and age or dementia 
The study may have lacked sufficient power to demonstrate an association between total 
CAA score and these variables, since the sample size was small and the age distribution 
of participants was narrow (median age 81 years; IQR 77-86 years.)  I classified a person 
as having dementia if this was listed in their medical (GP & hospital) records or if the 
IQCODE score was ≥64 [Jorm 1994], but since only 37% participants in the first year 
of the cohort had an IQCODE (Chapter 5) I may have classified some participants with 
dementia incorrectly as not having dementia.  
This is the first study to use the Bristol rating scale for rating CAA in adults with ICH 
and there is no established method as yet for using the scale for this purpose.   
Although using a total CAA score is one method of quantifying overall CAA, it assumes 
firstly, that the response categories for each item are integers with equal differences 
between levels, which is not the case.  The difference between ‘zero’ – no vasculopathy 
and ‘one’ –vasculopathy affecting occasional vessels may be more important than the 
difference between ‘one’ and ‘two’ where two- vasculopathy affecting many vessels.  
Secondly, it assumes that the differences have equal meaning – a scale difference of, for 
example five points, has the same meaning across all items in the scale [Hobart 2003] 
and lastly, that the scale is unidimensional; that is, all scale items measure the same 
characteristic, in this case CAA severity.   
10.5.3.7 CAA-related lobar ICH 
The prevalence of CAA-related lobar ICH in the cohort was 36% (95% CI 22-53%) 
which is lower than the 51% (95% CI 42-61%) prevalence of CAA in cases of lobar 
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ICH from my systematic review of hospital-based cross-sectional and case-control 
neuropathological studies of ICH with varied methods of CAA assessment (Chapter 9).   
I prospectively recruited participants in a population-based design and used a stringent 
definition of CAA-related lobar ICH which required evidence of severe CAA, with 
vasculopathy to be present in at least one of the lobes affected by the ICH.  This may 
have led to a reduction in sensitivity (cases of CAA-related ICH incorrectly classified as 
CAA-unrelated ICH) at the expense of maintaining specificity.  However, when 
determining the true prevalence of CAA-related ICH in the cohort, specificity appears 
to be more important than sensitivity, since small losses in specificity may grossly over-
inflate the prevalence estimate whereas small losses in sensitivity appear to have only 
modest effects on prevalence estimates [Copeland et al. 1977].   
10.5.4 Study findings from univariate analyses-Radiological features did not differ 
between the CAA-related ICH and CAA-unrelated ICH groups 
I did not identify any differences in the radiological features of CAA-related lobar ICH 
vs. CAA-unrelated lobar ICH.  This might be due to the study’s small sample size 
leading to a lack of power to detect differences between the groups if they do exist, the 
impact of measured and unmeasured variables on imaging features, the definitions of 
imaging features or the definitions of outcome. 
10.5.4.1 Impact of measured and unmeasured variables 
Radiological features of ICH are influenced by several factors including ICH volume 
and the time interval between symptom onset and imaging.  Intraventricular extension is 
associated with larger ICH volumes [Hallevi et al. 2008] and may be delayed [Maas et al. 
2013b], so might be missed if a patient is scanned soon after symptom onset.  The 
density of a haematoma also varies with time; being hyperdense  in the acute stage and 
increasing as clot retraction occurs, but becoming hypodense in the subacute stage and 
in those with anaemia [Kidwell & Wintermark 2008].  In this cohort, neither ICH 
volume nor the time interval between symptom onset and imaging differed between the 
CAA-related and CAA-unrelated ICH groups.  Intraventricular extension may be 
associated with white matter hyperintensities [Kim et al. 2013] which I did not assess 
and may be difficult to assess because of disruption of the brain parenchyma by the 
ICH.  Similarly haematoma density may be lower in those with anaemia (which I did not 
assess) or if the haematoma arises from multiple foci [Barras et al. 2009].  Therefore 
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ICH appearances might have been influenced by these unmeasured variables which 
affected the findings.  
10.5.4.2 Definitions of imaging features 
Previous studies have used various definitions of haematoma shape and density. 
Radio-pathological studies of CAA-related lobar ICH have either not defined the terms 
used to describe ICH shape [Yong et al. 1992;Izumihara et al. 1999] or used pictorial 
representations [Wagle, Smith, & Weiner 1984;Brown, Coates, & Gilbert 
1985;Minakawa et al. 1995;Lang et al. 2001].  ICH shape has been most frequently 
labelled as either round or irregular [Minakawa et al. 1995], sometimes with additional 
use of the term ‘lobulated’ [Izumihara et al. 1999;Lang et al. 2001] and inter-observer 
agreement has not been quantified. 
Other studies of ICH have used a variety of descriptive terms, including ICH classed as 
round (with round and smooth margins), irregular (with irregular, multinodular margins) 
or separated (with a fluid level in the cavity) [Fujii et al. 1994], round to ellipsoid, 
irregular (with frayed margins) or multinodular to separated [Huttner et al. 2006], round 
or irregular [Miyahara, Murata, & Abe 2007;Sheth et al. 2010] and regular vs. irregular 
defined using a five point categorical scale [Barras et al. 2009].  In one study which 
measured inter-rater agreement using the kappa statistic, agreement was substantial 
[Sheth et al. 2010], in two others raw agreement ranged from 85% [Barras et al. 2009] to 
93% [Huttner et al. 2006] and in the remainder agreement was not assessed [Fujii et al. 
1994;Miyahara, Murata, & Abe 2007]. 
Variable density has previously been rated using a five-point categorical scale in which 
grade one indicated a homogenous ICH and grades two to five indicated progressively 
increasing degrees of heterogeneity.  There was moderate inter-rater agreement (κ=0.61) 
[Barras et al. 2009]. 
I sought to clearly describe these terms by classifying an ICH as either irregular or not 
and either of uniform or variable density (Figure 41 on page 280 and Figure 42 on page 
281). 
I used a binary classification as the aim of the study was to assess for easily applicable 
CT imaging features of ICH which might differentiate CAA-related from other lobar 
ICH.  I assessed both whether an ICH was irregular and whether there were finger-like 
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protrusions to the cortex since ICH in a ‘superficial location’ has been a noted feature in 
CAA-related lobar ICH [Wagle, Smith, & Weiner 1984;Yong et al. 1992] and CAA may 
deposit in the leptomeningeal and neocortical vessels first [Thal et al. 2003].  Although a 
neuroradiologist reviewed all brain imaging, imaging features are subject to inter-
observer variation.  In a future study I would assess inter-observer variation not only of 
haematoma shape and density but also other imaging features such as ICH location. 
10.5.4.3 Definition of outcome 
Although the stringent definition of CAA-related ICH used may have led to differential 
misclassification of the outcome (by making it more likely that ICHs related to CAA 
were classified as unrelated to CAA), a sensitivity analysis which included both ICHs 
meeting the primary and secondary outcome measures for CAA-related lobar ICH, did 
not alter the findings.   
10.5.4.4 Subarachnoid haemorrhage may be more common in strictly lobar ICH 
Subarachnoid extension of the ICH tended to be more frequent in the CAA-related 
strictly lobar ICH group vs. CAA-unrelated strictly lobar ICH although this was not 
statistically significant and needs further exploration in a larger cohort.  Subarachnoid 
extension might be seen in CAA-related ICHs if leptomeningeal and cortical vessels are 
more vulnerable to CAA deposition than other vessels [Thal et al. 2003] and bleed 
preferentially but subarachnoid extension is also more common in lobar ICH (Chapter 
5).   
If subarachnoid haemorrhage is a marker for CAA-related lobar ICH it could improve 
the sensitivity of the Boston criteria [Knudsen et al. 2001] which have excellent 
specificity but only moderate sensitivity for the ante-mortem diagnosis of CAA-related 
ICH (Section 10.5.5.6, page 263).  
10.5.5 Future directions 
This study raises interesting questions regarding the assessment of CAA in pathological 
studies and its role in ICH. 
10.5.5.1 Assessment of the Bristol rating scale 
A pathological scale should measure what it claims to (be valid), should be reproducible 
(reliable) and for pathological scores, particularly when scale items are summed to 
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obtain a total score, all items included in the scale should measure the same 
characteristic [Hobart et al. 2007;Coste et al. 2014].  If items measuring different 
characteristics are included in the scale, then more than one trait is being assessed and a 
sum score is not valid.  
The Delphi-style survey [Linstone & Turoff 1975] used in the formation of the Bristol 
scale [Love et al. 2014] is one approach to gaining content validity.  The scale has 
reasonable external construct validity (that is, it behaves as predicted when tested with a 
different variable) since the presence of CAA, measured by the Bristol scale, was 
strongly associated with apolipoprotein ε2 and ε4 genotype when tested in persons with 
dementia although this is still to be tested in those with ICH.  Internal construct validity 
(the extent to which items on the scale expected to relate to each other, do so 
statistically) is satisfactory as shown by the positive correlations between parenchymal 
and leptomeningeal CAA and severe CAA and vasculopathy. 
A future study could assess convergent and discriminant construct validity [Hobart et al. 
2007].  The former might be assessed by applying different scales measuring CAA to the 
cohort to determine if the Bristol scale correlates with scales which measure similar 
features.  The validity of using the CAA sum score as a measure of total CAA severity 
could also be tested by comparing CAA sum scores from the Bristol scale[Love et al. 
2014] with other CAA scales which also use a summary measure of individual 
components to measure CAA severity [Ellis et al. 1996;Attems, Jellinger, & Lintner 
2005] rather than inferring CAA severity for an entire brain from a single tissue 
sample[Vonsattel et al. 1991;Olichney et al. 1996].  
Divergent construct validity might be assessed by applying scales measuring a different 
construct such as arteriolosclerosis to the sample and comparing scores to check that 
the scores from the two scales do not correlate.   
Inter-rater reliability of the Bristol scale was good when tested on samples from 20 
persons with Alzheimer’s dementia and five controls [Love et al. 2014].  I have not 
assessed inter-rater reliability in this study and a future study should do this, using 
samples from both ICH brains and controls and a pathologist blind to case/control 
status and sample location. 
  Chapter 10 
261 
10.5.5.2 Assessment of imaging features 
A future study should assess the inter-rater reliability of imaging variables using two 
neuroradiologists blinded to the pathological findings.  Definitions of haematoma 
density and ICH shape have varied in earlier studies (Section 10.5.4, page 257) and may 
be more likely to be subject to inter-rater variation.  Although there has been reasonable 
agreement regarding the classification of ICH location [Wermer et al. 2002;Battathiri et 
al. 2003], even with larger haematomas [Wermer et al. 2002], previous studies have 
classified ICH location as either lobar or deep and a future study should clearly define 
ICH location and examine inter-rater agreement for classifying ICHs as lobar, deep or 
mixed since some haematomas will inevitably involve both the lobar and deep regions 
of the brain (Chapter 5). 
10.5.5.3 Assessment of other small vessel diseases 
Given that only 36% lobar ICHs are explained by CAA, other small vessel diseases 
probably contribute to lobar ICH. 
Studies should assess the prevalence and severity of other small vessel diseases, 
especially arteriolosclerosis in lobar ICH.  CAA may be a risk factor for ischaemic stroke 
[Cadavid et al. 2000] and microinfarcts are associated with severe CAA 
[Soontornniyomkij et al. 2010] but the role of CAA in their formation is yet to be 
established.  It has been suggested that CAA leads to cerebral hypoperfusion and 
infarcts [Okamoto et al. 2012] but microinfarcts do not invariably correlate with CAA 
[Kovari et al. 2013] and the role of arteriolosclerosis is unclear.  Since participants with 
lobar ICH also have vascular risk factors (Chapter 5), co-existing arteriolosclerosis may 
modify the effect of CAA and influence the risk of ICH. 
10.5.5.4 Dementia 
Clinico-pathological studies of pre-morbid dementia and lobar ICH are scarce.  There 
have been no prospective population-based studies although one recent hospital-based 
prospective study of pre-stroke dementia and ICH included five post-mortem 
examination cases of lobar ICH all of which had either stage V or VI Braak [Braak et al. 
1996] Aβ pathology [Cordonnier et al. 2010b].   
Ten neuropathological studies (of 141 participants) have examined the prevalence of 
CAA in lobar ICH and assessed Alzheimer’s disease pathology.  The prevalence of 
  Chapter 10 
262 
Alzheimer’s pathology in CAA-related lobar ICH has varied from 37% [Gilles et al. 
1984] to ~ 70% [Yoshimura et al. 1992;Itoh et al. 1993] to ~100% [Jellinger 
1977;Vinters & Gilbert 1983;Ishii, Nishihara, & Horie 1984].  Two studies did not state 
the prevalence of parenchymal Aβ in those with lobar ICH [Tomonaga 1981;Attems, 
Lauda, & Jellinger 2008] and in two others no cases of lobar ICH had parenchymal 
Aβ[Cartier et al. 1999;Mastaglia et al. 2003].   
A larger population-based study would determine the prevalence of pre-existing 
dementia in persons with lobar ICH (and ICH in other locations) and might 
demonstrate an association between a prior history of dementia and CAA severity, as 
this is plausible given the established association between CAA and Alzheimer’s 
dementia [Neuropathology Group of the Medical Research Council Cognitive Function 
and Ageing Study (MRC CFAS) 2001].  The study should also assess parenchymal Aβ 
deposition (plaques), neurofibrillary tangles and vascular pathologies  which contribute 
to dementia and death [Matthews et al. 2009] since this may provide clues as to the 
presumed causes of cognitive decline in persons with ICH and correlate parenchymal 
Aβ  with CAA severity to assess if this differs according to apolipoprotein E genotype, 
since senile plaque density may increase with possession of an ε4 allele [Rebeck et al. 
1993] although studies conflict [Allen et al. 2013].  By comparing these pathologies in 
demented vs. undemented persons it might be possible to assess the relative 
contributions of different pathologies to dementia in persons with lobar ICH. 
10.5.5.5 Apolipoprotein E gene 
The ε4 allele of the apolipoprotein E gene has a dose-dependent relationship with 
pathologically-proven CAA [Rannikmae et al. 2013b], but both the ε2 and ε4 alleles are 
associated with lobar ICH [Biffi et al. 2010b].  The commonly proposed hypothesis is 
that ε4 promotes the deposition of CAA but the ε2 allele promotes progression to 
vasculopathy that leads to vessel rupture and ICH [McCarron et al. 1999a].   
However, a recent individual patient data meta-analysis of 497 adults without ICH (50% 
with dementia, 20% not demented and 30% dementia status unknown) with 
pathologically-proven CAA showed an association between the ε4 allele and 
vasculopathy but no such association with the ε2 allele although the number of 
participants with the ε2 allele was small [Rannikmae et al. 2013a].   
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A future study should compare the prevalence of ε2 and ε4 alleles in persons with CAA-
related lobar ICH (that is, severe CAA with vasculopathy meeting the primary outcome 
measure) in comparison to those with lobar ICH not related to CAA to determine 
whether the ε2 allele is more frequent in those with vasculopathy and confirm the 
presence of a dose dependent relationship between the ε4 allele and CAA severity in 
persons with ICH. Given the low prevalence of the ε2 allele, a multi-centre approach 
may be necessary.   
Since capillary CAA is associated with the ε4 allele in persons with Alzheimer’s 
dementia [Thal et al. 2002a;Allen et al. 2013], the study should assess whether the same 
association is seen in persons with ICH. 
10.5.5.6 Modification of diagnostic criteria for CAA 
The eventual aim of this study would be to improve the diagnostic utility of the Boston 
criteria for the ante-mortem diagnosis of CAA.  Currently the Boston criteria have 
excellent specificity (100% 95% CI 77-100%) so they do not misclassify those without 
CAA as having CAA, but their sensitivity is 44% (95% CI 28-62%), so are liable to 
classify those with CAA as not having a CAA-related lobar ICH.   
For the diagnostic criteria to be widely applicable in clinical settings, they need to 
comprise standards that have been tested and validated independently in population-
based cohorts representative of the patients likely to develop ICH, use technology that 
is applicable in lower-income countries where MRI is likely to be less accessible and lead 
to diagnoses that are meaningful to be able to guide prognosis and treatment for an 
individual patient [Brayne 2014].  Given the widespread use of CT in both high and low-
middle income countries, integration of any CT imaging variables which reliably 
differentiate between CAA-related lobar ICH and other lobar ICH would guide 
clinicians and limit unnecessary  investigations into other causes of ICH. 
A larger study would have greater power to determine if any of the four candidate 
imaging variables are actually associated with CAA-related lobar ICH and would be able 
to test other variables such as subdural extension which have been observed with CAA-
related lobar ICH in previous studies (Table 29 on page 265).
 
 
Table 28 Characteristics of radio-pathological studies of CAA-related lobar ICH (excluding studies of <five participants) 
Study (year) Number of 
participants with 










symptom onset  
and diagnostic CT 
scan 
Interval between 










Wagle (1984) 7 62-84 6 0-5 weeks ? 5/2 CR 
Brown (1985) 12 62-89 7 ? ? 7/5 CR 
Cosgrove (1985) 7 58-88 ? ? ? 7/0 CR 
Wakai (1992) 6 65-76 5 ? 0- ≥15 days 0/6 CR & IHC (on those positive 
with CR) 
Yong (1992) 6 54-86 ? 0- ≥2 weeks ? 0/6 CR & IHC 
Minakawa (1995) 10 61-80 ? 1-48 hours 0-2 days 0/10 CR 
Izumihara (1999) 37 61-91 26 ? ? 0/37 CR & IHC 
Miller (1999) 7 60-86 6 ? 1-120 days 7 /0 ? 
Lang (2001) 41 53-90 ? ? ? 0/41 CR 
Oide (2003) 64 61-91 42 ? ? 12/52 CR & IHC 
Chen (2004) 5 65-83 ? ? ? 0/5 CR 
Patel (2009) 12 ? ? ? ? 2/10 CR or IHC 





Table 29 Imaging (CT) characteristics observed with pathologically proven CAA-related lobar ICH 

















































































































































































































































Wagle (1984)  7  4 (57) 3 (43)     3 (43) 6 (86)  6 (86)   
Brown (1985)  12  6 (50)       7 (58)     
Cosgrove (1985) 7  3 (43) 6 (86) 3 (43)          
Wakai (1992) 6   6 (100)       6 (100)    
Yong (1992) 6   ●     ● ●     
Minakawa (1995) 10  6 (60) 9 (90)  7 (70)    9 (90)     
Izumihara (1999) 37 5 (14) 5 (14) 31(84) 9 (24)     8 (22) 23 (62)    
Millar (1999) 7 5 (71) 5 (71) 5 (71)  3 (43) 5 (71) ● 5 (71)  7 (100)  5 (71)  
Lang (2001) 41 7 (17) 10 (24) 26 (64)      15 (37) 17 (41)    
Oide (2003) 64 6 (9) 10 (16) 53 (83)         27(42)  
Chen (2004) 5  4 (80)            
Patel (2009) 12    8(67)          
Hirohata (2010) 41 ● ● ●           
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Table 30 Lobes affected by ICH in 33 participants with first-ever lobar ICH 











Table 31 Scores for each component of the Bristol scale in 24 participants with first-ever lobar ICH who had any CAA present in their brains 
pCAA= parenchymal CAA, lcaa=leptomeningeal CAA, vasc=vasculopathy, capCAA=capillary CAA 
Case Hemisphere 
(Right [R] or Left 
[L]) and Lobe(s) 
involved 





















































































1 R parietal         3 3 1 1     
2 L frontal 3 3 1 0             
3 R frontal 2 2 1 0             
4 L frontal 3 3 1 0             
5 R fronto-parietal 3 2 1 0     3 3 0 1     
6 L frontal 3 3 1 0             
7 L fronto-temporal 3 3 1 0 2 3 0 0         
8 R frontal 3 3 1 1             
9 L fronto-parieto-
temporal 
0 0 0 0 1 2 0 0 1 2 0 0     
10 R frontal 2 2 0 0             
11 R parietal         3 3 2 1     




(Right [R] or Left 
[L]) and Lobe(s) 
involved 





















































































13 R parieto-occipital         1 1 0 0 2 1 0 0 
14 L parietal         1 1 0 0     
15 R frontal 1 2 0 0             
16 R frontal 0 1 0 0             
17 L fronto-temporal* 0 0 0 0 0 0 0 0         
18 L parietal         1 1 1 0     
19 R frontal 1 3 0 0             
20 R frontal 3 3 2 1             
21 L occipital             1 3 0 1 
22 R frontal 3 3 1 0             
23 L fronto-parietal 3 2 0 0     1 3 0 0     
24 L parietal         3 3 0 0     
*CAA present in left parietal and left occipital lobe
 
 
Table 32 Frequency of CAA of any severity in lobes affected and unaffected by ICH in 33 participants with first-ever lobar ICH  
Lobe CAA concordant CAA discordant 
CAA present in 
corresponding lobes 
of both hemispheres 
CAA absent in 
corresponding lobes 
of both hemispheres 
CAA 
Affected hemisphere  
Unaffected hemisphere  
CAA 
Affected hemisphere  
Unaffected hemisphere  
Frontal (n=22) 15 7 0 0 
Parietal (n=16) 9 7 0 0 
Temporal (n=6) 2 4 0 0 
Occipital (n=2) 2 0 0 0 
 
Table 33 Frequency of vasculopathy of any severity in lobes affected and unaffected by ICH in 33 participants with first-ever lobar ICH 




of both hemispheres 
Vasculopathy absent 
in corresponding 
lobes of both 
hemispheres 
Vasculopathy 
Affected hemisphere  
Unaffected hemisphere  
Vasculopathy  
Affected hemisphere  
Unaffected hemisphere  
Frontal (n=22) 10 12 0 0 
Parietal (n=16) 3 13 0 0 
Temporal (n=6) 0 5 0 1 
Occipital (n=2) 0 2 0 0 
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Table 34 Correlation between parenchymal and leptomeningeal CAA in cerebral 
hemispheres affected and unaffected by ICH in 33 participants with first-ever lobar 
ICH 
Lobe Affected hemisphere Unaffected hemisphere 
      Correlation           p value 
      Coefficient 
     Correlation           p value 
     Coefficient 
Frontal 0.85 <0.001 0.86 <0.001 
Parietal 0.85 <0.001 0.89 <0.001 
Temporal 0.85 <0.001 0.83 <0.001 






Table 35 Presence of severe CAA (parenchymal or leptomeningeal CAA of at least grade 2 or above) and vasculopathy in each lobe in 33 
participants with first-ever lobar ICH with OR (95% confidence intervals) for the odds of vasculopathy in the presence of severe CAA 
 
Lobe Hemisphere Severe CAA  
Vasculopathy  
Severe CAA  
Vasculopathy  
Severe CAA  
Vasculopathy  
Severe CAA  
Vasculopathy  
OR (95% CI) p value 
Frontal Affected 13 12 8 0 18.0 (1.9-167.0) 0.01 
Unaffected 12 13 7 1 22.3 (2.4-208.8) 0.007 
Parietal Affected 9 12 11 1 9.8 (1.1-90.6) 0.04 
Unaffected 9 13 10 1 11.7 (1.3-108.2) 0.03 
Temporal Affected 10 12 10 1 12.0 (1.3-110.5) 0.03 
Unaffected 10 12 11 0 10 (1.9-92.0) 0.04 
Occipital Affected 10 11 12 0 8.3 (0.9-76.1) 0.06 
Unaffected 10 11 12 0 8.3 (0.9-76.1) 0.06 
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Table 36 Comparison of parenchymal and leptomeningeal CAA severity in lobes with 
and without capillary CAA in 33 participants with first-ever lobar ICH 
 
Lobe Hemisphere Sum score for parenchymal and 
leptomeningeal CAA; median (IQR) 
p value 
Lobes with 
capillary CAA  
Lobes without 
capillary CAA  
Frontal Affected 6 (6-6) 3 (0-5) 0.02 
Unaffected 6 (6-6) 4 (0-5) 0.005 
Parietal Affected 6 (5-6) 3 (0-5) 0.005 
Unaffected 5 (4-6) 2 (0-5) 0.06 
Temporal Affected 6 (6-6) 3 (0-4) 0.03 
Unaffected 6 (3-6) 3 (0-5) 0.06 
Occipital Affected 6 (5-6) 3 (0-4) <0.001 
Unaffected 6 (5-6) 3 (0-5) <0.001 
 
 
Table 37 Capillary CAA and vasculopathy in each lobe in 33 participants with first-ever lobar ICH 
Lobe Hemisphere capillary CAA  
Vasculopathy  
capillary CAA  
Vasculopathy  
capillary CAA  
Vasculopathy  
capillary CAA  
Vasculopathy  
OR (95% CI) p value 
Frontal Affected 3 19 1 10 5.7 (0.5-62.2) 0.15 
Unaffected 3 19 1 10 5.7 (0.5-62.2) 0.15 
Parietal Affected 4 20 3 6 4.4 (0.8-25.7) 0.10 
Unaffected 3 20 3 7 2.9 (0.5-17.6) 0.26 
Temporal Affected 3 20 2 8 3.7 (0.5-26.8) 0.19 
Unaffected 3 21 2 7 4.5 (0.6-32.7) 0.14 
Occipital Affected 6 19 4 4 7.1 (1.4-37.6) 0.02 
Unaffected 6 20 3 4 10.0 (1.7-57.7) 0.01 
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Table 38 Baseline clinical characteristics of 33 participants with first-ever lobar ICH 
 CAA-related lobar 
ICH (n=12) 
CAA-unrelated 
lobar ICH (n=21) 
p value 
Sex (male), (%) 8 (67) 7 (33) 0.08 
Age (years); median (IQR) 80 (77-84) 82 (79-87) 0.58 
History of hypertension 







History of dementia 







History of ischaemic 
stroke 











Antiplatelet use (n, %) 











  Chapter 10 
275 
Table 39 Baseline radiological characteristics of 33 participants with first-ever lobar 
ICH 
 CAA-related lobar 
ICH(n=12) 
CAA-unrelated 
lobar ICH (n=21) 
p value 
Interval between ICH date and  








Interval between date of first 
CT scan and post-mortem 











Strictly lobar ICH (vs. mixed) 







Multiple ICH; Yes (n, %) 1(8) 1(5) 1.00 
Intraventricular haemorrhage 























ICH volume; median (IQR) 68 (29-86) 57 (35-108) 0.85 
Presence of a blood/fluid 
level within the largest ICH 










ICH with an irregular border  







Irregular or lobulated ICH with 
≥1 finger like protrusion to 







Variable density within ICH 
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Table 40 Comparison of radiological characteristics in 17 participants with strictly 
lobar ICH 
 CAA-related 
strictly lobar ICH 
(n=8) 
CAA-unrelated 



















Irregular or lobulated ICH with 
≥1 finger like protrusion to 










Variable density within ICH 
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Figure 38 Tissue section stained with haematoxylin and eosin, showing cortical 
arterioles with eosinophilic amyloid deposits within the vessel walls (arrows) 
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Figure 39 Tissue section stained with haematoxylin and eosin showing cortical 
arterioles with double barrelling, indicative of severe CAA (arrows) 
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Figure 40 Tissue section immunohistochemically stained with antibodies to amyloid-
beta showing small leptomeningeal arterioles with dense deposits of amyloid-beta 
within their walls (arrows) 
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Figure 41 Irregular or lobulated ICH  
A & B ICH has an irregular border with finger-like protrusions to the cortex 
C & D ICH has an irregular border without finger-like protrusions to the cortex 
E & F ICH has a regular border without finger-like protrusions to the cortex 
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Figure 42 Variable density within an ICH 
A,B,C Variable density with an ICH. ICH appears ‘patchy’ or ‘dilute’ 
D,E    Blood within any single ICH is of uniform attenuation on CT 
 
        
 
   
  
D E 
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Figure 43 Histogram of frequency of CAA deposition of any severity per lobe in 33 
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Figure 44 Bubble scatterplot of scores for parenchymal and leptomeningeal CAA 
(according to the Bristol rating scale) in each lobe of a) hemisphere affected by ICH  
and b) hemisphere unaffected by ICH in 33 participants with first-ever lobar ICH  























































A) Affected hemisphere 
B) Unaffected hemisphere 
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Chapter 11 Consent for brain tissue donation after intracerebral 
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11 Consent for brain tissue donation after intracerebral haemorrhage: 
a community-based study 
11.1 Introduction 
ICH is a devastating form of stroke which has an increasing incidence with age (Chapter 
3).  Given the ageing population in the UK and other developed countries [Di Carlo A. 
2009], its incidence is likely to increase.    
Despite increasing understanding of factors which contribute to ICH [Ariesen et al. 
2003], the extent of the role of CAA and its interaction, if any, with other risk factors 
such as hypertension remains unknown.  The application of the modified Boston 
criteria [Knudsen et al. 2001;Linn et al. 2010] in my community-based cohort showed 
that the ante-mortem diagnosis of CAA remains difficult (Chapter 5) and CAA can only 
be diagnosed with certainty using pathological specimens obtained at biopsy or post-
mortem examination. 
Research using brain tissue samples both in the UK and elsewhere has been hampered 
by declining post-mortem examination rates [Kretzschmar 2009] and various organ 
retention scandals.  In the UK this came to light during an inquiry into paediatric heart 
surgery in the Bristol Royal Infirmary [Kennedy 2001] when it was disclosed that organs 
had been retained as part of the diagnostic process without the knowledge or informed 
consent of relatives.  Subsequent inquiries in Liverpool [Redfern 2001] and Scotland 
[Mclean 2003] led to the formation of the Human Tissue Act (2004) [Department of 
Health 2004] and Human Tissue (Scotland) Act 2006 [Department of Health (Scotland) 
2006] which made seeking written informed consent for the retention and use of human 
tissue samples for research purposes mandatory. 
There have been 11 studies of brain donation for research which have reported the 
proportion of participants giving consent (Figure 45 on page 305).  They have either 
sought control brains or focused on neurological disorders [King, Smith, & Jobst 
1993;Stevens 1998;Kaye et al. 1999;Schmitt et al. 2001;Millar et al. 2007;Garrick et al. 
2009;Danner, Darnell, & McGuire 2011;Angelini et al. 2011;Kuhta et al. 2011;Jefferson 
et al. 2011;Harris, Kiger, & Counsell 2012].  Two were set in the UK and predated the 
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organ retention scandals [King, Smith, & Jobst 1993;Stevens 1998].  Six were studies of 
healthy ageing and dementia [King, Smith, & Jobst 1993;Stevens 1998;Kaye et al. 
1999;Schmitt et al. 2001;Danner, Darnell, & McGuire 2011;Jefferson et al. 2011], three 
involved participants with chronic neurological disorders (movement disorders [Kuhta 
et al. 2011;Harris, Kiger, & Counsell 2012] and pontine glioma [Angelini et al. 2011]) 
and two studies involved participants who had a sudden death [Millar et al. 2007;Garrick 
et al. 2009].  Consent proportions have ranged from 21-96%.   
There have been no previous studies of consent in the setting of ICH.  It is also unclear 
whether any demographic characteristics of participants or factors related to the consent 
process are associated with obtaining consent for brain donation.  Studies of organ 
donation for transplant have identified the timing of the request and whether the 
request is made ‘collaboratively’ by both the organ donation and clinical teams as being 
predictors of obtaining consent [Simpkin et al. 2009].   
In this first community-based study of brain donation for ICH, I sought to ascertain the 
proportion giving consent, whether any characteristics of participants, their ICH or the 
consent process were associated with consent and whether those approached to give 
consent, those who consented and those who eventually became brain donors were 
representative of the entire cohort of patients with ICH.  I also identified reasons cited 
by participants for consenting or not consenting to brain donation.    
11.2 Methods 
11.2.1 Proportion giving consent to brain donation for research 
I used the first complete year of the study (1st June 2010-31st May 2011) to determine 
the proportions of those with spontaneous primary ICH who were approached to 
consider brain donation, those who were not approached and of those approached, the 
proportion who consented to brain donation vs. those who did not.   
11.2.2 Comparison of adults approached vs. those not approached to consider 
brain donation 
I compared the baseline demographic and clinical characteristics of adults with ICH 
who were approached to consider donation (either directly if they had mental capacity 
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or via their nearest relative if they lacked mental capacity) vs. those who were not 
approached. 
Demographic characteristics were the sex, age, ethnicity, level of education and 
socioeconomic status (using residential postcode as a surrogate marker) of participants. 
The level of education was defined as either basic (school only) or further/higher 
education (college, apprenticeships or university).   
To assess socioeconomic status I used the Scottish Index of Multiple Deprivation 
(http://www.scotland.gov.uk/Topics/Statistics/SIMD/BackgroundMethodology; 
2012) which ranks regions by postcode from the most deprived (rank one) to the least 
deprived (rank 20).  The level of deprivation is a combination of 38 indicators across the 
following domains: income, employment, health, education, skills and training, housing, 
geographic access and crime.   
Clinical characteristics were markers of ICH severity including GCS on admission, the 
presence of intraventricular extension, ICH location (lobar vs. non-lobar), ICH volume 
calculated using Quantomo computerised planimetry software (Cybertrial Inc, Calgary, 
Canada) [Kosior et al. 2011] and mean arterial pressure (diastolic blood pressure+1/3rd 
pulse pressure) [Gauer 1960]. 
11.2.3 Comparison of those who consented to brain donation vs. those who did not 
I compared demographic and ICH characteristics (GCS on admission, intraventricular 
extension and ICH volume) in those who consented vs. those who did not.  Based on 
existing knowledge from studies of organ donation for transplantation on features of 
the consent process which may influence whether consent is obtained [Simpkin et al. 
2009], I selected a priori four variables to compare between groups: whether a member 
of the clinical team or the research team first discussed post-mortem examination, the 
interval between the date of the ICH and the date post-mortem examination was first 
discussed, the hospital the patient was admitted to and whether consent was sought 
from the patient or their nearest relative.   
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11.2.4 Comparison of those who consent to brain donation vs. the remainder of the 
cohort 
I compared demographic and clinical characteristics of those with ICH who consented 
to brain donation vs. those who did not.  The characteristics assessed were those listed 
in Section 11.2.2, page 286. 
11.2.5 Reasons cited for consenting or not consenting to brain donation 
I contemporaneously documented the discussions that I had with participants or their 
nearest relatives.  If a participant or their relative declined to give consent, I explored 
their underlying reasons using open questions.  I reviewed these conversations to 
identify the main themes which influenced participants’ decisions and noted the 
frequency of each cited theme. 
11.2.6 Comparison of donors vs. the remainder of the cohort 
 I compared demographic and ICH characteristics (GCS on admission, intraventricular 
extension and ICH volume) in donors vs. other participants to assess how 
representative donors were of the entire cohort of participants with ICH. 
11.2.7 Statistical analysis  
I calculated 95% CIs around incidence estimates using the Wilson –score interval 
[Newcombe 1998].  I used parametric statistics for between group comparisons when 
the data had a normal distribution and log –transformed variables or used non-
parametric statistics when it did not.  If an estimated cell count was less than five I used 
the Fisher’s exact test.  I conducted all statistical analyses using Stata version 11.1 
(StataCorp LP, Texas, USA).  All p values are 2-sided.  
11.3 Results 
11.3.1 Participant flowchart 
Figure 46 on page 306 illustrates the identification of adults with spontaneous primary 
ICH (who were eligible for brain donation) from 1st June 2010-31st May 2011.   
Of 141 adults, 45 (32%) were not approached, leaving 96 adults of whom 47 (49%; 95% 
CI 39-59%) consented to brain tissue donation in case of death.  The most frequent 
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reason that participants were not approached was that they had died before being 
ascertained (n=24; 53%).  10 participants (22%) were ascertained late (at least two 
months after the date of their ICH) when it was no longer considered appropriate to 
approach participants to request brain donation.  Two participants (4%) were not 
approached because the clinical team advised that their families would be too upset by a 
request for brain donation.  I did not approach one participant (2%) because although 
her family had consented to organ donation for transplant they had specified to the 
organ donation co-ordinator that they would not want samples to be taken for 
educational or research purposes.  Figure 47 on page 307 is a diagram (to scale) of the 
cohort and those who were approached to consider brain donation, those who 
consented and those who became donors. 
11.3.2  Comparison of adults approached vs. those not approached to consider 
brain donation 
Table 41 on page 299 shows the characteristics of adults approached to consider brain 
donation (n=96) vs. those not approached to consider brain donation (n=45).  Adults 
who were not approached were older than those approached but this difference was not 
statistically significant.  Other baseline demographic characteristics were similar in both 
groups.  Adults not approached had significantly lower conscious levels on admission, 
higher mean arterial pressures and larger ICHs.  Of those who died (n=86), adults who 
were not approached had a significantly shorter interval between the date of their ICH 
and death (approached: median (days) 19; IQR (days) 3-265 vs. not approached: median: 
2; IQR 1-4; p=<0.001). 
11.3.3 Comparison of adults who consent to brain donation vs. those who decline 
consent 
Table 42 on page 300 shows the patient and ICH characteristics and features of the 
consent process in those who consent to brain donation vs. those who declined to 
consent.  Although there was a higher proportion who had reached further or higher 
education in the group who gave consent, this difference was not statistically significant.  
The only characteristic of the consent process which differed between the groups was 
the site of hospital admission with the highest consent proportion noted at Western 
General Hospital, Edinburgh. 
  Chapter 11 
290 
11.3.4 Comparison of those who consented to brain donation vs. the remainder of 
the cohort 
Table 43 on page 301 shows the characteristics of those who consented to brain 
donation (n=47) vs. the remainder of the cohort (n=94). There were no significant 
differences in either demographic or clinical characteristics.  
11.3.5 Reasons cited for giving and declining consent for brain donation 
Table 44 on page 302 lists the main themes cited by participants or their nearest 
relatives when consenting to brain donation.  The median number of themes cited was 
1; (IQR 1-1).  The most frequent reason given was the potential benefit as a result of 
their donation to others with the same condition.  
Table 45 on page 303 lists the main themes cited by participants or their nearest 
relatives when not giving consent.  The median number of themes cited per person was 
1; IQR (1-1).  The most frequent reason given was that the person asked did not feel 
able to make a decision. 
11.3.6 Explanations given for consenting to brain donation 
The following qualitative extracts are taken from conversations with participants or 
relatives who consented.  They highlight themes cited in Section 11.3.5, page 290 and 
the role of personal experiences in deciding whether to consent. 
11.3.6.1 Potential benefit to others with the same condition  
Daughter-in-law of a 92 year old lady with a non-lobar ICH: ‘I have tried to 
balance the wishes of my mother-in-law who used to be a nurse with her very private 
nature…..She had been a prisoner-of-war in Russia and after that was taken to 
Czechoslovakia and I think she had very traumatic experiences.  She refused to let us or 
the nurses in the home help with personal care……I have to not think about what a 
post-mortem might involve and instead think about the potential benefit to other 
people.’ 
Wife of a 79 year old man with a lobar ICH: ‘My husband didn’t want to complete 
the NHS Donor card when he renewed his driver’s licence because he thought that he 
would be ‘shuffled off’ if he was then admitted to hospital and he was very ill – but now 
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that that has happened, we know that was wrong and he would be supportive of 
this….as long as it helps others.’ 
11.3.6.2 Potential benefit to others/perception of body as a physical shell 
Wife of a 54 year old man with a lobar ICH: ‘If you’re dead, you’re dead and your 
body may as well benefit someone else.’ 
11.3.6.3 Wish to participate in research, repay previous medical care 
Wife of a 75 year old man with a non-lobar ICH: ‘My husband would have wanted 
to participate in research and had said that if this ever happened then they ‘could have 
whatever they want.’ I have had a liver transplant and would not be here had it not been 
for advances in medical care and donations of others.’ 
11.3.7 Explanations given for not consenting to brain donation 
The following qualitative extracts are taken from conversations with nearest relatives 
who did not give consent and highlight themes cited in Section 11.3.5, page 290: 
11.3.7.1 Nearest relative unable to decide 
Sons and partner of a 60 year old man with a deep ICH: ‘I would want him to be 
able to make the decision for himself….We’ve never talked about studies…….I 
wouldn’t want him to be a guinea pig.’ 
11.3.7.2 Perceived invasiveness of brain donation 
Son of a 68 year old lady with a lobar ICH: ‘My mother has arrived in this world 
whole and should leave intact.’ 
Husband of a 81 year old lady with lobar ICH: ‘I think that she might think it was 
too invasive.  She had refused to take Aricept for dementia because the doctors said that 
she would need a permanent pacemaker and she did not want an operation.’ 
Husband of a 58 year old lady with a lobar ICH: ‘I know you say that you cannot 
tell but I am sure I could tell if she had a post-mortem. One of my relatives did and 
afterwards the shape of his nose had changed.  I think she has been through enough.’ 
  Chapter 11 
292 
11.3.7.3 Consent was incompatible with prior wishes 
Son of a 80 year old lady with a deep ICH: ‘My parents talked about this (post-
mortem) when Dad was alive because post-mortem was mentioned.  He had 
Alzheimer’s disease…but they felt that it was too intrusive.’ 
11.3.7.4 Conflict in family 
Nephew of a 82 year old man with a lobar ICH: ‘I understand why research is 
important but some of the family are saying that because X did not carry a donor card, 
he should be ‘left whole’ and the post-mortem should not be done.’ 
11.3.8 Comparison of donors vs. the rest of the cohort 
Table 46 on page 304 shows the baseline demographic and clinical characteristics of 
donors (n=24) vs. the remainder of the cohort (n=117; comprising those who were not 
approached to consider brain donation, those who did not consent and those who gave 
consent and are alive.)  Although donors tended to be older, the difference was not 
statistically significant.  Donors had a lower conscious level on admission and larger 
ICHs.  Seven donors survived for longer than three months after their ICH (date of 
ICH to death (days); mean 415; SD 240.)  In a sensitivity analysis restricted to donors 
who died within three months of their ICH the results were unchanged.  
11.4 Summary 
• During 1st June 2010-31st May 2011, of 96 adults with spontaneous primary ICH 
approached to consider brain donation, 47 (49%) consented. 
• Adults not approached to consider brain donation were likely to have more 
extensive ICHs in comparison to those approached as indicated by their lower 
conscious level on admission, larger ICH volumes and higher mean arterial 
pressures. 
• There were no significant differences in the demographic or ICH characteristics of 
those who consented vs. those who declined brain donation. 
• The proportion of adults who consented to brain donation differed by hospital site. 
• Those who consented to brain donation were similar to the remainder of the cohort 
in both their demographic and ICH characteristics. 
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• Donors were similar to non-donors in their demographic characteristics but were 
likely to have more extensive ICHs as indicated by their lower conscious levels on 
admission, larger ICH volumes and increased frequency of intraventricular 
extension of the ICH. 
11.5 Discussion 
11.5.1 Strengths of the study 
This study is the first to report the proportions consenting to brain donation for 
research purposes in a community-based cohort of participants with ICH.  Patients with 
an ante-mortem diagnosis of ICH would not routinely undergo post-mortem 
examination unless unanswered clinical questions existed regarding the cause or 
management of their ICH. 
The community-based design increases the generalisability of the findings and permits 
an evaluation of the representativeness of those who were approached to consider brain 
donation, those who consented and those who eventually became brain donors in 
comparison to the remainder of the cohort.  The study has also benefitted from clear 
definitions and unbiased and comprehensive ascertainment of exposure variables.  
Donors were well phenotyped since the clinical history was ascertained prospectively 
prior to the outcome (obtaining consent) and ICH-related variables were ascertained 
blind to the outcome.  
11.5.2 Weaknesses of the study 
The study took place in a predominantly white population in South East Scotland.  It 
was likely that the study was underpowered to detect if ethnicity influenced the decision 
to donate and I was also unable to examine the role of different cultural beliefs on 
donation.  I sought consent for brain tissue samples to be taken from the brain for 
research purposes (without retention of the entire brain.)   Although there is some 
evidence that participants may be more likely to consent to retention of tissue samples 
rather than their brain [Millar et al. 2007], I was unable to explore this in our cohort.  
However, sampling of brain tissue is in any case likely to be preferable to whole brain 
retention since it avoids the tissue degradation associated with repeated freeze-thaw 
cycles [Monoranu et al. 2009]. 
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I did not explore any demographic or cultural factors pertaining to nearest relatives 
although these may influence participants’ perceptions of brain donation.  In addition, 
the study was largely quantitative in nature and studying the influence of cultural and 
spiritual beliefs and personal experience on donation is likely to be more suited to 
qualitative methodologies.  
11.5.3 Comparison with other studies 
11.5.3.1 Proportion consenting to brain donation for research purposes 
49% participants consented to a research post-mortem examination limited to the brain.  
The consent proportion in my cohort is comparable to other studies of brain donation 
in different settings (Figure 45 on page 305).   
Two studies; one in participants with dementia [King, Smith, & Jobst 1993] and the 
other in the setting of sudden death [Millar et al. 2007], reported significantly higher 
consent proportions of >95%.  The study of participants with dementia [King, Smith, & 
Jobst 1993] predated the much publicised organ retention scandals which led to a 
cultural shift in attitudes to organ retention for educational and research purposes and 
may have contributed to a decline in post-mortem examination rates [Burton & 
Underwood 2003].  In the setting of sudden death [Millar et al. 2007], nearest relatives 
may be more able to envisage consenting to additional brain tissue samples being taken 
for research when a fiscal post-mortem examination will already be required.  
11.5.3.2 Comparison of characteristics of participants approached vs. those not 
approached 
Adults who were not approached to consider brain donation had more extensive ICH 
and a shorter time interval between the ICH and death, which is consistent with the 
most frequent reason for a lack of approach being death before ascertainment.  
Nevertheless, adults who consented to post-mortem examination were similar in both 
demographic and ICH characteristics to those who either declined consent or were not 
approached (Table 41 on page 299 and Table 42 on page 300) and were therefore 
representative of the cohort.  Other studies have been hospital-based [Angelini et al. 
2011;Kuhta et al. 2011] or used previously established research registries [King, Smith, 
& Jobst 1993;Stevens 1998;Kaye et al. 1999;Schmitt et al. 2001;Danner, Darnell, & 
McGuire 2011;Jefferson et al. 2011] and none have reported whether the characteristics 
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of participants who were approached differed from others, making their findings 
potentially vulnerable to selection bias. 
11.5.3.3 Comparison of adults who consent to brain donation vs. those who do not   
There was no difference in demographic characteristics between adults who consented 
and those who declined donation.  There was a non-significant excess of adults who 
reached further or higher education in the group who consented and the study may have 
lacked sufficient power to detect a difference if one does exist.  Although other studies 
of brain donation have been heterogeneous both in terms of their settings and donor 
populations, they have similarly not shown any influence of donor sex [Stevens 
1998;Garrick et al. 2009;Kuhta et al. 2011;Jefferson et al. 2011], age [Stevens 
1998;Garrick et al. 2009;Jefferson et al. 2011], level of education [Stevens 1998;Jefferson 
et al. 2011] or socioeconomic status [Stevens 1998] on the decision to consent.  
There was no difference between groups regarding the person making the approach or 
the timing of it.  Since a joint approach by the clinical and research teams was rare in 
this cohort, it may be that there was insufficient power to demonstrate a difference.  
One other study of sudden death found that the longer the interval between death and 
the request for brain donation, the more likely that consent would be given [Garrick et 
al. 2009].  A systematic review of studies of organ donation for transplant identified that 
the timing of the approach, in particular separation of the request from the notification 
of brainstem death influenced consent [Simpkin et al. 2009].  Although the timing of the 
approach may influence the likelihood of consent, this might interact with other factors 
which are difficult to measure quantitatively such as the expertise of the person making 
the request, their interpersonal skills and the donor’s perceived satisfaction with clinical 
care [Simpkin et al. 2009].       
Interestingly the only potentially modifiable feature of the consent process which 
differed between groups was the admitting hospital.  The consent proportion was 
highest at the Western General Hospital.  The research team was based at this hospital 
and one possible explanation is that this allowed closer liaison with the clinical team to 
optimise the timing of any approach.   
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11.5.3.4 Reasons for brain donation 
These findings are in keeping with other studies in which donors have commonly 
reported altruistic motivations including a desire to help others [King, Smith, & Jobst 
1993;Stevens 1998;Garrick et al. 2009;Danner, Darnell, & McGuire 2011;Kuhta et al. 
2011;Harris, Kiger, & Counsell 2012] or support research [Stevens 1998;Millar et al. 
2007;Danner, Darnell, & McGuire 2011;Angelini et al. 2011;Jefferson et al. 2011] or 
express gratitude for medical care received [Stevens 1998;Garrick et al. 2009;Kuhta et al. 
2011].  The perception of the body as a mere physical shell has also been reported by 
relatives of donors with dementia who, observing the donor’s gradual deterioration, 
perceived a dualistic separation of the donor’s mind and body which encouraged them 
to authorise donation as they viewed the body at the time of death as bearing no 
resemblance to the relative they knew [King, Smith, & Jobst 1993].   
11.5.3.5 Reasons for not consenting to brain donation 
The most frequently cited reason for not giving consent in this cohort was that donors 
or their nearest relatives felt unable to make a decision, which was related in part to the 
distress caused by a diagnosis of ICH and a lack of clarity regarding what the donor’s 
wishes would have been.  This has not been cited in other studies of brain donation 
which have predominantly been conducted in either healthy participants or those with 
chronic neurological diseases where the decision regarding brain donation does not 
usually have to be made rapidly or unexpectedly.  Other reasons cited by our cohort are 
in keeping with previous studies of donation for research and transplantation which 
have identified previously expressed donor wishes [Barber et al. 2006], the perceived 
invasiveness of the procedure [Angelini et al. 2011;Jefferson et al. 2011], conflict within 
the family [Stevens 1998;Schmitt et al. 2001;Millar et al. 2007;Garrick et al. 2009] 
spiritual beliefs [Stevens 1998;Angelini et al. 2011;Kuhta et al. 2011;Jefferson et al. 2011] 
and unmet clinical expectations [Austrom et al. 2011] as barriers to donation. 
11.5.3.6 Comparison of donors vs. the remainder of the cohort 
Donors had more extensive ICH in comparison to the remainder of the cohort.  This is 
unsurprising since although those who consented are similar in both demographic and 
ICH characteristics to those who did not, those with less severe ICH will survive and 
would therefore only become donors over several years.  Other studies have not 
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compared the characteristics of those who actually donated brain tissue to the remainder 
of the sample.  Although donors are therefore not representative of the entire cohort in 
terms of ICH severity, since ICH carries an early case fatality (Chapter 7), they are likely 
to be representative of those who die early and for whom any advances have most 
benefit.   
11.5.4 Meaning of study 
A major dilemma continues to be how to increase the number of brains donated for 
research.  This is acknowledged as a priority by the UK Medical Research Council which 
in 2009 set up the UK Brain Banks Network with the aim of connecting the UK’s 12 
brain banks to provide samples for researchers and tackle the shortage of brains 
donated for research [Medical Research Council 2009].  This study demonstrates the 
feasibility of seeking consent for brain donation in ICH, a condition which affects 
10000 adults per year in the UK [Lovelock, Molyneux, & Rothwell 2007].   
Although reasons for refusing consent which were likely irreversible predominated in 
our cohort, potentially modifiable reasons included not knowing what the participant’s 
wishes would have been and dissatisfaction with medical care.  Conversely, being a 
registered organ donor has been associated with consent in other studies [Glaw et al. 
2009;Sundqvist, Garrick, & Harding 2010] since brain donation was viewed as being 
consistent with previously expressed wishes.  It is essential to increase public awareness 
of organ donation for transplant and research with the aim of empowering people to 
reach their own decisions and communicate this to relatives when they still have the 
mental capacity to do so [Sanner 2006].   
The lack of association between demographic characteristics and consent in this and 
other studies suggests that deciding whether to consent may be related to personal 
beliefs and unquantifiable aspects of the consent process.  Researchers or clinicians 
should avoid presuming on the basis of demographic variables that either consent will 
not be obtained or asking will cause upset [Burton & Underwood 2007;Medical 
Research Council 2009].  
11.5.5 Future directions 
Future studies should examine brain donation in different populations for other 
neurological diseases.  Qualitative studies should explore the influence of personal 
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beliefs and experiences on the decision to consent.  It would be useful to evaluate 
nearest relatives experiences of the consent and donation process to assess whether 
their expectations were met, whether they had any regrets regarding donation and any 
improvements that could be made.  
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Table 41 Baseline characteristics of adults with spontaneous ICH approached and not 











Sex male, (%) 45 (47) 20 (44) 0.79 
Age (years); mean (SD) 73 (14) 77 (13) 0.18 
Ethnicity non-white, (%) 3 (3) 1 (2) 0.76 
Socio-economic status  
(postcode rank) 12 (7-18) 11 (6-16) 0.31 
















Lobar ICH location  49 (51) 24 (53) 0.80 
Intraventricular extension^ 46 (48) 25 (56) 0.23 
ICH volume^ (ml); median (IQR) 20 (6-41) 36 (12-69) 0.04 
*missing in five cases; three of whom were not admitted to hospital 
**missing in 13 cases 
^not applicable in four cases in which the diagnosis was confirmed at post-mortem 
examination 
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Table 42 Demographic and clinical variables and characteristics of the consent 
process in adults who give consent to brain tissue donation and those who decline 
donation 








Non-modifiable patient characteristics  
Sex male, (%) 26 (55) 19 (39) 0.10 
Age (years); mean (SD) 73 (13) 73 (14) 0.96 
Ethnicity non-white, (%) 1 (2) 2 (4) 0.58 
Socio-economic status 
(postcode rank) 13 (6-19) 11 (7-16) 0.25 
Donor education*;  







Non-modifiable ICH characteristics  










Yes (n, %) 24 (51) 22 (45) 0.48 
ICH volume** (ml);median (IQR) 21 (6-45) 15 (6-39) 0.25 
Modifiable characteristics of the consent process  
Approached by clinical team and 







Interval between date of ICH and 









Western General hospital 
Royal Infirmary  

























*missing in two cases 
** not applicable in 1 case of ICH which was diagnosed at post-mortem examination 
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Table 43 Demographic and clinical characteristics in those who consented to brain 










Sex male, (%) 26 (55) 39 (41) 0.12 
Age (years); mean (SD) 73 (13) 75 (14) 0.55 
Ethnicity non-white, (%) 1 (2) 3 (6) 1.00 
Socio-economic status  
(postcode rank) 13 (6-19) 11 (6-16) 0.14 
















Lobar ICH location  27 (57) 46 (49) 0.34 
Intraventricular extension^ 24 (51) 47 (50) 0.94 
ICH volume^ (ml);median (IQR) 21 (6-46) 21 (7-50) 0.99 
*missing in five cases; three of whom were not admitted to hospital 
**missing in 13 cases 
^not applicable in four cases in which the diagnosis was confirmed at post-mortem 
examination 
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Table 44 Reasons given for consent to brain donation 
Reasons given for donation (most common first) Frequency  
Potential benefit to others with the same condition 21 
Wished to participate in a research study 18 
Perception of body as merely a physical shell  6 
Offer an explanation for the intracerebral haemorrhage 5 
Consistent with prior wish to donate body to medical science 2 
Wish to repay medical care provided 2 
No objection to research post-mortem examination  2 
Potential benefit to patient from participation in a research 
study 
1 
No reason given 1 
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Table 45 Reasons given for not consenting to brain donation 
Reasons given for refusal to consent  Frequency 
Nearest relative unable to decide 
- too upset by diagnosis of intracerebral haemorrhage 
- Did not know what the potential donor’s wishes would be 





Did not wish to be involved in a research study 8 
Consent was incompatible with previously expressed wishes 8 
Brain donation is ‘too invasive’ or ‘not something they wished to put 
their next-of-kin through’ 
4 
Conflict in family regarding post-mortem examination decision 5 
Dislike the idea of brain tissue donation  4 
Consent was incompatible with spiritual or religious beliefs 3 
Dissatisfaction with medical care 1 
Dissatisfaction with previous discussion regarding organ donation 1 
No reason given 6 
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Table 46 Demographic and clinical variables in donors and non-donors 
 
* missing in five cases, three of whom were not admitted to hospital 
**missing in four cases which were diagnosed at post-mortem examination  
 Donors (n=24) Non-donors (n=117) p value 
Sex (male), (%) 14 (58) 51 (44) 0.19 
Age (years); mean (SD) 78 (10) 73 (14) 0.10 
Ethnicity (non-white); (%) 0 (0) 4 (3) 0.47 
Socio-economic status 
(postcode rank) 12 (5-19) 12 (7-17) 0.95 
GCS on admission* 
median (IQR) 12 (9-13) 14 (9-15) 0.07 
Intraventricular 
extension**; n (%) 16 (70) 55 (48) 0.06 
ICH volume**   
median (IQR) 36 (22-85) 17 (5-48) 0.002 
 
 
Figure 45 Proportions of participants giving consent (and 95% confidence intervals) in studies of brain donation for research with donor 
characteristics and mode of approach (n=number of people giving consent to brain donation, N=sample size) 
  
0 20 40 60 80 100
Consent proportion (%)
Millar (2007) Nurse phone callControls, CNS disorders, UK 107/111 1-89
Garrick (2009) Nurse phone callControls, CNS disorders, Aus. 107/20018-85





Jefferson (2011) ?Alzheimer disease registry, USA 296/46476
Kuhta (2011) QuestionnaireMovement disorders, USA 114/20366
Stevens (1998) LetterMRC CFAS participants, UK 193/59467-100
Kaye (1999) ConsultationHealthy adults, Oregon, USA 65/14065-102
Schmitt (2001) LetterHealthy adults, USA 186/870>60
Angelini (2011) ConsultationPontine glioma, Canada 10/210-16.9
 Neurological disorders
Healthy ageing & dementia
Harris (2012)          ?Parkinson's disease, UK 14/40?
King (1993) ConsultationAlzheimer's disease study, UK 250/260?
Danner (2011) InterviewHealthy Africa-Americans, USA 13/25≥65
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Figure 46 Flowchart of participants with spontaneous primary ICH eligible to 




 May 2011 
First-ever spontaneous 
primary  ICH, eligible for brain 
tissue donation (n=141) 
Approached to consider brain 
tissue donation (n=96) 
Not approached (n=45) 
Patient died before ascertainment (n=24) 
Late ascertainment (n=10) 
No pathologist available for post mortem (n=6) 
No next-of-kin (n=2) 
Clinical team did not think it appropriate to 
discuss (n=2) 
Consent unlikely to be obtained (n=1) 
Did not give consent for 
brain donation (n=49) 
Gave consent for brain 
tissue donation (n=47) 
Did not 
consent to any 
research  
(n=32) 
Consented to other 
parts of research 
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12 Conclusions 
12.1 Main findings of thesis 
12.1.1 Methods of a prospective community-based study of ICH 
• I have set up a community-based, prospective incidence and longitudinal cohort 
study of spontaneous primary ICH which uses multiple sources of case 
ascertainment and follow-up. 
• The study includes adults aged 16 years or over at the time of their ICH, resident in 
the region served by the NHS Lothian Health board and diagnosed between 1st June 
2010-1st June 2016. 
• I confirmed the diagnosis of ICH by review of diagnostic imaging or post-mortem 
examination reports. 
• I ascertained cases of suspected ICH in which the history was suggestive of ICH but 
the diagnosis of ICH was unconfirmed before or after death.  
12.1.2 Methods of a cross-sectional study of MRI brain imaging features in lobar vs. 
non-lobar ICH 
• Inter-observer agreement when rating WMH, EPVS and atrophy on both the 
training scans and LINCHPIN MRI scans predominantly ranged from fair to 
moderate. 
• Inter-observer agreement when rating the presence of zero vs. ≥ one BMB on 
LINCHPIN MRI scans was similar to the inter-observer agreement achieved for 
training scans and ranged from moderate to substantial. 
12.1.3 Methods of a cross-sectional study of apolipoprotein E genotypes in lobar 
vs.non-lobar ICH 
• The genotyping process for apolipoprotein E fulfilled pre-specified quality control 
measures. 
• The genotype frequencies for SNPs rs429358 and rs7412 conformed to Hardy-
Weinberg equilibrium. 
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• There was no difference in the proportion of participants with an undetermined 
genotype between the lobar and non-lobar ICH groups. 
12.1.4 Results of a community-based, cross-sectional study of ICH-incidence and 
baseline characteristics 
• During 1st June 2010-31st May 2011 the crude incidence of spontaneous definite 
ICH was 0.24 per 1000 per year (95% CI 0.21 to 0.27) and the incidence of first-
ever spontaneous primary definite ICH was 0.18 per 1000 per year (95% CI 0.16 to 
0.22) and did not vary by ICH location. 
• Lobar ICHs were more likely to have a past history of dementia in comparison to 
non-lobar ICH, but there were no other differences in pre-ICH characteristics 
between lobar and non-lobar ICH. 
• Lobar ICHs were associated with a lower GCS score on admission.  
• Lobar ICHs were larger and associated with extension of the ICH into the 
subarachnoid and subdural compartments of the brain. 
• 12 out of 59 participants with first-ever lobar ICH eligible to be considered under 
the modified Boston criteria, fulfilled the criteria for definite or probable CAA-
related ICH. 
12.1.5 A cross-sectional study of MRI features in adults with lobar vs. non-lobar ICH 
• The proportion of participants with one or more non-lobar BMB was significantly 
higher in participants with non-lobar ICH.   
• There was no difference in the severity or distribution of lobar BMBs, WMH, EPVS 
and atrophy between lobar and non-lobar ICH. 
12.1.6 Results of a community-based study of ICH-death, prognosis and survival 
outcomes 
• Case fatality at one month was 43% and at one year was 56%. 
• Lobar ICH was independently associated with a lower odds of death in the first year 
after first-ever spontaneous primary ICH after adjusting for other covariates. 
• The ICH score discriminated well between those who survived and died in the first 
30 days following a first-ever spontaneous primary ICH. 
• There was a higher risk of recurrent ICH in the lobar ICH group. 
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• There was no difference in the risk of vaso-occlusive events observed in the lobar 
and non-lobar ICH groups. 
• Regardless of ICH location, there was a non-significant excess of vaso-occlusive 
events in comparison to recurrent ICH in the first year. 
12.1.7 A cross-sectional study of apolipoprotein E genotypes in lobar vs. non-lobar 
ICH 
• The ε4 allele was significantly more common in participants with lobar ICH in 
comparison to those with non-lobar ICH. 
• There was no difference in the frequency of the ε2 allele between those with lobar 
and non-lobar ICH. 
• The ε4 allele was more frequent in those participants with probable or definite 
CAA-related ICH in comparison to those with possible CAA-related ICH according 
to the modified Boston criteria for CAA but the difference was not significant. 
• The presence of at least one ε2 allele or ε4 allele was not associated with death in 
the first 30 days following a first-ever ICH or death or dependency at one year. 
12.1.8 The association between cerebral amyloid angiopathy and intracerebral 
haemorrhage-systematic review and meta-analysis 
• In a systematic review and meta-analysis of ten neuropathological cross-sectional or 
case-control studies involving 481 cases and 3,219 controls, I found a significant 
association between CAA and lobar ICH, but not with ICH in other locations. 
• There was wide variation in the methodological quality of included studies. 
• Strategies for both brain sampling and CAA detection varied between studies. 
12.1.9 A cross-sectional study of imaging and pathology findings in adults with lobar 
ICH 
• Of 33 participants with first-ever lobar ICH, nine participants (27%) did not have 
any CAA in their cerebral hemispheres. 
• The presence of CAA or vasculopathy and the severity of CAA in a lobe affected by 
ICH was concordant with that of the corresponding contralateral unaffected lobe. 
• The severity of parenchymal CAA was positively correlated with leptomeningeal 
CAA in all lobes of the brain, whether affected or unaffected by ICH. 
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• Severe CAA was associated with vasculopathy. 
• Capillary CAA was associated with more severe CAA in the same lobe, whether 
affected or unaffected by ICH. 
• Capillary CAA was associated with vasculopathy in the occipital lobes of both 
hemispheres but not in the other lobes of the brain. 
• The total CAA score was not associated with participant age or a prior history of 
dementia. 
• No imaging variables were statistically significantly associated with CAA-related 
lobar ICH. 
• Subarachnoid extension tended to be more frequent in those with CAA-related 
strictly lobar ICH vs. CAA-unrelated strictly lobar ICH, with a sensitivity of 100% 
and specificity of 44% for pathologically –proven CAA-related strictly lobar ICH. 
12.1.10 Consent for brain tissue donation after ICH-a community-based study 
• During 1st June 2010-31st May 2011, of 96 adults with spontaneous primary ICH 
approached to consider brain donation, 47 (49%) consented. 
• Adults not approached to consider brain donation were likely to have more 
extensive ICHs in comparison to those approached as indicated by their lower 
conscious level on admission, larger ICH volumes and higher mean arterial 
pressures. 
• There were no significant differences in the demographic or ICH characteristics of 
those who consented vs. those who declined brain donation. 
• The proportion of adults who consented to brain donation differed by hospital site. 
• Those who consented to brain donation were similar to the remainder of the cohort 
in both their demographic and ICH characteristics. 
• Donors were similar to non-donors in their demographic characteristics but were 
likely to have more extensive ICHs as indicated by their lower conscious levels on 
admission, larger ICH volumes and increased frequency of intraventricular 
extension of the ICH. 
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12.2 Implications for routine practice 
The incidence estimates of first-ever spontaneous primary definite ICH provide 
confirmation that ICH incidence increases with age which is of significance when 
planning healthcare provision for an ageing population. 
My first-ever validation of the ICH score in a community-based study shows that the 
ICH score discriminates well between those who survive and those who do not in the 
first 30 days following an ICH, providing clinicians with valuable prognostic 
information. 
Since adults with lobar ICH have a lower odds of death at one year despite larger ICHs 
but are also at higher risk of ICH recurrence in comparison to those with non-lobar 
ICH, secondary prevention with antihypertensive medications is of particular relevance 
to this patient group.  Following an ICH, survivors are at risk of both recurrent ICH 
and vaso-occlusive events underlining the need for randomised controlled trials to 
resolve the uncertainty about whether to restart antithrombotic medications after ICH. 
My systematic review of neuropathological case control studies of CAA and ICH 
confirmed an association between CAA and lobar ICH but the association was not as 
strong as one might expect if CAA was the sole cause of lobar ICH.  This was 
supported by the radio-pathological study of lobar ICH, in which 27% of adults with 
lobar ICH did not have any evidence of CAA in their cerebral hemispheres.  Clinicians 
should be aware that other factors, such as arteriolosclerosis may contribute to lobar 
ICH.   
The study of consent for research post-mortem examination indicates that adults with 
ICH and their relatives are willing to consider consenting to brain donation if this is 
discussed sensitively giving families sufficient time for questions and concerns to be 
explored.  Although I was seeking consent for a post-mortem examination for research 
purposes which was limited to the brain only, the findings may be applicable to 
clinicians seeking consent for post-mortem examination to ascertain the cause of a 
patient’s death.  
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12.3 Implications for future research 
12.3.1 Epidemiology 
Population-based studies of follow-up after ICH are scarce [Poon, Fonville, & Al-Shahi 
Salman 2013].  One future aim would be to quantify follow-up outcomes (both vaso-
occlusive events and recurrent ICH) after first-ever spontaneous ICH, stratified by ICH 
location, to confirm a) whether the risk of recurrent ICH is higher in the lobar ICH 
group, b) whether the risk of recurrent ICH varies over time and c) whether the risks of 
vaso-occlusive events and recurrent ICH remain similar in both lobar and non-lobar 
ICH.  It would be of interest to explore whether levels of certain biomarkers such as 
copeptin [Yu et al. 2014] or plasma Aβ [Marti-Fabregas et al. 2014] can help to predict 
prognosis.     
There has only been one population-based study of long term prognosis after ICH 
which followed up 172 adults surviving at least one year after ICH onset for 13 years 
and did not report any differential effect of ICH location on survival [Hansen et al. 
2013].  A long term follow up study should provide further information regarding both 
functional outcome and survival, explore whether any baseline factors affect long term 
survival after ICH and whether survival varies over time. 
12.3.2 Imaging 
Studies of ICH require a consistent definition of ICH location.  The two previous 
studies of inter-rater reliability of ICH location classified <100 supratentorial ICHs as 
either lobar or deep without a category for ‘mixed’ ICH [Wermer et al. 2002;Battathiri et 
al. 2003] although some ICHs will inevitably involve both lobar and deep regions.  It 
would be important to examine inter-rater reliability on a larger sample, rating 
supratentorial ICH as lobar, deep or mixed and using a variety of raters with different 
levels of radiology experience.   
Given the limited number of radiopathological studies of BMBs, a future study would 
aim to correlate microbleeds seen on MRI with their pathological appearances.  To 
overcome the logistical difficulties of either stroke patients being too unwell to have an 
MRI brain or a long time interval between those able to have MRI brain and death, 
post-mortem MRI might be used.  
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Centrum semiovale EPVS may be a marker of CAA [Charidimou et al. 2013c].  A future 
study might confirm this association using a larger sample of participants with CAA-
related ICH vs. ICH unrelated to CAA, potentially using Pittsburgh compound B 
positron emission tomography for in vivo detection of CAA [Park et al. 2013]. 
12.3.3 Genetics 
The apolipoprotein ε4 allele is associated with microbleeds in a lobar distribution both 
in the general population and persons with dementia [Schilling et al. 2013;Loehrer et al. 
2014].  Possession of two ε4 alleles is associated with increasing WMH burden in 
demented and non-demented individuals [Godin et al. 2009;Schilling et al. 2013].  The 
presence and strength of an association between apolipoprotein E and WMH in persons 
with ICH is yet to be determined.   
Future genetic studies might explore the relationship between apolipoprotein E and 
both WMH and EPVS to determine whether the spatial distribution varies according to 
genotype and therefore whether these neuroimaging correlates might be imaging 
markers of CAA.  
12.3.4 Pathology 
One of the initial aims of my PhD was to conduct a pathological case control study of 
CAA and ICH.  Unfortunately, this did not happen because it was not possible to rate 
control brains.  Although disappointing, this is one of the aims which I still intend to 
fulfil which would provide information regarding the strength of the association 
between CAA and lobar ICH, confirm that the association which I noted in my 
systematic review (Chapter 9) is consistent and assess whether there is a dose-response 
gradient; for example, whether individuals with multiple or recurrent ICHs have more 
severe CAA.  The paucity of pathological case control studies means that data regarding 
the presence and strength of any association between CAA and supratentorial deep or 
cerebellar ICH is also yet to be determined.  This is relevant since cerebellar ICH is 
permitted in the category of ‘probable CAA’ (without supporting pathology) in the 
Boston criteria for the diagnosis of CAA-related ICH[Knudsen et al. 2001].  Since 
cerebellar ICH is infrequent (10 (7%) in my cohort of first-ever ICH), a multicentre 
approach would be ideal.  However, other groups examining CAA, such as Boston, have 
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reported different sampling and rating methods making it more difficult to combine 
their samples with our cohort.  
The role of other small vessel diseases in ICH is yet to be explored.  The commonly 
accepted hypothesis is that CAA is implicated in lobar ICH and arteriolosclerosis in 
non-lobar ICH although since both lobar and non-lobar ICH share common risk 
factors such as hypertension (Chapter 5) and the recurrence risk of both is reduced with 
secondary prevention with antihypertensive medications [Arima et al. 2010], this 
division may be too simplistic. 
I would aim to examine the severity of arteriolosclerosis in persons with lobar and non-
lobar ICH vs. age-matched controls to determine whether the strength of the 
association differs according to ICH location.  Any association between 
arteriolosclerosis and ICH might be stronger in those with non-lobar ICH given the 
purported role of hypertension in supratentorial deep ICH.  Since CAA is thought to 
result from age-related stiffening of arterial walls leading to decreased propulsion of 
solutes along perivascular lymphatic pathways and a consequent failure of Aβ 
elimination from the brain [Weller et al. 2009b], it would be of interest to determine if 
the severity of arteriolosclerosis and CAA are correlated in persons with ICH and 
whether arteriolosclerosis might modify the strength of the association between CAA 
and lobar ICH. 
As alluded to in Chapter 10, little is known about the nature of dementia in persons 
with ICH.  A future study should examine the prevalence of pre-ICH cognitive 
impairment and dementia in persons with ICH and correlate pre-ICH dementia status 
with neuropathology at post-mortem examination including the presence of neuritic 
plaques, neurofibrillary tangles, Lewy bodies, multiple infarcts and hippocampal atrophy 
[Matthews et al. 2009].  Comparison of neuropathological substrates by lobar and non-
lobar ICH location, may shed light on the causes of pre-stroke dementia in ICH and the 
vasculopathies underlying lobar and non-lobar ICH. 
The eventual aim would be to develop clinical trials for potential treatments for CAA.  
Interventions might reduce Aβ production or enhance Aβ clearance.  A phase 2 trial for 
an anti-Aβ monoclonal antibody (Ponezumab) has begun (Study Evaluating the Safety, 
Tolerability and Efficacy of PF-04360365 in Adults with Probable Cerebral Amyloid 
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Angiopathy, NCT01821118) but no phase 3 trials have been conducted as yet.  Further 
knowledge about the contribution of different vasculopathies to ICH will allow 
potential interventions to be targeted more appropriately at subgroups of ICH 
survivors.
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Appendix of study materials 
 
Proformas 
1. LATCH proforma 
2. LINCHPIN scan reading form (MRI proforma) 
 
Patient information leaflets 
3. LATCH patient information leaflet 
4. LINCHPIN patient information leaflet 
5. LINCHPIN patient information leaflet (adults with incapacity) 
6. LINCHPIN patient information leaflet for relatives of people who have died from 
suspected intracerebral haemorrhage 
Consent forms 
7. LINCHPIN consent form-general 
8. LINCHPIN consent form-MRI 
9. LINCHPIN consent form-post-mortem examination 
10. LINCHPIN consent form-general (adults with incapacity) 
11. LINCHPIN consent form-MRI (adults with incapacity) 
12. LINCHPIN consent form-post-mortem examination (adults with incapacity) 
13. NHS Lothian post-mortem examination authorisation form 
 
Annual questionnaire 
14. LATCH annual questionnaire 
 
Sampling protocol 
15. LINCHPIN sampling protocol for brain tissue  
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Patient name: ……………………………………………Patient ID:        
 
LATCH       
Seen by BHT Yes: Leaflet given  Yes:  No leaflet given  No: not seen  Leaflet posted     
         Done?  Entered? 
Scan reviewed at Wednesday stroke imaging meeting      
Case reviewed with Rustam         
 
LINCHPIN   DD        /  M   M  / YYYY   Done?  Entered? 
Verbal consent given    /   /       
Clinical consent    /   /       
IQCODE consent    /   /       
Records consent    /   /       
Blood consent    /   /       
Blood taken?           
MRI consent    /   /       
MRI brain requested          
MRI completed           
Patient & GP informed of MRI result        
LP consent           
LP completed           
LINCHPIN consent letter sent         
Newsletter wanted?          
 
Autopsy consent     /   /       
Biopsy consent           
Donor card given to patient         
PM alert letter & donor card sent to GP        
Placement aware of PM consent and has forms?       
 
If the patient dies…        
Timescale for funeral: …………………………………………………………………………………………………………………………………….. 
Details of undertaker to be used: …………………………………………………………………………………………………………………… 
Clinical autopsy report received         
LINCHPIN autopsy report received         
Do NOK want PM results?  Yes  /  No      
Who should be informed (check NOK details)?.......................      
Inform by letter/phone?          
NOK informed of PM result         
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LATCH ID              LATCH opt out : dd/mm/yyyy 
Personal Information
Phone (H): Phone (Mob): Email: 
 






Phone (H): Phone (Mob): Email: 
 
GP details 
Name: Practice name: 
Address:  
 Postcode: 
Phone (H): Phone (Mob): Email: 
                                                 
i
 Mr, Mrs, Miss, Ms, Dr, Prof,  Lord, Lady, Sir,Dame, Reverend 
ii
 Bahai, Brahma Kumaris, Buddhism, Chinese, Christianity, Hinduism, Humanism, Islam, Jehovah’s witness, Judaism, Mormon, Paganism, Sikhism, 
Other 
iii
 Asian or asian british: Indian, Asian or asian british:Bangladeshi, Asian or asian british: Pakistani, Asian or asian british:Chinese, Asian or asian 




sister/cousin/friend/ Welfare guardian/legal representative/Other 
Title
i
: Forename: Surname: 
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Notification    
Source ✓ as appropriate 
Collaborator List collaborator names 
ISD  
SSCA  
CT search  
TRAK search  
NXR  
Autopsy report  
 
Is this patient excluded from LATCH?   Yes                          No  
 
If Yes: Reason for exclusion -   HTI         Intraventricular haemorrhage               Postcode 
Other non-ICH diagnosis      ICH without pathology/imaging  Trauma  
 
Has LINCHPIN been discussed?  Yes    No  
 
If No, give reason LINCHPIN not discussed: 
 
No next of kin found    Team did not think it was appropriate to discuss  
 
Consent unlikely to be obtained
v








Unable to do PM if consented            Secondary ICH 
 
Consented to any/all of LINCHPIN Yes      No   
(Document consent discussion on page 15) 
 




                                                 
v
 Clinical team did not advise against discussing LINCHPIN but BHT judged LINCHPIN inadvisable – e.g. patient failed to engage with clinical care. 
vi
 Late ascertainment – patient ascertained at least 3 months after date of ICH 
vii
 Patient ascertained whilst still alive but died before LINCHPIN discussed 
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viii
 If date & month unknown, insert mid-point of year (01/07/yy), Chronic kidney disease – should be stage 2 or above to be documented as Chronic 
renal failure 
Appendix 1: LATCH proforma 




Past medical history – ICH related 
1. History of ischaemic events?ix   
IF NO, GO TO QUESTION 
2 
a. Angina  
 
  
b. Myocardial Infarction  
 
  
c. Heart failure  
 
  
d. Diabetes mellitus  
 
  
e. Hyperlipidaemia  
 
  
f. Peripheral vascular disease  
 
  
g. Transient ischaemic attack  
 
  
h. Ischaemic Stroke  
 
  
i. Deep vein thrombosis  
 
  
j. Pulmonary embolus  
 
  
k. Atrial fibrillation  
 
  
     
2 History of hypertension?x  
 
 IF YES, YEAR OF DIAGNOSIS ? 
     
3 History of haemorrhagic events?xi   IF NO, GO TO QUESTION 
4 
                                                 
ix
 Any ischaemic event listed in 1a-1k, diagnosis made prior to admission with index ICH, recorded in GP or hospital notes (or for Diabetes mellitus, or hyperlipidaemia  
only, where a patient has been prescribed treatment commonly used for this indication) For heart failure,  a diagnosis of heart failure made prior to admission or clinical 
evidence from echocardiography. For atrial fibrillation, a diagnosis made prior to admission with index ICH or a previous ECG showing atrial fibrillation. 
x
 Diagnosis made prior to admission with index ICH recorded in GP or hospital notes or where a patient has been prescribed drugs used in the treatment of hypertension.  
xi
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4 History of Migraine?  
 
 IF NO, GO TO QUESTION 
5 
4a Type of migraine? (✓as appropriate)   COMMENTS 
 aura    
 no aura    
 acephalgic    
 Retinal    
 unknown    








     
6 History of dementia?  
 
 IF NO, GO TO QUESTION 
6 
6a Type of dementia? (✓as appropriate)   COMMENTS 
 Alzheimer’s disease    
 vascular    
 Mixed Alzheimer’s disease & vascular    
 Lewy-Body disease    
 Frontotemporal    
 Other (no formal dx, suspected by relatives)     
 Not specified (demented but type unknown)    
 Unknown    
6b Year of dementia diagnosis    
     








   
                                                 
xii
 Recurrent nosebleeds, bleeding following dental extraction, easy bruising, liver disease, abnormal premenopausal bleeding, post menopausal bleeding, idiopathic 
thrombocytopaenia purpura, thrombocytopaenia-other, haemophilia, other haematological disorder (excluding ICH) 
xiii
 Diagnosis made prior to admission with index ICH recorded in GP or hospital notes, Epilepsy types : Focal, generalised, unknown 
xiv
 confusion, decreased conscious level Sensory, hemiparesis/plegia, myoclonus, dysphasia, hemianopia, other visual disturbance, confusion, ataxia, chorea, tics, 
dystonia, movement disorder-unspecified, other 
xv
  Amnesia, behavioural change, confusion, cranial nerve palsies, decreased consciousness, decreased concentration, dyscalculia, dysgraphia, dyspraxia, dysphasia, 
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1b ICH definite / possible
xvii
?    
1c Single or multiple ICH?    
1d Symptomatic ICH?    
     
2. Date of ICH? dd/mm/yyyy   
     
3a.  Time of symptom onset?                                                                                                       hh:mm  
3b. Is the time stated : 
 
   
     
4. Who is the responsible consultant?    
     
5a. Date of hospital assessment dd/mm/yyyy   
5b. Time of hospital assessment hh:mm   
     
6a Referral date dd/mm/yyyy   
6b Date seen (BHT) dd/mm/yyyy   
6c Time seen (BHT) hh:mm   
     
7a Hospital
xviii
    
7b Inpatient/Outpatient    
7c Ward    
7d Date admitted to the stroke unit dd/mm/yyyy   
                                                 
xvi
 (F= first, R= recurrent, N/K=not known) 
xvii
 Definite ICH if confirmed by imaging/pathology 
xviii
 This is either the hospital where BHT first saw the patient or the hospital where the patient was admitted if BHT did not see the patient. If the 
patient was transferred between hospitals, enter the first hospital the patient was admitted to in 7e and the second hospital in 7a. WGH, RIE, SJH, 
Liberton, Astley Ainslie, Roodlands 
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8 Handedness (A= ambidextrous, 
N/K=not known) 
   




   
     
10a Head injury prior to the ICH?    




 IF YES: SPECIFY 
TRIMESTER/POST 
PARTUM 
10c Date of thrombolysis pre-ICH dd/mm/yyyy   
 
DHx on admission 




     
     
     
     
     
     
     
     
     
     
     
     
     
     
                                                 
xix
 WGH, RIE, SJH,  
R L N/K A 
Y N 
Y N 
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1. Is the participant adopted ?   
 
Yes    No              Unknown     does not want to answer 
 
2. Are you one of multiple births ?   
 
Twin – identical  Twin- non identical  
 
 
Triplet    Other    Unknown 
  
 
3. Draw the family tree of first degree relatives* only :  






   
 
     4.  
Relative* Alive? 




Cause of death Stroke? Dementia? 
Typexx Age Y/ N/Unknown Age 
        
        
        
        
        
        
        
        
                                                 
xx
 ICH, ischaemic stroke, Unknown 
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2a. Employment (Unemployed, Full 




2b Highest level of education 





2c Age left education (years)  
 
  
     















3d Last date drugs taken 
 
dd/mm/yyyy   
 
PRE MORBID MODIFIED RANKIN SCALE (✓as appropriate) 
Do you have any symptoms? (if No: 0, Yes: 1) 
0 – no symptoms at all  
Are you able to look after yourself and carry out all usual (previous) activities? (if No: 2) 
1 - No significant disability despite symptoms: Able to carry out all usual activities. 
Are you able to pay the bills, do the shopping, cleaning etc? (if Yes: 2, No: 3) 
2 - Slight disability (i.e. independent for ADL but unable to do all usual activities). 
Can you walk without the help of other people? (if Yes: 3, No: 4) 
3 - Moderate disability: Requiring some help but able to walk without assistance. 
Can you be left alone for at least some hours of the day or do you need constant attention?  
(if Yes: 4, No: 5) 
4 - Moderate to severe disability: Unable to walk without assistance and unable to  
attend to own bodily needs without assistance. 
5 - Severe disability: Bedridden, incontinent and requiring constant nursing car 
                                                 
xxi
 If recording from notes, use most recently documented alcohol history 
Y N N/K 
Basic Further Higher 
never current ex 
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Systolic BP on admission Diastolic BP on admission 
Glasgow coma scale  
Eyes
xxii
: 1 2 3 4 UN Verbal 
xxiii
: 1 2 3 4 5 T UN Motor
xxiv
: 1 2 3 4 5 6 UN 
Can talk? Yes / No / NK Orientated? Yes / No/ NK Able to lift both arms off bed? Yes / No / NK 





Hb (g/l)   Na (mmol/l)    Gluc(mmol/l) 
WCC (× 109 /l)   K (mmol/l)    Chol (mmol/l) 
Plts (× 109 / l)   Urea (mmol/l)    TG (mmol/l) 
PT (secs)   Creat (µmol/l)    CRP (mg/l) 
APTT (secs)   Bil (µmol/l) 
Fib (g/l)   Alb (g/l) 
INR    ALP (U/l) 






                                                 
xxii
 1 = Does not open eyes, 2 = Opens eyes in response to painful stimuli, 3 = Opens eyes in response to voice, 4 = Opens eyes spontaneously 
xxiii
 1 = No sounds, 2 = Incomprehensible sounds, 3 = Inappropriate words, 4 = Confused, disoriented, 5 = Oriented, converses normally, T= intubated 
xxiv
 1 = No movements, 2 = Extension to stimuli, 3 = Abnormal flexion to stimuli, 4 = Flexion/Withdrawal,  5 = Localizes, 6 = Obeys commands 
xxv
 LVH : LVH - R wave in leads V5 or 6 plus S wave in lead V1 >35 mm (BMJ, 2002;324:1264-1267) 
ECG AF :  Y / N / NK 
LVH
xxv
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xxvi
 Specify location as frontal / parietal / Temporal / occipital /  fronto-parietal / fronto-temporal / parieto-occipital /  
temporo-parietal/ temporo-occipital/ temporo-parieto-occipital/ basal ganglia/ thalamic/ brainstem 
cerebellar / midbrain / pontine / medulla   
 
xxvii
 ABC/2 method. Identify the CT slice with the largest area of haemorrhage on it.  A= largest diameter of 
haemorrhage on CT slice (cm), B= diameter perpendicular to A (cm, measured on the same slice), C= no of slices on 
which ICH visible × thickness of brain CT slices (1cm
3 
=1ml).  (Kothari et al. Stroke. 1996; 27: 1304–1305.) 
xxviii
 CLINCH classification: Acquired small vessel disease, cerebral amyloid angiopathy – without a detected genetic 
mutation, cerebral amyloid angiopathy – with a detected genetic mutation, genetic small artery diseases – CADASIL, 
genetic small artery diseases – COL4A1 mutation, genetic small artery diseases – familial without an identified 
mutation, moya-moya phenomenon, vasculitis, reversible cerebral vasoconstriction syndrome, haemorrhagic 
transformation of an infarct, arterial aneurysm, arteriovenous malformation, dural arteriovenous fistula, cavernous 
malformation, acute leucoencephalopathy syndromes, intracranial venous thrombosis, malignancy, multiple – 
evidence of at least 2 of the previously mentioned causes, unknown 
1. Scan ID  
2. Scan modality CT / MR 
3. Date of scan dd/mm/yyyy 
4. Time of scan hh:mm 
5. ICH classification Lobar / deep / cerebellum / brainstem 
6. ICH locationxxvi 
 
7. ICH side 
Left  / Right / Left and Right / Midline / 
unknown 
8. Intraventricular extension Yes / No 
9. Subarachnoid extension Yes / No 
10. Subdural extension Yes / No 
11. Midline shift (cm)  
12. ICH A dimension (cm) xxvii  
13. ICH B dimension (cm)  
14. ICH C dimension (cm)  
15. ICH computerised volume (ml)  
16. Cause of ICHxxviii  
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Date of auditable eventxxix : ____ / _____ / _________ 
A. Appropriate referral made as per audit criteria (✓one option)  
cerebellar ICH >2cm diameter     ICH causing brainstem compression 
ICH causing hydrocephalus   ICH within 1cm of cortical surface 
ICH causing deterioration in GCS from 9-12 to less than or equal to 8   
B. Patient referred when referral inappropriate as per audit criteria (✓one option)  
Small deep ICH     Large ICH & prior comorbidities 
Lobar ICH without either hydrocephalus or rapid neurological deterioriation 
GCS at time of referralxxx:  E  V  M   
Neurosurgical referral made?  Yes / No / Unknown 
Neurosurgical opinion :  (✓as appropriate) 
Opinion Yes No Not applicable 
Conservative management by other specialty    
Transfer ITU    
Transfer DCN (inc HDU)    
Further imaging    
Randomise STICH2    
Other investigation recommended    
 
Neurosurgical intervention: (✓as appropriate) 
Intervention Yes No Not applicable 
Conservative management    
ICP monitor    
Insertion of ventricular drain    
Burr hole/mini-craniotomy and aspiration of clot    
Craniotomy+evacuation of clot +/- craniectomy    
Decompressive craniectomy    
Excision of lesion    
                                                 
xxix
 Tick one option in A or B. Check up to 72hrs from the time of admission for auditable neurosurgical events 
xxx
 E: 1 = Does not open eyes, 2 = Opens eyes in response to painful stimuli, 3 = Opens eyes to voice, 4 = Opens eyes spontaneously 
V: 1 = No sounds, 2 = Incomprehensible sounds, 3 = Inappropriate words, 4 = Confused, disoriented, 5 = Oriented,T= intubated 
M: 1 = No movements, 2 = Extension to stimuli, 3 = Abnormal flexion to stimuli, 4 = Flexion/Withdrawal,  5 = Localizes, 6 = Obeys commands 
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Scan Date of 
scan 
Diagnostic scan CT/CTA/CTV/MRI /MRA/MRV /MRI&MRA /MRI &MRV/ 
DSA 
1.     
2.     
3.     
4.     
5.     
 
Date of DNAR:  
In-patient treatment (✓ as appropriate) 
Treatment Yes No Unknown 
Antihypertensives    
Platelets    
FFP    
PCC    









      
      
      
      
      
      
 
Treatment One Many No Unknown 
Antihypertensives     
Antiplatelets     
Anticoagulants     
 




Place of discharge:  Home  Residential home   Nursing home 
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Date of death : ____/____/________  Time of death :  
 
Place of death : hospital   community  (✓ one as appropriate) 
 


























PM performed : LINCHPIN                Fiscal   No        (✓ as appropriate) 
PM exam date : ____/____/________ 
Autopsy done by whom?    Colin Smith         James Ironside           Toni Torgersen 
    Ralph BouHaidar 
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First approach? (BHT vs Clinical team)  
Date of first approach to discuss PM  
Relationship between lead NOK & deceased  


















Other Trials : PATCH/STICH 2 (given dates of consent to any other ICH studies) 
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LINCHPIN: SCAN READING FORM
Adapted with permission from http://www.sbirc.ed.ac.uk/documents/
SCAN ID: _______________________ SCAN DATE: _______________________
LATCH/LINCHPIN ID____________________ READ DATE: _______________________
SCAN TYPE: CT - CONTRAST:  + CONTRAST: 
CT FORMAT: _______________________
CTA  CTV 
MR T1 sag  ADC  T2 sag 
T2 axial  GRE  T1 cor 
FLAIR  SWAN  MRA 
DWI  SWI  MRV 
2. Is there any sign of acute ischaemic change? Y N IF NO, GO TO Q.3
a. On which side of the brain is the ischaemia? R L TICK R AND L IF BOTH
3.
Is there any acute parenchymal 
haemorrhage? Y N IF NO, GO TO Q.6
1.
Is this scan for assessment of the notifying 
event (e.g. detection and / or classification of 
an acute infarct or haematoma)?
Y N IF NO, GO TO Q.6
P1
4.
Characterize each separate acute parenchymal haemorrhage starting with the largest / 
symptomatic/ most important at number 1. Rank haemorrhages in order of importance.










Frontal lobe (not basal ganglia)














Anatomic Location Codes for haemorrhages (use multiple codes if necessary)
b.
Is the main haemorrhage most likely 
Haemorrhagic Transformation of an Infarct or 
Primary Intracerebral Haemorrhage?
HTI PICH IF HTI, GO TO Q.6
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SCAN ID: _______________________ LINCHPIN P2
6.
Are there any chronic infarcts or 
haemorrhages (which are not microbleeds)? Y N IF NO, GO TO Q.7
a.
Classify the chronic infarcts and haemorrhage 
(for ICHs use anatomic location codes in 4a)




MCA cortical Other cortical Lacunar** Cerebellum
1  small  cortical 9    anterior ACA 15  int & ext capsules/lent nucleus 22  small cortical
2  basal ganglia 10  posterior ACA 16  internal border zone 23  <1/2 hemisph.
3  subcortical 11  anterior PCA 17  centrum semiovale 24  >1/2 hemisph.
4 ant half periph MCA  12  posterior PCA 18  thalamus
5  post half periph MCA 13  anterior BZ 19  brainstem Brainstem
6  whole peripheral MCA 14  posterior BZ 20  anterior (mainly) borderzone 25  small 
7  whole periph + lat BG 21  posterior (mainly) borderzone (i.e. <1/2 medulla)
8  whole MCA territory 26  extensive
1. Record in the following order: MCA cortical > other cortical > lacunar > cerebellum > brainstem
2. Defined as a ‘CSF-containing cavity’ in an appropriate site, measuring 3-20mm in diameter
a.
What is the size of haemorrhage no.1?
(A x B x C) method in centimeters (cm) A B C
f.
Is the main haemorrhage lobar or deep?
If lobar AND deep, tick both. L D Uncertain                n/a
b. Is there any intraventricular haemorrhage? Y N
c. Is there any subarachnoid extension? Y N
e. Is there any midline shift? Y N
5. Characterize the haemorrhage(s) listed in 4a further.
Vascular Territory Location Codes for infarcts
d. Is there any subdural extension? Y N
Adapted with permission from 
http://www.sbirc.ed.ac.uk/documents/ for use in:
b.
What is the size of haemorrhage no.2?
(A x B x C) method in centimeters (cm) A B C
c.
What is the size of haemorrhage no.3?
(A x B x C) method in centimeters (cm) A B C
e.
What is the size of haemorrhage no.5?
(A x B x C) method in centimeters (cm) A B C
d.
What is the size of haemorrhage no.4?
(A x B x C) method in centimeters (cm) A B C
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7. Is this scan a CT scan? Y N IF YES, STOP.
SCAN ID: _______________________ LINCHPIN P3
8. Rate any BASAL GANGLIA MINERAL DEPOSITS [GRE most useful]
Code:
0 1 2 3
9.
Rate any WHITE MATTER HYPERINTENSITIES
Fazekas scale: 0 1 2 3 
[FLAIR / T2 most useful]
a. Periventricular R L Overall
b. Deep (subcortical white matter) R L Overall
10
Rate any ATROPHY using normative age template 
0 = None.  1 = Mild.   2 = Moderate.   3 = Severe
[T2 to match template]
a. Deep Overall
b. Cortical / superficial Overall
11
Rate any ENLARGED PERIVASCULAR SPACES
0 = None.  1 = < 10.  2 = 11 – 20.  3 = 21 – 40.  4 = > 40.
[T2 best]
a. Hippocampus R L Overall
b. Basal ganglia R L Overall
c. Centrum semiovale R L Overall
Adapted with permission from 
http://www.sbirc.ed.ac.uk/documents/ for use in:
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12 Quantify MICROBLEEDS RIGHT LEFT Notes:
SCAN ID: _______________________ LINCHPIN P4
a.
Frontal lobe
Cortex / grey-white junction C U C U
Certain or Uncertain C U C U
b.
Frontal lobe
Subcortical white matter C U C U
c.
Temporal lobe
Cortex / grey-white junction C U C U
d.
Temporal lobe
Subcortical white matter C U C U
e.
Parietal lobe
Cortex / grey-white junction C U C U
f.
Parietal lobe
Subcortical white matter C U C U
g.
Occipital
Cortex / grey-white junction C U C U
h.
Occipital lobe
Subcortical white matter C U C U
Lobar Totals C U C U
i. Basal ganglia grey matter C U C U
j.
Internal & external 
capsules C U C U
k. Thalamus C U C U
Deep Totals C U C U
l. Cerebellum C U C U
m. Brainstem C U C U
Infratent Totals C U C U
Adapted with permission from 
http://www.sbirc.ed.ac.uk/documents/ for use in:





LOTHIAN AUDIT OF THE TREATMENT OF CEREBRAL HAEMORRHAGE 
(L.A.T.C.H.) 
 
An audit of the care of adults in Lothian who are affected by brain haemorrhage 
Patient information leaflet 
This leaflet is about a Lothian-wide clinical audit called LATCH, which involves you 
because you have been diagnosed as having a brain haemorrhage. It is important for 
you to understand why the audit exists and what it involves. 
What is LATCH? 
The purpose of LATCH is to monitor the quality of care, treatment and outcomes for 
adults with brain haemorrhages, in order to improve the care and services that we 
provide.  The audit also monitors how common the condition is, and the problems it 
causes for those affected. 
LATCH does this by trying to find every adult resident in Lothian, who is newly 
diagnosed with a brain haemorrhage and enrolling them in this confidential audit.  
We are looking for people who were diagnosed after 1st June 2010. 
How does LATCH work? 
In the course of your care we collect information about you, your diagnosis, your 
investigations, your treatment and how you get on. This information is obtained from 
your general practitioner (GP) and hospital medical records, brain scans, GP, 
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Information Services Division, General Register Office for Scotland and the NHS 
central register. The data are held confidentially under secure conditions. You may 
be invited to take part in associated research projects, and will be informed of them 
at a later date. 
How does LATCH handle information? 
The information is gathered and processed by the LATCH team and held securely in 
an electronic database within the NHS. All names, addresses and other identifying 
information are removed before the data are analysed.  We comply with the Data 
Protection Act, 1998. 
The team includes medical staff, as well as administrative and computing staff with 
NHS contracts and a duty of confidentiality. 
How can I obtain more information? 
In this leaflet we have attempted to give a basic description of the audit. For more 
information, you may contact the number below. You may also seek advice from 
your hospital consultant or general practitioner.  
What if I want my information removed from the audit? 
If you wish to opt out of the audit, contact LATCH using the details below. 
If you would like further information please contact: 
Rosemary Anderson or Dr Rustam Al-Shahi Salman, Bramwell Dott Building, Division 
of Clinical Neurosciences, Western General Hospital, Edinburgh. EH4 2XU 
Telephone: 0131 537 2944 / 07872416010
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Lothian study of INtraCerebral Haemorrhage Pathology, Imaging and Neurological outcome 
(LINCHPIN) 
 
        
 
Participant information sheet 
 
 We understand that you have had a stroke due to a bleed in the brain. This is also known as a 
‘brain haemorrhage’. We would like to invite you to take part in our research study on brain 
haemorrhages.  
Before you decide, we want you to understand why the research is being done and what it 
would involve. 
 
Brain haemorrhage team 
We are doctors and nurses who look after and have a special interest in patients with brain 
haemorrhage.  If required, we will provide the doctor looking after you with advice on tests 
and treatments that may help you. We will provide you with information about brain 
haemorrhage. We also do research into the causes of brain haemorrhage. This research 
project may help us to find out what caused your brain haemorrhage. 
One of our team will go through this information sheet with you and answer any questions 
you have. Part 1 tells you the purpose of this research study and what will happen to you if 
you take part. Part 2 gives you more detailed information about the research study. 
  
Part 1 
What is the purpose of the study? 
About 1 in every 5 strokes are caused by bleeding into the brain.  Around 15,000 people in the 
UK will have a bleed like this every year and the effects can be very serious.  At the moment, 
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we know very little about what causes a bleed and do not have any effective medical 
treatments for it.  This study will use blood samples, brain scans and samples of brain tissue 
from people who have had a brain haemorrhage to find out more about what causes them. 
This could lead to specific treatments, which might benefit you personally by preventing 
another brain haemorrhage. This might also benefit others in the future. 
 
Why have I been asked to take part? 
We understand that this is a difficult time for you. We are asking you to take part because you 
have had a bleed into the brain. We are giving you the opportunity to participate in this study 
because it may help us to understand why you have had a bleed and this could have 
implications for your future health or the health of your relatives.   
 
Do I have to take part? 
It is up to you. You have the option to participate in as much of the study as you wish.  If you 
agree to take part, we will ask you to sign a consent form. You are free to withdraw at any 
time, without giving a reason. This will not affect the care you receive. 
 
What will happen to me if I take part? 
There are five parts to the research and you can contribute to any or all of them. 
1. Assessment by the brain haemorrhage team 
As a clinical care team with a special interest in brain haemorrhage we would like to talk to 
you and/or your family to find out more about what led up to your bleed. We will ask your 
next of kin to complete a short questionnaire about your memory.   We will review your 
medical records to investigate what may have caused the bleed into your brain.  
2. Blood samples 
We invite you to provide a blood sample.  This will help study genetic and non-genetic 
influences on bleeding in the brain. The sample will be used in collaboration with researchers 
overseas, where laws governing the use of data and tissue differ from ours. 
3. Brain scan 
We would like to offer you the opportunity to have a detailed magnetic resonance imaging 
(MRI) brain scan, which is not usually performed for people with brain haemorrhage in 
standard practice.  This scan could identify a cause of your brain haemorrhage. The scan will 
also search for tiny deposits of blood in the brain, called microbleeds, which may indicate that 
your bleed has been caused by a protein called amyloid.  Amyloid might affect the risk of you 
having another bleed in the future. 
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This scan will take approximately 30 minutes to complete and does not involve any exposure 
to x-rays or other forms of radiation.  This should happen within one month of the bleed if you 
are well enough, or if you are well enough when we see you in clinic six months after the 
bleed. 
4. Checking how you get on in the future 
We would like to check how you get on either by telephone or in person in approximately six 
months time and by reviewing your medical records as well as sending your GP a short 
questionnaire every year. 
5. Examination of your brain tissue 
The best way of understanding what caused your brain haemorrhage is by examining your 
brain under the microscope. We are therefore inviting you to donate samples of your brain to 
our research study when you die. This could also be very helpful in establishing whether the 
‘microbleeds’ identified by the MRI scan do reliably identify the amyloid protein in the brain. 
We will provide you with a ‘card’ to carry identifying you as a member of the LINCHPIN study, 
so that if you choose to donate tissue, your wishes to do so are known. 
 
If the information in Part 1 has interested you and you are considering participation, please 
read the additional information in Part 2 before making any decision. 
  
Part 2 
Will my taking part in the study be kept confidential? 
Yes. Your identity is totally confidential and no identifying details will ever be made public. 
 
How will information about me be handled? 
The study is run by a team from the Department of Clinical Neurosciences in Edinburgh.  The 
information is processed by this team which includes medical, computing and administrative 
staff. All members have NHS contracts and a professional duty of confidentiality.  The 
information is held securely in a password protected database.  All identifying information is 
removed before the data are analysed.  We comply with the Data Protection Act, 1998. 
 
Which gene is being tested for and why? 
Your genes can affect your health in different ways. Firstly, an abnormality in one of your 
genes may directly cause an illness or secondly, a variation in a gene may make you more 
likely to have an illness.  We are looking at a gene called Apolipoprotein E which falls into the 
second group.  It will not directly cause a bleed into the brain, but may make a bleed more 
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likely to occur.  As far as we know, having different variations of the gene will not directly 
affect the health of you or your family.  
 
What happens to the results of my brain scan? 
The MRI scan will be reported by a doctor who specialises in looking at brain scans.   If the 
scan does reveal a specific cause for your bleed, or any other abnormality which has 
implications for your health or that of your family, we will inform you and the doctors who are 
looking after you. 
The scan will be kept securely so that it forms part of your medical record and can be seen by 
the doctors looking after you or if you have to return to hospital in future. The scans will be 
stored on University computers for analysis by University staff, only identified by study 
number, not by your name. We may want to come back to re-examine the data after the 
study is finished, and possibly to share scan data with other researchers to answer relevant 
research questions. These points are important because sometimes new ideas come out 
during or after the study and we can then go back and re-examine the study data to see if 
these new ideas might be true. 
 
What does examining my brain tissue involve? 
Brain tissue is essential to establish whether amyloid protein does cause brain haemorrhage, 
and whether microbleeds on MRI diagnose amyloid. If you choose to donate brain tissue, a 
doctor trained in tissue examination, called a pathologist, will carry out a post mortem 
examination restricted to the head only. Small samples of tissue from different areas of your 
brain will be taken and examined.  These would be 1cm by 1cm by 1cm in size.  A small sample 
of the fluid surrounding the brain will also be taken.  Afterwards, your brain will be returned 
to your body. Any funeral arrangements will not be affected by your decision to make a 
donation to this study. 
 
What are the potential disadvantages? 
Apart from the time taken considering your case in detail, there are no disadvantages of 
clinical examination. A blood test may be uncomfortable. Some people become 
claustrophobic in the MRI scanner – but if that happened to you, the scan would not have to 
continue. There is a 1 in 37 chance of finding an abnormality on your MRI scan that is 
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What happens to the samples I have donated? 
The blood samples and samples of brain tissue will be stored in a secure laboratory in an 
anonymous form. They may be used in other ethically approved research studies (including 
genetic research) to benefit human health in the future.  Neither your relatives nor the 
research groups would profit financially from any developments of this kind. 
 
What happens when the research study stops? 
Information about you and your samples will be retained indefinitely.  Retained tissue may be 
kept for future medical research and disposed of lawfully when they have served this purpose. 
 
Will my GP be informed about my participation? 
Yes. We will inform your GP if you decide to participate in this study.  
 
If I agree now, can I change my mind later? 
Yes. Do contact us if you need to discuss anything (see back page).  If you change your mind 
later on, any samples or brain scans done will be retained as part of your medical record but 
will not be used for research or education. 
 
What if there is a problem? 
If you have a concern about any aspect of this study, you should speak to one of the research 
team who will do their best to answer your questions. If you remain unhappy and wish to 
complain formally, you can do this via the NHS Complaints Procedure, whose details can be 
obtained from the hospital. 
 
Can I find out the results of the research? 
We would be very happy to send you a yearly newsletter about the results of the research, if 
you wish.   The results of the study will be submitted for publication in relevant professional 
journals and also made available in a format appropriate to the general public.  When the 
results of our study are published, we will not include any individual information about you 
that would be identifiable.   
 
Who is funding this research? 
The study is funded by the UK Medical Research Council and The Stroke Association. 
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Who has reviewed the study? 
The Multi-Centre Research Ethics Committee for Scotland, Committee A, approved this study.
  
Thank you for reading this information leaflet. 
Independent advice about this study is available from:
Professor M Dennis, Consultant Stroke Physician, Ward 55, Western General Hospital, 
Edinburgh. EH4 2XU. Telephone: 0131 537 2082.
If you would like further information please contact one of the study team:
Mrs Chris Lerpiniere or Mrs Tracey Millar (research 
Prof. Rustam Al-Shahi Salman (chief investigator)
Dr Neshika Samarasekera (clinical fellow)
Division of Clinical Neurosciences, Bramwell Dott Building, Western General Hospital, 
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Lothian study of INtraCerebral Haemorrhage Pathology, 
Imaging and Neurological outcome (LINCHPIN) 
 
                               
Information sheet for relatives of participants without 
capacity 
                                     
We understand that your relative has had a stroke due to a bleed in the brain. This is also 
known as a ‘brain haemorrhage’. We would like to invite your relative to take part in our 
research study on brain haemorrhages.  
Before you decide, we want you to understand why the research is being done and what it 
would involve. 
 
Brain Haemorrhage Team 
We are doctors and nurses who look after and have a special interest in patients with brain 
haemorrhage.  If required, we will provide the doctor looking after your relative with advice 
on tests and treatments that may help them. We will provide you and your relative with 
information about brain haemorrhage. We also do research into the causes of brain 
haemorrhage, because more needs to be known about them. This research project may help 
us to find out what caused your relative to have a brain haemorrhage. 
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We feel your relative is unable to decide for him/herself whether to take part in this study. 
We are therefore asking you for your consent on their behalf for them to join the study.  
We ask you to consider the following information about the study and to let us know 
whether you wish them to take part.  
We ask you to set aside your own views and consider their interests and what you feel 
would be their wishes and feelings, had they been able to make a decision for themselves.  
Any advance decisions they may have made and that you are aware of should take 
precedence. 
If you feel unable to decide whether or not to give consent, please say so.  You may seek 
independent advice. We will understand if you do not want this responsibility.  
 If you feel you cannot decide, it will not affect the care your relative receives. 
One of our team will go through this information sheet with you and answer any 
questions you have.   This information is the same as would have been provided to your 
relative.   
Part 1 tells you the purpose of this research study and what will happen to your relative if 
they take part.  
Part 2 gives you more detailed information about the research study. 
 
Part 1 
What is the purpose of the study? 
About 1 in every 5 strokes are caused by bleeding into the brain.  Around 15,000 people in 
the UK will have a bleed like this every year and the effects can be very serious.  At the 
moment, we know very little about what causes a bleed and do not have any effective 
medical treatments for it.  This study will use blood samples, brain scans and samples of 
brain tissue from people who have had a brain haemorrhage to find out more about what 
causes them. This could lead to specific treatments, which might benefit your relative 
personally by preventing another brain haemorrhage. This might also benefit others in the 
future. 
 
Why has my relative been asked to take part? 
We understand that this is a difficult time for you.  We are asking your relative to take part 
because they have had a bleed into the brain.  We are giving your relative the opportunity to 
participate in this study because it may help us to understand why they have had a bleed and 
this could have implications for their health in the future. 
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Does my relative have to take part? 
It is up to you. Your relative has the option to participate in as much or as little of the study 
as you wish.  If you agree to them taking part, we will ask you to sign a consent form. You 
are free to withdraw your relative at any time, without giving a reason. This will not affect 
the care your relative receives. 
What will happen to my relative if they take part? 
There are five parts to the research and your relative can contribute to any or all of 
them. 
1. Assessment by the Brain Haemorrhage Team 
As a clinical care team with a special interest in brain haemorrhage  we would like to talk 
to you to find out more about what led up to your relative’s bleed. We will ask you to 
complete a short questionnaire about their memory.   We will review their medical records 
to investigate what may have caused the bleed into their brain.  
2. Blood samples 
We invite you to provide a blood sample.  This will help study genetic and non-genetic 
influences on bleeding in the brain. The sample will be used in collaboration with 
researchers overseas, where laws governing the use of data and tissue differ from ours. 
3. Brain scan 
We would like to offer your relative the opportunity to have a detailed magnetic resonance 
imaging (MRI) brain scan, which is not usually performed for people with brain 
haemorrhage in standard practice.  This scan could identify a cause of their brain 
haemorrhage. The scan will also search for tiny deposits of blood in the brain, called 
microbleeds, which may indicate that their bleed has been caused by a protein called 
amyloid. Amyloid might affect the risk of them having another bleed in the future. This 
scan will take approximately 30 minutes to complete and does not involve any exposure to 
x-rays or other forms of radiation.  
 This should happen within one month of the bleed if they are well enough, or if they are 
well enough when we see them in clinic six months after the bleed. 
4. Checking how they get on in the future 
We would like to check how your relative gets on either by telephone or in person, in 
approximately six months time and by reviewing their medical records as well as sending 
their  GP a short questionnaire every year.  
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5. Examination of  brain tissue 
The best way of understanding what caused your relative’s brain haemorrhage is by 
examining their brain under the microscope. We are therefore inviting them to donate 
samples of their brain to our research study when they die. This could also be very helpful 
in establishing whether the ‘microbleeds’ identified by the MRI scan do reliably identify the 
amyloid protein in the brain. 
We will provide you or your relative with a ‘card’ to carry identifying them as a member of 
the LINCHPIN study, so that if they choose to donate tissue, their wishes to do so are 
known. 
If the information in Part 1 has interested you and you are considering participation, 
please read the additional information in Part 2 before making any decision. 
 
Part 2 
If my relative takes part in the study, will it be kept confidential? 
Yes. Your relative’s identity is totally confidential and no identifying details will ever be 
made public. 
 
How will information about my relative be handled? 
The study is run by a team from the Department of Clinical Neurosciences in Edinburgh.  
The information is processed by this team which includes medical, computing and 
administrative staff. All members have NHS contracts and a professional duty of 
confidentiality.  The information is held securely in a password protected database.  All 
identifying information is removed before the data are analysed.  We comply with the Data 
Protection Act, 1998. 
 
Which gene is being tested for and why? 
Your genes can affect your health in different ways. Firstly, an abnormality in one of your 
genes may directly cause an illness or secondly, a variation in a gene may make you more 
likely to have an illness.  We are looking at a gene called Apolipoprotein E which falls into 
the second group.  It will not directly cause a bleed into the brain, but may make a bleed 
more likely to occur.  As far as we know, having different variations of the gene will not 
directly affect the health of your relative or their family.  
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What happens to the results of the brain scan? 
The MRI scan will be reported by a doctor who specialises in looking at brain scans.   If the 
scan does reveal a specific cause for your relative’s bleed, or any other abnormality which 
has implications for their health or that of your family, we will inform the doctors who are 
looking after your relative.   
The scan will be kept securely so that it forms part of your relative’s medical record and 
can be seen by the doctors looking after them or if they have to return to hospital in 
future. The scans will be stored on University computers for analysis by University staff, 
only identified by a study number, not by your relative’s name. We may want to come back 
to re-examine the data after the study is finished, and possibly to share scan data with 
other researchers to answer relevant research questions. These points are important 
because sometimes new ideas come out during or after the study and we can then go back 
and re-examine the study data to see if these new ideas might be true. 
 
What does examining brain tissue involve? 
Brain tissue is essential to establish whether amyloid protein does cause brain 
haemorrhage, and whether microbleeds on MRI diagnose amyloid. In the event of your 
relative dying a doctor trained in tissue examination, called a pathologist, will carry out a 
post mortem examination restricted to the head only. Small samples of tissue from 
different areas of your relative’s brain will be taken and examined. These would be 1cm by 
1cm by 1cm in size.  A small sample of the fluid surrounding the brain will also be taken.  
Afterwards, their brain will be returned to their body. Any funeral arrangements will not be 
affected by your decision to make a donation to this study. 
 
What are the potential disadvantages? 
Apart from the time taken considering their case in detail, there are no disadvantages of 
clinical examination. A blood test may be uncomfortable. Some people become 
claustrophobic in the MRI scanner – but if that happened to your relative, the scan would 
not have to continue. There is a 1 in 37 chance of finding an abnormality on their MRI scan 
that is completely incidental to their brain haemorrhage. 
 
What happens to the samples I have donated? 
The blood samples and samples of brain tissue will be stored in a secure laboratory in an 
anonymous form. They may be used in other ethically approved research studies (including 
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genetic research) to benefit human health in the future.  Neither relatives nor the research 
groups would profit financially from any developments of this kind. 
 
What happens when the research study stops? 
Information about your relative and their samples will be retained indefinitely.  Retained 
tissue may be kept for future medical research and disposed of lawfully when they have 
served this purpose. 
 
Will my relative’s GP be informed about their participation? 
Yes. We will inform their GP if they participate in this study.  
 
If I agree now, can I change my mind later? 
Yes. Do contact us if you need to discuss anything.  If you change your mind later on, any 
samples or brain scans done will be retained as part of your relative’s medical record but 
will not be used for research or education. 
 
What if there is a problem? 
If you have a concern about any aspect of this study, you should speak to one of the 
research team who will do their best to answer your questions. If you remain unhappy and 
wish to complain formally, you can do this via the NHS Complaints Procedure, whose 
details can be obtained from the hospital. 
 
Can I find out the results of the research? 
We would be very happy to send you a yearly newsletter about the results of the research, 
if you wish.   The results of the study will be submitted for publication in relevant 
professional journals and also made available in a format appropriate to the general public.  
When the results of our study are published, we will not include any individual information 
about you or your relative that would be identifiable.   
 
Who is funding this research? 
The study is funded by the UK Medical Research Council and The Stroke Association. 
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Who has reviewed the study?
The study was approved by the Multi
Committee A. 
 
Thank you for reading this information leaflet. 
Independent advice about this study is available from:
Professor M Dennis, Consultant Stroke Physician, Ward 55
Edinburgh. EH4 2XU. Telephone: 0131 537 2082.
If you would like further information please contact one of the study team:
Mrs Chris Lerpiniere or Mrs Tracey Millar (research nurses)
Prof. Rustam Al-Shahi Salman (chief investigat
Dr Neshika Samarasekera (clinical fellow)
Division of Clinical Neurosciences, Bramwell Dott Building, Western General Hospital, 
Edinburgh. EH4 2XU. Telephone: 0131 537 2944. Mobile: 07872 416 010. Email: 
Rosemary.Anderson2@nhs.net
-Adults with incapacity 
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Lothian study of INtraCerebral Haemorrhage Pathology, Imaging and Neurological 
outcome (LINCHPIN) 
 
Information sheet for relatives of people who have died from suspected 
intracerebral haemorrhage 
We understand that your friend/relative has died from a suspected stroke due to a 
bleed in the brain. We also call this a ‘brain haemorrhage’.  We would like to offer you 
the opportunity to donate samples of your relative/friend’s brain tissue to our research 
study on brain haemorrhages. 
Before you decide, we want you to understand why the research is being done and 
what it would involve. 
 
Brain haemorrhage team 
We are doctors who look after patients with brain haemorrhage.  We also do research 
into the causes of brain haemorrhage. 
We ask you to consider the following information about the study and to let us know 
whether you wish to take part.   We ask you to set aside your own views and 
consider what you feel would have been your friend/relative’s wishes and feelings, 
had they been able to make a decision for themselves.  Any advance decisions they 
may have made and that you are aware of should take precedence. 
If you feel unable to decide whether or not to give consent, please say so.  You may 
seek independent advice. We will understand if you do not want this responsibility. 
One of our team will go through this information sheet with you and answer any 
questions you have.   
Part 1 tells you the purpose of this research study. Part 2 gives you more detailed 
information about the research study. 
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Part 1 
What is the purpose of the study? 
About 1 in every 5 strokes are caused by bleeding into the brain.  Around 15,000 
people in the UK will have a bleed like this every year and the effects can be very 
serious.  At the moment, we know very little about what causes a bleed and do not 
have any effective medical treatments for it.  This study uses samples of brain tissue 
from people who have had a brain haemorrhage to find out more about what causes 
them. This could give you a better idea of why your friend/relative had a brain 
haemorrhage.  It might also help others in the future by leading to specific 
treatments for brain haemorrhage. 
 
Why have you asked for tissue from my friend/relative? 
We are asking for a tissue donation from your friend/relative because they may have 
died as a result of a bleed into the brain.  We understand that this is a very difficult 
time for you.  However, we are giving you the opportunity to consent to tissue 
donation because it may help us to understand why your friend/relative could have 
had a bleed, and it will help us understand the cause of brain haemorrhage in 
general. 
 
Does my friend/relative have to donate tissue? 
It is up to you. If you consent to tissue donation, we will ask you to sign a consent 
form. You are free to withdraw your consent at any time, without giving a reason. 
 
What will happen if I provide consent? 
1. Assessment by the brain haemorrhage team 
We are neurology doctors with a special interest in brain haemorrhage and we will 
talk to you to find out more about what led up to your friend / relative’s bleed. We 
will review their medical records to look for any factors which may have contributed 
to the bleed into their brain. 
2. Examination of brain tissue 
We understand that the Procurator Fiscal has asked for a post mortem examination to 
be carried out.  The post mortem examination is done to try and confirm the cause of 
death. A doctor trained in tissue examination, called a pathologist, will take and 
examine small samples of tissue from different areas of your friend/relative’s brain.    
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The post mortem examination is also an opportunity for you to donate samples taken 
for use in research and if you wish, to donate additional tissue samples from the brain 
which may help us to understand why your friend/relative had a bleed.   We are 
therefore inviting donation of additional samples of brain tissue for our research. 
Any funeral arrangements will not be affected by your decision to make a donation 
to this study. 
If the information in Part 1 has interested you and you are considering participation, 
please read the additional information in Part 2 before making any decision. 
 
Part 2 
If my friend/relative donates tissue to the study, will it be kept confidential? 
Yes. Your identity and that of your friend / relative is totally confidential and no 
identifying details will ever be made public. 
 
How will information about my friend / relative be handled? 
The study is run by a team from the Department of Clinical Neurosciences in 
Edinburgh.  The information is processed by this team which includes medical, 
computing and administrative staff. All members have NHS contracts and a 
professional duty of confidentiality.  The information is held securely in a password 
protected database.  All identifying information is removed before the data are 
analysed.  We comply with the Data Protection Act, 1998. 
 
What does examining brain tissue involve? 
If you consent to tissue donation, the pathologist would use the routine samples taken 
at post mortem for research purposes and examine additional tissue samples from 
different areas of your friend / relative’s brain.  These samples would be 1cm by 1cm by 
1cm in size.  A small sample of the fluid surrounding the brain will also be taken.  
Afterwards, your friend/relative’s brain would be returned to their body. 
In some people a protein called amyloid is deposited in the brain and this protein may 
be one cause of brain haemorrhages.  Brain tissue is essential to determine whether 
amyloid is present.   The pathologist would look for different causes of brain 
haemorrhage, one of which would be amyloid. 
Any funeral arrangements will not be affected by your decision to make a donation to 
this study. 
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Will my decision affect the post mortem examination? 
You can be assured that whether you decide to participate in this study or not, this 
will not affect the care with which the post mortem examination is carried out. 
 
What happens to the results of the post mortem examination? 
The post mortem findings will be reported by the pathologist and a report will be 
sent to your friend/relative’s GP.  You can discuss the report with the GP.  We will 
also inform you if the post mortem reveals a specific cause for the bleed or any other 
abnormality which has implications for your family. 
 
What happens to the donated tissue samples? 
The samples of brain tissue will be stored in a secure laboratory in an anonymous 
form. They may be used in other ethically approved research studies (including 
genetic research) to benefit human health in the future.  Neither relatives nor the 
research groups would profit financially from any developments of this kind. 
 
What happens when the research study stops? 
Information about your friend/relative and their samples will be retained 
indefinitely.  Retained tissue may be kept for future medical research and disposed 
of lawfully when they have served this purpose. 
 
Will my friend/relative’s GP be informed about this study? 
Yes. We will seek relevant information from the GP records.  
 
If I agree now, can I change my mind later? 
Yes. Do contact us if you need to discuss anything (see back page).  If you change 
your mind later on, any samples taken will be retained as part of your 
friend/relative’s medical record but will not be used for research or education. 
 
What if there is a problem? 
If you have a concern about any aspect of this study, you should speak to one of the 
research team who will do their best to answer your questions. If you remain 
unhappy and wish to complain formally, you can do this via the NHS Complaints 
Procedure, whose details can be obtained from the hospital. 
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Can I find out the results of the research?
We could send you a yearly 
The results of the study will be submitted for publication in relevant professional 
journals and also made available in a format appropriate to the general public.  
When the results of our study 
information about you or your relative/friend that would be identifiable.  
 
Who has reviewed the study?
The study was approved by the Multi
Scotland, Committee A. 
Thank you for reading this information leaflet.
Independent advice about this study is available from:
Professor M Dennis, Consultant Stroke Physician, Ward 55, Western General 
Hospital, Edinburgh. EH4 2XU
Telephone: 0131 537 2082.
If you would like further inf
Dr Neshika Samarasekera, Division of Clinical Neurosciences, Bramwell Dott Building, 
Western General Hospital, Edinburgh. EH4 2XU
Telephone: 0131 537 2626 / 07872416010
-those who have died from ICH 
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 Appendix 7: LINCHPIN consent form-general         
Lothian study of INtraCerebral Haemorrhage Pathology, 
Imaging and Neurological outcome (LINCHPIN):  
Consent form  
[version 7] [5th December 2013] [1] 
Name of researcher:  Prof Rustam Al-Shahi Salman 
 
I have read the information leaflet for the above study and had the 
opportunity to ask questions.  
 
I understand that my participation is voluntary and I am free to withdraw from 
the project at any time and my medical care will not be affected.  
 
I give my consent for my general practitioner and consultant to be contacted 
about the study, for follow up and for my medical records to be examined.  
 
I give my consent to a clinical assessment and a questionnaire to be 
completed by my next of kin / nearest relative / friend. 
I agree to being contacted in about 6 months to see how I am getting on.  
 
I consent to two blood samples being taken; one for genetic analysis and one 
to be stored for use in future studies of stroke.  
 
I consent to DNA, tissue and anonymised information about me being shared 
with collaborators within or outside the European Union.  
 
I understand that my doctor and I/my family will be informed if any of the 
results of the medical tests done as a part of the research have implications 
for my health or that of my family. 
In the event of my death I would like the wishes that I have expressed here to  
be respected by others. 
I would / would not * like to receive information about the results of the  
research. (*delete as appropriate) 
 
________________________ _____________                ____________________ 
Name of Participant  Date                                  Participant’s signature 
_________________________ ________________          ____________________ 
Researcher  Date                                  Signature 
_________________________ ________________           ___________________ 
Name of Person taking consent Date                                  Signature 
(if different from the researcher) 
Please initial box 
Appendix 8: LINCHPIN consent form-MRI                                                
Lothian study of INtraCerebral Haemorrhage Pathology, 
Imaging and Neurological outcome (LINCHPIN): 
Consent form for magnetic resonance imaging (MRI) 
 
 
Version 2  17.2.10 1 
 
Name of researcher: Prof Rustam Al-Shahi Salman  
 
 
I consent to have a magnetic resonance imaging (MRI) scan of my brain.   
 
I consent to my doctor and I / my family being informed of any scan findings 
which have implications for my health. 
 
I agree that my brain scans, may be used in other ethically approved 
research studies in the future as long as all the information including the 
images is anonymised. 
 
 
________________________ _____________                ____________________ 
Name of Participant  Date                                  Participant’s signature 
_________________________ ________________          ____________________ 
Researcher  Date                                  Signature 
 
_________________________ ________________           ___________________ 
Name of Person taking consent Date                                  Signature 
(if different from the researcher) 
 
Please initial box 
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Lothian study of INtraCerebral Haemorrhage Pathology, 
Imaging and Neurological outcome (LINCHPIN): 
Consent form for post mortem examination 
 
Version 4       06.04.10   1 
 
Name of researcher: Prof Rustam Al-Shahi Salman  
When I die, I consent to a post mortem examination limited to my brain, to 
look into the cause of my brain haemorrhage. 
 
 
I consent to tissue samples and fluid taken at the time of a post-mortem 
examination being retained by the University of Edinburgh and being used for 
audit, ethically approved research and the education and teaching of 
healthcare staff. 
 
I consent that the University of Edinburgh may keep indefinitely, any tissues 
and fluid donated for medical research and dispose of them lawfully when the 
research is complete or they are no longer usable. 
 
_______________________ _____________ ______             ___________________ 
Name of Participant  Date                                                 Participant’s signature 
 
__________________ ________________          ________________ 
Researcher  Date                                                 Signature 
 
__________________ ________________           ________________ 
Name of Person taking consent Date                                                 Signature 
(if different from the researcher) 
Please initial box 
Appendix 10: LINCHPIN consent form-general (adults with incapacity)      
Lothian study of INtraCerebral Haemorrhage Pathology, 
Imaging and Neurological outcome (LINCHPIN):  
Consent form for participants with incapacity 
Version 3 05.12.2013 1 
 
 
Name of researcher: Prof Rustam Al-Shahi Salman 
 
I have been consulted about my relative’s participation in this research 
project. 
I have had the opportunity to ask questions about the study, understand 
what is involved and give consent on behalf of my relative. 
I understand that I am free to withdraw him/her from the study at any time 
without giving a reason and his/her medical care will not be affected.  
I give my consent for his/her general practitioner and consultant to be 
contacted about the study and for follow up and for his/her medical records 
to be examined. 
I consent to a clinical assessment of my relative and to completing a 
questionnaire. 
I agree to being contacted in 6 months to see how he/she is getting on.  
I consent to two blood samples being taken; one for genetic analysis and 
one to be stored for use in future studies of stroke.  
 I consent to DNA, tissue and anonymised information about him/her being 
shared with collaborators within or outside the European Union.  
I understand that his/her doctor will be informed if any of the results of the 
medical tests done as a part of the research have implications for their 
health or that of their family. 
I would / would not * like to receive information about the results of the  
research. (*delete as appropriate) 
________________________ 
Name of Participant  
_________________________ ________________          ____________________ 
Researcher  Date                                     Signature 
_________________________ ________________           ___________________ 
Name of Person providing consent Date                                      Signature 
   (on behalf of the participant) 
 
I am ( one):   Welfare guardian / legal representative 
      Nearest relative     & there is no closer relative:  Yes / No [circle one]
Please initial box 
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Lothian study of INtraCerebral Haemorrhage Pathology, 
Imaging and Neurological outcome (LINCHPIN):  
Consent form for participants with incapacity-MRI 




Name of researcher: Prof Rustam Al-Shahi Salman 
         
 
 
I consent to my relative having a magnetic resonance imaging (MRI) scan of 
his/her brain.   
 
I consent to my relative’s doctor being informed of any scan findings which 
have implications for his/her health. 
I agree that my relative’s brain scans, may be used in other ethically 
approved research studies in the future as long as all the information 
including the images is anonymised. 
 
________________________ 
Name of Participant 
 
_________________________ ________________          ____________________ 
Researcher  Date                                  Signature 
 
_________________________ ________________           ___________________ 
Name of Person providing consent Date                                      Signature 
   (on behalf of the participant) 
 
 
I am ( one):     Welfare guardian / legal representative 
        Nearest relative     & there is no closer relative:  Yes / No [circle one]
Please initial box 
Appendix 12: LINCHPIN consent form-post mortem examination (adults with incapacity)      
Lothian study of INtraCerebral Haemorrhage Pathology, 
Imaging and Neurological outcome (LINCHPIN):  
Consent form for participants with incapacity 
post mortem examination 
Version 3 05.12.2013 1 
 
 
Name of researcher: Prof Rustam Al-Shahi Salman 
I consent to a post mortem examination limited to the brain, to look into 
the cause of my relative’s brain haemorrhage. 
 
I consent to tissue samples and fluid taken at the time of a post-mortem 
examination being retained by the University of Edinburgh and being used 
for audit, ethically approved research and the education and teaching of 
healthcare staff. 
 
I consent that the University of Edinburgh may keep indefinitely, any 
tissues and fluid donated for medical research and dispose of them 
lawfully when the research is complete or they are no longer usable. 
 
_______________________ 
Name of Participant 
 
__________________ ________________          _______________ 
Researcher  Date                                                 Signature 
 
__________________ ________________           _______________ 
Name of Person providing consent Date                                      Signature 
   (on behalf of the participant) 
 
 
I am ( one):   Welfare guardian / legal representative 
      Nearest relative     & there is no closer relative:  Yes / No [circle] 
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<Title> <Initials> <surname of GP> 
<Practice name> 





Dear <insert GP title and surname> 
 
Re: <Name><Address><Postcode> 
Date of birth: <DOB> 
CHI: <CHI number> 
 
It is now approximately one year since the NHS Lothian Audit of the Treatment of 
Cerebral Haemorrhage (LATCH) collected data on <insert forename and 
surname of person>.   
We would be very grateful to you for completing the attached one page 
questionnaire. There is vital follow-up information that only you will be able to 
contribute to this NHS Lothian audit.  
Please return the attached form with the relevant copies of their GP notes, if 
applicable, to us in the freepost envelope provided. Do let us know if we can help 




    
Dr Neshika Samarasekera    Dr Rustam Al-Shahi Salman 
Clinical fellow in neurology    Consultant neurologist 
GMC No. 6076136     GMC No. 4067993
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Patient name  «PatForename» «PatSurname» 
Date of birth  «PatDOB» 
Patient address «PatAddress» «PatPostCode» 
Our ref LATCH Annual questionnaire, LATCH ID <Insert LINCHPIN ID> 
 
 
1. Is «PatTitle» «PatSurname» still alive? 
     If you answered ‘No’, please provide date of death: 
2. Is their address the same (as above)? 
     If you answered ‘No’, please amend the address. 
3. I enclose an electronic summary of «PatTitle» 
«PatSurname»’s comorbidities and prescriptions 
4. Has «PatTitle» «PatSurname» suffered from any of the following in the 
last year? If they have,        please provide brief information below, and send 
relevant copies of their case notes. 
 
 a. Ischaemic/thromobotic event                                     Yes / No ____________  
 (ischaemic stroke,TIA, DVT, PE,acute coronary syndrome)    day/month/year   
  
 b. Haemorrhagic event                                     Yes / No ____________  
 (intracerebral or other intracranial haemorrhage,gastrointestinal  day/month/year 
 bleed, other extracranial bleeding)   
 
c. New diagnosis of dementia                                     Yes / No ____________ 
      day/month/year 
    
         d. New diagnosis of hypertension                                     Yes / No ____________ 
      day/month/year 
    
5. Please give «PatTitle» «PatSurname»’s last BP recording ____________  
 BP ____ / _____ mmHg         day/month/year 
6. Which of these best describes <Patient forename & surname>’s current 
state? 
     No symptoms 
 Minor symptoms, which do not interfere with her lifestyle 
 Some restrictions to her lifestyle, but she looks after herself 
 Requiring some help with activities of daily living but able to walk unaided 
                 Requiring help to walk and attend to bodily needs but doesn’t need constant attention 
 Severe handicap, totally dependent, requiring attention night and day 
 
 
Signature __________________________     Date      __________ 




Please tick (✓) 
appropriate box 
Yes No 
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BLOCK SHEET FOR LINCHPIN RESEARCH CASES 
Name …………………………………………  Date of 
PM……………………................. 
SD Number…………………………………….  Brain 
weight……………………………… 




Sent to Neuropathologist………………….. 
 Neuropathologist………………………… 
Region Left  Right Immuno Comments 
Frontal Parasagittal      
Frontal Convexity     
Frontal white matter     
Basal Ganglia   (Ant.Comm)     
Basal Ganglia  (Mamm body)     
Amygdala     
Temporal Superior     
Parietal Parasagittal     
Parietal Convexity     
Hippocampus                  
Thalamus                        
Occipital      
Occipital white matter                                
Midbrain                          
Pons                             
Medulla                           
Vermis     
Cerebellum                      
Cervical Spinal Cord       
Thoracic spinal cord      
Lumbar spinal cord     
Caudia equina     
Dura     
Other     
Unspecified     
Author; Chris-Anne McKenzie                                                     Date 04/05/2012 
SOP Number  Version                                         Review Date 
 
